TOHOKU UNIVERSITY Researchers

Details of the Researcher

Home

日本語 English

Hideo Harigae

Section

Board Member

Job title

Executive Vice President

Degree

博士（医学）（東北大学）

researchmap

https://researchmap.jp/read0191469

J-GLOBAL ID

200901028764362918

Research History 6

2025/03 - Present

Tohoku University Hostipal
2022/09 - Present

Tohoku University Hostipal
2019/04 - 2025/03

Tohoku University Hospital　University Hospital Clinical Laboratory
2011/04 - 2025/03

Tohoku University Hospital　University Hospital Division of Blood Transfusion and Cell Therapy
2012/04 -

東北大学病院　副病院長
2007/07 -

東北大学大学院医学系研究科血液免疫病学分野　教授

Show all Show first 5

Committee Memberships 26

一般社団法人日本内科学会　理事

2020/04 - Present
日本造血細胞移植学会　理事

2018/02 - Present
公益財団法人日本骨髄バンク　調整医師

2016/04 - Present
一般社団法人日本内科学会　評議員

2016/04 - Present
公益財団法人日本骨髄バンク　地区代表協力医師

2015/04 - Present
一般社団法人日本鉄バイオサイエンス学会　理事

2015/01 - Present
厚生労働省　厚生科学審議会疾病対策部会造血幹細胞移植委員会専門委員

2015/01 - Present
日本血液学会　理事

2010/09 - Present
検査血液学会　評議員

2009/07 - Present
日本検査血液学会　理事

2009/07 - Present
日本臨床腫瘍学会　評議員

2008/10 - Present
日本臨床腫瘍学会　評議員

2008/10 - Present
日本血液学会　評議員

2006/09 - Present
日本臨床血液学会　評議員

2006/09 - Present
日本臨床検査医学会　評議員

2004/09 - Present
日本臨床検査医学会　評議員

2004/09 - Present
日本臨床検査学会東北支部　評議員

2003/04 - Present
特定非営利活動法人さい帯血バンクサポート宮城　理事

2015/04 - 2019/03
公益財団法人日本骨髄バンク　地区代表協力医師

2015/04 - 2019/03
特定非営利活動法人さい帯血バンクサポート宮城　理事

2015/04 - 2019/03
厚生労働省　厚生科学審議会疾病対策部会造血幹細胞移植委員会専門委員

2015/01 - 2019/01
宮城県　宮城県献血推進協議委員

2015/09 - 2018/08
宮城県合同輸血療法委員会　委員

2016/06 - 2018/05
一般社団法人日本造血細胞移植学会　監事

2016/03 - 2018/02
日本学術振興会学術システム研究センター　研究員

2012/04 - 2015/03
日本臨床検査医学会東北支部　評議員

2003/09 - 2004/09

Show all ︎Show first 5

Professional Memberships 24

鉄バイオサイエンス学会(2007/10-)
検査血液学会(2009/07- 評議員)
日本臨床腫瘍学会(2008/10- 評議員)
日本臨床腫瘍学会(2007/07-)
日本癌学会(2007/07-)
日本臨床免疫学会(2006/10-)
日本リウマチ学会(2006/10-)
日本免疫学会(2007/07-)
日本感染症学会(2003/10-)
日本内科学会(1989/04-)
日本臨床検査専門医会(1999/04-)
日本造血細胞移植学会(1990/10-)
アメリカ血液学会(2000/06-)
日本臨床検査学会(1999/04-)
日本臨床血液学会(1989/04-)
日本血液学会(1989/04-)
東北止血血栓研究会(2007/09- 世話人)
日本臨床検査学会東北支部(2003/04- 評議員)
日本血液学会東北地方会(2000/04- 世話人)
日本臨床血液学会(2006/09- 評議員)
日本血液学会(2006/09- 評議員)
日本臨床検査医学会(2004/09- 評議員)
日本臨床検査医学会東北支部(2003/09-2004/09 評議員)
日本血液学会・日本臨床血液学会東北地方会(2001/09-2004/09 世話人)

︎Show all ︎Show first 5

Research Interests 1

Hematology

Research Areas 2

Life sciences / Hematology and oncology / hematology
Other / Other / Clinical laboratory medicine Laboratory medicine

Awards 1

東北大学医学部奨学賞金賞

2006/01

Papers 339

Angioimmunoblastic T-cell lymphoma harboring a t(8;14)(q24;q11.2)/TCR::MYC translocation that presented with intestinal infiltration. International-journal

Satoshi Ichikawa, Hiroki Kato, Naoya Morota, Hiroaki Abe, Akihisa Kawajiri, Kyoko Inokura, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Satoko Sato, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

Annals of hematology　2024/12/18

DOI： 10.1007/s00277-024-06148-2 　

More details Close

Although rearrangement of the MYC oncogene (MYC-R) is frequently observed in aggressive B-cell lymphomas, it is extremely rare in T-cell malignancies. A 64-year-old man who had been under observation for several years because of asymptomatic pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALToma) was admitted to our hospital because of poor general condition and hypotension. Blood tests revealed thrombocytopenia and elevated serum lactate dehydrogenase levels, whereas computed tomography revealed systemic lymphadenopathy and splenomegaly. An inguinal lymph node biopsy precipitated a diagnosis of angioimmunoblastic T-cell lymphoma (AITL). Shortly after admission, the patient experienced spontaneous intestinal perforation and hemorrhage caused by multiple intestinal infiltrations of the AITL. Although chemotherapy was administered, the patient died several weeks after admission. A 46,XY,t(8;14)(q24;q11.2) karyotype was identified, and fluorescence in situ hybridization analyses showed split signals for the MYC and T-cell receptor (TCR) alpha genes, by which a TCR::MYC translocation was confirmed. Pathological autopsy analysis revealed systemic infiltration of the AITL and no MALToma lesions. Only a few cases of mature T-cell lymphoma harboring MYC-R have been reported in the literature thus far. To the best of our knowledge, this is the first reported case of AITL with TCR::MYC rearrangement. This condition could be associated with refractoriness to chemotherapy and aggressive clinical course with systemic infiltration that included the intestine.
Effectiveness and safety of low-energy shock wave therapy for digital ulcers associated with systemic sclerosis: a phase 3 pivotal clinical trial. International-journal

Tomonori Ishii, Yasushi Kawaguchi, Osamu Ishikawa, Hiromitsu Takemori, Naruhiko Takasawa, Hitoshi Kobayashi, Yuichi Takahashi, Hidekata Yasuoka, Takao Kodera, Osamu Takai, Izaya Nakaya, Yukio Sato, Tomomasa Izumiyama, Hiroshi Fujii, Yukiko Kamogawa, Yuko Shirota, Tsuyoshi Shirai, Yoko Fujita, Shinichiro Saito, Shih-Wei Chiu, Takuhiro Yamaguchi, Hiroaki Shimokawa, Hideo Harigae

Modern rheumatology　2024/11/18

DOI： 10.1093/mr/roae104 　

More details Close

OBJECTIVES: Systemic sclerosis is characterised by ischaemic skin ulcers on the fingertips, and low-energy shock wave therapy is suggested as a novel treatment for ischaemic lesions with angiogenic effects. We aimed to investigate the efficacy and safety of shock wave therapy for skin ulcers in patients with systemic sclerosis. METHODS: In this phase 3 pivotal study, we analysed 60 systemic sclerosis patients with digital ulcers that did not disappear after >4 weeks of existing treatment: 30 patients were treated with extracorporeal shock wave therapy and 30 with conventional treatment. The ulcer count reduction observed after an 8-week treatment period was compared between the shock wave therapy and conventional treatment groups. RESULTS: After an 8-week treatment period, the mean reduction in the number of ulcers was 0.83 (standard deviation [SD] 2.79) in the conventional treatment group compared to a more pronounced reduction of 4.47 (SD 2.65) in the shock wave therapy group. CONCLUSIONS: The study findings indicate the efficacy of extracorporeal shock wave therapy for refractory digital ulcers associated with systemic sclerosis, which has limited therapeutic options. This therapy is non-invasive and safe and can be used without restriction in combination with other therapies, thus serving as a novel therapeutic method.
T細胞とミエロイド細胞の運命決定におけるGata2の役割

佐野沙矢香, 加藤浩貴, 古川瑛次郎, 燕艶, 道又大吾, 田中悠也, 櫻井一貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 藤原亨, 張替秀郎

日本血液学会学術集会　86回　O1-1　2024/10
Publisher: (一社)日本血液学会
造血幹前駆細胞におけるSAM合成によるDNAの安定化とp53経路抑制を介した恒常性の維持

古川瑛次郎, 加藤浩貴, 佐野沙矢香, 燕艶, 道又大吾, 田中裕也, 櫻井一貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 三枝大輔, 藤原亨, 五十嵐和彦, 張替秀郎

日本血液学会学術集会　86回　O1-4　2024/10
Publisher: (一社)日本血液学会
Targeting patient-specific vulnerabilities in anti-apoptotic pathway combined with CXCR4 expressing CAR-T cells eliminates high-risk leukemia(タイトル和訳中)

中川諒, 福原規子, 鈴木紅音, 小松弘香, 諸田直哉, 八田俊介, 神波圭太, 渡邊樹也, 木葉大地, 橋本和貴, 猪倉恭子, 小野寺晃一, 大西康, 張替秀郎

日本血液学会学術集会　86回　O1-6　2024/10
Publisher: (一社)日本血液学会
骨破壊を伴う巨大頭蓋腫瘍として発症した成人T細胞白血病/リンパ腫

諸田直哉, 市川聡, 安部宇明, 久保龍大, 中村嘉詞, 橋本和貴, 中川諒, 猪倉恭子, 小野寺晃一, 大西康, 福原規子, 張替秀郎

日本血液学会学術集会　86回　P1-9　2024/10
Publisher: (一社)日本血液学会
Targeting patient-specific vulnerabilities in anti-apoptotic pathway combined with CXCR4 expressing CAR-T cells eliminates high-risk leukemia(タイトル和訳中)

中川諒, 福原規子, 鈴木紅音, 小松弘香, 諸田直哉, 八田俊介, 神波圭太, 渡邊樹也, 木葉大地, 橋本和貴, 猪倉恭子, 小野寺晃一, 大西康, 張替秀郎

日本血液学会学術集会　86回　TGP-7　2024/10
Publisher: (一社)日本血液学会
t(8;14)(q24;q11.2)/TCR::MYCを伴った血管免疫芽球性T細胞リンパ腫

市川聡, 加藤浩貴, 諸田直哉, 安部宇明, 川尻昭寿, 猪倉恭子, 中川諒, 八田俊介, 小野寺晃一, 福原規子, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

日本血液学会学術集会　86回　P2-6　2024/10
Publisher: (一社)日本血液学会
Successful Cord Blood Transplantation for Myeloid/Natural Killer Precursor Acute Leukemia: A Case Report and Literature Review.

Satoshi Ichikawa, Hiroaki Abe, Hiroka Komatsu, Kenta Takenaka, Hiroshi Nakamura, Naoya Morota, Kazuki Sakurai, Akihisa Kawajiri, Ryo Nakagawa, Kyoko Inokura, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Hisayuki Yokoyama, Hideo Harigae

Internal medicine (Tokyo, Japan)　2024/09/27

DOI： 10.2169/internalmedicine.4221-24 　

More details Close

A 21-year-old man was diagnosed with myeloid/natural killer precursor leukemia (MNKPL) with bone marrow infiltration of blasts of cyCD3+, CD7+, CD33+, CD34dim, CD56+/-, HLA-DR+, cyMPO+, and TdT- immunophenotypes. Although hyper-CVAD therapy was unsuccessful, induction treatment with idarubicin and cytarabine resulted in complete remission (CR). The patient subsequently underwent cord blood transplantation with a myeloablative conditioning regimen, which resulted in durable CR and complete donor chimerism. He had been in good health without relapse for over nine months since transplantation. Timely allogeneic hematopoietic stem cell transplantation using an available donor source may be a promising treatment strategy for MNKPL.
Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma.

Tatsuo Oyake, Takahiro Maeta, Takenori Takahata, Yoshiko Tamai, Yoshihiro Kameoka, Naoto Takahashi, Yasuro Miyairi, Kazunori Murai, Kenji Shimosegawa, Kozue Yoshida, Kyoko Inokura, Noriko Fukuhara, Hideo Harigae, Ryo Sato, Kenichi Ishizawa, Katsushi Tajima, Souichi Saitou, Masahiko Fukatsu, Takayuki Ikezoe, Saburo Tsunoda, Masayuki Mita, Jinichi Mori, Shugo Kowata, Shigeki Ito

Journal of clinical and experimental hematopathology : JCEH　2024/07/31

DOI： 10.3960/jslrt.24021 　

More details Close

Immune checkpoint inhibitors (ICI) are promising therapeutic agents for relapsed or refractory classical Hodgkin's lymphoma (RRcHL). This retrospective study evaluated patients with RRcHL registered in the clinical research program Tohoku-Hematology-Forum-26, between 2016 and 2020, and treated with ICI in 14 centers in Northeast Japan. We analyzed the usage, efficacy, and safety of ICI therapy (ICIT). Among a total of 27 patients with RRcHL, 21 and nine were treated with nivolumab and/or pembrolizumab, respectively. The best response was complete response (CR), partial response (PR), stable disease (SD), and progressive disease in 11 (40.8%), seven (25.9%), eight (29.6%), and one (3.7%) patient, respectively. In all patients undergoing ICIT, the 2-year progression-free survival and 2-year overall survival (OS) were 48.6% and 87.4%, respectively. The 2-year OS for patients with CR, PR, and SD were 100%, 68.6%, and 87.5%, respectively. A total of 36 events of immune-related adverse events (irAEs) or immune-related like adverse events (irlAEs) were observed in 19 of the 27 patients (70.4%). Two thirds of these irAEs or irlAEs were grade 1-2 and controllable. During the observation period, ICIT was discontinued in 22 of 27 (81.4%) patients due to CR, inadequate response, irAE and patient circumstances in five (22.7%), seven (31.8%), eight (36.4%) and two patients (9.1%), respectively. Therapy-related mortality-associated irAE were observed in only one patient during ICIT. These results suggest that ICIT for RRcHL is effective and safe in real-world settings. The optimal timing of induction and duration of ICIT remains to be established.
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers. International-journal

Nobuko Matsushima, Sayori Shibata, Jocelyn H Leu, An Vermeulen, Jay Duffner, Leona E Ling, Lisa B Schwartz, Hideo Harigae

Clinical drug investigation　44　(8)　587-599　2024/07/29

DOI： 10.1007/s40261-024-01380-0 　

More details Close

BACKGROUND AND OBJECTIVES: Nipocalimab is a high-affinity, fully human, effectorless immunoglobulin G1 monoclonal antibody targeting the neonatal Fc receptor and is currently under evaluation for the treatment of rare and prevalent immunoglobulin G autoantibody-mediated and alloantibody-mediated diseases. This phase I, randomized, double-blind, placebo-controlled, single-dose escalation study in healthy Japanese volunteers (N = 24) assessed the safety, pharmacokinetics, and effect on the serum immunoglobulin G level of single doses of nipocalimab. METHODS: Volunteers were grouped into three cohorts and received intravenous nipocalimab at 10, 30, or 60 mg/kg or placebo. To complement the study, genetic variation in the Fcγ receptor and transporter subunit of the neonatal Fc receptor was analyzed in Japanese and diverse populations. RESULTS: Nipocalimab was generally safe and well tolerated at all dose levels, with three (12.5% [3/24]) volunteers experiencing treatment-emergent adverse events across all nipocalimab doses. Mean serum immunoglobulin G levels decreased in a dose-dependent manner from baseline with nipocalimab treatment compared with placebo. Maximum serum nipocalimab concentrations demonstrated proportional increases with dose, while the area under the concentration-time curve was dose dependent and demonstrated non-linear increases with dose. Mean observed half-life was longer as the dose increased. Analysis of genetic variation in Fcγ receptor and transporter identified no unique Japanese variants or variants that alter amino acid sequences in or near the neonatal Fc receptor immunoglobulin G binding site targeted by nipocalimab. CONCLUSIONS: The comparable pharmacokinetic/pharmacodynamic profiles and highly conserved neonatal Fc receptor structure among diverse populations further support the clinical development of nipocalimab for the treatment of various immunoglobulin G autoantibody-mediated and alloantibody-mediated diseases across global sites and populations, including the Japanese population.
当院における同種クリオプレシピテート適正使用への取り組み

細川真梨, 成田香魚子, 藤原実名美, 三浦歩, 黒崎友里衣, 伊藤智啓, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 岩木啓太, 関修, 張替秀郎

日本輸血細胞治療学会誌　70　(3)　466-466　2024/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. International-journal

Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A Riedell, P Joy Ho, José Antonio Pérez-Simón, Andy I Chen, Loretta J Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E M Patten, Joseph P McGuirk, Andreas L Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Ines Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O'Donovan, Roberto Ramos, Harald J Maier, Aisha Masood, Catherine Thieblemont, Stephen J Schuster

Blood　143　(17)　1713-1725　2024/04/25

DOI： 10.1182/blood.2023021567 　

More details Close

Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial reported high response rates and excellent safety profile in patients with extensively pretreated r/r FL. Here, we report longer-term efficacy, safety, pharmacokinetic, and exploratory biomarker analyses after median follow-up of 29 months (interquartile range, 22.2-37.7). As of 29 March 2022, 97 patients with r/r FL (grades 1-3A) received tisagenlecleucel infusion (0.6 × 108-6 × 108 chimeric antigen receptor-positive viable T cells). Bridging chemotherapy was allowed. Baseline clinical factors, tumor microenvironment, blood soluble factors, and circulating blood cells were correlated with clinical response. Cellular kinetics were assessed by quantitative polymerase chain reaction. Median progression-free survival (PFS), duration of response (DOR), and overall survival (OS) were not reached. Estimated 24-month PFS, DOR, and OS rates in all patients were 57.4% (95% confidence interval [CI], 46.2-67), 66.4% (95% CI, 54.3-76), and 87.7% (95% CI, 78.3-93.2), respectively. Complete response rate and overall response rate were 68.1% (95% CI, 57.7-77.3) and 86.2% (95% CI, 77.5-92.4), respectively. No new safety signals or treatment-related deaths were reported. Low levels of tumor-infiltrating LAG3+CD3+ exhausted T cells and higher baseline levels of naïve CD8+ T cells were associated with improved outcomes. Tisagenlecleucel continued to demonstrate highly durable efficacy and a favorable safety profile in this extended follow-up of 29 months in patients with r/r FL enrolled in ELARA. This trial was registered at www.clinicaltrials.gov as #NCT03568461.
高強度化学療法の適応を有する再発・難治急性骨髄性白血病患者に対するアザシチジン+ベネトクラクス併用療法による救援療法

中村嘉詞, 小野寺晃一, 安部宇明, 久保龍大, 諸田直哉, 橋本和貴, 中川諒, 猪倉恭子, 市川聡, 福原規子, 大西康, 張替秀郎

臨床血液　65　(4)　284-285　2024/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
自己末梢血幹細胞の動員は良好であったが実際の採取細胞数が予測を大幅に下回った悪性リンパ腫の一例

関修, 細川真梨, 石岡夏子, 黒崎友里衣, 伊藤智啓, 郷野辰幸, 阿部真知子, 佐藤裕子, 成田香魚子, 岩木啓太, 柴田浩明, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　70　(2)　301-301　2024/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
多発髄外腫瘤を伴ったIgH::MYC陽性多発性骨髄腫

佐々木勇杜, 市川聡, 櫻井一貴, 中村嘉詞, 猪倉恭子, 小野寺晃一, 福原規子, 大西康, 横山寿行, 張替秀郎

臨床血液　65　(3)　147-152　2024/03
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Diffuse large B-cell lymphoma of the skull vault.

Satoshi Ichikawa, Hisayuki Yokoyama, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

International journal of hematology　119　(3)　215-216　2024/03

DOI： 10.1007/s12185-024-03717-z 　
A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19. International-journal

Toyohiro Hirai, Koichiro Asano, Isao Ito, Yasunari Miyazaki, Hisatoshi Sugiura, Mehmet Agirbasli, Seiichi Kobayashi, Makoto Kobayashi, Daishi Shimada, Ichiro Natsume, Tsutomu Kawasaki, Takehiko Ohba, Sakurako Tajiri, Fumio Sakamaki, Masamichi Mineshita, Takahisa Takihara, Kiyoshi Sekiya, Keisuke Tomii, Hiromi Tomioka, Hideo Kita, Yasuo Nishizaka, Motonari Fukui, Toshio Miyata, Hideo Harigae

Scientific reports　14　(1)　165-165　2024/01/02

DOI： 10.1038/s41598-023-50445-1 　

More details Close

An inhibitor of plasminogen activator inhibitor (PAI)-1, TM5614, inhibited thrombosis, inflammation, and fibrosis in several experimental mouse models. To evaluate the efficacy and safety of TM5614 in human COVID-19 pneumonia, phase IIa and IIb trials were conducted. In an open-label, single-arm trial, 26 Japanese COVID-19 patients with mild to moderate pneumonia were treated with 120-180 mg of TM5614 daily, and all were discharged without any notable side effects. Then, a randomized, double-blind, placebo-controlled trial was conducted in Japanese COVID-19 patients with mild to moderate pneumonia. The number of study participants was set to be 50 in each arm. Even after extension of the enrollment period, the number of study participants did not reach the initially intended sample size, and 75 patients were enrolled in the study. The total oxygenation scale from Day 1 to Day 14 as the primary endpoint was 1.5 in the TM5614 group vs 4.0 in the placebo group (p = 0.22), and the number of days of oxygen administration required as the secondary endpoint was 2.0 days in the TM5614 group vs 3.5 days in the placebo group (p = 0.34). Further studies will be necessary to verify the efficacy of PAI-1 inhibition for the treatment of COVID-19 pneumonia.Clinical trial registration: Two studies were conducted: a prospective, multicenter, open-label phase II study at https://jrct.niph.go.jp (jRCT2021200018) (First registration date 18/08/2020) and a prospective, multicenter, randomized, double-blind, placebo-controlled, phase II study at https://jrct.niph.go.jp (jRCT2021210006) (First registration date 28/05/2021).
Successful Allogeneic Hematopoietic Stem Cell Transplantation for Nodal Epstein-Barr Virus-positive T/NK-cell Lymphoma

Satoshi Ichikawa, Hiroaki Abe, Naoya Morota, Akihisa Kawajiri, Ryo Nakagawa, Kyoko Inokura, Shunsuke Hatta, Yuna Katsuoka, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Internal Medicine　2024
Publisher: Japanese Society of Internal Medicine
DOI： 10.2169/internalmedicine.4672-24 　

ISSN： 0918-2918

eISSN： 1349-7235
[Academia-Industry Alliance: Recent Trend].

Atsuhiro Nakagawa, Leor Perl, John Lee, Narumi Harada-Shoji, Chiharu Ota, Takuya Shiga, Sako Sunami, Kuniyasu Niizuma, Hidenori Endo, Hideo Harigae, Teiji Tominaga

No shinkei geka. Neurological surgery　52　(1)　213-225　2024/01

DOI： 10.11477/mf.1436204899 　

More details Close

Industry-academia Collaboration is an academic activity within academia(educational institutions such as universities, research institutes, etc.)formed to research and develop new technologies, create new businesses and knowledge, and recruit outsourcing human resources. There is a collaboration between an industry(a private company, a group that engages in broad commercial activities and links research and development directly to economic activity)and academia. Amidst the dramatic changes in the environment surrounding the goals of research and development of new technologies and the creation of new businesses, there are changes in what academia can do complementarily. We will outline the changes and current situation, including the efforts of the Tohoku University Hospital.
[Multiple myeloma with IgH::MYC and multiple extramedullary lesions].

Yuto Sasaki, Satoshi Ichikawa, Kazuki Sakurai, Hiroshi Nakamura, Kyoko Inokura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Hideo Harigae

[Rinsho ketsueki] The Japanese journal of clinical hematology　65　(3)　147-152　2024

DOI： 10.11406/rinketsu.65.147 　

More details Close

A 41-year-old woman with right shoulder pain was found to have multiple tumors with osteolysis and M-proteinemia. Abnormal plasma cells (CD38+, CD138+, Igλ≫κ) were detected in 1.4% of bone marrow nucleated cells, and G-banding analysis revealed a 46,XX,t (8;14), (q24;q32) karyotype in 4 of 20 cells analyzed. A biopsy specimen from an extramedullary lesion had a packed proliferation of aberrant plasmacytoid cells with positive IgH::MYC fusion signals on fluorescence in situ hybridization. The patient was diagnosed with symptomatic multiple myeloma and treated with the BLd regimen, which significantly reduced M protein levels. Extramedullary lesions were initially reduced, but increased again after four cycles. The lesions disappeared with subsequent EPOCH chemotherapy and radiation, and complete remission was confirmed. The patient was then treated with high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Complete remission was maintained for over one year with lenalidomide maintenance therapy. A solitary IgH::MYC chromosomal translocation is extremely rare in multiple myeloma and may be associated with high tumor proliferative capacity, multiple extramedullary lesions, and poor prognosis. Combined therapeutic modalities with novel and conventional chemotherapy and radiation might be a promising treatment strategy for patients with this type of multiple myeloma.
Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine. International-journal

Jun Nomura, Masafumi Seki, Syori Abe, Tadahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Shinichiro Takahashi, Hideo Harigae, Junichi Kameoka

Human vaccines & immunotherapeutics　19　(1)　2165381-2165381　2023/12/31

DOI： 10.1080/21645515.2023.2165381 　

More details Close

Herein, we report the case of a 22-year-old woman with hereditary spherocytosis (HS) whose condition worsened after administration of the coronavirus disease 2019 (COVID-19), mRNA vaccine 'BNT162b2 Pfizer-BioNTech.' The woman had been diagnosed with HS in 2005, and her condition remained stable until February 2021. In March 2021, she received the first dose of the above vaccine and experienced pain at the injection site. After the second dose in April 2021, she developed fever and general malaise. Investigations revealed progression of hemolysis, which improved after a few days. To the best of our knowledge, this is the first report of progression of hemolysis in a patient with HS after administration of the mRNA vaccine COVID-19, BNT162b2 'Pfizer-BioNTech.'
ABO異型臍帯血移植後に血液型検査において予期せぬ反応を呈した1例

関修, 伊藤智啓, 黒崎友里衣, 保坂優奈, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 成田香魚子, 岩木啓太, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　69　(6)　684-684　2023/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Phospholipase D4 as a signature of toll-like receptor 7 or 9 signaling is expressed on blastic T-bet + B cells in systemic lupus erythematosus. International-journal

Ken Yasaka, Tomohide Yamazaki, Hiroko Sato, Tsuyoshi Shirai, Minkwon Cho, Koji Ishida, Koyu Ito, Tetsuhiro Tanaka, Kouetsu Ogasawara, Hideo Harigae, Tomonori Ishii, Hiroshi Fujii

Arthritis research & therapy　25　(1)　200-200　2023/10/16

DOI： 10.1186/s13075-023-03186-5 　

More details Close

BACKGROUND: In systemic lupus erythematosus (SLE), autoreactive B cells are thought to develop by-passing immune checkpoints and contribute to its pathogenesis. Toll-like receptor (TLR) 7 and 9 signaling have been implicated in their development and differentiation. Although some B cell subpopulations such as T-bet + double negative 2 (DN2) cells have been identified as autoreactive in the past few years, because the upregulated surface markers of those cells are not exclusive to them, it is still challenging to specifically target autoreactive B cells in SLE patients. METHODS: Our preliminary expression analysis revealed that phospholipase D4 (PLD4) is exclusively expressed in plasmacytoid dendritic cells (pDCs) and B cells in peripheral blood mononuclear cells (PBMCs) samples. Monoclonal antibodies against human PLD4 were generated, and flow cytometry analyses were conducted for PBMCs from 23 healthy donors (HDs) and 40 patients with SLE. In vitro cell culture was also performed to study the conditions that induce PLD4 in B cells from HDs. Finally, recombinant antibodies were synthesized from subpopulations of PLD4 + B cells from a patient with SLE, and their antinuclear activity was measured through enzyme-linked immunosorbent assay. RESULTS: pDCs from both groups showed comparable frequency of surface PLD4 expression. PLD4 + B cells accounted for only a few percent of HD B cells, whereas they were significantly expanded in patients with SLE (2.1% ± 0.4% vs. 10.8% ± 1.2%, P < 0.005). A subpopulation within PLD4 + B cells whose cell size was comparable to CD38 + CD43 + plasmablasts was defined as "PLD4 + blasts," and their frequencies were significantly correlated with those of plasmablasts (P < 0.005). PLD4 + blasts phenotypically overlapped with double negative 2 (DN2) cells, and, in line with this, their frequencies were significantly correlated with several clinical markers of SLE. In vitro assay using healthy PBMCs demonstrated that TLR7 or TLR9 stimulation was sufficient to induce PLD4 on the surface of the B cells. Finally, two out of three recombinant antibodies synthesized from PLD4 + blasts showed antinuclear activity. CONCLUSION: PLD4 + B cells, especially "blastic" ones, are likely autoreactive B cells undergoing TLR stimulation. Therefore, PLD4 is a promising target marker in SLE treatment.
臍帯血移植後の深在性真菌感染症抗糸状菌活性を有する抗真菌薬の有効性

橋本和貴, 大西康, 福原規子, 横山寿行, 市川聡, 小野寺晃一, 猪倉恭子, 川尻昭寿, 中村嘉詞, 櫻井一貴, 諸田直哉, 久保龍大, 安倍宇明, 張替秀朗

日本血液学会学術集会　85回　72-72　2023/10
Publisher: (一社)日本血液学会
進行胃癌に対するニボルマブ投与後に発症した後天性血小板減少性紫斑病の一例

渡邉樹也, 小野寺晃一, 鳴海善洋, 橋本和貴, 内堀雄介, 小松弘香, 竹中健人, 中村嘉詞, 櫻井一貴, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会　85回　192-192　2023/10
Publisher: (一社)日本血液学会
同種移植前微小残存病変がNPM1変異陽性急性骨髄性白血病の移植予後に及ぼす影響

横山寿行, 鈴木千恵, 真山晃史, 小松弘香, 竹中健太, 鳴海善洋, 渡邉樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 大西康, 藤巻慎一, 張替秀郎

日本血液学会学術集会　85回　203-203　2023/10
Publisher: (一社)日本血液学会
初発時限局病変として発症し治療後に再発した節外性NK/T細胞リンパ腫の予後

鳴海善洋, 市川聡, 福原則子, 小野寺晃一, 大西康, 横山寿行, 一迫玲, 張替秀郎

日本血液学会学術集会　85回　293-293　2023/10
Publisher: (一社)日本血液学会
当院における再発難治性の濾胞性リンパ腫に対するCAR-T療法の後方視的検討

内堀雄介, 福原規子, 小松弘香, 竹中健太, 鳴海善洋, 渡邉樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会　85回　412-412　2023/10
Publisher: (一社)日本血液学会
正常造血及び白血病におけるヘム合成の役割

燕艶, 加藤浩貴, 佐野沙矢香, 古川瑛次郎, 藤原亨, 大西康, 福原規子, 横山寿行, 張替秀郎

日本血液学会学術集会　85回　934-934　2023/10
Publisher: (一社)日本血液学会
AML with RNUX1::RUNX1T1における血縁者間HLA一致同種移植と非血縁臍帯血移植成績の比較

櫻井一貴, 横山寿行, 小松弘香, 鳴海善洋, 竹中健太, 渡邉樹也, 中村嘉詞, 橋本和貴, 内堀雄介, 猪倉恭子, 市川聡, 小野寺晃一, 福原規子, 大西康, 齋藤慧, 八田俊介, 勝岡優奈, 斎藤陽, 鎌田真弓, 原崎頼子, 遠宮靖雄, 和泉透, 佐々木治, 張替秀郎

日本血液学会学術集会　85回　1247-1247　2023/10
Publisher: (一社)日本血液学会
ICC基準により分類したMDSの移植成績

小野寺晃一, 安部宇明, 久保龍大, 諸田直哉, 中村嘉詞, 橋本和貴, 川尻昭寿, 猪倉恭子, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

日本血液学会学術集会　85回　1252-1252　2023/10
Publisher: (一社)日本血液学会
症候性貧血(ACD)の原因、検査学的特徴およびアウトカム

亀岡淳一, 小林匡洋, 沖津庸子, 野村順, 阿部正理, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 藤原実名美, 高橋伸一郎, 張替秀郎

日本血液学会学術集会　85回　1453-1453　2023/10
Publisher: (一社)日本血液学会
EBV関連節性細胞障害性T細胞リンパ腫は極めてアグレッシブな臨床経過を辿る

市川聡, 福原規子, 横山寿行, 八田俊介, 沖津庸子, 小野寺晃一, 大西康, 一迫玲, 張替秀郎

日本血液学会学術集会　85回　1472-1472　2023/10
Publisher: (一社)日本血液学会
Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP.

Yusuke Uchibori, Koichi Onodera, Yasushi Onishi, Hiroka Komatsu, Kenta Takenaka, Yoshihiro Narumi, Tatsuya Watanabe, Hiroshi Nakamura, Kazuki Sakurai, Kazuki Hashimoto, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Hideo Harigae

The Tohoku journal of experimental medicine　261　(2)　123-127　2023/08/10

DOI： 10.1620/tjem.2023.J063 　

More details Close

The presence of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) against anti-HLA-A, -B, -C, and -DRB1 in HLA-mismatched hematopoietic stem cell transplantation (HSCT) is associated with graft failure. DSAs against HLA-A, -B, -C, and -DRB1 with a mean fluorescence intensity (MFI) of greater than > 1,000 was shown to increase the risk of graft failure in single-unit umbilical cord blood transplantation (UCBT). Nevertheless, the impact of DSAs against HLA-DP or -DQ on transplantation outcomes is not fully understood. In this report, we present a case of UCBT in a patient with myelodysplastic syndrome who was positive for DSAs against HLA-DP with MFI of 1,263 before UCBT but successfully achieved neutrophil engraftment. If HLA-DP or -DQ is mismatched in UCBT, evaluating DSAs against HLA-DP or -DQ is crucial to avoid graft failure. However, the criteria for DSAs against HLA-A, -B, -C, and -DRB1 may not be directly applicable to those against HLA-DP or -DQ.
赤血球製剤期限延長に向けた院内在庫の使用実態の解析

阿部真知子, 岩木啓太, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　69　(3)　493-494　2023/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
自己リンパ球採取中の赤血球輸血により採取効率が改善した3例

藤原実名美, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 阿部真知子, 石岡夏子, 佐藤裕子, 関修, 成田香魚子, 張替秀郎

日本輸血細胞治療学会誌　69　(3)　494-495　2023/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Blood Culture Result Profile in Patients With Central Line-Associated Bloodstream Infection (CLABSI): A Single-Center Experience. International-journal

Tetsuya Akaishi, Koichi Tokuda, Makoto Katsumi, Shin-Ichi Fujimaki, Tetsuji Aoyagi, Hideo Harigae, Tadashi Ishii

Cureus　15　(6)　e40202　2023/06

DOI： 10.7759/cureus.40202 　

More details Close

Background Central line-associated bloodstream infection (CLABSI) is among the most common bloodstream infections in the university hospital and intensive care unit settings. This study evaluated the routine blood test findings and microbe profiles of bloodstream infection (BSI) by the presence and types of central vein (CV) access devices (CVADs). Methods A total of 878 inpatients at a university hospital who were clinically suspected for BSI and underwent blood culture (BC) testing between April 2020 and September 2020 were enrolled. Data regarding age at BC testing, sex, WBC count, serum C-reactive protein (CRP) level, BC test results, yielded microbes, and usage and types of CVADs were evaluated. Results The BC yields were detected in 173 patients (20%), suspected contaminating pathogens in 57 (6.5%), and 648 (74%) with a negative yield. The WBC count (p=0.0882) and CRP level (p=0.2753) did not significantly differ between the 173 patients with BSI and the 648 patients with negative BC yields. Among the 173 patients with BSI, 74 used CVADs and met the diagnosis of CLABSI; 48 had a CV catheter, 16 had CV access ports, and 10 had a peripherally inserted central catheter (PICC). Patients with CLABSI showed lower WBC counts (p=0.0082) and serum CRP levels (p=0.0024) compared to those with BSI who did not use CVADs. The most commonly yielded microbes in those with CV catheters, CV-ports, and PICC were Staphylococcus epidermidis (n=9; 19%), Staphylococcus aureus (n=6; 38%), and S. epidermidis (n=8; 80%), respectively. Among those with BSI who did not use CVADs, Escherichia coli (n=31; 31%) was the most common pathogen, followed by S. aureus (n=13; 13%). Conclusion Patients with CLABSI showed lower WBC counts and CRP levels than those with BSI who did not use CVADs. Staphylococcus epidermidis was among the most common microbes in CLABSI and accounted for the majority of yielded microbes in patients who used PICC.
Severe Bone Marrow Aplasia Following Macrophage Activation Syndrome in Systemic Lupus Erythematosus.

Hirona Ichimura, Satoshi Ichikawa, Koya Ono, Kyoko Inokura, Yosuke Hoshi, Tsuyoshi Shirai, Noriko Fukuhara, Hisayuki Yokoyama, Hiroshi Fujii, Hideo Harigae

The Tohoku journal of experimental medicine　260　(4)　301-304　2023/05/11

DOI： 10.1620/tjem.2023.J037 　

More details Close

Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases, characterized by activated macrophages with hemophagocytosis and multiple organ damage. We report a case of MAS associated with systemic lupus erythematosus that initially presented with severe liver dysfunction. Although it was improved with steroids and plasmapheresis, severe pancytopenia was subsequently experienced, and the bone marrow showed severe aplasia similar to aplastic anemia. Nevertheless, the administration of immunosuppressants resulted in the recovery of blood counts within two weeks. When severe MAS results in cytokine overproduction, bone marrow aplasia may occur, for which immunosuppressive therapy may be highly effective.
Hepatic niche leads to aggressive natural killer cell leukemia proliferation through transferrin-transferrin receptor 1 axis International-journal

Kazuaki Kameda, Ryo Yanagiya, Yuji Miyatake, Joaquim Carreras, Hiroshi Higuchi, Hiromichi Murayama, Takashi Ishida, Asahi Ito, Shinsuke Iida, Noriko Fukuhara, Hideo Harigae, Yuki Fujioka, Naoto Takahashi, Hidenori Wada, Fumihiro Ishida, Hideyuki Nakazawa, Rei Ishihara, Yuki Murakami, Hiroyuki Tagawa, Tadashi Matsuura, So Nakagawa, Sadahiro Iwabuchi, Shinichi Hashimoto, Ken-Ichi Imadome, Naoya Nakamura, Kenichi Ishizawa, Yoshinobu Kanda, Kiyoshi Ando, Ai Kotani

Blood Journal　142　(4)　352-364　2023/05/05
Publisher: American Society of Hematology
DOI： 10.1182/blood.2022018597 　

ISSN： 0006-4971

eISSN： 1528-0020

More details Close

Aggressive natural killer cell leukemia (ANKL) is a rare lymphoid neoplasm frequently associated with Epstein-Barr virus, with a disastrously poor prognosis. Owing to the lack of samples from patients with ANKL and relevant murine models, comprehensive investigation of its pathogenesis including the tumor microenvironment (TME) has been hindered. Here we established three ANKL-patient-derived xenograft mice (PDXs), which enabled extensive analysis of tumor cells and their TME. ANKL cells primarily engrafted and proliferated in the hepatic sinusoid. Hepatic ANKL cells were characterized by an enriched Myc-pathway and proliferated faster than those in other organs. Interactome analyses and in vivo CRISPR-Cas9 analyses revealed transferrin (Tf)-transferrin receptor 1 (TfR1) axis as a potential molecular interaction between the liver and ANKL. ANKL cells were rather vulnerable to iron deprivation. PPMX-T003, a humanized anti-TfR1 monoclonal antibody, showed remarkable therapeutic efficacy in a preclinical setting using ANKL-PDXs. These findings indicate that the liver, a non-canonical hematopoietic organ in adults, serves as a principal niche for ANKL, and that inhibition of the Tf-TfR1 axis is a promising therapeutic strategy for ANKL.
骨髄異形成症候群に対する同種造血幹細胞移植後に発症したノカルジア症の1例

竹中健太, 市川聡, 横山寿行, 小松弘香, 鳴海善洋, 渡邊樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, 福原規子, 大西康, 張替秀郎

臨床血液　64　(5)　432-432　2023/05
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
抗BIの特異性を示す抗体を検出し赤血球輸血を行った1症例

岩木啓太, 細川真梨, 伊藤智啓, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　69　(2)　358-358　2023/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL

Yasushi Onishi, Eijiro Furukawa, Mayumi Kamata, Masahiko Fukatsu, Yoshihiro Kameoka, Shunsuke Hatta, Hiroyuki Hamada, Tatsuo Oyake, Tatsuyuki Kai, Masumi Sukegawa, Shinji Nakajima, Ryo Yanagiya, Kohei Yamaguchi, Taro Takahashi, Yoriko Harazaki, Toru Izumi, Kazunori Murai, Shigeki Ito, Takayuki Ikezoe, Kenichi Ishizawa, Naoto Takahashi, Hideo Harigae

International Journal of Hematology　117　(5)　738-747　2023/02/09

DOI： 10.1007/s12185-023-03546-6 　

More details Close

Early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) is generally considered to be a high-risk subtype. We retrospectively analyzed the clinical outcomes of adult patients diagnosed with ETP-ALL or other T-cell ALL (non-ETP T-ALL). The subjects were 82 patients (ETP-ALL: n = 18, non-ETP T-ALL: n = 64) for whom relevant immunophenotype data needed for classification were available. ETP-ALL patients were older (median age, 50.5 vs. 33.5 years, P = 0.042) and had less mediastinal involvement (27.8 vs. 73.4%, P < 0.001). The rate of complete remission (CR) with the first induction therapy was significantly lower in the ETP group (33.3 vs. 64.0%, P = 0.03), but the CR rate within 2 cycles of chemotherapy did not differ significantly (61.1 vs. 76.6%, P = 0.232). The 3-year overall survival (OS) rate was also similar in both groups (43.2 vs. 45.8%, P = 0.992). The ETP phenotype had no impact on survival in the transplant group or the non-transplant group. A multivariate analysis identified the male sex as a poor prognostic factor (HR: 4.43, P < 0.01), but not the immunophenotype of ETP. The prognosis for adult patients with ETP-ALL was comparable to that of non-ETP T-ALL patients. However, further studies aimed at improving the remission rate for ETP-ALL are needed.
Shirai T, Toyohara T, Hashimoto H, Sato H, Fujii H, Ishii T, Harigae H.

Coexistence of IgA nephropathy, renal artery stenosis in, Takayasu arteritis, case repor, literature review

Rheumatol Int.　43　(2)　391-398　2023/02
Acute Adverse Events at a Mass Vaccination Site after the 3rd and 4th COVID-19 Vaccinations in Japan.

Tetsuya Akaishi, Tamotsu Onodera, Tatsuya Takahashi, Hideo Harigae, Tadashi Ishii

The Tohoku journal of experimental medicine　259　(4)　263-271　2023/01/13

DOI： 10.1620/tjem.2023.J002 　

More details Close

The third and fourth doses of the vaccine against coronavirus disease 2019 (COVID-19) were widely administered in Japan since December 2021. Currently, however, data are scarce regarding acute adverse events with the third and fourth doses. The present study reports the profiles of acute adverse events after the third and fourth COVID-19 vaccine doses, seen at the site of a mass vaccination center in Japan. Between December 2021 and July 2022, 267,515 individuals received the third, and 32,934 received the fourth COVID-19 vaccine dose at the mass vaccination center, of whom 442 recipients of the third (0.19%), and 22 recipients of the fourth (0.07%) dose reported acute adverse events and were examined by doctors on site. The most common diagnosis was vasovagal syncope/presyncope (incidence: 0.01-0.10%), followed by other miscellaneous complaints, acute allergic reactions (0.05-0.005%), and anaphylaxis (< 0.005%). Vasovagal syncope/presyncope occurred most frequently in recipients in those in their 20s, whereas acute allergic reactions were most frequent in those in their 40s. Both reactions were more frequent in women than men. The peak occurrence of vasovagal syncope/presyncope was earlier than 15 min after the injection, whereas that of acute allergic reaction was later than 15 min after the injection. The incidence of acute allergic reactions appeared to differ between various vaccine manufacturers, whereas that of vasovagal syncope/presyncope did not. These real-world data may benefit the safe and efficient implementation of mass vaccination campaigns for citizens who want to receive COVID-19 vaccines now and in the future.
Heme-dependent induction of mitophagy program during differentiation of murine erythroid cells. International-journal

Masatoshi Ikeda, Hiroki Kato, Hiroki Shima, Mitsuyo Matsumoto, Eijiro Furukawa, Yan Yan, Ruiqi Liao, Jian Xu, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Emery H Bresnick, Kazuhiko Igarashi

Experimental hematology　118　21-30　2022/12/05

DOI： 10.1016/j.exphem.2022.11.007 　

More details Close

Although establishment and maintenance of mitochondria are essential for the production of massive amounts of heme in erythroblasts, mitochondria must be degraded upon terminal differentiation to red blood cells (RBCs), thus creating a biphasic regulatory process. Previously, we reported that iron deficiency in mice promotes mitochondrial retention in RBCs, suggesting that a proper amount of iron and/or heme is necessary for the degradation of mitochondria during erythroblast maturation. Because the transcription factor GATA1 regulates autophagy in erythroid cells, which involves mitochondrial clearance (mitophagy), we investigated the relationship between iron or heme and mitophagy by analyzing the expression of genes related to GATA1 and autophagy and the impact of iron or heme restriction on the amount of mitochondria. We found that heme promotes the expression of GATA1-regulated mitophagy-related genes and the induction of mitophagy. GATA1 might induce the expression of the autophagy-related genes Atg4d and Stk11 for mitophagy through a heme-dependent mechanism in murine erythroleukemia (MEL) cells and a genetic rescue system with G1E-ER-GATA1 erythroblast cells derived from Gata1-null murine embryonic stem cells. These results provide evidence for a biphasic mechanism in which mitochondria are essential for heme generation, and the heme generated during differentiation promotes mitophagy and mitochondrial disposal. This mechanism provides a molecular framework for understanding this fundamentally important cell biological process.
ABO血液型不適合生体肝移植後にPassenger Lymphocyte Syndromeを発症した1例

伊藤智啓, 岩木啓太, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 菅原新吾, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　68　(6)　573-573　2022/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.

Noriko Fukuhara, Koji Kato, Hideki Goto, Tajima Takeshi, Mayu Kawaguchi, Kota Tokushige, Koichi Akashi, Takanori Teshima, Hideo Harigae, Stephen J Schuster, Catherine Thieblemont, Martin Dreyling, Nathan Fowler

International journal of hematology　117　(2)　251-259　2022/11/21

DOI： 10.1007/s12185-022-03481-y 　

More details Close

BACKGROUND: Tisagenlecleucel yielded a high durable response rate in patients with relapsed/refractory (r/r) follicular lymphoma (FL) in the global phase 2 ELARA trial. Here, we report the efficacy, safety, and cellular kinetics of tisagenlecleucel in a subgroup of Japanese patients with r/r FL from ELARA. METHODS: ELARA (NCT03568461) is a global single-arm trial of tisagenlecleucel in patients with r/r FL who received ≥ 2 prior lines of therapy. The primary endpoint was the complete response rate (CRR), and the secondary endpoints were the overall response rate, duration of response, progression-free survival, overall survival, safety, and cellular kinetics. RESULTS: As of March 29, 2021, nine Japanese patients were enrolled and received tisagenlecleucel with a median follow-up of 13.6 months (range, 10.5‒19.3). Per independent review committee, CRR was 100% (95% CI 63.1‒100). Within 8 weeks of infusion, cytokine release syndrome (CRS) of any grade was reported in 6 patients (66.7%); however, no grade ≥ 3 CRS or any grade serious neurological events or treatment-related deaths were observed. CONCLUSION: Tisagenlecleucel showed high efficacy and manageable safety in adult Japanese patients with r/r FL. Moreover, the clinical outcomes were similar to the global population, which supports the potential of tisagenlecleucel in Japanese patients with r/r FL.
Elucidation of the Role of FAM210B in Mitochondrial Metabolism and Erythropoiesis. International-journal

Chie Suzuki, Tohru Fujiwara, Hiroki Shima, Koya Ono, Kei Saito, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

Molecular and cellular biology　42　(12)　e0014322　2022/11/14

DOI： 10.1128/mcb.00143-22 　

More details Close

Mitochondria play essential and specific roles during erythroid differentiation. Recently, FAM210B, encoding a mitochondrial inner membrane protein, has been identified as a novel target of GATA-1, as well as an erythropoietin-inducible gene. While FAM210B protein is involved in regulate mitochondrial metabolism and heme biosynthesis, its detailed function remains unknown. Here, we generated both knockout and knockdown of endogenous FAM210B in human induced pluripotent stem-derived erythroid progenitor (HiDEP) cells using CRISPR/Cas9 methodology. Intriguingly, erythroid differentiation was more pronounced in the FAM210B-depleted cells, and this resulted in increased frequency of orthochromatic erythroblasts and decreased frequencies of basophilic/polychromatic erythroblasts. Comprehensive metabolite analysis and functional analysis indicated that oxygen consumption rates and the NAD (NAD+)/NADH ratio were significantly decreased, while lactate production was significantly increased in FAM210B deletion HiDEP cells, indicating involvement of FAM210B in mitochondrial energy metabolism in erythroblasts. Finally, we purified FAM210B-interacting protein from K562 cells that stably expressed His/biotin-tagged FAM210B. Mass spectrometry analysis of the His/biotin-purified material indicated interactions with multiple subunits of mitochondrial ATP synthases, such as subunit alpha (ATP5A) and beta (ATP5B). Our results suggested that FAM210B contributes prominently to erythroid differentiation by regulating mitochondrial energy metabolism. Our results provide insights into the pathophysiology of dysregulated hematopoiesis.
著明な血小板減少を伴った血管免疫芽球性T細胞リンパ腫の1例

渡邉樹也, 市川聡, 鳴海善洋, 中村嘉詞, 櫻井一貴, 猪倉恭子, 小松弘香, 竹中健太, 橋本和貴, 内堀雄介, 小野寺晃一, 福原規子, 大西康, 横山寿行, 一迫玲, 張替秀郎

臨床血液　63　(11)　1588-1588　2022/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
高感度デジタルPCR法を用いて中枢神経再発を診断し得たMYD88 L265P変異陽性B細胞性リンパ腫の1例

小松弘香, 小野寺晃一, 竹中健太, 橋本和貴, 内堀雄介, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

臨床血液　63　(11)　1589-1589　2022/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Sjögren's Syndrome Presenting with Temporary Hemiplegia Mimicking Transient Ischemic Attack.

Yukiko Kamogawa, Kanae Akita, Hiroko Sato, Tsuyoshi Shirai, Tomonori Ishii, Hideo Harigae, Hiroshi Fujii

The Tohoku journal of experimental medicine　258　(3)　207-211　2022/10/26

DOI： 10.1620/tjem.2022.J079 　

More details Close

Sjögren's syndrome manifests with a wide variety of neurologic symptoms. This case report presents a 53-year-old woman with Sjögren's syndrome associated with temporal hemiplegia, which was suspected to be a transient ischemic attack. After induction of immunosuppressive therapies [high-dose prednisolone (1 mg/kg/day) and intravenous cyclophosphamide (total 5 g)], the hemiplegia did not reappear and the blood flow abnormalities remarkably improved as depicted on electroencephalography and single photon emission computed tomography. This case suggests that temporal hemiplegia presenting with transient ischemia-like attack symptoms may be a neurologic manifestation of Sjögren's syndrome and responsive to immunosuppressive therapy.
造血器腫瘍遺伝子パネル検査の有用性について

真山晃史, 鈴木千恵, 藤巻慎一, 藤原亨, 横山寿行, 張替秀郎

日本染色体遺伝子検査学会雑誌　40　(2)　46-46　2022/10
Publisher: 日本染色体遺伝子検査学会
ISSN： 1884-3026
Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. International-journal

Naoto Takahashi, Yoshihiro Kameoka, Makoto Onizuka, Yasushi Onishi, Fumiaki Takahashi, Takashi Dan, Toshio Miyata, Kiyoshi Ando, Hideo Harigae

Cancer medicine　12　(4)　4250-4258　2022/09/23

DOI： 10.1002/cam4.5292 　

More details Close

BACKGROUND: We recently showed that pharmacological inhibition of plasminogen activator inhibitor-1 (PAI-1) activity, based on TM5614, increases cell motility and induces the detachment of hematopoietic stem cells from their niches. In this TM5614 phase II clinical trial, we investigated whether the combination of a PAI-1 inhibitor and tyrosine kinase inhibitors (TKIs) would induce a deep molecular response (DMR) in patients affected by chronic myeloid leukemia (CML) by quantifying BCR-ABL1 transcripts. METHODS: Patients with chronic phase CML treated with a stable daily dose of TKIs for at least 1 year and yielding a major molecular response (MMR) but not achieving MR4.5 were eligible for this study. After inclusion, patients began to receive TM5614 as well as a TKI. The primary objective was an evaluation of the cumulative incidence of patient progression from an MMR/MR4 to MR4.5 by 12 months. RESULTS: Thirty-three patients were enrolled in the study. The median age was 59.0 years and 58% were male. No Sokal high-risk patients were enrolled in this trial. The median TKI treatment duration was 4.8 years. At the start of this study, seven patients and 26 patients received imatinib and second-generation TKIs, respectively. The cumulative MR4.5 incidence by 12 months was 33.3% (95% confidence interval, 18.0%-51.8%). The cumulative MR4.5 spontaneous conversion over 12 months was estimated as 8% with TKIs alone based on historical controls. The halving time of BCR-ABL1 at 2 months was significantly shorter for patients who achieved an MR4.5 , by 12 months than for the other patients (cutoff value: 48 days; sensitivity: 0.80; specificity: 0.91; ROC-AUC: 0.83). During this study, bleeding events and abnormal coagulation related to the drug were not reported, and TM5614 was found to be highly safe. CONCLUSION: TM5614 combined with TKI was well tolerated and induced MR4.5 in more patients than stand-alone TKI treatment.
Reports of acute adverse events in mRNA COVID-19 vaccine recipients after the first and second doses in Japan. International-journal

Tetsuya Akaishi, Tamotsu Onodera, Tatsuya Takahashi, Hideo Harigae, Tadashi Ishii

Scientific reports　12　(1)　15510-15510　2022/09/15

DOI： 10.1038/s41598-022-19936-5 　

More details Close

Mass vaccination against coronavirus disease 2019 (COVID-19) is ongoing in many countries worldwide. This study reports the occurrence of acute adverse events among vaccine recipients at a mass vaccination center in Japan. Between August and November 2021, approximately 130,000 individuals received two mRNA vaccine doses (mRNA-1273; Moderna) at the vaccination center. Acute adverse events at the site were observed in 1.1% of the recipients after the first dose and in 0.4% of the recipients after the second dose. The most common event was vasovagal syncope/presyncope, followed by acute allergic reactions. The occurrence rate of vasovagal syncope/presyncope was highest in the young population of those aged 16-29 years, but such age-dependency was not apparent in acute allergic reactions. Both symptoms were more prevalent in women than in men. Vasovagal syncope/presyncope occurred mainly within 20 min of the injection, whereas nearly half of the episodes of acute allergic reactions occurred after 20 min. The vaccine being injected while the recipient was in the supine position effectively reduced the occurrence of vasovagal syncope/presyncope. In summary, the suggested risk factors for vasovagal syncope/presyncope included a young age and female sex. The vaccine being injected while the recipient was in the supine position would reduce the risk of vasovagal syncope/presyncope.
Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia. International-journal

Kei Saito, Satoshi Ichikawa, Rina Ohtomo, Shunsuke Hatta, Yuna Katsuoka, Hideo Harigae, Tohru Izumi

Annals of hematology　101　(9)　2103-2105　2022/09

DOI： 10.1007/s00277-022-04875-y 　
Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. International-journal

Tetsuro Ochi, Tohru Fujiwara, Koya Ono, Chie Suzuki, Maika Nikaido, Daichi Inoue, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

Scientific reports　12　(1)　14562-14562　2022/08/26

DOI： 10.1038/s41598-022-18921-2 　

More details Close

Acquired sideroblastic anemia, characterized by bone marrow ring sideroblasts (RS), is predominantly associated with myelodysplastic syndrome (MDS). Although somatic mutations in splicing factor 3b subunit 1 (SF3B1), which is involved in the RNA splicing machinery, are frequently found in MDS-RS, the detailed mechanism contributing to RS formation is unknown. To explore the mechanism, we established human umbilical cord blood-derived erythroid progenitor-2 (HUDEP-2) cells stably expressing SF3B1K700E. SF3B1K700E expressing cells showed higher proportion of RS than the control cells along with erythroid differentiation, indicating the direct contribution of mutant SF3B1 expression in erythroblasts to RS formation. In SF3B1K700E expressing cells, ABCB7 and ALAS2, known causative genes for congenital sideroblastic anemia, were downregulated. Additionally, mis-splicing of ABCB7 was observed in SF3B1K700E expressing cells. ABCB7-knockdown HUDEP-2 cells revealed an increased frequency of RS formation along with erythroid differentiation, demonstrating the direct molecular link between ABCB7 defects and RS formation. ALAS2 protein levels were obviously decreased in ABCB7-knockdown cells, indicating decreased ALAS2 translation owing to impaired Fe-S cluster export by ABCB7 defects. Finally, RNA-seq analysis of MDS clinical samples demonstrated decreased expression of ABCB7 by the SF3B1 mutation. Our findings contribute to the elucidation of the complex mechanisms of RS formation in MDS-RS.
今月の症例自己免疫性膵炎に対するステロイド維持療法中にIgG4関連下垂体炎を発症した1例

大黒顕佑, 尾股慧, 手塚雄太, 小野美澄, 森本玲, 白井剛志, 宮崎真理子, 張替秀郎, 佐藤文俊

日本内科学会雑誌　111　(8)　1588-1593　2022/08
Publisher: (一社)日本内科学会
ISSN： 0021-5384

eISSN： 1883-2083
The path from stem cells to red blood cells.

Hideo Harigae

International journal of hematology　116　(2)　160-162　2022/08

DOI： 10.1007/s12185-022-03413-w 　

More details Close

As oxygen is essential for energy production in mitochondria, a sufficient amount of oxygen should be continuously delivered to the tissues to maintain life. Therefore, the number of red blood cells which carry the oxygen is considerable, at up to 25 trillion in the body, and 2 million new red blood cells are generated per second.
Myeloid immune checkpoint ILT3/LILRB4/gp49B can co-tether fibronectin with integrin on macrophages. International-journal

So Itoi, Naoyuki Takahashi, Haruka Saito, Yusuke Miyata, Mei-Tzu Su, Dai Kezuka, Fumika Itagaki, Shota Endo, Hiroshi Fujii, Hideo Harigae, Yuzuru Sakamoto, Toshiyuki Takai

International immunology　34　(8)　435-444　2022/07/26

DOI： 10.1093/intimm/dxac023 　

More details Close

LILRB4 (B4, also known as ILT3/CD85k) is an immune checkpoint of myeloid lineage cells, albeit its mode of function remains obscure. Our recent identification of a common ligand for both human B4 and its murine ortholog gp49B as the fibronectin (FN) N-terminal 30 kDa domain poses the question of how B4/gp49B regulate cellular activity upon recognition of FN in the plasma and/or the extracellular matrix. Since FN in the extracellular matrix is tethered by FN-binding integrins, we hypothesized that B4/gp49B would tether FN in cooperation with integrins on the cell surface, thus they should be in close vicinity to integrins spatially. This scenario suggests a mode of function of B4/gp49B by which the FN-induced signal is regulated. The FN pull-down complex was found to contain gp49B and integrin β 1 in bone marrow-derived macrophages. The confocal fluorescent signals of the three molecules on the intrinsically FN-tethering macrophages were correlated to each other. When FN-poor macrophages adhered to culture plates, the gp49-integrin β 1 signal correlation increased at the focal adhesion, supporting the notion that gp49B and integrin β 1 become spatially closer to each other there. Adherence of RAW264.7 and THP-1 cells to immobilized FN induced phosphorylation of spleen tyrosine kinase, whose level was augmented under B4/gp49B deficiency. Thus, we concluded that B4/gp49B can co-tether FN in cooperation with integrin in the cis configuration on the same cell, forming a B4/gp49B-FN-integrin triplet as a regulatory unit of a focal adhesion-dependent pro-inflammatory signal in macrophages.
Diffuse Large B-cell Lymphoma Presenting as Peritoneal Lymphomatosis: A Case Report and Literature Review.

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Internal medicine (Tokyo, Japan)　61　(13)　2057-2060　2022/07/01

DOI： 10.2169/internalmedicine.8793-21 　

More details Close

Peritoneal lymphomatosis (PL) is a rare presentation of malignant lymphoma cases, many of which are diagnosed as diffuse large B-cell lymphoma (DLBCL) and characterized by aggressive clinical courses. We herein report a 63-year-old woman presenting with the rapid development of abdominal distention due to bulky peritoneal tumors. The pathological evaluation of a needle biopsy sample, combined with flow cytometry, yielded the diagnosis of DLBCL. Prompt chemotherapeutic intervention resulted in favorable disease control and sustained complete remission. It is necessary to diagnose cases of DLBCL presenting as PL early to ensure prompt treatment and prevent mortality.
Association of various myositis-specific autoantibodies with dermatomyositis and polymyositis triggered by pregnancy. International-journal

Chikaho Akiyama, Tsuyoshi Shirai, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

Rheumatology international　42　(7)　1271-1280　2022/07

DOI： 10.1007/s00296-021-04851-1 　

More details Close

Although pregnancy is an important risk factor for autoimmune rheumatic diseases, little is known regarding the association between pregnancy and dermatomyositis (DM) or polymyositis (PM). Herein, we present two patients with DM that developed during the perinatal period. The first patient was positive for anti-aminoacyl synthetase (ARS) antibody and developed DM in the 14th week of pregnancy. Despite treatment, her foetus died of intrauterine growth restriction in the 27th week. The second patient was positive for anti-melanoma differentiation-associated gene 5 (MDA-5) antibody and developed DM 1 week after miscarriage at 9 weeks of gestation. The patient developed severe interstitial pneumonia, and intensive therapy including tofacitinib and rituximab administration was required. Our cases and a literature review revealed that various myositis-specific autoantibodies, including anti-ARS, anti-Mi-2, anti-TIF-1γ, and anti-MDA-5, are associated with DM and PM triggered by pregnancy. We also found that delay in commencing treatment in case of active disease including myositis and interstitial pneumonia, and poor response to corticosteroids were related to poor foetal outcomes in DM and PM. Although rare in pregnant women, it is critical to consider the possibility of DM and PM in patients presenting with rash, fever, weakness, and cough, and testing for myositis-specific autoantibodies is recommended.
TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia.

Katsuyuki Sasaki, Tohru Fujiwara, Tetsuro Ochi, Koya Ono, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Toshio Miyata, Hideo Harigae

The Tohoku journal of experimental medicine　257　(3)　211-224　2022/06/25

DOI： 10.1620/tjem.2022.J036 　

More details Close

Chronic myeloid leukemia (CML) is triggered by t(9;22)(q34;q11.2) translocation, leading to the formation of the BCR-ABL1 fusion gene. Although the development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has dramatically improved the prognosis of CML, the disease could often relapse, presumably because leukemic stem cell fraction of CML (CML-LSC) may reside in specific niches, and also acquire an ability to resist the cytotoxic agents. Recently a study indicated that pharmacological inhibition of plasminogen activator inhibitor-1 (PAI-1, also known as SERPINE1) would cause detachment of CML-LSCs from their niche by inducing maturation of membrane-type matrix metalloprotease-1 (MT1-MMP), leading to increased susceptibility of CML-LSCs against TKIs. However, the direct antitumor effect of PAI-1 inhibition in CML remains unclear. Because PAI-1 mRNA expression was lower in CML cell line (K562) than bone marrow mononuclear cells derived from CML patients, we established K562 cell clones stably expressing exogenous PAI-1 (K562/PAI-1). We found that TM5614 treatment significantly suppressed cell proliferation and induced apoptosis in K562/PAI-1 cells, accompanied by increased activity of Furin protease, which is a known target of PAI-1. Besides processing mature MT1-MMP, Furin is in charge of cleaving the NOTCH receptor to form a heterodimer before exporting it to the cell surface membrane. In K562/PAI-1 cells, TM5614 treatment increased NOTCH1 intracellular domain (NICD) protein expression as well as NOTCH1 target of HEY1 mRNA levels. Finally, forced expression of either Furin or NICD in K562/PAI-1 cells significantly inhibited cell proliferation and induced apoptosis. Collectively, PAI-1 inhibition may have an antitumor effect by modulating the Furin/NICD pathway.
Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.

Masahiro Miyazaki, Satoshi Ichikawa, Yasushi Onishi, Noriko Fukuhara, Eijiro Furukawa, Koichi Onodera, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Journal of clinical and experimental hematopathology : JCEH　62　(3)　164-168　2022/06/22

DOI： 10.3960/jslrt.22003 　

More details Close

ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) has a favorable prognosis in general; however, some cases are resistant to chemotherapy, which leads to a poor clinical outcome. We herein report the case of a 32-year-old male with aggressive ALK+ ALCL who presented with hemorrhage from a large tumor in the duodenum and multiple tumors in the lungs, mediastinum, and peritoneal cavity. Although induction chemotherapy resulted in a marked reduction of the tumor lesions, premature progression with massive pulmonary infiltration and central nervous system invasion occurred immediately after the completion of chemotherapy. The patient was then promptly treated with brentuximab vedotin (BV) and high-dose methotrexate, which resulted in complete remission. Subsequently, he successfully underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an unrelated donor and has been healthy and did not relapse for more than 3 years after transplantation without any additional therapy. Allo-HSCT may be a promising treatment option for ALK+ ALCL due to its graft-versus-lymphoma effect. In addition, molecular targeting agents, such as BV, may be promising as a bridging therapy before allo-HSCT to achieve disease remission.
輸血用血液製剤からの移行抗体によりHBV感染が疑われた1例

岩木啓太, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　68　(3)　461-461　2022/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Development of severe colitis in Takayasu arteritis treated with tocilizumab. International-journal

Kae Ishii, Tsuyoshi Shirai, Yoichi Kakuta, Tomoaki Machiyama, Hiroko Sato, Tomonori Ishii, Hideo Harigae, Hiroshi Fujii

Clinical rheumatology　41　(6)　1911-1918　2022/06

DOI： 10.1007/s10067-022-06108-z 　

More details Close

Relapse of Takayasu arteritis (TAK) is frequent, and the use of biologics is required in refractory cases. Tocilizumab (TCZ), a biological agent used in TAK, is known to increase the incidence of diverticulitis in patients with rheumatoid arthritis. Adverse events of TCZ in TAK have been poorly recognised. This study aimed to investigate the occurrence of severe colitis among patients with TAK receiving TCZ. We enrolled 116 patients with TAK who met the criteria of the American College of Rheumatology and visited our department between 2018 and 2020. The occurrence of severe colitis and its clinical characteristics were retrospectively evaluated. TCZ was introduced in 34 of 116 patients (29.3%). Severe colitis that required hospitalisation was observed in three of the 34 patients receiving TCZ (8.8%). All patients were female and had Numano type V artery lesions, and the ascending colon was commonly affected. Wide lesions that reached the sigmoid colon, colonic perforation, bacteraemia, or positive stool cultures were observed in some patients. All patients received antibiotics and intestinal rest, and TCZ was resumed in one patient. IL-6 plays a physiological role in the intestine, including recovery from ischaemic damage. In addition to infectious aetiology, blocking the physiological roles of IL-6 by TCZ is considered important for the development of colitis in TAK. Severe colitis is an important adverse event in patients with TAK who receive TCZ. The risk of bloodstream infection associated with colitis should be recognised, especially in patients who have undergone vascular surgery. Key Points • Severe colitis was observed in 8.8% of patients with TAK receiving tocilizumab • Patients had type V artery lesions and ascending colon involvement and were under long-term use of corticosteroids • Inhibition of the physiological roles of IL-6 in the intestinal tract might also be involved.
Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.

Yasushi Onishi, Koichi Onodera, Noriko Fukuhara, Hiroki Kato, Satoshi Ichikawa, Tohru Fujiwara, Hisayuki Yokoyama, Minami Yamada-Fujiwara, Hideo Harigae

International journal of hematology　115　(6)　873-881　2022/06

DOI： 10.1007/s12185-022-03313-z 　

More details Close

Adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders (EBV-T/NK-LPDs) often progress rapidly, and require allogeneic stem cell transplantation early in the course of treatment. Unrelated cord blood transplantation (UCBT) is a readily available option for patients without HLA-matched donors. We retrospectively analyzed the outcomes of 12 UCBT in adult patients with chronic active EBV infection (CAEBV, n = 8), EBV-positive hemophagocytic lymphohistiocytosis following primary EBV infection (n = 2), hydroa vacciniforme-like lymphoproliferative disorder (n = 1), and systemic EBV-positive T-cell lymphoma of childhood (STCLC, n = 1). The median age at transplantation was 31.5 years (range 19-58). At the median follow-up time for survivors, which was 6.3 years (range 0.3-11.3), 3-year overall survival (OS) rates in all patients and 8 CAEBV patients were 68.2% (95% CI 28.6-88.9) and 83.3% (95% CI 27.3-97.5), respectively. Graft failure occurred in 4 of 8 CAEBV patients, requiring a second UCBT to achieve neutrophil engraftment. The cumulative incidence of grade II-IV acute GVHD was 33.3% (95% CI 9.1-60.4%). The EBV-DNA load became undetectable or very low after UCBT in all cases. UCBT may be a promising treatment option for adult-onset EBV-T/NK-LPDs.
Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosis. International-journal

Koya Ono, Tohru Fujiwara, Kei Saito, Hironari Nishizawa, Noriyuki Takahashi, Chie Suzuki, Tetsuro Ochi, Hiroki Kato, Yusho Ishii, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Rie Yamada, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

Scientific reports　12　(1)　9024-9024　2022/05/30

DOI： 10.1038/s41598-022-12940-9 　

More details Close

X-linked sideroblastic anemia (XLSA), the most common form of congenital sideroblastic anemia, is caused by a germline mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. In XLSA, defective heme biosynthesis leads to ring sideroblast formation because of excess mitochondrial iron accumulation. In this study, we introduced ALAS2 missense mutations on human umbilical cord blood-derived erythroblasts; hereafter, we refer to them as XLSA clones. XLSA clones that differentiated into mature erythroblasts showed an increased frequency of ring sideroblast formation with impaired hemoglobin biosynthesis. The expression profiling revealed significant enrichment of genes involved in ferroptosis, which is a form of regulated cell death induced by iron accumulation and lipid peroxidation. Notably, treatment with erastin, a ferroptosis inducer, caused a higher proportion of cell death in XLSA clones. XLSA clones exhibited significantly higher levels of intracellular lipid peroxides and enhanced expression of BACH1, a regulator of iron metabolism and potential accelerator of ferroptosis. In XLSA clones, BACH1 repressed genes involved in iron metabolism and glutathione synthesis. Collectively, defective heme biosynthesis in XLSA clones could confer enhanced BACH1 expression, leading to increased susceptibility to ferroptosis. The results of our study provide important information for the development of novel therapeutic targets for XLSA.
Dental care using an oral appliance to support hematopoietic stem cell transplantation for NK/T cell lymphoma, nasal type, with palatal perforation.

Hanako Suenaga, Masahiro Iikubo, Toru Tamahara, Mina Dodo, Chris Peck, Takeyoshi Koseki, Hideo Harigae, Keiichi Sasaki

Journal of prosthodontic research　66　(2)　353-356　2022/04/27

DOI： 10.2186/jpr.JPR_D_20_00270 　

More details Close

PATIENT: A 33-year-old man diagnosed with extranodal natural killer cell/T-cell lymphoma, nasal type (ENKTCL-NT) inducing palatal perforation was referred to the perioperative oral care support center of Tohoku University Hospital for dental care to support cancer treatment including chemotherapy and hematopoietic stem cell transplantation (HSCT). Dental review during chemotherapy revealed mucositis suspected to be caused by mucosal trauma from altered jaw function (chewing and speech) due to palatal perforation. Although the patient was already in the cleanroom, an oral appliance as well as conservative care as recommended in oral management guidelines for HSCT were used to prevent worsening of oral mucositis at subsequent HSCT including High-dose chemotherapy and total body irradiation. After HSCT, a prosthodontist fitted a palatal obturator made by a dental technician and an oral surgeon reviewed the necrotic bone and removed the sequestra according to the changes in the palate. This approach involving a multidisciplinary team including a hematologist improved the impaired oral function and minimized oral complications . DISCUSSION: ENKTCL-NT and its treatment have a significant impact on patients' oral status. Hence, it is important to provide customized dental care based on previously endorsed guidelines according to the type of disease, treatment requirements, and oral and systemic status. CONCLUSIONS: This report indicated the importance of dental care with a customized plan before, during, and after HSCT for ENKTCL-NT with multidisciplinary supportive care for cancer patients to improve the impaired oral function and to minimize oral complications.
周術期管理にメチロシンを用いた褐色細胞腫の3症例

関由美加, 手塚雄太, 尾股慧, 小野美澄, 森本玲, 宮城重人, 伊藤明宏, 山内正憲, 張替秀郎, 宮崎真理子, 佐藤文俊

日本内分泌学会雑誌　98　(1)　300-300　2022/04
Publisher: (一社)日本内分泌学会
ISSN： 0029-0661

eISSN： 2186-506X
敗血症スクリーニングにおけるMonocyte distribution width(MDW)測定の評価

佐々木麻美, 病院, 検査部, 佐々木克幸, 菅原新吾, 鈴木千恵, 藤巻慎一, 藤原亨, 張替秀郎

日本臨床検査医学会誌(2436-2727)　70　(4)　301-306　2022/04
血圧降下剤α-メチルドパの輸血関連検査に対する影響の後方視的解析

岩木啓太, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　68　(2)　285-285　2022/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
心臓血管外科手術血液準備量設定における診療科との協力体制について

成田香魚子, 藤原実名美, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 張替秀郎

日本輸血細胞治療学会誌　68　(2)　290-290　2022/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
東北大学病院における血液製剤廃棄削減活動の取り組み

関修, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 阿部真知子, 石岡夏子, 佐藤裕子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　68　(2)　351-351　2022/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination. International-journal

Kei Saito, Satoshi Ichikawa, Shunsuke Hatta, Yuna Katsuoka, Hideo Harigae, Tohru Izumi

Annals of hematology　101　(4)　885-887　2022/04

DOI： 10.1007/s00277-021-04666-x 　
T-cell receptor-silent peripheral T-cell lymphoma complicated with hemophagocytic lymphohystiocytosis. International-journal

Koya Ono, Yasushi Onishi, Koichi Onodera, Daigo Michimata, Eijiro Furukawa, Kazuki Sakurai, Naoya Morota, Takumi Sawada, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Hirofumi Watanabe, Chie Suzuki, Hideo Harigae

Annals of hematology　101　(4)　901-903　2022/04

DOI： 10.1007/s00277-021-04628-3 　
Picture in Clinical Hematology(No.149)

63　(3)　169　2022/03
Hypertrophic Pachymeningitis Development in Eosinophilic Granulomatosis with Polyangiitis at Relapse of Disease: A Case-Based Review.

Machi Kiyohara, Tsuyoshi Shirai, Shuhei Nishiyama, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

The Tohoku journal of experimental medicine　256　(3)　241-247　2022/03

DOI： 10.1620/tjem.256.241 　

More details Close

Hypertrophic pachymeningitis (HP) presents with thickening of the dura mater in the cerebrum and spine, and its symptoms vary depending on the affected location. The association of HP with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been recognized, and most cases are complicated by granulomatosis with polyangiitis. We report the case of a 47-year-old man who presented with HP upon relapse of eosinophilic granulomatosis with polyangiitis (EGPA), with literature review. He presented with disturbance of consciousness, and magnetic resonance imaging (MRI) revealed thickening of the dura mater around the left parietal lobe. Although myeloperoxidase (MPO)-ANCA was positive on EGPA diagnosis, the elevation of MPO-ANCA was not documented at the onset of HP. Brain perfusion scintigraphy showed an increase in blood flow in the left parietal lobe and temporal lobe, and electroencephalogram (EEG) revealed slow waves in the left parietal lobe. He was treated with a high dose of corticosteroid and rituximab, and the slow waves on EEG and brain perfusion were normalized. Although the most frequent symptom of HP is headache, disturbance of consciousness can be the manifestation of HP, and inflammation of HP could affect the cerebral parenchyma, which can be documented as abnormal EEG and perfusion scintigraphy. Literature review revealed that most of the HP in EGPA developed when EGPA relapsed, and was observed in patients with MPO-ANCA positivity. HP develops without evidence of other clinical features of EGPA; therefore, adequate imaging, including contrast-enhanced MRI, is necessary. Rituximab may be effective for treating HP complicated with EGPA.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. International-journal

Michael R Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian Flinn, Werner Rabitsch, Yok-Lam Kwong, Marie J Kersten, Monique C Minnema, Harald Holte, Esther H L Chan, Joaquin Martinez-Lopez, Antonia M S Müller, Richard T Maziarz, Joseph P McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David Bond, Charalambos Andreadis, Peter McSweeney, Mohamed Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher Del Corral, Giovanna Andreola, Aisha Masood, Stephen J Schuster, Ulrich Jäger, Peter Borchmann, Jason R Westin

The New England journal of medicine　386　(7)　629-639　2022/02/17

DOI： 10.1056/NEJMoa2116596 　

More details Close

BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines. METHODS: We conducted an international phase 3 trial involving patients with aggressive lymphoma that was refractory to or progressing within 12 months after first-line therapy. Patients were randomly assigned to receive tisagenlecleucel with optional bridging therapy (tisagenlecleucel group) or salvage chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT) (standard-care group). The primary end point was event-free survival, defined as the time from randomization to stable or progressive disease at or after the week 12 assessment or death. Crossover to receive tisagenlecleucel was allowed if a defined event occurred at or after the week 12 assessment. Other end points included response and safety. RESULTS: A total of 322 patients underwent randomization. At baseline, the percentage of patients with high-grade lymphomas was higher in the tisagenlecleucel group than in the standard-care group (24.1% vs. 16.9%), as was the percentage with an International Prognostic Index score (range, 0 to 5, with higher scores indicating a worse prognosis) of 2 or higher (65.4% vs. 57.5%). A total of 95.7% of the patients in the tisagenlecleucel group received tisagenlecleucel; 32.5% of the patients in the standard-care group received autologous HSCT. The median time from leukapheresis to tisagenlecleucel infusion was 52 days. A total of 25.9% of the patients in the tisagenlecleucel group had lymphoma progression at week 6, as compared with 13.8% of those in the standard-care group. The median event-free survival in both groups was 3.0 months (hazard ratio for event or death in the tisagenlecleucel group, 1.07; 95% confidence interval, 0.82 to 1.40; P = 0.61). A response occurred in 46.3% of the patients in the tisagenlecleucel group and in 42.5% in the standard-care group. Ten patients in the tisagenlecleucel group and 13 in the standard-care group died from adverse events. CONCLUSIONS: Tisagenlecleucel was not superior to standard salvage therapy in this trial. Additional studies are needed to assess which patients may obtain the most benefit from each approach. (Funded by Novartis; BELINDA ClinicalTrials.gov number, NCT03570892.).
アルドステロン新測定系の検証

小野美澄, 尾股慧, 手塚雄太, 森本玲, 宮崎真理子, 張替秀郎, 佐藤文俊

日本内科学会雑誌　111　(臨増)　171-171　2022/02
Publisher: (一社)日本内科学会
ISSN： 0021-5384

eISSN： 1883-2083
Focus On 鉄剤不応の鉄欠乏性貧血

藤原亨, 張替秀郎

内科　129　(2)　300-303　2022/02
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. International-journal

Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A Riedell, P Joy Ho, José Antonio Pérez-Simón, Andy I Chen, Loretta J Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E M Patten, Joseph P McGuirk, Andreas L Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J Schuster, Catherine Thieblemont

Nature medicine　28　(2)　325-332　2022/02

DOI： 10.1038/s41591-021-01622-0 　

More details Close

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r follicular lymphoma (FL), 71% of patients achieved a complete response (CR). Here we report the primary, prespecified interim analysis of the ELARA phase 2 multinational trial of tisagenlecleucel in adults with r/r FL after two or more treatment lines or who relapsed after autologous stem cell transplant (no. NCT03568461). The primary endpoint was CR rate (CRR). Secondary endpoints included overall response rate (ORR), duration of response, progression-free survival, overall survival, pharmacokinetics and safety. As of 29 March 2021, 97/98 enrolled patients received tisagenlecleucel (median follow-up, 16.59 months; interquartile range, 13.8-20.21). The primary endpoint was met. In the efficacy set (n = 94), CRR was 69.1% (95% confidence interval, 58.8-78.3) and ORR 86.2% (95% confidence interval, 77.5-92.4). Within 8 weeks of infusion, rates of cytokine release syndrome were 48.5% (grade ≥3, 0%), neurological events 37.1% (grade ≥3, 3%) and immune effector cell-associated neurotoxicity syndrome (ICANS) 4.1% (grade ≥3, 1%) in the safety set (n = 97), with no treatment-related deaths. Tisagenlecleucel is safe and effective in extensively pretreated r/r FL, including in high-risk patients.
"Coexistence of IgA nephropathy and renal artery stenosis in Takayasu arteritis: case report and literature review". International-journal

Nono Ito, Tsuyoshi Shirai, Takafumi Toyohara, Hideaki Hashimoto, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

Rheumatology international　43　(2)　391-398　2022/01/11

DOI： 10.1007/s00296-021-05066-0 　

More details Close

Although Takayasu arteritis (TAK) is a form of large vessel vasculitis, complications of glomerulonephritis have occasionally been observed, with mesangial proliferative glomerulonephritis as the most common. The aim of this work was to present a case-based review regarding the association of glomerulonephritis and IgA nephropathy (IgAN) with TAK. A literature search was carried out using the PubMed and Scopus databases for articles published in English, and the Ichu-shi Web for Japanese. A 34-year-old Japanese man was evaluated for proteinuria, and IgAN was diagnosed by renal biopsy. Simultaneously, aortic wall thickening and right renal artery stenosis confirmed a coexisting TAK. Prednisolone and methotrexate improved both diseases, and percutaneous transluminal renal angioplasty resulted in right renal artery reopening. Our case and literature review revealed that membranous proliferative glomerulonephritis and IgAN are common in eastern Asia, while focal segmental glomerulosclerosis and mesangial proliferative glomerulonephritis are common in other regions. The incidence of IgAN is higher in TAK cases and is mostly reported in Asia. Abdominal aortic involvement and renal artery stenosis are common in cases with preceding TAK. IgAN could be related to the cytokine network involving interleukin-6, suggesting the usefulness of tocilizumab in patients with TAK accompanied by IgAN. The type of glomerulonephritis complicated with TAK differs among regions, and patients with TAK are more likely to experience IgAN than the healthy population.
巨細胞性動脈炎に対するトシリズマブ導入後にサルモネラ敗血症を来した1例

星陽介, 成田衛, 丹野唯人, 秋田佳奈恵, 佐藤紘子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会北海道・東北支部学術集会抄録集　31回　54-54　2022/01
Publisher: (一社)日本リウマチ学会-北海道・東北支部
エタネルセプト開始後に抗MDA5抗体陽性皮膚筋炎を発症した関節リウマチの一例

岡崎創司, 白井剛志, 高橋幹弘, 石井悠翔, 秋田佳奈恵, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会北海道・東北支部学術集会抄録集　31回　45-45　2022/01
Publisher: (一社)日本リウマチ学会-北海道・東北支部
Aleukemic T-lymphoblastic leukemia/lymphoma with massive cerebrospinal fluid infiltration

Ichikawa, S., Fukuhara, N., Doman, T., Kiba, D., Tanaka, Y., Inokura, K., Morota, N., Ono, K., Onodera, K., Onishi, Y., Yokoyama, H., Ichinohasama, R., Harigae, H.

Journal of Hematopathology　15　(2)　105-109　2022

DOI： 10.1007/s12308-022-00495-7 　

ISSN： 1865-5785 1868-9256

eISSN： 1865-5785
Anaplastic multiple myeloma with MYC rearrangement. International-journal

Satoshi Ichikawa, Noriko Fukuhara, Ko Hashimoto, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

Leukemia research reports　17　100288-100288　2022

DOI： 10.1016/j.lrr.2021.100288 　

More details Close

A 52-year-old man with rapidly progressive paraplegia was presented to us with paravertebral tumors. Laminectomy with tumor resection was performed, and pathological analysis of the tumor revealed compact proliferation of anaplastic plasmacytoid cells. G-band analysis of the tumor revealed a complex karyotype, including IgH/MYC translocation. The patient was diagnosed with anaplastic multiple myeloma (AMM) with MYC arrangement, and cytotoxic chemotherapy followed by autologous hematopoietic stem cell transplantation resulted in long-term disease-free remission. This is the first report describing a case of de novo AMM with MYC rearrangement, suggesting that conventional chemotherapy could be a treatment option for this formidable disease.
Utility of a new notation to visualize flow cytometry analysis results: first preliminary comparison with immunohistochemistry to detect CD30 expression on T-cell lymphoma cells. International-journal

Fumiyoshi Fujishima, Noriko Fukuhara, Hiroki Katsushima, Yasuhiro Nakamura, Hideo Harigae, Hironobu Sasano, Ryo Ichinohasama

BMC cancer　21　(1)　1352-1352　2021/12/20

DOI： 10.1186/s12885-021-09098-4 　

More details Close

BACKGROUND: It is important to confirm CD30 expression in T-cell lymphoma cases, but immunohistochemical staining for CD30 is not commonly performed and no comparison has been done between the results of flow cytometry (FCM) and immunohistochemical staining for CD30. Therefore, we devised a notation that we termed proportion of immunoreactivity/expression for FCM (PRIME-F notation), based on the cellular proportion showing different antigen-antibody reactivity. METHODS: We retrospectively compiled 211 cases of T-cell lymphoma, assessed via FCM, from major hospitals in Miyagi Prefecture from January 2012 to January 2019, and compared 52 of these cases with the immunohistochemical immunoreactive (IR) pattern of CD30 (PRIME-I notation). The PRIME-F notation was divided into five levels: notations starting with "-" followed by 3, 2, and 1 ">" correspond to level-I, level-II, or level-III; notations starting with "(dim)+" correspond to level-IV; and those starting with "+" or "(bright)+" correspond to level-V. RESULTS: The 52 cases of PRIME-F notation with "+" included 16 cases of peripheral T-cell lymphoma (PTCL/NOS), 3 of follicular T-cell lymphoma (FTL), 3 of angioimmunoblastic T-cell lymphoma (AITL), 6 of extranodal NK/T-cell lymphoma/nasal type (ENKL), 18 of adult T-cell lymphoma (ATL), and 6 cases of anaplastic large cell lymphoma (ALCL). Eight of the 52 cases were immunohistochemically CD30-negative. In the PRIME-F level-I to III group (excluding false-positive cases), 21.7% (5 out of 23 cases) were < 10% positive for CD30 upon immunohistochemistry (IHC). Contrarily, in the level-IV & -V group, no CD30 positivity rate of < 10% upon IHC was found (0%) (p = 0.0497). In level-IV, 42.9% of cases presented a CD30 negative rate > 1/3 upon IHC, while in level-V, only 7.1% (one out of 14 cases) did. The CD30 negative rate tended to be low (p = 0.0877) in level-V. CONCLUSIONS: To our knowledge, this is the first report describing the correspondence between FCM and immunohistochemistry findings for CD30 through newly proposed notations. The PRIME-F and PRIME-I notations for CD30 showed a minor positive correlation. The PRIME notation is considered universally applicable to antibodies, and notations of both FCM and IHC show great potential for big data.
【2020年代の内科診療-26テーマの近未来予想】血液内科赤血球系疾患鉄欠乏性貧血,腎性貧血,骨髄異形成症候群に対する新たな治療薬

藤原亨, 張替秀郎

内科(0022-1961)　128　(6)　1197-1200　2021/12
micro BCR-ABL1を認めた慢性骨髄性白血病の一例

鈴木千恵, 菅原新吾, 佐々木麻美, 藤原亨, 平泉敦子, 藤巻慎一, 張替秀郎

日本臨床検査医学会誌(2436-2727)　69　(12)　919-922　2021/12
東北大学病院における血液製剤廃棄削減活動の取り組み

関修, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 阿部真知子, 石岡夏子, 佐藤裕子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　67　(6)　628-628　2021/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
The feasible maintenance dose of corticosteroid in Takayasu arteritis in the era of biologic therapy

T Shirai, H Sato, H Fujii, T Ishii, H Harigae

Scand J Rheumatol.　50　(6)　462-468　2021/11
特殊染色を極める-正しい手法・評価とピットフォールペルオキシダーゼ染色

菅原新吾, 佐藤亜耶, 藤巻慎一, 藤原亨, 張替秀郎

日本検査血液学会雑誌(1347-2836)　22　(3)　425-433　2021/11
Sustained remission of giant pancreatic plasmacytoma with daratumumab. International-journal

Satoshi Ichikawa, Eijiro Furukawa, Kei Saito, Noriko Fukuhara, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Annals of hematology　100　(10)　2633-2634　2021/10

DOI： 10.1007/s00277-020-04145-9 　
Salvage Cord Blood Transplantation for Sustained Remission of Acute Megakaryoblastic Leukemia That Relapsed Early after Myeloablative Transplantation.

Satoshi Ichikawa, Tohru Fujiwara, Kei Saito, Kazuki Sakurai, Kyoko Inokura, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Junichi Kameoka, Hideo Harigae

Internal medicine (Tokyo, Japan)　60　(18)　3015-3019　2021/09/15

DOI： 10.2169/internalmedicine.6796-20 　

More details Close

Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia accompanied by an aggressive clinical course and dismal prognosis. We herein report a case of AMKL preceded by mediastinal germ cell tumor that relapsed early after allogeneic hematopoietic stem cell transplantation with myeloablative conditioning but was successfully treated using salvage cord blood transplantation (CBT) with reduced-intensity conditioning. Although several serious complications developed, sustained remission with a favorable general condition was ultimately achieved. Although an optimal therapeutic strategy remains to be established, the graft-versus-leukemia effect of CBT may be promising, even for the treatment of refractory AMKL.
2回目のSARS-CoV-2 mRNAワクチン接種後に溶血が進行した遺伝性球状赤血球症(HS)の1例

野村順, 関雅文, 阿部正理, 小林匡洋, 沖津庸子, 福原規子, 高橋伸一郎, 張替秀郎, 亀岡淳一

臨床血液　62　(9)　1415-1415　2021/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
幹細胞から赤血球への通り道メチオニン代謝によるエピゲノム調節をかいした赤血球造血制御(Methionine metabolism controls erythropoiesis by epigenetic regulation)

加藤浩貴, Long Nugyen, 石井悠翔, 松本光代, 三枝大輔, 舟山亮, 岡江寛明, 藤原亨, 武藤哲彦, 中山啓子, 有馬隆博, Scadden David, 五十嵐和彦, 張替秀郎

日本血液学会学術集会　83回　PSY-4　2021/09
Publisher: (一社)日本血液学会
成人初期前駆T細胞性急性リンパ性白血病の臨床的特徴と予後に関する後方視的研究 THF-24(Clinical features and prognosis of adult early T-cell precursor acute lymphoblastic leukemia: THF-24)

古川瑛次郎, 大西康, 遠宮靖雄, 原崎頼子, 深津真彦, 池添隆之, 亀岡吉弘, 高橋直人, 八田俊介, 勝岡優奈, 濱田宏之, 村井一範, 小宅達郎, 伊藤薫樹, 甲斐龍幸, 助川真純, 中嶌真治, 柳谷稜, 石澤賢一, 山口公平, 高橋太郎, 張替秀郎

日本血液学会学術集会　83回　OS3-5　2021/09
Publisher: (一社)日本血液学会
BCR-ABL1陽性急性骨髄性白血病(AML with BCR-ABL1)の2例

櫻井一貴, 勝岡優奈, 横山寿行, 斎藤慧, 八田俊介, 猪倉恭子, 市川聡, 福原規子, 小野寺晃一, 大西康, 和泉透, 張替秀郎

臨床血液　62　(9)　1417-1417　2021/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
CRAB症候にて発症した骨髄原発B細胞リンパ腫の1例

道満剛之, 市川聡, 猪倉恭子, 櫻井一貴, 木葉大地, 田中悠也, 福原規子, 横山寿行, 小野寺晃一, 大西康, 張替秀郎

臨床血液　62　(9)　1418-1418　2021/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
血球貪食症候群を伴い発症したTCR陰性末梢性T細胞リンパ腫、非特定型の1例

澤田拓実, 諸田直哉, 小野浩弥, 道又大吾, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

臨床血液　62　(9)　1418-1418　2021/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
妊婦検診を契機に発見された第XI因子欠乏症の一例

牧優冶, 菅原新吾, 石塚静江, 大久保礼由, 佐藤亜耶, 藤巻慎一, 藤原亨, 石井智徳, 市川聡, 張替秀郎

日本検査血液学会雑誌　22　(学術集会)　S127-S127　2021/08
Publisher: (一社)日本検査血液学会
ISSN： 1347-2836
Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report. International-journal

Koichi Onodera, Yasushi Onishi, Jun Inoue, Yuya Tanaka, Lee Yonha, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Kazunori Murai, Atsushi Masamune, Hideo Harigae

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy　27　(8)　1230-1233　2021/08

DOI： 10.1016/j.jiac.2021.02.002 　

More details Close

Hepatitis C virus (HCV) infection has an adverse impact on outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). It is recommended that HSCT candidates infected with HCV receive the treatment prior to transplantation. Although the recent approval of direct-acting antivirals (DAAs) has led to great advances in the treatment of HCV infection, little information is available on the efficacy and safety of DAA therapy in patients receiving allogeneic HSCT. Herein, we report the clinical course of an umbilical cord blood (UCB) recipient treated with DAAs for HCV infection. The patient achieved HCV RNA negativity with glecaprevir and pibrentasvir after consolidation therapy for acute myeloid leukemia (AML), and underwent transplantation before confirming sustained virological response (SVR) at 12 weeks. The HCV viral load became detectable on day +28 after transplantation and second HCV treatment with sofosbuvir, velpatasvir, and ribavirin was required. It is important to confirm SVR prior to transplantation, but it is often difficult. If early transplantation is required, close monitoring of HCV RNA after transplantation is needed. Further investigation is required to clarify the optimal management of HCV infection for allogeneic HSCT recipients in the DAA era.
Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review. International-journal

Tomoyuki Mutoh, Tsuyoshi Shirai, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

Rheumatology international　42　(11)　2069-2076　2021/07/21

DOI： 10.1007/s00296-021-04950-z 　

More details Close

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic autoimmune disorder classified under anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, predominantly affecting small- to medium-sized vessels, characterized by asthma, eosinophilia, and necrotizing granulomatous inflammation. Most patients with EGPA experience peripheral neuropathy, whereas intracerebral hemorrhage is rare as EGPA-related presentation in central nervous system involvement, causing severe morbidity and mortality. Here, we present a 45-year-old man with refractory EGPA who developed intracerebral hemorrhage as the first manifestation, followed by cardiac involvement. This patient with a history of bronchial asthma developed a right putaminal hemorrhage caused by EGPA. Although intravenous cyclophosphamide (IVCY) and mepolizumab (MPZ) induced remission, relapse was frequently observed. Subsequently, he developed cardiomyopathy despite administration of rituximab (RTX) substituted from IVCY and MPZ. Combined immunosuppressive therapy, including IVCY, MPZ, and RTX was required to inhibit vascular inflammation, leading to sustained remission. We review previously published literature while focusing on the clinical features of patients with intracerebral hemorrhage caused by EGPA and describe clinical characteristics for detecting EGPA in patients with intracerebral hemorrhage, emphasizing rapid evaluation and recognition of EGPA and adequate intervention in the early vasculitic phase of this disease. We also refer to the immunological aspects of this case. It is important to consider "multi-targeted therapy" through interleukin-5 suppression and B cell depletion in the management of refractory EGPA.
血液形態診断のためのケースカンファレンス下肢のしびれと持続する不明熱、汎血球減少を呈した血管内大細胞型B細胞リンパ腫の1例

菅原新吾, 藤巻慎一, 藤原亨, 張替秀郎

日本検査血液学会雑誌(1347-2836)　22　(2)　270-276　2021/07
末梢血幹細胞採取におけるHematopoietic Progenitor Cells(HPC)測定の有用性の検討

関修, 細川真梨, 石岡夏子, 伊藤智啓, 郷野辰幸, 岩木啓太, 阿部真知子, 佐藤裕子, 成田香魚子, 菅原新吾, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　67　(3)　479-480　2021/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Cyclophosphamide-associated enteritis presenting with severe protein-losing enteropathy in granulomatosis with polyangiitis: A case report. International-journal

Hiroko Sato, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

World journal of gastroenterology　27　(20)　2657-2663　2021/05/28

DOI： 10.3748/wjg.v27.i20.2657 　

More details Close

BACKGROUND: Although cyclophosphamide (CPA) is the key drug for the treatment of autoimmune diseases including vasculitides, it has some well-known adverse effects, such as myelosuppression, hemorrhagic cystitis, infertility, and infection. However, CPA-associated severe enteritis is a rare adverse effect, and only one case with a lethal clinical course has been reported. Therefore, the appropriate management of patients with CPA-associated severe enteritis is unclear. CASE SUMMARY: We present the case of a 61-year-old woman diagnosed with granulomatosis with polyangiitis based on the presence of symptoms in ear, lung, and, kidney with positive myeloperoxidase-antineutrophil cytoplasmic antibody. She received pulsed methylprednisolone followed by prednisolone 55 mg/d and intravenous CPA at a dose of 500 mg/mo. Ten days after the second course of intravenous CPA, she developed nausea, vomiting, and diarrhea, and was admitted to the hospital. Laboratory testing revealed hypoalbuminemia, suggesting protein-losing enteropathy. Computed tomography revealed wall thickening of the stomach, small intestine, and colon with contrast enhancement on the lumen side. Antibiotics and immunosuppressive therapy were not effective, and the patient's enteritis did not improve for > 4 mo. Because her condition became seriously exhausted, corticosteroids were tapered and supportive therapies including intravenous hyperalimentation, replenishment of albumin and gamma globulin, plasma exchange, and infection control were continued. These supportive therapies improved her condition, and her enteritis gradually regressed. She was finally discharged 7 mo later. CONCLUSION: Immediate discontinuation of CPA and intensive supportive therapy are crucial for the survival of patients with CPA-associated severe enteritis.
赤血球系疾患

張替秀郎

スタンダード検査血液学第４版日本検査血液学会編 ISBN:978-4-263-22691-9　354-365　2021/05
輸血管理システムにおける造血細胞及び再生医療等製品保管管理機能拡充の取り組み

岩木啓太, 阿部真知子, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　67　(2)　282-282　2021/05
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
当科における臓器移植後リンパ増殖性疾患の経験

渡邊正太郎, 福原規子, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

日本リンパ網内系学会会誌　61　98-98　2021/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer. International-journal

Kotaro Abe, Masahiko Kanehira, Shinya Ohkouchi, Sakiko Kumata, Yamato Suzuki, Hisashi Oishi, Masafumi Noda, Akira Sakurada, Eisaku Miyauchi, Tohru Fujiwara, Hideo Harigae, Yoshinori Okada

Cancer medicine　10　(9)　3085-3100　2021/05

DOI： 10.1002/cam4.3852 　

More details Close

Lung cancer is the most common cause of cancer-related death in developed countries; therefore, the generation of effective targeted therapeutic regimens is essential. Recently, gene therapy approaches toward malignant cells have emerged as attractive molecular therapeutics. Previous studies have indicated that stanniocalcin-1 (STC-1), a hormone involved in calcium and phosphate homeostasis, positively regulates proliferation, apoptosis resistance, and glucose metabolism in lung cancer cell lines. In this study, we investigated if targeting STC-1 in tumor cells could be a promising strategy for lung cancer gene therapy. We confirmed that STC-1 levels in peripheral blood were higher in lung cancer patients than in healthy donors and that STC-1 expression was observed in five out of eight lung cancer cell lines. A vector expressing a suicide gene, uracil phosphoribosyltransferase (UPRT), under the control of the STC-1 promoter, was constructed (pPSTC-1 -UPRT) and transfected into three STC-1-positive cell lines, PC-9, A549, and H1299. When stably transfected, we observed significant cell growth inhibition using 5-fluorouracil (5-FU) treatment. Furthermore, growth of the STC-1-negative lung cancer cell line, LK-2 was significantly arrested when combined with STC-1-positive cells transfected with pPSTC-1 -UPRT. We believe that conferring cytotoxicity in STC-1-positive lung cancer cells using a suicide gene may be a useful therapeutic strategy for lung cancer.
Disseminated gonococcal infection in a patient with paroxysmal nocturnal haemoglobinuria receiving eculizumab. International-journal

Ikumi Niitsuma-Sugaya, Hajime Kanamori, Satoshi Ichikawa, Noriko Fukuhara, Issei Seike, Kentaro Takei, Hiroaki Baba, Kengo Oshima, Tetsuji Aoyagi, Hideo Harigae, Koichi Tokuda

The Lancet. Infectious diseases　21　(5)　741-741　2021/05

DOI： 10.1016/S1473-3099(20)30930-0 　
Retrospective study revealed that Zn relate to improvement of swallowing function in the older adults. International-journal

Yumika Seki, Kota Ishizawa, Tetsuya Akaishi, Michiaki Abe, Koji Okamoto, Junichi Tanaka, Ryutaro Arita, Shin Takayama, Akiko Kikuchi, Mariko Miyazaki, Hideo Harigae, Mayumi Sato, Masaya Hoshi, Kazuaki Hatsugai, Tadashi Ishii

BMC geriatrics　21　(1)　279-279　2021/04/26

DOI： 10.1186/s12877-021-02224-8 　

More details Close

BACKGROUND: Zinc is an essential micronutrient for maintaining biological activity. The level of zinc in the blood is known to decrease with age, especially in those over 75 years of age. In older adults patients with impaired functional status, aspiration pneumonia based on dysphagia often becomes problematic. However, the relationship between zinc deficiency and swallowing function has not been studied before. METHODS: A total of 52 older adults subjects (15 males and 37 females) living in a nursing home were enrolled for this study. At the time of enrollment, data of gender, age, body weight, serum zinc levels, serum albumin levels, and the time in a simple 2-step swallowing provocation test (S-SPT) were collected. In patients with serum zinc levels < 60 μg/dL, we initiated 2 months of oral zinc supplementation therapy with a 34 mg/day zinc load. Those who underwent zinc supplementation were re-evaluated after the treatment period and serum zinc levels and S-SPT time were measured. RESULTS: At the time of enrollment, serum zinc level was significantly correlated with serum albumin levels (Pearson's R = 0.58, p < 0.0001) and time in the S-SPT (Spearman's rho = - 0.32, p = 0.0219). Twenty-five of the 52 patients had zinc deficiency with a serum zinc level < 60 μg/dL. After 2 months of oral zinc supplementation, both serum zinc levels (p < 0.0001) and time in the S-SPT (p = 0.04) significantly improved. Meanwhile, serum albumin level (p = 0.48) or body weight (p = 0.07) did not significantly change following zinc supplementation. Zinc supplementation significantly improved swallowing function, especially in the older adults who had comorbid dysphagia and zinc deficiency. CONCLUSIONS: Zinc deficiency is associated with compromised swallowing function in older adults patients with impaired general functions. Oral zinc supplementation can alleviate dysphagia in older adults patients with zinc deficiency even though this is a retrospective study. Further study will be needed to confirm this positive effect.
移植後早期再発した急性巨核芽球性白血病に対して臍帯血移植を行い長期寛解を達成した1例

櫻井一貴, 市川聡, 齋藤慧, 猪倉恭子, 福原規子, 横山寿行, 小野寺晃一, 大西康, 藤原亨, 亀岡淳一, 張替秀郎

臨床血液　62　(4)　323-323　2021/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
クローン病に合併した腫瘍内循環障害を伴う副腎オンコサイトーマの一例

尾股慧, 山崎有人, 古田銀次, 大黒顕佑, 小野美澄, 森本玲, 鈴木秀幸, 神山篤史, 大沼忍, 諸井林太郎, 正宗淳, 川守田直樹, 伊藤明宏, 宮崎真理子, 張替秀郎, 笹野公伸, 佐藤文俊

日本内分泌学会雑誌　96　(4)　1180-1180　2021/04
Publisher: (一社)日本内分泌学会
ISSN： 0029-0661

eISSN： 2186-506X
血管炎診療の進歩高安動脈炎における自己抗体の意義

石井智徳, 白井剛志, 武藤智之, 藤井博司, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　65回　183-183　2021/03
Publisher: (一社)日本リウマチ学会
Cutting-edge knowledge on pathogenic autoantibodies and immune tolerance SARFによる高安動脈炎の新規自己抗原の同定とその病的意義について

藤井博司, 白井剛志, 武藤智之, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　65回　229-229　2021/03
Publisher: (一社)日本リウマチ学会
ベーチェット病ベーチェット病における血管病変の特徴と再燃に関連する因子の検討

佐藤紘子, 丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 町山智章, 秋田佳奈恵, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　65回　425-425　2021/03
Publisher: (一社)日本リウマチ学会
リウマチ性疾患の合併症当院の関節リウマチ患者におけるMTX関連リンパ増殖性疾患40例の診断契機に関する検討

高橋美岐, 丹野唯人, 岡崎創司, 町山智章, 星陽介, 秋田佳奈恵, 佐藤紘子, 白井剛志, 石井智徳, 藤井博司, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　65回　4.37-4.37　2021/03
Publisher: (一社)日本リウマチ学会
当科における関節リウマチに対するゴリムマブの長期継続率の検討

武藤智之, 永井泰地, 佐藤紘子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　65回　569-569　2021/03
Publisher: (一社)日本リウマチ学会
腹部大動脈周囲炎を合併した好酸球性多発血管炎性肉芽腫症の一例

秋田佳奈恵, 藤井博司, 丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 佐藤紘子, 白井剛志, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　65回　662-662　2021/03
Publisher: (一社)日本リウマチ学会
再燃を繰り返した治療抵抗性好酸球性多発血管炎性肉芽腫症に対してシクロホスファミド、リツキシマブ、メポリズマブ併用療法が有効であった1例

武藤智之, 白井剛志, 永井泰地, 佐藤紘子, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　65回　663-663　2021/03
Publisher: (一社)日本リウマチ学会
【病気とくすり2021 基礎と実践Expert's Guide】循環器系の病気とくすり血液・造血器系疾患貧血

斎藤陽, 張替秀郎, 鈴木文子, 眞野成康

薬局　72　(4)　1032-1043　2021/03
Publisher: (株)南山堂
ISSN： 0044-0035
シクロホスファミドとアザチオプリンによる寛解維持が困難でインフリキシマブが有効であった再発性多発軟骨炎の一例

秋田佳奈恵, 白井剛志, 丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 佐藤紘子, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会北海道・東北支部学術集会抄録集　30回　41-41　2021/02
Publisher: (一社)日本リウマチ学会-北海道・東北支部
トシリズマブ、サリルマブで加療を行ったTAFRO症候群の一例

丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 秋田佳奈恵, 町山智章, 佐藤紘子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会北海道・東北支部学術集会抄録集　30回　53-53　2021/02
Publisher: (一社)日本リウマチ学会-北海道・東北支部
SLE、Sjogren症候群を伴う肺多発結節影を来した肺MALT lymphomaの一例

高橋幹弘, 岡崎創司, 秋田佳奈恵, 石井悠翔, 丹野唯人, 高橋美岐, 星陽介, 白井剛志, 石井智宏, 藤井博司, 張替秀郎

日本リウマチ学会北海道・東北支部学術集会抄録集　30回　65-65　2021/02
Publisher: (一社)日本リウマチ学会-北海道・東北支部
破砕赤血球の形態学的判定におけるばらつきの原因にアプローチした判定基準の考案(原著論文)

菅原新吾, 千葉拓也, 大井惇矢, 小笠原脩, 菊地優子, 佐藤牧子, 鈴木千恵, 中村美雪, 藤巻慎一, 藤原亨, 張替秀郎

日本検査血液学会雑誌 (1347-2836)　22　(1)　8-15　2021/02
Acquisition of monosomy 7 and a RUNX1 mutation in Pearson syndrome. International-journal

Akira Nishimura, Shinsuke Hirabayashi, Daisuke Hasegawa, Kenichi Yoshida, Yuichi Shiraishi, Miho Ashiarai, Yosuke Hosoya, Tohru Fujiwara, Hideo Harigae, Satoru Miyano, Seishi Ogawa, Atsushi Manabe

Pediatric blood & cancer　68　(2)　e28799　2021/02

DOI： 10.1002/pbc.28799 　

More details Close

Pearson syndrome (PS) is a very rare and often fatal multisystem disease caused by deletions in mitochondrial DNA that result in sideroblastic anemia, vacuolization of marrow precursors, and pancreatic dysfunction. Spontaneous recovery from anemia is often observed within several years of diagnosis. We present the case of a 4-month-old male diagnosed with PS who experienced prolonged severe pancytopenia preceding the emergence of monosomy 7. Whole-exome sequencing identified two somatic mutations, including RUNX1 p.S100F that was previously reported as associated with myeloid malignancies. The molecular defects associated with PS may have the potential to progress to advanced myelodysplastic syndrome .
The Potential of Computed Tomography Volumetry for the Surgical Treatment in Bilateral Macronodular Adrenal Hyperplasia: A Case Report.

Hiromu Matsunaga, Yuta Tezuka, Tomo Kinoshita, Hiroko Ogata, Yuto Yamazaki, Beata Shiratori, Kei Omata, Yoshikiyo Ono, Ryo Morimoto, Masataka Kudo, Kazumasa Seiji, Kei Takase, Yoshihide Kawasaki, Akihiro Ito, Hironobu Sasano, Hideo Harigae, Fumitoshi Satoh

The Tohoku journal of experimental medicine　253　(2)　143-150　2021/02

DOI： 10.1620/tjem.253.143 　

More details Close

Although adrenal resection is a major option to control hypercortisolemia in patients with bilateral macronodular adrenal hyperplasia, a predictive method for postoperative cortisol production has not been established. A 53-year-old man with ulcerative colitis was referred to our hospital for bilateral multiple adrenal nodules and hypertension. Physical and endocrinological examination revealed inappropriate cortisol production and suppressed secretion of adrenocorticotropic hormone with no typical signs of Cushing's syndrome. Imaging analysis revealed bilateral adrenal nodular enlargement, the nodules of which had the radiological features of adrenocortical adenomas without inter-nodular heterogeneity. In addition, computed tomography volumetry demonstrated that the left adrenal gland (70 mL) accounts for three quarters of the total adrenal volume (93 mL). The patient was diagnosed as subclinical Cushing's syndrome due to bilateral macronodular adrenal hyperplasia, and subsequently underwent a left laparoscopic adrenalectomy with the estimation of 75% decrease in the cortisol level based on the adrenal volume. The surgical treatment ultimately resulted in control of the cortisol level within the normal range, which was compatible to our preoperative prediction. However, regardless of the sufficient cortisol level, ulcerative colitis was exacerbated after the surgery, which needed a systemic therapy for remission. This case indicates successful surgical control of hypercortisolemia based on computed tomography volumetry in bilateral macronodular adrenal hyperplasia, as well as the perioperative exacerbation risk for inflammatory diseases in Cushing's syndrome. We report the potential utility of computed tomography volumetry as a quantitative method with retrospective evaluation of our historical cases.
Treatment of Refractory Hypertension with Timely Angioplasty in Total Renal Artery Occlusion with Atrophic Kidney.

Yuri Sasaki, Eikan Mishima, Koichi Kikuchi, Takafumi Toyohara, Takehiro Suzuki, Hideki Ota, Kazumasa Seiji, Mariko Miyazaki, Hideo Harigae, Sadayoshi Ito, Kei Takase, Takaaki Abe

Internal medicine (Tokyo, Japan)　60　(2)　287-292　2021/01/15

DOI： 10.2169/internalmedicine.5290-20 　

More details Close

Angioplasty for cases of chronic total occlusion of renal artery with/without atrophic kidney is generally not recommended. We herein report a 57-year-old man who presented with renin-mediated refractory hypertension caused by occlusion of a unilateral renal artery leading to kidney atrophy (length: 69 mm). Angioplasty favorably achieved blood pressure control with normalized renin secretion and enlargement of the atrophic kidney to 85 mm. Timely angioplasty can be beneficial in select patients, even with an atrophic kidney and total occlusion, especially in cases with deterioration of hypertension within six months and the presence of collateral perfusion to the affected kidney.
Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease. International-journal

Satoshi Kumakura, Emiko Sato, Akiyo Sekimoto, Yamato Hashizume, Shu Yamakage, Mariko Miyazaki, Sadayoshi Ito, Hideo Harigae, Nobuyuki Takahashi

Toxins　13　(1)　2021/01/11

DOI： 10.3390/toxins13010050 　

More details Close

Nicotinamide adenine dinucleotide (NAD+) supplies energy for deoxidation and anti-inflammatory reactions fostering the production of adenosine triphosphate (ATP). The kidney is an essential regulator of body fluids through the excretion of numerous metabolites. Chronic kidney disease (CKD) leads to the accumulation of uremic toxins, which induces chronic inflammation. In this study, the role of NAD+ in kidney disease was investigated through the supplementation of nicotinamide (Nam), a precursor of NAD+, to an adenine-induced CKD mouse model. Nam supplementation reduced kidney inflammation and fibrosis and, therefore, prevented the progression of kidney disease. Notably, Nam supplementation also attenuated the accumulation of glycolysis and Krebs cycle metabolites that occurs in renal failure. These effects were due to increased NAD+ supply, which accelerated NAD+-consuming metabolic pathways. Our study suggests that Nam administration may be a novel therapeutic approach for CKD prevention.
Massive bone marrow infiltration of neuroendocrine carcinoma mimicking aggressive hematological malignancy

Ichikawa, S., Inokura, K., Kawamura, Y., Fukuhara, N., Yokoyama, H., Ouchi, K., Fujishima, F., Harigae, H.

Journal of Hematopathology　14　(4)　337-339　2021

DOI： 10.1007/s12308-021-00475-3 　

ISSN： 1865-5785 1868-9256

eISSN： 1865-5785
Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation International-journal

Mio Tsuruoka, Jun Inoue, Yasushi Onishi, Masashi Ninomiya, Eiji Kakazu, Tomoaki Iwata, Akitoshi Sano, Kosuke Sato, Hideo Harigae, Atsushi Masamune

Case Reports in Gastroenterology　15　(1)　178-187　2021

DOI： 10.1159/000512397 　

eISSN： 1662-0631
Concurrent analogous organ damage in the brain, eyes, and kidneys in malignant hypertension: reversible encephalopathy, serous retinal detachment, and proteinuria. International-journal Peer-reviewed

Eikan Mishima, Yukino Funayama, Takehiro Suzuki, Fumiko Mishima, Fumihiko Nitta, Takafumi Toyohara, Koichi Kikuchi, Hiroshi Kunikata, Junichiro Hashimoto, Mariko Miyazaki, Hideo Harigae, Toru Nakazawa, Sadayoshi Ito, Takaaki Abe

Hypertension research : official journal of the Japanese Society of Hypertension　44　(1)　88-97　2021/01

DOI： 10.1038/s41440-020-0521-2 　

More details Close

Malignant hypertension, a form of hypertensive emergency, causes acute damage in vital organs such as the brain, eyes, and kidneys. We aimed to examine the concurrency of acute hypertensive damage across the target organs to elucidate the underlying analogous pathophysiology. This single-center retrospective study evaluated the characteristics of organ damage, short-term clinical course, and interorgan relationships in patients with malignant hypertension treated between 2008 and 2019. Baseline characteristics of 20 patients who met our inclusion criteria were mean age 48 ± 13 years and blood pressure 222 ± 18/142 ± 16 mmHg; the median estimated glomerular filtration rate and urinary protein level were 49 mL/min/1.73 m2 (interquartile range [IQR] 27-79) and 1.9 g/g creatinine (IQR 0.2-4.0), respectively. Posterior reversible encephalopathy syndrome (PRES) was found in 60% of patients with major involvement and a wide variety of distribution patterns in the brainstem. In the fundus, serous retinal detachment was found in 60% of patients. Patients with PRES and serous retinal detachment showed higher levels of urinary protein than those without symptoms (P = 0.007 and 0.02, respectively), and proteinuria >1 g/g creatinine highly complicated both PRES and serous retinal detachment (91%). Matrix analysis also showed that the three symptoms were highly associated with each other. These results demonstrate the close relationship and concurrency of hypertensive acute organ damage in the brain, eyes, and kidneys. A common analogous mechanism, such as hyperperfusion-induced capillary leakage in each organ, implies an underlying pathophysiology of PRES, serous retinal detachment, and proteinuria.
心臓血管外科開胸手術における同種クリオ導入前後の比較

関修, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 阿部真知子, 石岡夏子, 佐藤裕子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　66　(6)　766-766　2020/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
アルブミン製剤使用量削減に伴う心臓血管外科開胸手術の臨床的アウトカムへの影響

関修, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 秋山正年, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　66　(6)　743-749　2020/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
臍帯血移植により持続的寛解を得られた治療抵抗性血管免疫芽球性T細胞リンパ腫の1例

本江史門, 市川聡, 福原規子, 齋藤慧, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

臨床血液　61　(11)　1631-1631　2020/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
臍帯血移植により持続的寛解を得られた治療抵抗性血管免疫芽球性T細胞リンパ腫の1例

本江史門, 市川聡, 福原規子, 齋藤慧, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

臨床血液　61　(11)　1631-1631　2020/11
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Kidney enlargement effect of angioplasty for nonatherosclerotic renovascular disease: reversibility of ischemic kidney. International-journal

Tomoyuki Iwasaki, Eikan Mishima, Takehiro Suzuki, Koichi Kikuchi, Takafumi Toyohara, Kazumasa Seiji, Kei Takase, Mariko Miyazaki, Hideo Harigae, Sadayoshi Ito, Takaaki Abe

Hypertension research : official journal of the Japanese Society of Hypertension　43　(11)　1214-1221　2020/11

DOI： 10.1038/s41440-020-0473-6 　

More details Close

Renal artery stenosis causes kidney ischemia, reducing the size of the affected kidney, which eventually results in atrophy. Although renal atrophy is considered irreversible, resolution of the ischemia occasionally restores kidney size when the cause is renal artery stenosis. Angioplasty is effective in patients with nonatherosclerotic renovascular diseases (non-ARVDs). Nevertheless, renal enlargement after angioplasty has not been fully examined. We conducted a retrospective study to examine this phenomenon in non-ARVD patients. Ten patients with a <100-mm pole-to-pole length of the poststenotic kidney were treated with angioplasty. Data were collected up to 12 months after angioplasty. The mean age was 28 years; the estimated glomerular filtration rate was 92 ± 7 mL/min/1.73 m2 (mean ± SEM); blood pressure was 150/99 mmHg; 80% were women; and fibromuscular dysplasia was present in 90% of the patients. All patients had hypertension. The lengths of the poststenotic and contralateral kidney before angioplasty were 91 ± 1 and 111 ± 3 mm, respectively. After angioplasty, the length of the poststenotic kidney gradually increased during the 3 months after treatment (+5.4 mm) and that of the contralateral kidney decreased over the same time course (-3.7 mm). Enlargement was also found in the moderate atrophy subgroup (length < 92 mm), and it was greater in the <30 years old group. In a noteworthy case, renal size in the poststenotic kidney recovered from 87 to 102 mm after angioplasty. Our findings demonstrated that reduced renal size can be reversed after optimal angioplasty in non-ARVD patients, especially young patients, suggesting reversibility of the ischemic kidney.
Successful Treatment of Primary Refractory Angioimmunoblastic T-cell Lymphoma With Cord Blood Transplantation. International-journal

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Eijiro Furukawa, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Clinical lymphoma, myeloma & leukemia　20　(11)　e926-e929　2020/11

DOI： 10.1016/j.clml.2020.07.009 　
Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus.

Satoshi Ichikawa, Noriko Fukuhara, Tsuyoshi Shirai, Tomonori Ishii, Ryo Ichinohasama, Hideo Harigae

International journal of hematology　112　(4)　592-596　2020/10

DOI： 10.1007/s12185-020-02914-w 　

More details Close

Increased incidence of lymphoproliferative disorders is reported in patients with autoimmune diseases, majority of which have a B-cell phenotype and are pathogenetically associated with the reactivation of Epstein-Barr virus (EBV). However, EBV-associated T/NK-cell lymphoma has hardly been reported. We present the case of a 68-year-old-woman, who had been diagnosed with systemic lupus erythematosus (SLE) 28 years back and was treated with various immunosuppressive agents including steroids, cyclophosphamide, and tacrolimus. She presented with a progressively worsening swelling of the right thigh for the last few months. Radiological examination revealed an intramuscular bulky tumor without any other lesions and the biopsy results led to a diagnosis of extranodal NK/T-cell lymphoma, nasal type (ENKL). Concurrent chemoradiotherapy resulted in a complete response, which has been sustained for more than 2 years without requiring additional therapy. After the initiation of chemotherapy, SLE did not worsen with the administration of low-dose corticosteroids. To the best of our knowledge, this is the first case report of a localized extranasal ENKL developing in a patient with SLE.
Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma. International-journal

Yasushi Onishi, Hisayuki Yokoyama, Yuna Katsuoka, Toshihiro Ito, Tomohumi Kimura, Joji Yamamoto, Shinji Nakajima, Osamu Sasaki, Takahide Ara, Koichiro Minauchi, Osamu Fukuhara, Naoki Kobayashi, Hideyoshi Noji, Shuichi Ota, Hideo Harigae

Annals of hematology　99　(10)　2351-2356　2020/10

DOI： 10.1007/s00277-020-04240-x 　

More details Close

Lenalidomide (Len) and dexamethasone (dex) therapy is a standard therapy in patients with multiple myeloma. Elderly or unfit patients may reduce Len or dex doses to prevent toxicities that lead to treatment discontinuation. However, there have been few studies evaluating the efficacy and safety of lower doses of Len and dex. We conducted a phase II study of 1.5-year low-dose Len and dex therapy following melphalan and prednisolone (MP), the number of which cycles was determined by a response within 9 cycles. The Len dose was 10 mg daily and the dex dose was 20 mg weekly, which were continued for 1.5 years. Twenty-one patients were enrolled. The median number of cycles of MP was 3 (range, 2-9). The overall response rate was 81% and a very good partial response or better was achieved in 33.3% of patients. The median follow-up time for survivors was 70.5 months (range, 42-83 months), the median progression-free survival (PFS) was 27 months (95% CI, 21-33 months), and the median overall survival was not reached. Grade 3 or 4 adverse events were observed in 28.6% of patients. In conclusion, the low-dose Len and dex therapy safely achieved comparable efficacies to the standard-dose regimen in elderly patients with newly diagnosed multiple myeloma. UMIN000007889.
One after another retinal involvement in lupus. International-journal

Tomoyuki Mutoh, Yuko Shirota, Azusa Ito, Hiroshi Fujii, Tomonori Ishii, Toru Nakazawa, Hideo Harigae

European journal of rheumatology　8　(2)　111-2　2020/09/03

DOI： 10.5152/eurjrheum.2020.20022 　
Questionnaire survey on the prescription of renal replacement therapy for acute phase patients on maintenance dialysis who developed cerebrovascular disease

Maho Akiu, Tae Yamamoto, Emi Fujikura, Koji Okamoto, Atsuhiro Nakagawa, Mai Yoshida, Takashi Nakamichi, Taro Fukushi, Tasuku Nagasawa, Yuji Oe, Masaaki Nakayama, Hiroshi Sato, Teiji Tominaga, Sadayoshi Ito, Hideo Harigae, Mariko Miyazaki

Clinical and Experimental Nephrology　24　(9)　821-828　2020/09
Publisher: Springer Science and Business Media LLC
DOI： 10.1007/s10157-020-01905-9 　

ISSN： 1342-1751

eISSN： 1437-7799

More details Close

BACKGROUND: There is limited information about acute phase renal replacement therapy (RRT) for maintenance hemodialysis patients after the onset of cerebrovascular disease. This study aimed to investigate which modality of renal replacement therapy is currently selected in practice. METHODS: We conducted a mail-based survey in 317 dialysis facilities that were certified by three academic societies that focus on dialysis, neurology, and neurosurgery in Japan. RESULTS: We received responses from 103 facilities (32.5%). In cases of cerebral infarction (CI) and intracerebral hemorrhage (ICH), more than 80% of the facilities selected only intermittent RRT, and 22.3% (CI)/8.7% (ICH) of the facilities selected intermittent HD which is the same setting in normal conditions. Although continuous hemodiafiltration and peritoneal dialysis are recommended in the Japanese guidelines, these were selected in only a few facilities: 16.5% and 0% in CI, 16.5% and 1% in ICH, respectively. RRT on the day of onset tended to be avoided, irrespective of the duration following the last HD session. Furthermore, physicians preferred to modify anticoagulants and reduce dialysis performance in the acute phase. CONCLUSION: This questionnaire survey uncovered a gap between guidelines and actual practice, even in hospitals accredited as educational facility, which is a novel and important finding. Further studies with larger sample sizes are needed to determine the optimal modality of RRT for the acute phase of cerebrovascular disease.
A novel case of γδ T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis. International-journal

Satoshi Ichikawa, Tohru Fujiwara, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Shunsuke Hatta, Koichi Onodera, Yasushi Onishi, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

Annals of hematology　100　(10)　2665-2668　2020/08/31

DOI： 10.1007/s00277-020-04241-w 　
全身性結合織疾患の難治性病態 SLEに合併したADAMTS13インヒビター陰性二次性血栓性血小板減少性紫斑病の一例

佐藤紘子, 永井泰地, 武藤智之, 町山智章, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　64回　390-390　2020/08
Publisher: (一社)日本リウマチ学会
大型血管炎大型血管炎におけるステロイド寛解維持量の検討

白井剛志, 佐藤紘子, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　64回　451-451　2020/08
Publisher: (一社)日本リウマチ学会
中小型血管炎(ANCA関連血管炎) 多発血管炎性肉芽腫症における臓器別にみた治療反応性についての検討

城田祐子, 白井剛志, 藤井博司, 佐藤紘子, 町山智章, 堤智美, 武田朋樹, 岡友美子, 小寺隆雄, 桑田亮, 石井智徳, 張替秀郎, 亀岡淳一

日本リウマチ学会総会・学術集会プログラム・抄録集　64回　511-511　2020/08
Publisher: (一社)日本リウマチ学会
ループスモデルマウスに対するMat2a阻害効果の検討

石井悠翔, 藤井博司, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　64回　707-707　2020/08
Publisher: (一社)日本リウマチ学会
中小型血管炎(ANCA関連血管炎) 多発血管炎性肉芽腫症における臓器別にみた治療反応性についての検討

城田祐子, 白井剛志, 藤井博司, 佐藤紘子, 町山智章, 堤智美, 武田朋樹, 岡友美子, 小寺隆雄, 桑田亮, 石井智徳, 張替秀郎, 亀岡淳一

日本リウマチ学会総会・学術集会プログラム・抄録集　64回　511-511　2020/08
Publisher: (一社)日本リウマチ学会
末梢性T細胞リンパ腫/非特異型の分子病態による分類免疫組織化学での応用も見据えて

齋藤慧, 藤島史喜, 福原規子, 張替秀郎, 一迫玲

血液内科　81　(1)　107-113　2020/07
Publisher: (有)科学評論社
ISSN： 2185-582X
JAK2 mutation-positive polycythaemia vera associated with IgA vasculitis and nephrotic syndrome: a case report. International-journal

Hinako Kondo, Ryu Watanabe, Soshi Okazaki, Kaori Kuriyama, Tetsuro Ochi, Gen Yamada, Akira Sugiura, Hiromu Chiba, Akira Tsukada, Shinji Taniuchi, Takehiko Igarashi, Masataka Kudo, Hideo Harigae, Hiroshi Fujii

Modern rheumatology case reports　4　(2)　289-295　2020/07

DOI： 10.1080/24725625.2020.1728061 　

More details Close

We report a case of polycythaemia vera (PV) associated with IgA vasculitis. A 45-year-old man was admitted for evaluation of abdominal pain and palpable purpura. IgA vasculitis was diagnosed, and oral prednisolone therapy (30 mg/day) was initiated. On day 6, the patient developed left hemiparesis, and magnetic resonance imaging revealed acute cerebral infarction. Bone marrow biopsy results and the identification of a Janus kinase 2 (JAK2) mutation led to the diagnosis of PV. Despite steroid therapy, urine protein levels increased to 15 g/g・Cre. Renal biopsy demonstrated mild mesangial proliferation with IgA deposits, but immunosuppressive therapy was partially effective. This case suggests that PV can be a complication of IgA vasculitis and that preventive measures for thrombosis should be taken in such cases.
Comment on: Aortarctia: a rare manifestation of relapsing polychondrits Peer-reviewed

Tsuyoshi Shirai, Koji Murakami, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

RHEUMATOLOGY　59　(7)　1784-1785　2020/07

DOI： 10.1093/rheumatology/keaa019 　

ISSN： 1462-0324

eISSN： 1462-0332
Rheumatoid Arthritis After Cord Blood Cell Transplantation. International-journal

Tsuyoshi Shirai, Yu Mori, Takuya Izumiyama, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases　27　(7)　e276-e277-277　2020/06/12

DOI： 10.1097/RHU.0000000000001430 　
Rheumatoid Arthritis After Cord Blood Cell Transplantation International-journal

Tsuyoshi Shirai, Yu Mori, Takuya Izumiyama, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

JCR: Journal of Clinical Rheumatology　Publish Ahead of Print　(7)　e276-e277　2020/06/12
Publisher: Ovid Technologies (Wolters Kluwer Health)
DOI： 10.1097/rhu.0000000000001430 　

ISSN： 1076-1608
Kidney function, blood pressure and proteinuria were associated with pregnancy outcomes of pregnant women with chronic kidney disease: a single-center, retrospective study in the Asian population.

Satoshi Kumakura, Koji Okamoto, Saeko Takeuchi, Mai Yoshida, Takashi Nakamichi, Tasuku Nagasawa, Emi Fujikura, Tae Yamamoto, Masatoshi Saito, Takushi Hanita, Michihiro Satoh, Hiroshi Sato, Sadayoshi Ito, Hideo Harigae, Mariko Miyazaki

Clinical and experimental nephrology　24　(6)　547-556　2020/06

DOI： 10.1007/s10157-020-01865-0 　

More details Close

BACKGROUND: Studies among pregnant Asian women with chronic kidney disease (CKD) have not been widely performed; therefore, clinical criteria for these patients have not been well established. METHODS: We conducted a retrospective study among pregnant women with CKD who received prenatal care at our institution for 8 consecutive years. Primary outcome was the development of severe adverse events (SAEs). We analyzed correlations between primary outcome and CKD parameters [age, body mass index (BMI), estimated glomerular filtration rate (eGFR), urinary protein-creatinine ratio (UP), systolic blood pressure (SBP), diastolic blood pressure (DBP), and not normal blood pressure (non-NBP)] at the time of referral. Secondary outcomes were low birth weight (LBW), preterm delivery (PreD), and small for gestational age (SGA). We divided into two categories, CKD stage G1, and G2 or higher according to eGFR, and proteinuria negative and proteinuria positive according to UP, respectively. RESULTS: We observed 89 pregnancies. SAE was observed in 28 pregnancies. In live birth cases, there were 28 PreD, 28 LBW and 13 SGA. Major SAEs included preeclampsia, superimposed preeclampsia, unscheduled cesarean section, neonatal intensive care unit admission, and fetal death. Stepwise logistic regression analysis selected eGFR (OR = 0.847, p = 0.026), SBP (OR = 1.897, p = 0.006) and proteinuria positive (OR = 2.96, p = 0.046) as the significant predictors of SAEs. There were no significant differences among the baseline characteristics stratified by SGA. CONCLUSIONS: This is the first study to report pregnancy outcomes among Japanese non-disease-oriented patients with CKD. In Asians, especially in the Japanese population, kidney function, blood pressure and proteinuria might affect pregnancy outcomes.
High Relapse Rate in Patients with Polymyalgia Rheumatica despite the Combination of Immunosuppressants and Prednisolone: A Single Center Experience of 89 patients. Peer-reviewed

Soshi Okazaki, Ryu Watanabe, Hinako Kondo, Masataka Kudo, Hideo Harigae, Hiroshi Fujii

The Tohoku journal of experimental medicine　251　(2)　125-133　2020/06

DOI： 10.1620/tjem.251.125 　

More details Close

Polymyalgia rheumatica (PMR) is an inflammatory disorder in the elderly and is characterized by pain in the shoulders and lower back. Previous studies from western countries have shown that relapse is frequent; however, there are only a few reports on the relapse rate in Japan. Here we examined the relapse rate, and sought to identify factors that predict recurrence in patients with PMR. Of 110 patients who fulfilled the Bird's criteria for PMR between May 2011 and June 2019, 21 patients were excluded, and the remaining 89 patients were followed up until July 2019. Relapse was defined when clinical symptoms were exacerbated and serum C-reactive protein level increased. The relapse-free survival curves were plotted using the Kaplan-Meier method, and log-rank test was used for statistical analysis. The mean age of the 89 patients (50 males and 39 females) was 71.8 years. The mean dose of initial prednisolone (PSL) was 11.8 mg/day. The 1-, 3-, and 5-year relapse-free survival rates were 81.6%, 58.0%, and 52.3% (N = 59, 21, and 7), respectively. In patients who experienced recurrence, the 1- and 3-year second relapse-free survival rates were 58.3% and 27.3% (N = 18 and 3), respectively. Immunosuppressants, such as methotrexate and tacrolimus, were added to PSL in 19 of 30 patients who experienced relapse at the discretion of the attending physicians; however, none of the immunosuppressants worked for preventing second relapses and had steroid-sparing effects. These results indicate that effective immunosuppressants are required to suppress relapse in the treatment of PMR.
Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab. International-journal Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

Leukemia & lymphoma　61　(6)　1504-1507　2020/06

DOI： 10.1080/10428194.2020.1713322 　
Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection. Peer-reviewed

Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Yuya Tanaka, Yoonha Lee, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

Internal medicine (Tokyo, Japan)　59　(10)　1303-1308　2020/05/15

DOI： 10.2169/internalmedicine.4142-19 　

More details Close

Acquired factor X deficiency (AFXD) is a very rare coagulation disorder. A 40-year-old man with no comorbidities suffering from a fever, malaise, and severe hemorrhagic symptoms, including massive hematuria, was emergently admitted. His platelet count was normal, but his prothrombin time and activated partial thromboplastin time were markedly prolonged, which was thought to be due to autoantibody against a coagulation factor in the common pathway. Despite severe massive hematuria resulting in transient renal failure, he was successfully treated with urgent immunosuppressive therapy. Computed tomography revealed bronchopneumonia, which improved with antibiotic administration. AFXD without evidence of amyloidosis was subsequently diagnosed.
Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Koichi Onodera, Tsuyoshi Shirai, Yasushi Onishi, Hisayuki Yokoyama, Hiroshi Fujii, Ryo Ichinohasama, Hideo Harigae

International journal of hematology　111　(5)　667-672　2020/05

DOI： 10.1007/s12185-020-02822-z 　

More details Close

Methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) is unlikely to regress following discontinuation of MTX, and its treatment usually requires chemotherapy. Standard chemotherapy for CHL is the ABVD regimen, which contains pneumotoxic bleomycin. This can be problematic in MTX-CHL patients suffering from an autoimmune disease (AID), such as rheumatoid arthritis (RA), as they frequently have pulmonary complications. However, brentuximab vedotin (BV)-containing chemotherapy without bleomycin (A + AVD regimen) was recently reported to show favorable efficacy for CHL, and could therefore be beneficial in MTX-CHL. We treated three cases of MTX-CHL using the A + AVD regimen. All were female and had received MTX for more than 15 years. Underlying AIDs in these patients were RA in two patients, and overlap syndrome with systemic lupus erythematosus and dermatomyositis in one patient. The A + AVD regimen resulted in a complete response in all patients. Peripheral neuropathy developed in two patients, necessitating reduction of the BV dose. All three patients experienced hematological toxicity necessitating dose reduction; however, no severe adverse effects, including infection or pulmonary complication, were documented. RA was well-controlled without additional immunosuppressants. The A + AVD regimen is a promising chemotherapy for MTX-CHL with favorable efficacy and tolerable toxicity profiles.
BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with t(9;22);BCR-ABL1? International-journal Peer-reviewed

Taro Takahashi, Satoshi Ichikawa, Ryo Ichinohasama, Hideo Harigae

LEUKEMIA & LYMPHOMA　61　(5)　1265-1267　2020/04

DOI： 10.1080/10428194.2019.1706736 　

ISSN： 1042-8194

eISSN： 1029-2403
【血液・造血器疾患】赤血球数の異常を生じる疾患（造血器腫瘍を除く）鉄欠乏性貧血・鉄芽球性貧血

張替秀郎

新臨床内科学第10版医学書院 ISBN978-4-260-03806-5　973-975　2020/03/25
Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. International-journal Peer-reviewed

Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii, Yuko Shirota, Fumiyoshi Fujishima, Fumiaki Takahashi, Yoichi Kakuta, Yoshitake Kanazawa, Atsushi Masamune, Yoshikatsu Saiki, Hideo Harigae, Hiroshi Fujii

Nature communications　11　(1)　1253-1253　2020/03/09

DOI： 10.1038/s41467-020-15088-0 　

More details Close

The presence of antiendothelial cell antibodies (AECAs) has been documented in Takayasu arteritis (TAK), a chronic granulomatous vasculitis. Here, we identify cell-surface autoantigens using an expression cloning system. A cDNA library of endothelial cells is retrovirally transfected into a rat myeloma cell line from which AECA-positive clones are sorted with flow cytometry. Four distinct AECA-positive clones are isolated, and endothelial protein C receptor (EPCR) and scavenger receptor class B type 1 (SR-BI) are identified as endothelial autoantigens. Autoantibodies against EPCR and SR-BI are detected in 34.6% and 36.5% of cases, respectively, with minimal overlap (3.8%). Autoantibodies against EPCR are also detected in ulcerative colitis, the frequent comorbidity of TAK. In mechanistic studies, EPCR and SR-BI function as negative regulators of endothelial activation. EPCR has also an effect on human T cells and impair Th17 differentiation. Autoantibodies against EPCR and SR-BI block the functions of their targets, thereby promoting pro-inflammatory phenotype.
【病気とくすり2020 基礎と実践Expert's Guide】循環器系・泌尿器系・生殖器系の病気とくすり血液・造血器系疾患貧血

斎藤陽, 張替秀郎, 鈴木文子, 眞野成康

薬局　71　(4)　1046-1057　2020/03
Publisher: (株)南山堂
ISSN： 0044-0035
Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis. Peer-reviewed

Soshi Okazaki, Ryu Watanabe, Hideo Harigae, Hiroshi Fujii

The Tohoku journal of experimental medicine　250　(3)　153-159　2020/03

DOI： 10.1620/tjem.250.153 　

More details Close

Recently, biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionized the treatment of rheumatoid arthritis (RA) and provided patients with a higher chance of achieving clinical remission. Among them, abatacept (ABT), which selectively inhibits T cell activation through blocking costimulation signal, has been reported efficacious in controlling disease activity. Previous studies have shown that ABT has a high retention rate of up to three years with tolerable adverse events; however, it remains unclear whether this is maintained in the longer term. Here we conducted a retrospective five-year follow-up study to explore prognostic factors concerning better retention. In total, 98 patients who were treated with ABT from May 2011 to July 2019 in Osaki Citizen Hospital were enrolled, including 73 female patients (74.5%). The Kaplan-Meier method was used to estimate the retention rate of ABT. The mean age of ABT initiation was 72.1 years. Concomitant methotrexate was prescribed for 39 patients, and ABT was used as the first-line bDMARD for 65 patients. Rheumatoid factor (RF) was positive in 79 patients. One-, three-, and five-year retention rates of ABT were 83.3%, 66.2%, and 62.7%, respectively. Approximately two-thirds of discontinuation resulted from an inadequate response. Multivariate logistic regression analysis revealed that positive RF was associated with better drug retention. Receiver operating characteristics analysis showed that patients with high RF (≥ 45 IU/mL) had better retention rate of ABT. In conclusion, ABT shows high retention rate among patients with positive RF. The present study may provide better insights when selecting bDMARDs.
Primary ovarian diffuse large B-cell lymphoma preceded by autoimmune hemolytic anemia Peer-reviewed

Satoshi Ichikawa, Asami Sasaoka, Noriko Fukuhara, Yoko Okitsu, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

Journal of Hematopathology　13　(1)　63-67　2020/03
Publisher: Springer Science and Business Media LLC
DOI： 10.1007/s12308-019-00377-5 　

ISSN： 1868-9256

eISSN： 1865-5785
Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody International-journal Peer-reviewed

Yusho Ishii, Hiroshi Fujii, Koichiro Sugimura, Tsuyoshi Shirai, Yosuke Hoshi, Yoko Fujita, Yuko Shirota, Tomonori Ishii, Hiroaki Shimokawa, Hideo Harigae

Case Reports in Rheumatology　2020　1926908-1926908　2020/02/26

DOI： 10.1155/2020/1926908 　

More details Close

Systemic sclerosis (SSc) is characterized by skin sclerosis and multiple organ damages which may cause mortality and is usually accompanied with several specific autoantibodies, each of which is associated with characteristic complications. Among them, anticentriole antibody is recently reported to be highly associated with SSc-associated pulmonary arterial hypertension (SSc-PAH). In general, several vasodilators are used as therapeutic drugs for SSc-PAH, whereas immunosuppressive therapies are not. Here, we report the case of a 62-year-old female with anticentriole antibody-positive SSc-PAH treated with immunosuppressants and vasodilators. She presented with two-year exertional dyspnea and was diagnosed with PAH and SSc owing to the centriole staining pattern and other symptoms without digital sclerosis. Oral vasodilators were initially administered but were not sufficiently effective on dyspnea. Immunosuppressants such as prednisolone and cyclophosphamide were started. Both of them improved mean pulmonary arterial pressure and 6-minute walk distance, and the anticentriole antibody also disappeared. In this case, SSc-PAH with anticentriole antibody was properly diagnosed and immunosuppressants and vasodilators improved the hemodynamics of PAH with anticentriole antibody and stably maintained it and, in addition, reduced the titer of anticentriole antibody. This indicates that anticentriole antibody might represent a good responsive group to therapies among subgroups of patients with SSc-PAH.
Unique Sex Steroid Profiles in Estrogen-Producing Adrenocortical Adenoma Associated With Bilateral Hyperaldosteronism International-journal Peer-reviewed

Yuta Tezuka, Yuto Yamazaki, Yoshikiyo Ono, Ryo Morimoto, Kei Omata, Kazumasa Seiji, Kei Takase, Yoshihide Kawasaki, Akihiro Ito, Yasuhiro Nakamura, Hideo Harigae, Hironobu Sasano, Fumitoshi Satoh

JOURNAL OF THE ENDOCRINE SOCIETY　4　(2)　bvaa004　2020/02

DOI： 10.1210/jendso/bvaa004 　

eISSN： 2472-1972
Long-term survival after cord blood transplantation for acute myeloid leukemia complicated with disseminated fusariosis. International-journal Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Shotaro Watanabe, Yoko Okitsu, Koichi Onodera, Yasushi Onishi, Hideo Harigae

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy　26　(2)　292-295　2020/02

DOI： 10.1016/j.jiac.2019.08.022 　

ISSN： 1341-321X

More details Close

Fusariosis is a critical infectious complication that can develop in immunocompromised hosts, mainly under conditions of prolonged neutropenia, and is often disseminated and associated with a high mortality rate. Disseminated fusariosis developing during the course of hematopoietic stem cell transplantation (HSCT) is a critical condition, and there have been few reports of successful treatment of cases complicated with fusariosis before HSCT. Here, we present a case of acute myeloid leukemia (AML) with the development of fungal endophthalmitis during chemotherapy. Vitrectomy was performed and Fusarium solani infection was confirmed by vitreal culture. The infection was also disseminated to the lung, triceps, and spleen. The splenic lesions disappeared with the administration of antifungal agents, and residual lesions in the lung and triceps were surgically resected. After two courses of consolidation chemotherapy, the patient received cord blood transplantation (CBT) twice because of graft failure in the first transplantation. Antifungal agents were administered continuously during chemotherapy and transplantation. Although Fusarium sinusitis developed after neutrophil engraftment, it was well controlled by surgical resection. Thereafter, the patient has been well without recurrence of fusariosis for more than 2 years since transplantation. A combination of continuous administration of antifungal agents and vigorous surgical intervention may be important for management of disseminated fusariosis in the setting of HSCT.
Primary adrenal extranodal NK/T-cell lymphoma: A case report and literature review. International-journal

Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

Leukemia research reports　14　100223-100223　2020

DOI： 10.1016/j.lrr.2020.100223 　

More details Close

A 37-year-old man was admitted to our department following the detection of bulky tumors in his bilateral adrenal glands. A biopsy resulted in the diagnosis of extranodal NK/T cell lymphoma, nasal type (ENKL). After debulking by chemotherapy, allogeneic hematopoietic stem cell transplantation (alloHCT) was performed. Relapses in the liver and adrenal glands were identified 2 months post alloHCT, for which temporary administration of l-asparaginase resulted in complete metabolic response. However, multiple relapses in the central nervous system and lethal lymphomatous meningitis successively developed. Primary adrenal ENKL could tend to present as bulky lesion and follow an aggressive clinical course.
Interferon α Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus. International-journal

Kanae Akita, Ken Yasaka, Tsuyoshi Shirai, Tomonori Ishii, Hideo Harigae, Hiroshi Fujii

Frontiers in immunology　11　498703-498703　2020

DOI： 10.3389/fimmu.2020.498703 　

More details Close

Systemic lupus erythematosus (SLE) is an autoimmune disease. It is characterized by the production of various pathogenic autoantibodies and is suggested to be triggered by increased type I interferon (IFN) signature. Previous studies have identified increased plasmablasts in the peripheral blood of SLE patients. The biological characteristics of SLE plasmablasts remain unknown, and few treatments that target SLE plasmablasts have been applied despite the unique cellular properties of plasmablasts compared with other B cell subsets and plasma cells. We conducted microarray analysis of naïve and memory B cells and plasmablasts (CD38+CD43+ B cells) that were freshly isolated from healthy controls and active SLE (n = 4, each) to clarify the unique biological properties of SLE plasmablasts. The results revealed that all B cell subsets of SLE expressed more type I IFN-stimulated genes. In addition, SLE plasmablasts upregulated the expression of cell cycle-related genes associated with higher FOXM1 and FOXM1-regulated gene expression levels than that in healthy controls. This suggests that a causative relationship exists between type I IFN priming and enhanced proliferative capacity through FOXM1. The effects of pretreatment of IFNα on B cell activation and FOXM1 inhibitor FDI-6 on B cell proliferation and survival were investigated. Pretreatment with IFNα promoted B cell activation after stimulation with anti-IgG/IgM antibody. Flow cytometry revealed that pretreatment with IFNα preferentially enhanced the Atk and p38 pathways after triggering B cell receptors. FDI-6 inhibited cell division and induced apoptosis in activated B cells. These effects were pronounced in activated B cells pretreated with interferon α. This study can provide better understanding of the pathogenic mechanism of interferon-stimulated genes on SLE B cells and an insight into the development of novel therapeutic strategies.
Migratory Aortitis Associated with Granulocyte-colony-stimulating Factor Peer-reviewed

Tsuyoshi Shirai, Hiroka Komatsu, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

INTERNAL MEDICINE　59　(12)　1559-1563　2020

DOI： 10.2169/internalmedicine.4331-19 　

ISSN： 0918-2918

eISSN： 1349-7235
Protein-losing gastroenteropathy with severe hypoalbuminemia associated with Sjögren's syndrome: A case report and review of the literature. Peer-reviewed

Tetsuya Akaishi, Ken Yasaka, Michiaki Abe, Hiroshi Fujii, Mika Watanabe, Tsuyoshi Shirai, Kota Ishizawa, Shin Takayama, Yutaka Kagaya, Hideo Harigae, Tadashi Ishii

Journal of general and family medicine　21　(1)　24-28　2020/01

DOI： 10.1002/jgf2.281 　

More details Close

A 30-year-old man with severe hypoalbuminemia (serum albumin: 0.9 g/dL) was admitted with severe bilateral leg edema and unilateral pleural effusion. Serum anti-SS-A and SS-B antibody levels were abnormally elevated, and his symptoms fulfilled the diagnostic criteria for Sjögren's syndrome. Technetium-99m albumin scintigraphy revealed protein leakage from a large area of the small intestine. Immunohistochemistry revealed perivascular deposition of C1q, C3d, and immunoglobulin G in the duodenal mucosa. The patient was diagnosed with protein-losing gastroenteropathy associated with Sjögren's syndrome. Within 2 months of treatment with oral prednisolone and mycophenolate mofetil, the clinical symptoms of hypoalbuminemia and Sjögren's syndrome disappeared completely.
Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach.

Prabhakar S Kedar, Hideo Harigae, Etsuro Ito, Hideki Muramatsu, Seiji Kojima, Yusuke Okuno, Tohru Fujiwara, Rashmi Dongerdiye, Prashant P Warang, Manisha R Madkaikar

International journal of hematology　110　(5)　618-626　2019/11

DOI： 10.1007/s12185-019-02716-9 　

ISSN： 0925-5710

More details Close

Most patients with anemia are diagnosed through clinical phenotype and basic laboratory testing. Nonetheless, in cases of rare congenital anemias, some patients remain undiagnosed despite undergoing an exhaustive workup. Genetic testing is complicated by the large number of genes that are involved in rare anemias, due to similarities in the clinical presentation. We sought to enhance the diagnosis of patients with congenital anemias by using targeted next-generation sequencing. The genetic diagnosis was performed by gene capture followed by next-generation sequencing of 76 genes known to cause anemia syndromes. Genetic diagnosis was achieved in 17 of 21 transfusion-dependent patients and undiagnosed by conventional workup. Four cases were diagnosed with red cell membrane protein defects, four patients were diagnosed with pyruvate kinase deficiency, one case of adenylate kinase deficiency, one case of glucose phosphate isomerase deficiency, one case of hereditary xerocytosis, three cases having combined membrane and enzyme defect, two cases with Diamond-Blackfan anemia (DBA) and 1 with CDA type II with 26 different mutations, of which 21 are novel. Earlier incorporation of this NGS method into the workup of patients with congenital anemia may improve patient care and enable genetic counselling.
Coexistence of rheumatoid arthritis and systemic lupus erythematosus is still rare in the biologic era: Report of seven cases and literature review. International-journal Peer-reviewed

Hinako Kondo, Ryu Watanabe, Soshi Okazaki, Kaori Kuriyama, Hideo Harigae, Hiroshi Fujii

Modern rheumatology　30　(6)　1-2　2019/10/30

DOI： 10.1080/14397595.2019.1682795 　
Ⅱ-2 巨赤芽球性貧血

張替秀郎

血液疾患最新の治療2020-2022 南江堂　100-1002　2019/10/25
第Ⅷ章-3.巨赤芽球貧血

張替秀郎

血液専門医テキスト（改訂第3版）南江堂　179-182　2019/10/20
1章-A 鉄欠乏性貧血

藤原亨, 張替秀郎

未来型血液治療学中外医学社　1-5　2019/10/15
なんでも健康相談-血液内科フェリチン値が高い。下げる方法は？

張替秀郎

NHKテキストきょうの健康　116　2019/10
Successful cord blood transplantation for a paroxysmal nocturnal hemoglobinuria complicated with Budd-Chiari syndrome and myelodysplastic syndrome International-journal Peer-reviewed

Taro Takahashi, Satoshi Ichikawa, Hideo Harigae

ANNALS OF HEMATOLOGY　98　(10)　2427-2428　2019/10

DOI： 10.1007/s00277-019-03781-0 　

ISSN： 0939-5555

eISSN： 1432-0584
FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis. International-journal Peer-reviewed

Naoko Nakamura, Rumiko Izumi, Yosuke Hoshi, Yoshiki Takai, Risako Ono, Naoki Suzuki, Taichi Nagai, Yusho Ishii, Tomonori Ishii, Hideo Harigae, Shuko Okada, Setsuya Aiba, Naoko Okiyama, Manabu Fujimoto, Hiroshi Kuroda, Maki Tateyama, Masashi Aoki

Rheumatology (Oxford, England)　58　(10)　1888-1888　2019/10/01

DOI： 10.1093/rheumatology/kez083 　

ISSN： 1462-0324
Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. Peer-reviewed

Keita Iwaki, Tohru Fujiwara, Takako Ito, Chie Suzuki, Katsuyuki Sasaki, Koya Ono, Kei Saito, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Tohru Tanaka, Hideto Tamura, Minami Fujiwara, Hideo Harigae

The Tohoku journal of experimental medicine　249　(1)　19-28　2019/09

DOI： 10.1620/tjem.249.19 　

ISSN： 0040-8727

More details Close

Multiple myeloma is the cancer of plasma cells. Along with the development of new and effective therapies, improved outcomes in patients with multiple myeloma have increased the interest in minimal residual disease (MRD) monitoring. However, the considerable heterogeneity of immunophenotypic and molecular markers of myeloma cells has limited its clinical application. 5-Aminolevulinic acid (ALA) is a natural compound in the heme biosynthesis pathway. Following ALA treatment, tumor cells preferentially accumulate porphyrins because of the differential activities of aerobic glycolysis, known as Warburg effect. Among various porphyrins, protoporphyrine IX is a strong photosensitizer; thus, ALA-based photodynamic diagnosis has been widely used in various solid cancers. Here, the feasibility of flow cytometry-based photodynamic detection of MRD was tested in multiple myeloma. Among various human cell lines of hematological malignancies, including K562 erythroleukemia, Jurkat T-cell leukemia, Nalm6 pre-B cell leukemia, KG1a myeloid leukemia, and U937 monocytic leukemia, human myeloma cell line, KMS18, and OPM2 abundantly expressed ALA transporters, such as SLC36A1 and SLC15A2, and 1 mM ALA treatment for 24 h resulted in nearly 100% porphyrin fluorescence expression, which could be competitively inhibited by ALA transport with gamma-aminobutyric acid. Titration studies revealed that the lowest ALA concentration required to achieve nearly 100% porphyrin fluorescence in KMS18 cells was 0.25 mM, with an incubation period of 2 h. Under these conditions, incubation of primary peripheral blood mononuclear cells resulted in only 1.8 % of the cells exhibiting porphyrin fluorescence. Therefore, flow cytometry-based photodynamic diagnosis is a promising approach for detecting MRD in multiple myeloma.
Refractory Takayasu arteritis successfully treated with rituximab: case-based review. International-journal Peer-reviewed

Mutoh T, Ishii T, Shirai T, Akita K, Kamogawa Y, Fujita Y, Sato H, Shirota Y, Fujii H, Harigae H

Rheumatology international　39　(11)　1989-1994　2019/08

DOI： 10.1007/s00296-019-04390-w 　

More details Close

Takayasu arteritis (TAK) is a subtype of the large-vessel vasculitis, affecting the aorta and its major branches. Although T cell-mediated autoimmunity is mainly involved in vascular inflammation, in recent years, accumulating evidence suggests the important role of B cells in the pathogenesis and effectiveness of B-cell-targeted therapy with rituximab (RTX), a chimeric anti-CD20 monoclonal antibody in refractory TAK. Herein, we report for the first time a case involving a 34-year-old man with TAK who was refractory to four different biologic agents, such as one selective T-cell co-stimulation modulator (abatacept), one anti-interleukin-6 receptor monoclonal antibody (tocilizumab), and two tumor necrosis factor-α inhibitors (infliximab and etanercept), but eventually achieved remission with RTX. He received a total of six courses of RTX, and doses of prednisolone and methotrexate were tapered without relapse. The current case provided further evidence to the potential role of RTX therapy in patients with refractory TAK, and its efficacy needs to be validated in a controlled trial.
Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. International-journal Peer-reviewed

Ryo Nakagawa, Yasushi Onishi, Akihisa Kawajiri, Koichi Onodera, Eijiro Furukawa, Sayaka Sano, Kei Saito, Satoshi Ichikawa, Tohru Fujiwara, Noriko Fukuhara, Hideo Harigae

Annals of hematology　98　(8)　1999-2001　2019/08

DOI： 10.1007/s00277-019-03645-7 　

ISSN： 0939-5555
IgG型抗B抗体価4096倍のABO血液型不適合肝移植への検査支援体制

石岡夏子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　65　(3)　668-669　2019/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
ゲルカラム凝集法の血球分注位置の違いにより反応強度に差が生じたweakDの1例

岩木啓太, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　65　(3)　670-670　2019/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Daratumumab併用療法後にCD38陰性化した再発難治性多発性骨髄腫の1症例

大久保礼由, 菅原新吾, 鈴木千恵, 佐々木麻美, 平泉敦子, 藤巻慎一, 齋藤慧, 市川聡, 張替秀郎, 賀来満夫

日本検査血液学会雑誌　20　(学術集会)　S213-S213　2019/06
Publisher: (一社)日本検査血液学会
ISSN： 1347-2836
microBCR-ABL1を認めた慢性骨髄性白血病の1例

鈴木千恵, 菅原新吾, 佐藤亜耶, 安久美子, 平泉敦子, 藤巻慎一, 賀来満夫, 市川聡, 藤原亨, 張替秀郎

日本検査血液学会雑誌　20　(学術集会)　S214-S214　2019/06
Publisher: (一社)日本検査血液学会
ISSN： 1347-2836
IDENTIFICATION OF ENDOTHELIAL PROTEIN C RECEPTOR AND SCAVENGER RECEPTOR CLASS B TYPE 1 AS MAJOR AUTOANTIGENS IN TAKAYASU ARTERITIS Peer-reviewed

Tsuyoshi Shirai, Tomoyuki Mutoh, Tomonori Ishii, Hiroshi Fujii, Hideo Harigae

ANNALS OF THE RHEUMATIC DISEASES　78　437-438　2019/06

DOI： 10.1136/annrheumdis-2019-eular.602 　

ISSN： 0003-4967

eISSN： 1468-2060
免疫抑制療法中に濾胞性リンパ腫と古典的ホジキンリンパ腫を合併した2例

渡邊正太郎, 福原規子, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 市川聡, 大西康, 中村直哉, 一迫玲, 張替秀郎

日本リンパ網内系学会会誌　59　134-134　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
クローン病に合併したびまん性大細胞型B細胞リンパ腫再発に対して臍帯血移植を施行した一例

古川瑛次郎, 福原規子, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 大西康, 張替秀郎

日本リンパ網内系学会会誌　59　147-147　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248

eISSN： 1883-681X
Insufficient use of corticosteroids without immunosuppressants results in higher relapse in Takayasu arteritis. International-journal Peer-reviewed

Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H

The Journal of rheumatology　47　(2)　255-263　2019/05

DOI： 10.3899/jrheum.181219 　

ISSN： 0315-162X

More details Close

OBJECTIVE: Although prednisolone (PSL) and immunosuppressants are key drugs for Takayasu arteritis (TA) treatment, there is limited evidence on the optimal PSL dose. The aim of this study was to investigate the correlation between the initial PSL dose and relapse in TA. METHODS: We enrolled 105 patients with TA who satisfied the criteria of the Japanese Circulation Society and American College of Rheumatology from 1990 to 2015. The clinical characteristics and outcomes of patients with TA were retrospectively evaluated. The relapse-free period was assessed according to the difference in initial treatments. RESULTS: Relapse was observed in 57 (59.4%) of 96 patients treated with immunosuppressive therapy at diagnosis during a median followup of 56 months. Male sex and younger age of onset were significantly associated with relapse. Although ≤ 30 mg/day PSL monotherapy was preferably prescribed for patients with lower inflammatory markers, compared with > 30 mg/day (87.2% vs 52.6%), a significantly higher relapse rate was observed in the ≤ 30 mg/day group (HR 1.78; p = 0.047). Further, the relapse-free period was longer in patients treated with ≥ 50 mg/day PSL compared with those treated with ≤ 40 mg/day PSL. Combination therapy improved the relapse-free period compared with PSL monotherapy in the short term. The initial PSL dose was not associated with adverse events. CONCLUSION: A higher dose of PSL was associated with a significant decrease in the relapse rate. The effect of combination therapy on relapse needs to be further investigated. Lower-dose PSL monotherapy is an undesirable strategy for remission induction in TA, despite low disease activity.
アルブミン製剤使用量削減に伴う臨床的アウトカムへの影響

関修, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 秋山正年, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　65　(2)　437-437　2019/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
巨大な膵形質細胞腫を伴った再発難治性多発性骨髄腫の1例

古川瑛次郎, 市川聡, 福原規子, 齋藤慧, 佐野沙矢香, 中川諒, 川尻昭寿, 小野寺晃一, 大西康, 張替秀郎

臨床血液　60　(4)　331-331　2019/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Daratumumab併用療法後にCD38陰性化を伴って病勢増悪を来した再発難治性多発性骨髄腫の1例

齋藤慧, 古川瑛次郎, 佐野沙矢香, 中川諒, 川尻昭寿, 小野寺晃一, 市川聡, 大西康, 福原規子, 張替秀郎

臨床血液　60　(4)　337-337　2019/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Generation and Molecular Characterization of Human Ring Sideroblasts: a Key Role of Ferrous Iron in Terminal Erythroid Differentiation and Ring Sideroblast Formation. International-journal Peer-reviewed

Saito K, Fujiwara T, Hatta S, Morita M, Ono K, Suzuki C, Fukuhara N, Onishi Y, Nakamura Y, Kawamata S, Shimizu R, Yamamoto M, Harigae H

Molecular and cellular biology　39　(7)　2019/04

DOI： 10.1128/MCB.00387-18 　

ISSN： 0270-7306

More details Close

Ring sideroblasts are a hallmark of sideroblastic anemia, although little is known about their characteristics. Here, we first generated mutant mice by disrupting the GATA-1 binding motif at the intron 1 enhancer of the ALAS2 gene, a gene responsible for X-linked sideroblastic anemia (XLSA). Although heterozygous female mice showed an anemic phenotype, ring sideroblasts were not observed in their bone marrow. We next established human induced pluripotent stem cell-derived proerythroblast clones harboring the same ALAS2 gene mutation. Through coculture with sodium ferrous citrate, mutant clones differentiated into mature erythroblasts and became ring sideroblasts with upregulation of metal transporters (MFRN1, ZIP8, and DMT1), suggesting a key role for ferrous iron in erythroid differentiation. Interestingly, holo-transferrin (holo-Tf) did not induce erythroid differentiation as well as ring sideroblast formation, and mutant cells underwent apoptosis. Despite massive iron granule content, ring sideroblasts were less apoptotic than holo-Tf-treated undifferentiated cells. Microarray analysis revealed upregulation of antiapoptotic genes in ring sideroblasts, a profile partly shared with erythroblasts from a patient with XLSA. These results suggest that ring sideroblasts exert a reaction to avoid cell death by activating antiapoptotic programs. Our model may become an important tool to clarify the pathophysiology of sideroblastic anemia.
Immunohistochemical pattern of c-MYC protein judged as "+/(weak)+/-" by a new notation correlates with MYC gene nontranslocation in large B-cell lymphoma. International-journal Peer-reviewed

Fujishima F, Katsushima H, Fukuhara N, Konosu-Fukaya S, Nakamura Y, Usubuchi H, Sato S, Ota Y, Yashima-Abo A, Nakamura T, Nakaya N, Harigae H, Sasano H, Ichinohasama R

Human pathology　85　112-118　2019/03

DOI： 10.1016/j.humpath.2018.10.025 　

ISSN： 0046-8177

More details Close

Immunohistochemistry is not only the most important tool for pathologists to establish a final diagnosis, but it can also inform decisions regarding optimal treatment methods. However, there is no universal standard notation for expressing immunohistochemical findings. For a diagnosis of malignant lymphoma, it is important to confirm the presence or absence of MYC translocation and communicate these results to a clinical audience. However, the criteria for selecting cases for fluorescence in situ hybridization (FISH) analysis to confirm MYC translocation are ill defined. We therefore devised a notation that we termed proportion of immunoreactivity/expression for immunohistochemistry (PRIME notation) based on the cellular proportion showing different antigen-antibody reactivity in immunohistochemistry (CPAR) and used it to examine the relationship between MYC translocation and the proportion of c-MYC+ lymphoma cells. We reviewed 82 cases diagnosed as diffuse large B-cell lymphoma or diffuse large B-cell lymphoma coexisting with grade 3A to 3B follicular lymphoma. The most common notation was "+/(weak)+/-" (49/82 cases [59.8%]); cases that were CPAR positive, weakly positive, and negative for tumor cells each accounted for about one-third of the total. Unexpectedly, no MYC translocation was observed by FISH in this group. Thus, FISH is not needed even if more than half of cells are c-MYC positive by PRIME notation. This is the first report describing a correspondence between immunohistochemical findings and chromosomal abnormality, reflecting findings at the protein and gene levels, respectively.
Iron as Soul of Life on Earth Revisited: From Chemical Reaction, Ferroptosis to Therapeutics. International-journal Peer-reviewed

Harigae H, Hino K, Toyokuni S

Free radical biology & medicine　133　1-2　2019/03

DOI： 10.1016/j.freeradbiomed.2019.01.042 　

ISSN： 0891-5849
「クリオプレシピテート院内作製プロトコール」に準じて調製した同種クリオプレシピテートの品質検討結果

細川真梨, 岩木啓太, 伊藤智啓, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 大久保礼由, 菅原新吾, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　65　(1)　93-97　2019/02
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Umbilical Cord Blood Transplantation Using Reduced-Intensity Conditioning without Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia. International-journal Peer-reviewed

Tetsuro Ochi, Yasushi Onishi, Kentaro Nasu, Koichi Onodera, Masahiro Kobayashi, Satoshi Ichikawa, Tohru Fujiwara, Noriko Fukuhara, Minami Yamada-Fujiwara, Hideo Harigae

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation　25　(2)　e55-e59-e59　2019/02

DOI： 10.1016/j.bbmt.2018.09.039 　

ISSN： 1083-8791

More details Close

Umbilical cord blood transplantation (UCBT) is a possible option for patients with aplastic anemia (AA) without a related or unrelated HLA-matched donor, particularly if immunosuppressive therapy (IST) has failed or transplantation is urgently needed. However, a higher rate of graft failure after UCBT remains a major problem, and the optimal conditioning regimen for stable engraftment after UCBT has not been established. Here we investigated 6 adult patients with AA who underwent UCBT using a reduced-intensity conditioning (RIC) regimen comprising fludarabine 125 mg/m2, cyclophosphamide 120 mg/kg, and 4 Gy of total body irradiation (Flu/CY/TBI4Gy) without antithymocyte globulin (ATG). Five patients underwent UCBT after IST failure, and 1 patient underwent UCBT as a first-line treatment due to a fulminant clinical finding of a neutrophil count of 0, despite granulocyte colony-stimulating factor administration. Regarding graft-versus-host disease (GVHD) prophylaxis, 2 patients received tacrolimus plus short-term methotrexate and 4 patients received tacrolimus plus mycophenolate mofetil, and all patients achieved sustained engraftment of both neutrophils and platelets, at a median of 17.5 days (range, 14 to 37 days) and 38.5 days (range, 31 to 86 days), respectively, with complete donor chimerism confirmed in all patients at a median of 14 days (range, 14 to 32 days). Three patients developed grade II acute GVHD (aGVHD), but grade III/IV aGVHD was not observed, whereas 4 patients developed chronic GVHD involving only skin. At the time of this report, all 6 patients were alive without the need for blood transfusion, at a median follow-up of 16 months (range, 12 to 131 months). Although further study is needed, our findings suggest that conditioning with Flu/CY/TBI4Gy without ATG might allow stable engraftment in UCBT for adults with AA.
Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries. Peer-reviewed

Shirai T, Shirota Y, Fujii H, Ishii T, Harigae H

Scandinavian journal of rheumatology　48　(4)　308-314　2019/01

DOI： 10.1080/03009742.2018.1551965 　

More details Close

OBJECTIVE:Within the spectrum of polyarteritis nodosa (PAN), cutaneous PAN (cPAN) is further classified into mild cPAN and severe cPAN which presents with ulcers, necrosis, or neuritis. As distinguishing between severe cPAN and systemic PAN can be difficult, this study evaluated the clinical characteristics of patients with necrotizing arteritis of medium-sized arteries. METHODS:Forty-one patients diagnosed with necrotizing arteritis of medium-sized arteries between 2008 and 2017 at our institution were enrolled in this study. Clinical background, laboratory findings, treatments, and rates of relapse and death were evaluated. RESULTS:Thirty-six patients were classified as having cPAN (mild, 15; ulcer, nine; neuritis, eight; both, four), and five cases manifested systemic vasculitis. Clinical characteristics of mild cPAN included female predominance (84.6%) and younger age (median 31 years); those of systemic PAN included older age (median 71 years) and higher levels of inflammatory markers. Severe cPAN manifested with intermediate phenotypes. The median doses of prednisolone used to treat mild cPAN, severe cPAN, and systemic PAN were 20.0, 40.0, and 40.0 mg/day, respectively. Immunosuppressants were used in 20.0% of mild cPAN, 90.5% of severe cPAN, and 80.0% of systemic PAN patients. Although the mortality rates were indistinguishable, the relapse rates of severe cPAN (ulcer type) were significantly higher than those of other types (88.9%). CONCLUSION:The clinical characteristics of mild cPAN, severe cPAN (ulcer type), severe cPAN (neuritis type), and systemic PAN were distinct from each other. In particular, patients with severe cPAN (ulcer type) had higher relapse rates, indicating the importance of combination therapy.
アルブミン製剤使用量削減に伴う臨床的アウトカムへの影響

関修, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 秋山正年, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　64　(6)　802-802　2018/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial

Takashi Watanabe, Kensei Tobinai, Masashi Wakabayashi, Yasuo Morishima, Hirofumi Kobayashi, Tomohiro Kinoshita, Takayo Suzuki, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Masafumi Taniwaki, Naokuni Uike, Tadashi Yoshino, Sigeru Nawano, Takashi Terauchi, Tomomitsu Hotta, Hirokazu Nagai, Kunihiro Tsukasaki, Mitsutoshi Kurosawa, Kayo Yamagishi, Naoki Kobayashi, Koichiro Minauchi, Hideo Harigae, Noriko Fukuhara, Naoto Takahashi, Yoshihiro Kameoka, Shin Matsuda, Yurie Saitoh, Norifumi Tsukamoto, Akihiko Yokohama, Nobuko Kubota, Yosuke Minami, Nobuhiko Yamauchi, Kyoya Kumagai, Hideki Tsujimura, Koji Izutsu, Dai Maruyama, Nobuyuki Takayama, Kazuma Ohyashiki, Daigo Akahane, Tatsu Shimoyama, Takaki Shimada, Yutaro Kamiyama, Nobuaki Dobashi, Izumi Wasada, Fumiaki Sano, Madoka Takimoto, Takaaki Chou, Takuro Ishiguro, Yasufumi Masaki, Takahiro Yamauchi, Takaaki Ono, Kazuhito Yamamoto, Harumi Kato, Takashi Tokunaga, Kazuyuki Shimada, Yoko Ushijima, Shinsuke Iida, Shigeru Kusumoto, Toshiki Uchida, Ichiro Hanamura, Jo Kanasugi, Yoshitoyo Kagami, Junji Hiraga, Kana Miyazaki, Takahiko Utsumi, Junya Kuroda, Tsutomu Kobayashi, Itaru Matsumura, Shinya Rai, Tohru Murayama, Hiroshi Gomyo, Kazutaka Sunami, Masanori Makita, Tatsuo Ichinohe, Noriyasu Fukushima, Isao Yoshida, Yoshihiro Yakushijin, Hiroaki Asai, Youko Suehiro, Ilseung Choi, Yasushi Takamatsu, Hidenori Sasaki, Satoshi Yamasaki, Junichi Tsukada, Hiroaki Morimoto, Shinya Kimura, Masako Yokoo, Shinichiro Yoshida, Yukiyoshi Moriuchi, Yasushi Miyazaki, Yoshitaka Imaizumi, Tatsuro Jo, Kisato Nosaka, Hiro Tatetsu, Michihiro Hidaka, Naoko Harada, Eiichi Ohtsuka, Kenji Ishitsuka, Makoto Yoshimitsu

The Lancet Haematology　5　(11)　e520-e531　2018/11

DOI： 10.1016/S2352-3026(18)30155-8 　

eISSN： 2352-3026
Diagnosis of Inherited Bone Marrow Failure Syndromes Using Sequencing Approaches

Narita Atsushi, Muramatsu Hideki, Okuno Yusuke, Yoshida Kenichi, Shiraishi Yuichi, Sakaguchi Hirotoshi, Kawashima Nozomu, Wang Xinan, Xu Yinyan, Chiba Kenichi, Tanaka Hiroko, Hama Asahito, Sanada Masashi, Hitoshi Kanno, Yamaguchi Hiroki, Ohga Shouichi, Manabe Atsushi, Harigae Hideo, Kunishima Shinji, Ishii Eiichi, Kobayashi Masao, Koike Kenichi, Watanabe Kenichiro, Ito Etsuro, Takata Minoru, Yabe Miharu, Ogawa Seishi, Miyano Satoru, Kojima Seiji, Takahashi Yoshiyuki

PEDIATRIC BLOOD & CANCER　65　S7-S7-S7　2018/11

ISSN： 1545-5009

eISSN： 1545-5017
シーケンスによる先天性骨髄不全症の診断(Diagnosis of Inherited Bone Marrow Failure Syndromes Using Sequencing Approaches)

Narita Atsushi, Muramatsu Hideki, Okuno Yusuke, Yoshida Kenichi, Shiraishi Yuichi, Sakaguchi Hirotoshi, Kawashima Nozomu, Wang Xinan, Xu Yinyan, Chiba Kenichi, Tanaka Hiroko, Hama Asahito, Sanada Masashi, Kanno Hitoshi, Yamaguchi Hiroki, Ohga Shouichi, Manabe Atsushi, Harigae Hideo, Kunishima Shinji, Ishii Eiichi, Kobayashi Masao, Koike Kenichi, Watanabe Kenichiro, Ito Etsuro, Takata Minoru, Yabe Miharu, Ogawa Seishi, Miyano Satoru, Kojima Seiji, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌　55　(4)　153-153　2018/10
Publisher: (一社)日本小児血液・がん学会
ISSN： 2187-011X

eISSN： 2189-5384
Infection perturbs Bach2- and Bach1-dependent erythroid lineage 'choice' to cause anemia. International-journal Peer-reviewed

Hiroki Kato, Ari Itoh-Nakadai, Mitsuyo Matsumoto, Yusho Ishii, Miki Watanabe-Matsui, Masatoshi Ikeda, Risa Ebina-Shibuya, Yuki Sato, Masahiro Kobayashi, Hironari Nishizawa, Katsushi Suzuki, Akihiko Muto, Tohru Fujiwara, Yasuhito Nannya, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Hideo Harigae, Kazuhiko Igarashi

Nature immunology　19　(10)　1059-1070　2018/10

DOI： 10.1038/s41590-018-0202-3 　

ISSN： 1529-2908

More details Close

Elucidation of how the differentiation of hematopoietic stem and progenitor cells (HSPCs) is reconfigured in response to the environment is critical for understanding the biology and disorder of hematopoiesis. Here we found that the transcription factors (TFs) Bach2 and Bach1 promoted erythropoiesis by regulating heme metabolism in committed erythroid cells to sustain erythroblast maturation and by reinforcing erythroid commitment at the erythro-myeloid bifurcation step. Bach TFs repressed expression of the gene encoding the transcription factor C/EBPβ, as well as that of its target genes encoding molecules important for myelopoiesis and inflammation; they achieved the latter by binding to their regulatory regions also bound by C/EBPβ. Lipopolysaccharide diminished the expression of Bach TFs in progenitor cells and promoted myeloid differentiation. Overexpression of Bach2 in HSPCs promoted erythroid development and inhibited myelopoiesis. Knockdown of BACH1 or BACH2 in human CD34+ HSPCs impaired erythroid differentiation in vitro. Thus, Bach TFs accelerate erythroid commitment by suppressing the myeloid program at steady state. Anemia of inflammation and myelodysplastic syndrome might involve reduced activity of Bach TFs.
Scurfyマウスにおける全身性のNRF2活性化がもたらす炎症抑制作用の解析(Systemic activation of NRF2 alleviates lethal autoimmune inflammation in scurfy mice)

鈴木琢磨, 村上昌平, 張替秀郎, 本橋ほづみ

臨床血液　59　(9)　1515-1515　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
X連鎖性鉄芽球性貧血の細胞モデルの解析(Characterization of in vitro model of X-linked sideroblastic anemia)

齋藤慧, 藤原亨, 八田俊介, 小野寺晃一, 市川聡, 福原規子, 大西康, 中村幸夫, 張替秀郎

臨床血液　59　(9)　1498-1498　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
APTT単独延長疾患の原因の検討(Causes of isolated prolonged APTT in Tohoku University Hospital over the past seven years)

亀岡淳一, 沖津庸子, 小林匡洋, 市川聡, 城田祐子, 岡友美子, 小寺隆雄, 高橋伸一郎, 張替秀郎

臨床血液　59　(9)　1539-1539　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
CD56陽性皮膚T細胞リンパ腫6例の後方視的解析(A clinicopathological analysis of CD56-positive cutaneous T cell lymphoma)

大地哲朗, 福原規子, 佐野沙矢香, 那須健太郎, 小林匡洋, 市川聡, 沖津庸子, 大西康, 藤原実名美, 藤村卓, 一迫玲, 張替秀郎

臨床血液　59　(9)　1549-1549　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
T-LGL白血病に対するシクロスポリンA治療単施設の経験(Cyclosporine A treatment for T-cell large granular lymphocytic leukemia: a single-center experience)

大西康, 藤原実名美, 佐野沙矢香, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 藤原亨, 張替秀郎

臨床血液　59　(9)　1569-1569　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
成熟T細胞性リンパ腫に対する臍帯血移植 10例の報告(Umbilical cord blood transplantation for mature T-cell lymphoma: report of 10 cases)

佐野沙矢香, 大西康, 古川瑛次郎, 中川諒, 齋藤慧, 川尻昭寿, 小野寺晃一, 市川聡, 福原規子, 張替秀郎

臨床血液　59　(9)　1680-1680　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
転写因子GATA-2の制御因子同定のためのスクリーニング法の確立(Establishment of a screening system to identify novel GATA-2 transcriptional regulators)

大橋圭一, 藤原亨, 小野寺晃一, 齋藤陽, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 大西康, 張替秀郎

臨床血液　59　(9)　1696-1696　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
びまん性大細胞型B細胞リンパ腫におけるsIL-2R値の層別化予後因子としての意義(Serum sIL-2R level is a prognostic stratification marker of diffuse large B-cell lymphoma)

市川聡, 福原規子, 小林匡洋, 沖津庸子, 大西康, 一迫玲, 石澤賢一, 張替秀郎

臨床血液　59　(9)　1785-1785　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
ダラツムマブ投与中にサイトメガロウイルス抗原血症陽性化を示した多発性骨髄腫の2例(Two cases of multiple myeloma with cytomegalovirus antigenemia during daratumumab therapy)

小林匡洋, 佐野沙矢香, 大地哲朗, 那須健太郎, 市川聡, 福原規子, 大西康, 亀岡淳一, 張替秀郎

臨床血液　59　(9)　1805-1805　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis Peer-reviewed

Tsuyoshi Shirai, Tomoyuki Muto, Yuko Shirota, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　70　2018/09

ISSN： 2326-5191

eISSN： 2326-5205
Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases Peer-reviewed

Yuko Shirota, Tomonori Ishii, Tsuyoshi Shirai, Hiroshi Fujii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　70　2018/09

ISSN： 2326-5191

eISSN： 2326-5205
多発性骨髄腫治療薬daratumumab投与期間中に赤血球輸血を複数回実施した1症例

伊藤智啓, 岩木啓太, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　64　(3)　565-565　2018/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
「クリオプレシピテート作製プロトコール」に準じた院内調製同種クリオプレシピテートの品質検討

細川真梨, 岩木啓太, 伊藤智啓, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 大久保礼由, 菅原新吾, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　64　(2)　337-337　2018/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
東北大学病院における輸血副作用の動向

郷野辰幸, 伊藤智啓, 細川真梨, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　64　(2)　405-405　2018/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Dasatinibによる治療を行ったphiladelphia染色体陽性骨髄異形成症候群

大地哲朗, 大西康, 佐野沙矢香, 大橋圭一, 那須健太郎, 市川聡, 小林匡洋, 沖津庸子, 福原規子, 張替秀郎

臨床血液　59　(4)　448-448　2018/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
院内調製同種クリオプレシピテートの品質検討

細川真梨, 岩木啓太, 伊藤智啓, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 大久保礼由, 菅原新吾, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　63　(6)　803-804　2017/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
転写因子Bach1及びBach2の環境変化に応じた赤血球-ミエロイド分化制御(Bach1 and Bach2 orchestrate erythro-myeloid differentiation responding to environmental changes)

Kato Hiroki, Itoh Ari, Matsumoto Mitsuyo, Shibuya Risa, Sato Yuki, Kobayashi Masahiro, Muto Akihiko, Fujiwara Tohru, Harigae Hideo, Igarashi Kazuhiko

臨床血液　58　(9)　1489-1489　2017/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity Peer-reviewed

Tomoko Ikeda, Hiroshi Fujii, Masato Nose, Yukiko Kamogawa, Tsuyoshi Shirai, Yuko Shirota, Tomonori Ishii, Hideo Harigae

Arthritis Research & Therapy　19　(1)　2017/08
Publisher: Springer Nature
DOI： 10.1186/s13075-017-1397-7 　

ISSN： 1478-6362
骨髄濃縮処理におけるCOBE SpectraおよびSpectra Optiaの後方視的比較検討

岩木啓太, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 関修, 佐藤裕子, 成田香魚子, 工藤善範, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　63　(3)　424-424　2017/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
東北大学病院でのアルブミン使用適正化への取り組み

成田香魚子, 関修, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 工藤善範, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　63　(3)　515-515　2017/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
急性白血病を伴う播種性血管内血液凝固患者に対する組み換え型可溶性トロンボモジュリンの安全性と有効性の評価東北血液フォーラムによる多施設共同前向き試験(Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum)

Yokoyama Hisayuki, Takahashi Naoto, Katsuoka Yuna, Inomata Mitsue, Ito Toshihiro, Meguro Kuniaki, Kameoka Yoshihiro, Tsumanuma Riko, Murai Kazunori, Noji Hideyoshi, Ishizawa Kenichi, Ito Shigeki, Onishi Yasushi, Harigae Hideo, the Tohoku Hematology Forum

International Journal of Hematology　105　(5)　606-613　2017/05
Publisher: (一社)日本血液学会
ISSN： 0925-5710

eISSN： 1865-3774
脳死肺移植・心臓移植における血液製剤使用量の解析

岩木啓太, 伊藤智啓, 細川真梨, 郷野辰幸, 阿部真知子, 石岡夏子, 関修, 佐藤裕子, 成田香魚子, 松浦健, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　63　(2)　159-159　2017/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
リウマチ性疾患の合併症 11C-BF-227-PETによる全身アミロイド計測を試みたアミロイドーシス6症例の検討

城田祐子, 石井悠翔, 星陽介, 藤田洋子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　61回　585-585　2017/03
Publisher: (一社)日本リウマチ学会
心臓MRIで遅延造影なく心臓生検で心筋炎の診断がついた全身性エリテマトーデス(SLE)の一例

藤田洋子, 星陽介, 石井悠翔, 武藤智之, 町山智章, 秋田佳奈恵, 鴨川由起子, 白井剛志, 城田祐子, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　61回　674-674　2017/03
Publisher: (一社)日本リウマチ学会
免疫抑療法制が奏効した抗セントリオール抗体陽性全身性強皮症関連肺動脈性肺高血圧症の1例

石井悠翔, 藤田洋子, 白井剛志, 城田祐子, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　61回　748-748　2017/03
Publisher: (一社)日本リウマチ学会
ABOマイナーミスマッチ骨髄処理における用手的血漿除去と、機器による骨髄濃縮の比較検討

岩木啓太, 伊藤智啓, 細川真梨, 郷野辰幸, 阿部真知子, 石岡夏子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　63　(1)　64-64　2017/02
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
[Successful Treatment of Severe and Refractory Thrombotic Thrombocytopenic Purpura with Early Rituximab Administration]. Peer-reviewed

Satoshi Ichikawa, Masahito Himuro, Yoko Okitsu, Noriko Fukuhara, Mai Watanabe, Shunsuke Hatta, Masahiro Kobayashi, Yasushi Onishi, Masanori Matsumoto, Hideo Harigae

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine　106　(1)　99-106　2017/01

ISSN： 0021-5384
細胞外環境を転写とエピゲノムへ統合する分子機構 Inner Myeloidの遺伝子制御ネットワークとその環境応答機構

五十嵐和彦, 加藤浩貴, 張替秀郎, 武藤哲彦, 松本光代, 伊藤亜里, AMED-CREST

日本生化学会大会プログラム・講演要旨集　89回　[2S01-2]　2016/09
Publisher: (公社)日本生化学会
東北大学病院でのアルブミン使用適正化への取り組み

成田香魚子, 関修, 加藤愛美, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 佐藤裕子, 工藤善範, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　62　(3)　500-500　2016/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
当院における同種クリオプレシピテートの使用状況

細川真梨, 成田香魚子, 加藤愛美, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 関修, 佐藤裕子, 工藤善範, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　62　(2)　347-347　2016/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
東北大学病院におけるアルブミン製剤の使用状況と適正使用の取り組み

関修, 成田香魚子, 加藤愛美, 細川真梨, 郷野辰幸, 岩木啓太, 阿部真知子, 石岡夏子, 佐藤裕子, 工藤善範, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　62　(2)　377-377　2016/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Activation of the NLRP3 inflammasome by cellular labile iron Peer-reviewed

Kyohei Nakamura, Toru Kawakami, Naoki Yamamoto, Miyu Tomizawa, Tohru Fujiwara, Tomonori Ishii, Hideo Harigae, Kouetsu Ogasawara

Experimental Hematology　44　(2)　116-124　2016/02/01
Publisher: Elsevier Inc.
DOI： 10.1016/j.exphem.2015.11.002 　

ISSN： 1873-2399 0301-472X
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival Peer-reviewed

Hiroto Ohguchi, Teru Hideshima, Manoj K. Bhasin, Gullu T. Gorgun, Loredana Santo, Michele Cea, Mehmet K. Samur, Naoya Mimura, Rikio Suzuki, Yu-Tzu Tai, Ruben D. Carrasco, Noopur Raje, Paul G. Richardson, Nikhil C. Munshi, Hideo Harigae, Takaomi Sanda, Juro Sakai, Kenneth C. Anderson

Nature Communications　7　10258　2016/01/05
Publisher: Nature Publishing Group
DOI： 10.1038/ncomms10258 　

ISSN： 2041-1723

eISSN： 2041-1723
Overview

HARIGAE Hideo

Rinsho Ketsueki　57　(2)　90-90　2016
Publisher: The Japanese Society of Hematology
DOI： 10.11406/rinketsu.57.90 　

ISSN： 0485-1439
Advanced Lymphocyte-rich Classical Hodgkin Lymphoma Complicated with Fatal Hemophagocytic Syndrome Peer-reviewed

Satoshi Ichikawa, Taro Takahashi, Hiroki Katsushima, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

INTERNAL MEDICINE　55　(2)　191-196　2016

DOI： 10.2169/internalmedicine.55.5942 　

ISSN： 0918-2918

eISSN： 1349-7235
Thrombotic thrombocytopenic purpura associated with \textit{Klebsiella} pneumonia in the background of alcoholic liver cirrhosis Peer-reviewed

Ichikawa S, Sasaki K, Takahashi T, Hayakawa M, Matsumoto M, Harigae H

Case Reports in Internal Medicine　3　30-35　2016

DOI： 10.5430/crim.v3n3p30 　
Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL) Peer-reviewed

Kinoshita Tomohiro, Fukuhara Noriko, Nagai Hirokazu, Izutsu Koji, Kobayashi Yukio, Higuchi Yusuke, Harigae Hideo, Tokunaga Takashi, Adewoye Henry, Robeson Michelle, Sharma Shringi, Fukui Masato, Gao Jie, Christenson Christine, Tobinai Kensei

BLOOD　126　(23)　2015/12/03

DOI： 10.1182/blood.V126.23.5089.5089 　

ISSN： 0006-4971
Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia Peer-reviewed

Naoyoshi Maeda, Takashi Ohashi, Haorile Chagan-Yasutan, Toshio Hattori, Yayoi Takahashi, Hideo Harigae, Hiroo Hasegawa, Yasuaki Yamada, Masahiro Fujii, Katsumi Maenaka, Toshimitsu Uede

Retrovirology　12　(1)　2015/11/24
Publisher: BioMed Central Ltd.
DOI： 10.1186/s12977-015-0225-x 　

ISSN： 1742-4690
白血病合併DICに対する遺伝子組み換えthrombomodulinの安全性と有効性多施設共同第II相試験(Safety and efficacy of recombinant thrombomodulin for DIC with leukemia: multicenter, phase II study)

Yokoyama Hisayuki, Takahashi Naoto, Kameoka Yoshihiro, Noji Hideyoshi, Murai Kazunori, Omoto Eijiro, Katsuoka Yuna, Itou Toshihiro, Meguro Kuniaki, Ishizawa Kenichi, Ogawa Kazuei, Ishida Yoji, Sawada Kenichi, Harigae Hideo

臨床血液　56　(9)　1422-1422　2015/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
難治性または再発性DLBCL患者のサルベージ治療としてのR-GDP療法(R-GDP therapy as salvage treatment of patients with refractory or relapsed DLBCL)

Kameoka Yoshihiro, Ubukawa Kumi, Nara Miho, Yokoyama Hisayuki, Ito Shigeki, Ishizawa Kenichi, Ishida Yoji, Harigae Hideo, Takahashi Naoto

臨床血液　56　(9)　1506-1506　2015/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
頻回輸血により複数抗体を産生し対応に苦慮した例

阿部真知子, 成田香魚子, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 関修, 佐藤裕子, 工藤善範, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　61　(3)　438-438　2015/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
東北大学病院における大量輸血の現状

岩木啓太, 成田香魚子, 細川真梨, 郷野辰幸, 阿部真知子, 石岡夏子, 関修, 佐藤裕子, 工藤善範, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　61　(2)　266-266　2015/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
食道穿孔を合併したびまん性大細胞型B細胞性リンパ腫の2症例 Peer-reviewed

齋藤慧, 鈴木, 琢磨, 大橋, 圭一, 突田, 真紀子, 小林, 匡洋, 沖津, 庸子, 福原, 規子, 大西, 康, 藤原, 亨, 藤原, 実名美, 亀岡, 淳一, 張替秀郎

臨床血液　56　(4)　436-436　2015/04
東北大学病院における過去3年間の緊急輸血の解析

佐藤裕子, 成田香魚子, 岩木啓太, 細川真梨, 郷野辰幸, 阿部真知子, 石岡夏子, 関修, 工藤善範, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　61　(1)　35-35　2015/02
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Pseudothrombocytosis caused by cryoglobulin crystals in a patient with primary Sjogren's syndrome Peer-reviewed

Naoko Takada, Ryu Watanabe, Hiroshi Fujii, Yukiko Kamogawa, Yoko Fujita, Yuko Shirota, Shinichiro Saito, Tomonori Ishii, Hideo Harigae

MODERN RHEUMATOLOGY　25　(5)　814-815　2015

DOI： 10.3109/14397595.2014.926851 　

ISSN： 1439-7595

eISSN： 1439-7609
Synovitis in a Patient with IgG4-related Disease Peer-reviewed

Fumiko Tomiyama, Ryu Watanabe, Hiroshi Fujii, Yukiko Kamogawa, Yoko Fujita, Yuko Shirota, Takashi Nakamichi, Hiroshi Sato, Tomonori Ishii, Hideo Harigae

INTERNAL MEDICINE　54　(11)　1427-1432　2015

DOI： 10.2169/internalmedicine.54.4320 　

ISSN： 0918-2918

eISSN： 1349-7235
Biology of Heme in Mammalian Erythroid Cells and Related Disorders Peer-reviewed

Tohru Fujiwara, Hideo Harigae

BioMed Research International　2015　278536　2015
Publisher: Hindawi Publishing Corporation
DOI： 10.1155/2015/278536 　

ISSN： 2314-6141 2314-6133
Update on the biology of heme synthesis in erythroid cells. Peer-reviewed

Fujiwara, Tohru, Harigae, Hideo

Rinsho Ketsueki　56　(2)　119-127　2015

DOI： 10.11406/rinketsu.56.119 　
凍結保存臍帯血の解凍後および洗浄後の品質評価

岩木啓太, 藤原実名美, 工藤善範, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 成田香魚子, 高橋博之, 大西康, 張替秀郎, 峯岸正好

日本輸血細胞治療学会誌　60　(6)　619-620　2014/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
臍帯血移植後の自己造血回復から3ヵ月後に完全ドナー型キメラを達成した原発性骨髄線維症の1例 Peer-reviewed

渡邊正太郎, 大西, 康突田, 真紀子, 齋藤慧, 鈴木, 琢磨, 大橋, 圭一, 小林, 匡洋, 沖津, 庸子, 福原, 規子, 藤原, 亨, 藤原, 実名美, 亀岡, 淳一, 石澤, 賢一, 張替秀郎

臨床血液　55　(11)　2356-2357　2014/11

DOI： 10.11406/rinketsu.55.2356 　
慢性骨髄性白血病の臍帯血移植後中枢神経再発に対しdasatinibが奏効した1例 Peer-reviewed

加藤浩貴, 福原, 規子, 大橋, 圭一, 近藤, 愛子, 長谷川, 慎, 鎌田, 真弓, 市川, 聡, 沖津, 庸子, 大西, 康, 藤原, 亨, 藤原, 実名美, 石澤, 賢一, 亀岡, 淳一, 張替秀郎

臨床血液　55　(11)　2353-2353　2014/11
Effect of 5-aminolevulinic acid on erythropoiesis: A preclinical in vitro characterization for the treatment of congenital sideroblastic anemia Peer-reviewed

Tohru Fujiwara, Koji Okamoto, Ryoyu Niikuni, Kiwamu Takahashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Yukio Nakamura, Motowo Nakajima, Tohru Tanaka, Hideo Harigae

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS　454　(1)　102-108　2014/11

DOI： 10.1016/j.bbrc.2014.10.050 　

ISSN： 0006-291X

eISSN： 1090-2104
GATA2 regulates differentiation of bone marrow-derived mesenchymal stem cells. International-journal Peer-reviewed

Mayumi Kamata, Yoko Okitsu, Tohru Fujiwara, Masahiko Kanehira, Shinji Nakajima, Taro Takahashi, Ai Inoue, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

Haematologica　99　(11)　1686-96　2014/11

DOI： 10.3324/haematol.2014.105692 　

ISSN： 0390-6078

More details Close

The bone marrow microenvironment comprises multiple cell niches derived from bone marrow mesenchymal stem cells. However, the molecular mechanism of bone marrow mesenchymal stem cell differentiation is poorly understood. The transcription factor GATA2 is indispensable for hematopoietic stem cell function as well as other hematopoietic lineages, suggesting that it may maintain bone marrow mesenchymal stem cells in an immature state and also contribute to their differentiation. To explore this possibility, we established bone marrow mesenchymal stem cells from GATA2 conditional knockout mice. Differentiation of GATA2-deficient bone marrow mesenchymal stem cells into adipocytes induced accelerated oil-drop formation. Further, GATA2 loss- and gain-of-function analyses based on human bone marrow mesenchymal stem cells confirmed that decreased and increased GATA2 expression accelerated and suppressed bone marrow mesenchymal stem cell differentiation to adipocytes, respectively. Microarray analysis of GATA2 knockdowned human bone marrow mesenchymal stem cells revealed that 90 and 189 genes were upregulated or downregulated by a factor of 2, respectively. Moreover, gene ontology analysis revealed significant enrichment of genes involved in cell cycle regulation, and the number of G1/G0 cells increased after GATA2 knockdown. Concomitantly, cell proliferation was decreased by GATA2 knockdown. When GATA2 knockdowned bone marrow mesenchymal stem cells as well as adipocytes were cocultured with CD34-positive cells, hematopoietic stem cell frequency and colony formation decreased. We confirmed the existence of pathological signals that decrease and increase hematopoietic cell and adipocyte numbers, respectively, characteristic of aplastic anemia, and that suppress GATA2 expression in hematopoietic stem cells and bone marrow mesenchymal stem cells.
OX40 and IL-7 play synergistic roles in the homeostatic proliferation of effector memory CD4(+) T cells Peer-reviewed

Satoshi Yamaki, Shouji Ine, Takeshi Kawabe, Yuko Okuyama, Nobu Suzuki, Pejman Soroosh, Seyed Fazlollah Mousavi, Hiroyuki Nagashima, Shu-lan Sun, Takanori So, Takeshi Sasaki, Hideo Harigae, Kazuo Sugamura, Hironori Kudo, Motoshi Wada, Masaki Nio, Naoto Ishii

EUROPEAN JOURNAL OF IMMUNOLOGY　44　(10)　3015-3025　2014/10

DOI： 10.1002/eji.201444701 　

ISSN： 0014-2980

eISSN： 1521-4141
再発性緩慢性B細胞リンパ腫に対するFR療法に続く90Y-ibritumomab tiuxetan投与の第I相試験(FR therapy followed by 90Y-ibritumomab tiuxetan for relapsed indolent B cell lymphoma, phase 1 study)

Himuro Masahito, Kamata Mayumi, Kameoka Yoshihiro, Takahashi Naoto, Okitsu Youko, Fukuhara Noriko, Onishi Yasushi, Ishizawa Kenichi, Harigae Hideo, Ishida Youji, Sawada Kenichi

臨床血液　55　(9)　1278-1278　2014/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
再発または難治性DLBCLに対するMCNUベースの高用量化学療法とそれに続くASCTの分析(Analysis of the MCNU-based high dose chemotherapy followed by ASCT for relapsed or refractory DLBCL)

Kameoka Yoshihiro, Takahashi Naoto, Akagi Tomoaki, Nara Miho, Ine Syouzi, Kato Yuichi, Yokoyama Hisayuki, Noji Hideyoshi, Itou Shigeki, Ishida Yoji, Harigae Hideo, Sawada Kenichi

臨床血液　55　(9)　1314-1314　2014/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Autophagy plays a protective role as an anti-oxidant system in human T cells and represents a novel strategy for induction of T-cell apoptosis Peer-reviewed

Ryu Watanabe, Hiroshi Fujii, Tsuyoshi Shirai, Shinichiro Saito, Tomonori Ishii, Hideo Harigae

EUROPEAN JOURNAL OF IMMUNOLOGY　44　(8)　2508-2520　2014/08

DOI： 10.1002/eji.201344248 　

ISSN： 0014-2980

eISSN： 1521-4141
機器判定によるpapain2段法とficin2段法について

郷野辰幸, 成田香魚子, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 工藤善範, 高橋博之, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　60　(3)　490-490　2014/06
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
【赤血球造血と疾患をめぐる最近の進歩】赤血球系造血における転写制御機構 Invited

藤原亨, 小林, 匡洋, 張替秀郎

血液内科　68　(5)　557-563　2014/05
Publisher:
ISSN： 2185-582X
過去5年間に当院産科で施行された緊急または大量輸血症例の検討

石岡夏子, 成田香魚子, 郷野辰幸, 岩木啓太, 阿部真知子, 佐藤裕子, 工藤善範, 高橋博之, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　60　(2)　304-304　2014/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
ABO血液型マイナーミスマッチ同種造血幹細胞移植後の抗A、抗B抗体価の推移

藤原実名美, 阿部真知子, 郷野辰幸, 岩木啓太, 石岡夏子, 佐藤裕子, 成田香魚子, 工藤善範, 高橋博之, 張替秀郎

日本輸血細胞治療学会誌　60　(2)　391-391　2014/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011

eISSN： 1883-0625
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib. Peer-reviewed

Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K

Biomarker research　2　(1)　6　2014/03
Publisher: 1
DOI： 10.1186/2050-7771-2-6 　

eISSN： 2050-7771
Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome Peer-reviewed

H. Kato, Y. Onishi, S. Nakajima, Y. Okitsu, N. Fukuhara, T. Fujiwara, M. Yamada-Fujiwara, J. Kameoka, K. Ishizawa, H. Harigae

BONE MARROW TRANSPLANTATION　49　(3)　458-459　2014/03

DOI： 10.1038/bmt.2013.198 　

ISSN： 0268-3369

eISSN： 1476-5365
本邦における遺伝性鉄芽球性貧血の臨床病理学的特徴 Peer-reviewed

藤原亨, 大場, 理恵, 古山, 和道, 福原, 規子, 大西, 康, 伊藤, 悦朗, 小澤, 敬也, 小島, 勢二, 小川, 誠司, 張替秀郎

日本内科学会雑誌　103　(Suppl.)　262-262　2014/02
Publisher:
ISSN： 0021-5384

eISSN： 1883-2083
Immune-mediated Hematological Diseases

Harigae Hideo

Nihon Naika Gakkai Kaishi　103　(7)　1561-1563　2014
Publisher: The Japanese Society of Internal Medicine
DOI： 10.2169/naika.103.1561 　

ISSN： 0021-5384
Fatal visceral varicella-zoster developing early after autologous hematopoietic stem cell transplantation for refractory diffuse large B-cell lymphoma. Peer-reviewed

Satoshi Ichikawa, Mihyun Kim, Shin Hasegawa, Keiichi Ohashi, Aiko Kondo, Hiroki Kato, Mayumi Kamata, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

Journal of clinical and experimental hematopathology : JCEH　54　(3)　237-41　2014

DOI： 10.3960/jslrt.54.237 　

ISSN： 1346-4280

eISSN： 1880-9952

More details Close

A middle-aged woman who had undergone autologous hematopoietic stem cell transplantation (HSCT) 1 month previously suffered severe epigastralgia and relapse of lymphoma. The epigastralgia was not relieved by chemotherapy. Thereafter, her pancreatic and hepatic enzyme levels were markedly elevated and disseminated varicella emerged. Despite acyclovir administration, her general condition deteriorated rapidly and she died. Serum varicella zoster virus (VZV) DNA level was shown to be elevated and a diagnosis of disseminated VZV infection was established postmortem. In patients with severe abdominal pain following HSCT, early suspicion and therapeutic intervention for VZV are important, even in the absence of skin lesions.
Granulomatosis with Polyangiitis Preceded by Central Diabetes Insipidus Peer-reviewed

So Sampei, Ryu Watanabe, Tomonori Ishii, Hideo Harigae

INTERNAL MEDICINE　53　(15)　1725-1726　2014

DOI： 10.2169/internalmedicine.53.2216 　

ISSN： 0918-2918

eISSN： 1349-7235
NK-cell fratricide: Dynamic crosstalk between NK and cancer cells. Peer-reviewed

Nakamura K, Nakayama M, Kawano M, Ishii T, Harigae H, Ogasawara K

Oncoimmunology　2　(11)　e26529　2013/11

DOI： 10.4161/onci.26529 　

ISSN： 2162-4011
BLOOD REQUIREMENT IN ORGAN TRANSPLANT RECIPIENTS FROM BRAIN-DEAD DONORS

Iwaki Keita, Takahashi Hiroyuki, Kudo Yoshinori, Narita Ayuko, Sato Yuko, Abe Machiko, Ishioka Natsuko, Ikeda Tomoko, Ota Masataka, Ito Tsuneo, Minegishi Masayoshi, Harigae Hideo

Journal of the Japan Society of Blood Transfusion　59　(5)　747-751　2013/10/01
Publisher: The Japan Society of Transfusion Medicine and Cell Therapy
DOI： 10.3925/jjtc.59.747 　

ISSN： 1881-3011

More details Close

Organ transplantation from brain-dead donors has become increasingly common since the organ transplant law was revised in July 2010. The revision led to a 6-fold increase in the procedure in Tohoku University Hospital in 1 year and transfusion requirements at the time of organ transplantation have been expanding. The transfusion records of sixty recipients undergoing organ transplantations in Tohoku University Hospital for 11 years (January 2001 to December 2011) were reviewed. The average number of units of red cell concentrates, fresh frozen plasma, and platelet concentrates used were 14, 16, and 12 in 26 single-lung transplantations, 64, 52, and 50 in 14 double-lung transplantations, 39, 33, and 34 in 5 heart transplantations, 7, 4, and 0 in 5 simultaneous pancreas-kidney transplantations, 9, 13, and 7 in 7 small intestine transplantations, and 97, 102, and 37 in 3 liver transplantations. In the cases of two or three organ transplantations on the same day, double-lung transplantation, and liver transplantation, a large amount of blood products were needed. Characteristically, about a half of the organ transplantations were performed on weekends and national holidays. These data suggests that it is important for the transfusion service to develop surgical blood order schedules and to prepare blood products for use in organ transplant procedures from brain-dead donors in close communication with the surgical departments as well as the blood center.
Tocilizumab Efficiently Halts Radiographic Progression In Patients With Rheumatoid Arthritis and Swollen Joint Counts Within a Year Predict Long-Term Radiographic Outcomes: Three Year Results From Michinoku Tocilizumab Study Group Peer-reviewed

Ryu Watanabe, Hiroshi Okuno, Tomonori Ishii, Yasuhiko Hirabayashi, Hideo Harigae

ARTHRITIS AND RHEUMATISM　65　S1012-S1013　2013/10

ISSN： 0004-3591

eISSN： 1529-0131
再発性緩慢性B細胞リンパ腫患者における地固め放射免疫療法の有効性(The efficacy of consolidation radioimmunotherapy in patients with relapsed indolent B cell lymphoma)

Himuro Masahito, Kamata Mayumi, Kimura Jun, Ichikawa Satoshi, Takagawa Masanori, Yamamoto Jouji, Kohata Katsura, Sasaki Osamu, Tohmiya Yasuo, Harazaki Yoriko, Ine Syouji, Fujii Masami, Kimura Tomofumi, Kameoka Yoshihiro, Nomura Jun, Meguro Kuniaki, Ishikawa Izumi, Suzuki Makiko, Nakajima Shinji, Katsuoka Yuna, Fujiwara Tohru, Okitsu Youko, Fukuhara Noriko, Onishi Yasushi, Kameoka Junichi, Ishizawa Kenichi, Harigae Hideo

臨床血液　54　(9)　1062-1062　2013/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
悪性リンパ腫に対するMEAMに続くauto-HSCTの安全性と有効性 THF多施設研究(Safety and efficacy of MEAM followed by auto-HSCT for malignant lymphoma: THF multicenter study)

Kameoka Yoshihiro, Takahashi Naoto, Akagi Tomoaki, Nara Miho, Ine Shouji, Kato Yuichi, Yokoyama Hisayuki, Noji Hideyoshi, Murai Kazunori, Ishida Yoji, Harigae Hideo, Sawada Kenichi

臨床血液　54　(9)　1123-1123　2013/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
大球性貧血の原因疾患の知識に医学教育が与える影響の解析

亀岡淳一, 小熊絵美, 荒田悠太郎, 高橋文恵, 石井誠一, 張替秀郎, 金塚完

医学教育　44　(Suppl.)　175-175　2013/07
Publisher: (一社)日本医学教育学会
ISSN： 0386-9644
遺伝子組み換え第IX因子製剤の持続輸注により冠動脈バイパス術を施行した血友病Bの1例 Peer-reviewed

沖津庸子, 石川, 正明, 鈴木, 宗三, 鈴木, 智之, 勝岡, 優奈, 福原, 規子, 大西, 康, 川本, 俊輔, 石澤, 賢一, 齋木, 佳克, 張替秀郎

日本血栓止血学会誌　24　(2)　206-206　2013/04
Publisher:
ISSN： 0915-7441

eISSN： 1880-8808
土-P2-266 同種臍帯血移植直後にボリコナゾールの血中濃度が低下した一症例(TDM・投与設計,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

鈴木裕之, 眞野成康, 北村奈央子, 柳利樹, 相馬真志, 佐藤祐司, 前川正充, 石澤賢一, 張替秀郎, 島田美樹

日本医療薬学会年会講演要旨集　23　(0)　296-296　2013
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.23.0_296_2 　
Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics Peer-reviewed

Katsuyoshi Takata, Yasuharu Sato, Naoya Nakamura, Mami Tokunaka, Yukari Miki, Yara Yukie Kikuti, Kazuhiko Igarashi, Etsuro Ito, Hideo Harigae, Seiichi Kato, Eiko Hayashi, Takashi Oka, Yoshinobu Hoshii, Akira Tari, Hiroyuki Okada, Abd Alkader Lamia Mohamad, Yoshinobu Maeda, Mitsune Tanimoto, Tomohiro Kinoshita, Tadashi Yoshino

MODERN PATHOLOGY　26　(1)　22-31　2013/01

DOI： 10.1038/modpathol.2012.127 　

ISSN： 0893-3952
Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma Peer-reviewed

Yoshihi Kameoka, Naoto Takahashi, Kenichi Ishizawa, Yuichi Kato, Jugo Ito, Osamu Sasaki, Kazunor Murai, Hideyos Noji, Makoto Hirokawa, Katsusi Tajima, Tsutomu Shichishima, Yoji Ishida, Hideo Harigae, Kenichi Sawada

International Journal of Hematology　96　(5)　624-630　2012/11

DOI： 10.1007/s12185-012-1186-7 　

ISSN： 0925-5710 1865-3774
Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor Peer-reviewed

Kyoko Inokura, Yasushi Onishi, Kenji Shimosegawa, Yoko Okitsu, Yuna Katsuoka, Tohru Fujiwara, Noriko Fukuhara, Kenichi Ishizawa, Hideo Harigae

Annals of Hematology　91　(11)　1825-1826　2012/11

DOI： 10.1007/s00277-012-1477-3 　

ISSN： 0939-5555 1432-0584
CD20-positive and CD4/CD8-double-negative peripheral T-cell lymphoma of spleen complicated with severe disseminated intravascular coagulation and enteropathy. Peer-reviewed

Satoshi Ichikawa, Shunsuke Hatta, Yo Saito, Jun Kimura, Keisuke Onishi, Mikio Matsuda, Ryo Ichinohasama, Hideo Harigae

Journal of clinical and experimental hematopathology : JCEH　52　(2)　133-6　2012

DOI： 10.3960/jslrt.52.133 　

ISSN： 1346-4280

eISSN： 1880-9952

More details Close

A 71-year-old woman presented with massive splenomegaly. Open splenectomy was performed, and the diagnosis of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), was made, with a characteristic immunophenotype of CD3(+), CD4(-), CD8(-), T-cell receptor (TCR)αβ(+), and TCRγδ(-). After splenectomy, she suffered abrupt exacerbation of the lymphoma with disseminated intravascular coagulation and enteropathy. Although chemotherapy was started, her medical condition did not improve and she died a week later. Postmortem reevaluation of the pathological specimen confirmed her diagnosis as CD20(+) PTCL-NOS. Although it is a rare disease entity, CD20(+) T-cell lymphoma can demonstrate aggressive clinical behavior.
Gene expression profiling identifies HOXB4 as a direct downstream target of GATA-2 in human CD34+ hematopoietic cells. International-journal Peer-reviewed

Tohru Fujiwara, Hisayuki Yokoyama, Yoko Okitsu, Mayumi Kamata, Noriko Fukuhara, Yasushi Onishi, Shinichi Fujimaki, Shinichiro Takahashi, Kenichi Ishizawa, Emery H Bresnick, Hideo Harigae

PloS one　7　(9)　e40959　2012

DOI： 10.1371/journal.pone.0040959 　

More details Close

Aplastic anemia is characterized by a reduced hematopoietic stem cell number. Although GATA-2 expression was reported to be decreased in CD34-positive cells in aplastic anemia, many questions remain regarding the intrinsic characteristics of hematopoietic stem cells in this disease. In this study, we identified HOXB4 as a downstream target of GATA-2 based on expression profiling with human cord blood-derived CD34-positive cells infected with control or GATA-2 lentiviral shRNA. To confirm the functional link between GATA-2 and HOXB4, we conducted GATA-2 gain-of-function and loss-of-function experiments, and HOXB4 promoter analysis, including luciferase assay, in vitro DNA binding analysis and quantitative ChIP analysis, using K562 and CD34-positive cells. The analyses suggested that GATA-2 directly regulates HOXB4 expression through the GATA sequence in the promoter region. Furthermore, we assessed GATA-2 and HOXB4 expression in CD34-positive cells from patients with aplastic anemia (n = 10) and idiopathic thrombocytopenic purpura (n = 13), and demonstrated that the expression levels of HOXB4 and GATA-2 were correlated in these populations (r = 0.6573, p<0.01). Our results suggested that GATA-2 directly regulates HOXB4 expression in hematopoietic stem cells, which may play an important role in the development and/or progression of aplastic anemia.
悪性リンパ腫に対するMEAM療法後自家HSCTの安全性および実施可能性(Safety and feasibility of MEAM therapy followed by auto-HSCT for malignant lymphoma)

Kameoka Yoshihiro, Takahashi Naoto, Akagi Tomoaki, Hiroshima Yuki, Yokoyama Hisayuki, Murai Kazunori, Tajima Katsushi, Shichishima Tutomu, Ishida Yoji, Harigae Hideo, Sawada Kenichi

臨床血液　52　(9)　1104-1104　2011/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
低悪性度B細胞性リンパ腫に対する90Y-ibritumomab tiuxetanの有効性長期奏効者の解析(Efficacy of 90Y-ibritumomab tiuxetan for low grade B cell lymphoma:analysis of long term responders)

Kamata Mayumi, Kimura Jun, Niitu Hidetaka, Kimura Tomohumi, Sasaki Toru, Takagawa Masanori, Sasaki Osamu, Harasaki Yoriko, Tohmiya Yasuo, Ine Syoji, Yokoyama Hisayuki, Nomura Jun, Kameoka Yoshihiro, Inokura Kyoko, Fukuhara Noriko, Katsuoka Yuna, Ohba Rie, Kohata Katsura, Oonishi Yasushi, Yamamoto Joji, Ishizawa Kenichi, Harigae Hideo

臨床血液　52　(9)　1127-1127　2011/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
リコンビナント抗原を使用したELISA法によるANCA測定キット(コスミック社)の基礎的・臨床的検討 Peer-reviewed

白井剛志, 石井智徳, 中村恭平, 渡部龍, 田島結実, 藤井博司, 高澤徳彦, 張替秀郎

医学と薬学　65　(4)　517-523　2011/04
血痰、血尿で発症した後天性第V因子インヒビターの1例

大口裕人, 沖津庸子, 小林匡洋, 横山寿行, 鈴木宗三, 石川正明, 大場理恵, 山本譲司, 石澤賢一, 張替秀郎

日本内科学会雑誌　100　(1)　182-184　2011/01
Publisher: (一社)日本内科学会
ISSN： 0021-5384

eISSN： 1883-2083
【β2-ミクログロブリンその多様な病因,病態と検査アプローチ】 <病態疾患と動態解析> 多発性骨髄腫とβ2-ミクログロブリン国際ステージ分類

大口裕人, 張替秀郎

臨床検査　55　(1)　51-57　2011/01
Publisher: (株)医学書院
DOI： 10.11477/mf.1542102514 　

ISSN： 0485-1420
The low expression allele (IVS3-48C) of the ferrochelatase gene leads to low enzyme activity associated with erythropoietic protoporphyria Peer-reviewed

Tsuyoshi Tahara, Masayoshi Yamamoto, Reiko Akagi, Hideo Harigae, Shigeru Taketani

INTERNATIONAL JOURNAL OF HEMATOLOGY　92　(5)　769-771　2010/12

DOI： 10.1007/s12185-010-0725-3 　

ISSN： 0925-5710

eISSN： 1865-3774
【肺高血圧症の臨床における最新薬物治療】膠原病専門医が診る肺高血圧症ボセンタンと免疫抑制療法が奏功した原発性シェーグレン症候群にともなう肺動脈性肺高血圧症の1例 Peer-reviewed

渡部龍, 石井智徳, 張替秀郎

Modern Physician　30　(臨時増刊)　66-68　2010/10
日本におけるT細胞性前リンパ球性白血病の臨床的および生物学的特徴(Clinical and biological features of T-cell prolymphocytic leukemia in Japan)

Kameoka Junichi, Takahashi Naoto, Noji Hideyoshi, Murai Kazunori, Tajima Katsushi, Kameoka Yoshihiro, Shichishima Tsutomu, Ishida Yoji, Harigae Hideo, Sawada Kenichi

臨床血液　51　(9)　1172-1172　2010/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Peer-reviewed

Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, Harigae H, Ishii T

Int J Hematol.　49　(12)　1263-1264　2010/06/15

DOI： 10.1007/s12185-010-0528-6. 　
3. Iron and Inflammation.

Harigae Hideo

Nihon Naika Gakkai Kaishi　99　(6)　1282-1286　2010/06/10
Publisher: The Japanese Society of Internal Medicine
DOI： 10.2169/naika.99.1282 　

ISSN： 0021-5384
Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia Peer-reviewed

Satoshi Nishiwaki, Koichi Miyamura, Chiaki Kato, Seitaro Terakura, Kazuteru Ohashi, Hisashi Sakamaki, Shinji Nakao, Hideo Harigae, Yoshihisa Kodera

Anticancer Research　30　(6)　2415-2418　2010/06

ISSN： 0250-7005
Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells Peer-reviewed

Akemi Imoto, Mami Okada, Toshio Okazaki, Hidero Kitasato, Hideo Harigae, Shinichiro Takahashi

Journal of Biological Chemistry　285　(14)　10300-10309　2010/04/02
Publisher: 14
DOI： 10.1074/jbc.M109.095810 　

ISSN： 0021-9258 1083-351X
【骨髄不全治療の新しい展開新規免疫抑制剤と経口鉄キレート剤の導入】デフェラシロクスの造血刺激効果

大場理恵, 張替秀郎

血液フロンティア　20　(5)　725-731　2010/04
Publisher: (株)医薬ジャーナル社
ISSN： 1344-6940
The endoplasmic reticulum stress-inducible protein, Herp, is a potential triggering antigen for anti-DNA response Peer-reviewed

Yasuhiko Hirabayashi, Yumiko Oka, Tomoko Ikeda, Hiroshi Fujii, Tomonori Ishii, Takeshi Sasaki, Hideo Harigae

Journal of Immunology　184　(6)　3276-3283　2010/03/15

DOI： 10.4049/jimmunol.0900670 　

ISSN： 0022-1767 1550-6606
Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer. Peer-reviewed

Hiroki Kato, Katsura Kohata, Joji Yamamoto, Satoshi Ichikawa, Mika Watanabe, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

International journal of hematology　91　(2)　328-30　2010/03

DOI： 10.1007/s12185-010-0491-2 　
Successful allogeneic hematopoietic stem cell transplantation for aggressive NK cell leukemia. Peer-reviewed

Satoshi Ichikawa, Noriko Fukuhara, Joji Yamamoto, Makiko Suzuki, Shinji Nakajima, Yoko Okitsu, Katsura Kohata, Yasushi Onishi, Kenichi Ishizawa, Junichi Kameoka, Hideo Harigae

Internal medicine (Tokyo, Japan)　49　(17)　1907-10　2010

DOI： 10.2169/internalmedicine.49.3814 　

ISSN： 0918-2918

eISSN： 1349-7235

More details Close

Aggressive natural killer cell leukemia (ANKL) is a highly aggressive lymphoproliferative disease. An appropriate therapeutic strategy for ANKL remains to be established, but a few case reports have suggested that allogeneic hematopoietic stem cell transplantation (allo-HCT) can be curative. Here, we report a young woman with ANKL showing central nervous system (CNS) invasion, who has been in complete remission for more than a year after allo-HCT following two courses of intravenous chemotherapy and several rounds of intrathecal chemotherapy. Intensive remission induction chemotherapy followed by conventional myeloablative allo-HCT is a promising approach for long-term remission in cases of this aggressive malignancy.
Human umbilical cord-derived mesenchymal stromal cells differentiate into functional schwann cells that sustain peripheral nerve regeneration Peer-reviewed

Dai Matsuse, Masaaki Kitada, Misaki Kohama, Kouki Nishikawa, Hideki Makinoshima, Shohei Wakao, Yoshinori Fujiyoshi, Toshio Heike, Tatsutoshi Nakahata, Hidenori Akutsu, Akihiro Umezawa, Hideo Harigae, Jun-Ichi Kira, Mari Dezawa

Journal of Neuropathology and Experimental Neurology　69　(9)　973-985　2010
Publisher: Lippincott Williams and Wilkins
DOI： 10.1097/NEN.0b013e3181eff6dc 　

ISSN： 0022-3069
[Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia]. Peer-reviewed

Yokoyama H, Harigae H

Nihon rinsho. Japanese journal of clinical medicine　67　(10)　1974-1977　2009/10

ISSN： 0047-1852

More details Close

It is important for achieving complete remission of acute myelogenous leukemia to manage anemia and bone marrow hypoplasia, which cause serious complications. Anemia and bone marrow hypoplasia are mainly treated by supportive therapies consisting of granulocyte-colony stimulating factor, red blood cell transfusion and platelet transfusion, which are given according to recommendations of guidelines. In addition to these supportive therapies, new drugs such as DNA demethylating agents are developed for myelodysplastic syndrome (MDS). These drugs are expected to improve a cytopenia, and reduce the frequency of transfusions.
Occurrence of poroid hidradenomas after haematopoietic stem cell transplantation

R. Okuyama, R. Shimada, J. Kameoka, H. Harigae, S. Aiba

Journal of the European Academy of Dermatology and Venereology　23　(9)　1109-1111　2009/09

DOI： 10.1111/j.1468-3083.2009.03110.x 　

ISSN： 0926-9959 1468-3083
腎細胞癌に対する同種造血幹細胞移植とソラフェニブ併用療法の有効性の検討(Sorafenib exacerbates GVHD following hematopoietic stem cell transplantation for metastatic Renal cell carcinoma)

横山寿行, Lundqvist Andreas, 張替秀郎, Childs Richard

日本癌学会総会記事　68回　296-296　2009/08
Publisher: 日本癌学会
ISSN： 0546-0476
眼球突出、PR3-ANCA高値を呈しWegener肉芽腫との鑑別を要したT細胞リンパ腫の一例

白井剛志, 田島結実, 高橋令子, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　53回・18回　320-320　2009/03
Publisher: (一社)日本リウマチ学会
S2-4 大型血管の画像診断(膠原病の病態解明と治療最前線,第59回日本アレルギー学会秋季学術大会)

石井智徳, 白井剛史, 藤井博司, 張替秀郎

アレルギー　58　(8)　1110-1110　2009
Publisher: 一般社団法人日本アレルギー学会
DOI： 10.15036/arerugi.58.1110_2 　
Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy Peer-reviewed

Masahiro Abe, Hisayuki Yokoyama, Yasuo Tohmiya, Yoko Okitsu, Hiroto Ohguchi, Katsura Kohata, Joji Yamamoto, Yasushi Onishi, Kenichi Ishizawa, Junichi Kameoka, Hideo Harigae

Internal Medicine　48　(20)　1833-1835　2009

DOI： 10.2169/internalmedicine.48.2389 　

ISSN： 0918-2918 1349-7235

eISSN： 1349-7235
同種末梢血幹細胞移植施行7年後にドナー由来の再生不良性貧血を発症した1例

高橋太郎, 沖津庸子, 大西康, 鈴木真紀子, 山本譲司, 山田実奈美, 馬淵洋, 松崎有未, 亀岡淳一, 張替秀郎

臨床血液　49　(9)　1031-1031　2008/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
PU.1発現低下細胞におけるエピジェネティックな制御異常

高橋伸一郎, 岡田真実, 井本明美, 中原正子, 向井梓, 猪股美津恵, 井堰裕子, 岡崎登志夫, 北里英郎, 張替秀郎

臨床血液　49　(9)　879-879　2008/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
濾胞性リンパ腫における転写抑制因子BACH2の発現(Expression of BACH2, a transcription repressor, in follicular lymphoma)

山本譲司, 石澤賢一, 五十嵐和彦, 一迫玲, 張替秀郎

日本癌学会総会記事　67回　317-317　2008/09
Publisher: 日本癌学会
ISSN： 0546-0476
ダサチニブ投与中腫瘍崩壊症候群を併発した慢性骨髄性白血病 Peer-reviewed

木幡桂, 市川, 聡, 白井, 剛志, 中嶌, 真治, 鈴木, 真紀子, 井上あい, 三浦, 由紀子, 高橋, 太郎, 沖津, 庸子, 福原, 規子, 大西, 康, 藤原, 亨, 山本, 譲司, 藤原, 実名美, 石澤, 賢一, 亀岡, 淳一, 張替秀郎

臨床血液　49　(9)　1018-1018　2008/09
Imatinib抵抗性獲得後Dasatinib使用にて同種骨髄移植を施行した慢性骨髄性白血病 Peer-reviewed

山本譲司, 市川, 聡, 白井, 剛志, 中嶌, 真治, 鈴木, 真紀子, 高橋, 太郎, 田島, 結実, 井上あい, 三浦, 由希子, 沖津, 庸子, 木幡, 桂, 藤原, 亨, 福原, 規子, 大西, 康山田, 実名美, 石澤, 賢一, 亀岡, 淳一, 張替秀郎

臨床血液　49　(9)　1017-1017　2008/09
ヒトパルボウイルスB19による関節リウマチ患者由来樹状細胞の機能亢進

高橋令子, 伊藤貴子, 石井智徳, 岡友美子, 高澤徳彦, 石井恵子, 平林泰彦, 佐々木毅, 張替秀郎

日本臨床免疫学会会誌　31　(4)　293-293　2008/08
Publisher: (一社)日本臨床免疫学会
ISSN： 0911-4300

eISSN： 1349-7413
アンチゲネミア陰性を示した汎血球減少を伴うサイトメガロウイルス感染症の一例

白井剛志, 高橋令子, 平林泰彦, 石井智徳, 高澤徳彦, 田島結実, 張替秀郎

日本臨床免疫学会会誌　31　(4)　335-335　2008/08
Publisher: (一社)日本臨床免疫学会
ISSN： 0911-4300

eISSN： 1349-7413
自己抗原免疫により正常マウスにループス腎炎を再構築する試み

平林泰彦, 岡友美子, 田島結実, 高橋令子, 高澤徳彦, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　52回・17回　239-239　2008/04
Publisher: (一社)日本リウマチ学会
インフリキシマブが有効だった好中球性皮膚症の一例

田島結実, 平林泰彦, 高澤徳彦, 高橋令子, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　52回・17回　425-425　2008/04
Publisher: (一社)日本リウマチ学会
多発性筋炎加療中に顕在化した粟粒結核の1例

加藤量広, 田島結実, 長澤将, 小泉賢治, 高澤徳彦, 高橋令子, 石井智徳, 平林泰彦, 張替秀郎, 國島広之, 宮里明子, 山本夏男, 平潟洋一, 賀来満夫

結核　83　(6)　481-481　2008
HIGH-THROUGHPUT STRATEGY FOR QUANTITATIVE ANALYSIS OF HUMAN TRANSPORTER PROTEINS BASED ON INFORMATICS AND PROTEOMICS APPROACH: EXPRESSION PROFILING OF HUMAN ABC TRANSPORTER PROTEINS IN VINCRISTINE RESISTANT LEUKEMIA CELLS Peer-reviewed

Iwase Ryo, Ohmine Ken, Kamiie Junichi, Harigae Hideo, Ohtsuki Sumio, Terasaki Tetsuya

Drug Metabolism Reviews　39　280-281　2007
悪性リンパ腫治療中にChryseobacterium indologenesによる肺炎、敗血症を呈した一例

豊原敬文, 横山寿行, 三浦由希子, 木幡桂, 藤原亨, 山本譲司, 藤原実名美, 石澤賢一, 張替秀郎, 亀岡淳一, 佐々木毅, 光武耕太郎

臨床血液　47　(9)　1146-1146　2006/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
再生不良性貧血(AA)に対する免疫抑制療法後のcyclosporine(CYA)依存性の検討

亀岡淳一, 阿部正理, 井根省二, 藤原亨, 関正則, 木幡桂, 山本譲司, 横山寿行, 遠宮靖雄, 山田実名美, 石澤賢一, 張替秀郎, 佐々木毅

臨床血液　47　(5)　413-413　2006/05
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
[Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].

Izumi Ishikawa, Koichi Miyamura, Minami Yamada, Osamu Sasaki, Hideo Harigae, Junichi Kameoka, Kuniaki Meguro, Takeshi Sasaki

[Rinsho ketsueki] The Japanese journal of clinical hematology　46　(12)　1288-92　2005/12

ISSN： 0485-1439

More details Close

We describe a 56-year-old woman with chronic myeloid leukemia (CML) and a past history of stroke, who underwent nonmyeloablative hematopoietic stem cell transplantation (NST) with conditioning consisting of fludarabine and cyclophosphamide. The regimen related toxicity was minimal and patient did not require transfusions of any blood products nor did she have any infections after the NST Since mixed chimerism was observed in both lymphocytes (70% were donor type) and granulocytes (none were donor type) at 56 days after NST, donor lymphocyte infusion (DLI) was performed on day 68 and then immunosuppressant therapy was discontinued. DLI resulted in graft versus leukemia (GVL) effect, causing pancytopenia and bone marrow aplasia. A second hematopoietic stem cell transplantation was performed without conditioning on day 157, and complete donor type hematopoiesis and molecular remission of CML were achieved. Although engraftment of donor hematopoietic stem cells was not obtained after the first transplantation, donor lymphocytes were engrafted by nonmyeloablative conditioning and immunosuppression. That is, the same result might have been achieved even if the patient had received transfusion of only donor lymphocyte subsets in the first step. Based on this case report, a potential cell therapy is proposed composed of the preceding donor lymphocyte infusion alone, which induces GVL effects, and subsequent donor hematopoietic stem cell transplantation.
造血幹細胞移植(SCT)後の慢性下痢に対する真武湯投与

山田実名美, 山本譲司, 横山寿行, 遠宮靖雄, 石澤賢一, 張替秀郎, 亀岡淳一, 佐々木毅, 関隆志

日本血液学会・日本臨床血液学会総会プログラム・抄録集　67回・47回　866-866　2005/09
Publisher: 日本臨床血液学会
悪性リンパ腫におけるリンパ管新生についての検討

門脇育子, 一迫玲, 張替秀郎, 石澤賢一, 沖津庸子, 山本譲司, 横山寿行, 遠宮靖雄, 藤原実名美, 亀岡淳一, 佐々木毅

日本血液学会・日本臨床血液学会総会プログラム・抄録集　67回・47回　893-893　2005/09
Publisher: 日本臨床血液学会
定量PCRに基づいた慢性骨髄性白血病に対するImatinib(グリベック)の治療成績

張替秀郎, 石川泉, 石澤賢一, 藤原実名美, 遠宮靖雄, 横山寿行, 山本譲司, 菅原知広, 宮村耕一, 亀岡淳一, 佐々木毅

日本血液学会・日本臨床血液学会総会プログラム・抄録集　67回・47回　900-900　2005/09
Publisher: 日本臨床血液学会
濾胞性リンパ腫初回治療におけるRituximab療法

山本譲司, 横山寿行, 門脇育子, 遠宮靖雄, 藤原実名美, 石澤賢一, 張替秀郎, 亀岡淳一, 一迫玲, 佐々木毅

日本血液学会・日本臨床血液学会総会プログラム・抄録集　67回・47回　925-925　2005/09
Publisher: 日本臨床血液学会
再発,治療抵抗性濾胞性リンパ腫に対するRituximab-FND療法の実施可能性検証試験

奥田光崇, 石澤賢一, 菅原知広, 野村順, 石川泉, 山本譲司, 横山寿行, 遠宮靖雄, 藤原実名美, 張替秀郎, 亀岡淳一, 佐々木毅

日本血液学会・日本臨床血液学会総会プログラム・抄録集　66回・46回　917-917　2004/09
Publisher: 日本臨床血液学会
Flow Cytometry of GATA Transcription Factors Peer-reviewed

Toshihiko Miura, Hisayuki Yokoyama, Naoko Minegishi, Takeshi Sasaki, Mitsuo Kaku, Hideo Harigae

Cytometry Part B - Clinical Cytometry　56　(1)　1-7　2003
Publisher: Wiley-Liss Inc.
DOI： 10.1002/cyto.b.10047 　

ISSN： 1552-4949
ヒト及びマウス骨髄間質細胞におけるleptin発現の検討

亀岡淳一, 山田実名美, 横山寿行, 木村朋文, 佐々木治, 張替秀郎, 宮村耕一, 佐々木毅

臨床血液　43　(8)　129-129　2002/08
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
GATA転写因子による多機能蛋白YB-1の発現調節

横山寿行, 張替秀郎, 高橋伸一郎, 山田実名美, 佐々木治, 石澤賢一, 宮村耕一, 亀岡淳一, 高橋智, 山本雅之, 佐々木毅

臨床血液　43　(8)　183-183　2002/08
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
CD4+,CD8+T細胞性慢性リンパ性白血病(T-CLL)の2例

関正則, 亀岡淳一, 木村朋文, 横山寿行, 山田実名美, 佐々木治, 石澤賢一, 張替秀郎, 宮村耕一, 佐々木毅

臨床血液　43　(8)　460-460　2002/08
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
新規因子Klp1の構造及び発現調節機構の解析(Structure and regulation of a novel factor, Klp1)

高橋伸一郎, 張替秀郎, 横山寿行, 石川泉, 佐々木治, 亀岡淳一, 宮村耕一, 目黒邦昭, 佐々木毅

International Journal of Hematology　73　(Suppl.1)　56-56　2001/03
Publisher: (一社)日本血液学会
ISSN： 0925-5710

eISSN： 1865-3774
Cloning of a coproporphyrinogen oxidase promoter regulatory element binding protein Peer-reviewed

Shinichiro Takahashi, Kazumichi Furuyama, Akira Kobayashi, Shigeru Taketani, Hideo Harigae, Masayuki Yamamoto, Kazuhiko Igarashi, Takeshi Sasaki, Norio Hayashi

Biochemical and Biophysical Research Communications　273　(2)　596-602　2000/07/05
Publisher: Academic Press Inc.
DOI： 10.1006/bbrc.2000.2991 　

ISSN： 0006-291X
[Molecular diagnosis of hereditary sideroblastic anemia and model mouse of the disease] (Rinsho Ketsueki)

Yamamoto M, Nakajima O, Furuyama K, Harigae H, Hayashi N

Rinsho Ketsueki　41　(7)　540-543　2000
Identification of human GATA-2 gene distal IS exon and its expression in hematopoietic stem cell fractions Peer-reviewed

Xiaoqing Pan, Naoko Minegishi, Hideo Harigae, Hironori Yamagiwa, Masayoshi Minegishi, Yasuyuki Akine, Masayuki Yamamoto

Journal of Biochemistry　127　(1)　105-112　2000
Publisher: Japanese Biochemical Society
DOI： 10.1093/oxfordjournals.jbchem.a022570 　

ISSN： 0021-924X
[Complete remission by cytarabine ocfosfate plus G-CSF therapy in a patient with hypoplastic RAEB-T]

Kadowaki I, Sasaki O, Sasaki T, Ishizawa K, Kimura J, Nomura J, Furuyama K, Harigae H, Shishido T, Okuda M

Gan To Kagaku Ryoho　22　(1)　145-147　1995
マウス胸腺中のT細胞初期分化におけるGATA-3の発現

松崎有未, 張替秀郎, 山本雅之, 中内啓光

日本免疫学会総会・学術集会記録　23　347-347　1993/10
Publisher: (NPO)日本免疫学会
ISSN： 0919-1984
Differentiating Effect of Oral Administration of Retinol Palmitate (Chocola-A^®) for An Aged AML (M3) with Severe Complications

NOMURA Jun, FUKUHARA Osamu, WATANABE Norimichi, YOSHINAGA Kaoru, ENDO Kazuyasu, FURUYAMA Kazumichi, HARIGAE Hideo, SATOU Akiyoshi, SHISHIDO Tomoaki, OKUDA Mitsutaka, SUGAWARA Tomohiro, MEGURO Kuniaki

Rinsho Ketsueki　33　(11)　1673-1678　1992
Publisher: 一般社団法人日本血液学会
DOI： 10.11406/rinketsu.33.1673 　

ISSN： 0485-1439

More details Close

A 74 year-old woman, who had been diagnosed as AML (M3) in poor condition, was treated with Retinol Palmitate (Chocola-A&reg;, 150,000unit/m2 per os, after informed consent. An increase of white blood cells (neutrophil) counts was observed after 7 days. After 4weeks, WBC counts were increased to 20,700/&mu;l (neutrophil conuts 6,400/&mu;l) Maturation tendency of leukemic cells was also proved in the bone marrow. In vitro studies showed that morphological difrerentiation was recognizable in cultured leukemic cells treated with 10-6M all-trans retinoic acid after 6 days, but not in controls. Responses in the NBT reduction test were slightly less than in the clinical study. The administration of Retinol Palmitate may be a new regimen to treat AML (M3) in aged patients. in poor condition.

Show all ︎Show first 5

Misc. 306

ヒト赤芽球細胞株を用いた造血性プロトポルフィリン症の病態解明

二階堂舞香, 藤原亨, 鈴木千恵, 鈴木千恵, 小野浩弥, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎, 張替秀郎

日本鉄バイオサイエンス学会学術集会プログラム・抄録集　47th　2023
CAR-T療法後に長期病勢制御を得られた治療抵抗性濾胞性リンパ腫grade3Bの1例

金輝, 市川聡, 福原規子, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

臨床血液　64　(10)　2023

ISSN： 0485-1439
Peritoneal lymphomatosisによって腹部コンパートメント症候群を来したB細胞性リンパ腫の1例

田中悠也, 小野寺晃一, 木葉大地, 諸田直哉, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 一迫玲, 張替秀郎

臨床血液　63　(5)　491-492　2022/05
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
アカデミア発の再生医療シーズの実用化へ向けた東北大学再生医療ユニットの取り組み

沖田ひとみ, 伊藤貴子, 伊藤貴子, 黒田康, 若尾昌平, 出澤真理, 後藤昌史, 張替秀郎

日本再生医療学会総会(Web)　21st　2022
プログラムフリーザー故障時のバックアップ凍結プランによるアフェレーシス材料レスキュー

伊藤貴子, 伊藤貴子, 沖田ひとみ, 阿部真知子, 岩木啓太, 藤原実名美, 後藤昌史, 後藤昌史, 張替秀郎, 張替秀郎

日本再生医療学会総会(Web)　21st　2022
Blinatumomab for ALL relapse after allogeneic hematopoietic stem cell transplantation

小野寺晃一, 小松弘香, 竹中健太, 渡邉樹也, 鳴海善洋, 中村嘉詞, 橋本和貴, 櫻井一貴, 内堀雄介, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　45th　2022
Retrospective comparison of CBT with RIC using FLU-BU-MEL and FLU-MEL-TBI: single institute analysis

橋本和貴, 小野寺晃一, 大西康, 内堀雄介, 小松弘香, 竹中健太, 横山寿行, 福原規子, 市川聡, 猪倉恭子, 櫻井一貴, 中村嘉詞, 鳴海善洋, 渡邊樹也, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　45th　2022
The impact of leucovorin rescue on outcomes after cord blood transplantation

小野寺晃一, 木葉大地, 諸田直哉, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　44th　2022
Two cases of conjunctival lesions due to acute GVHD after allogeneic HSCT

諸田直哉, 小野寺晃一, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血・免疫細胞療法学会総会プログラム・抄録集　44th　2022
エタネルセプト開始後に抗MDA5抗体陽性皮膚筋炎を発症した関節リウマチの一例

岡崎創司, 白井剛志, 高橋幹弘, 石井悠翔, 秋田佳奈恵, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会北海道・東北支部学術集会抄録集　31回　45-45　2022/01
Publisher: (一社)日本リウマチ学会-北海道・東北支部
巨細胞性動脈炎に対するトシリズマブ導入後にサルモネラ敗血症を来した1例

星陽介, 成田衛, 丹野唯人, 秋田佳奈恵, 佐藤紘子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会北海道・東北支部学術集会抄録集　31回　54-54　2022/01
Publisher: (一社)日本リウマチ学会-北海道・東北支部
濾胞性リンパ腫におけるリツキシマブ維持療法の長期生存東北血液フォーラム前向き多施設共同研究結果(Long-term survival in patients with follicular lymphoma following Rituximab maintenance in THF-19)

大本英次郎, 妻沼りこ, 熊谷裕昭, 相澤桂子, 吉田こず恵, 池田和彦, 亀岡吉弘, 石澤賢一, 張替秀郎, 高橋直人

日本血液学会学術集会　83回　BPA-6　2021/09
Publisher: (一社)日本血液学会
ベンダムスチン、オビヌツズマブ療法後に潰瘍性大腸炎様の薬剤性大腸炎を発症した濾胞性リンパ腫の一例(Follicular lymphoma with drug-induced ulcerative colitis after bendamustine and obinutuzumab)

猪倉恭子, 福原規子, 橋本和貴, 櫻井一貴, 道又大吾, 古川瑛次郎, 小野寺晃一, 市川聡, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会　83回　PS-4　2021/09
Publisher: (一社)日本血液学会
【がん診療トピックス】血液がん貧血の鑑別診断と専門医へ紹介すべき貧血

張替秀郎

クリニシアン　68　(2-3)　178-182　2021/03
Publisher: エーザイ(株)
ISSN： 0387-1541
【病気とくすり2021 基礎と実践Expert's Guide】循環器系の病気とくすり血液・造血器系疾患貧血

斎藤陽, 張替秀郎, 鈴木文子, 眞野成康

薬局　72　(4)　1032-1043　2021/03
Publisher: (株)南山堂
ISSN： 0044-0035
Methionine metabolism controls erythropoiesis by epigenetic regulation

加藤浩貴, 加藤浩貴, 加藤浩貴, NGUYEN Long, 石井悠翔, 石井悠翔, 松本光代, 三枝大輔, 舟山亮, 岡江寛明, 藤原亨, 武藤哲彦, 中山啓子, 有馬隆博, SCADDEN David, 五十嵐和彦, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
The impact of KIR-ligand mismatch on the efficacy of GVHD-prophylaxis in cord blood transplantation

横山寿行, 櫻井一貴, 橋本和貴, 古川瑛次郎, 齋藤慧, 八田俊介, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 勝岡優奈, 大西康, 和泉透, 張替秀朗

日本造血細胞移植学会総会プログラム・抄録集　43rd　2021
Two cases of relapsed follicular lymphoma as presenting neurolymphomatosis after allogenic HSCT

阿部未玲, 福原規子, 櫻井一貴, 橋本和貴, 古川瑛次郎, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 藤原実名美, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　43rd　2021
Cytomegalovirus reactivation after letermovir prophylaxis in allogeneic HSCT

古川瑛次郎, 大西康, 橋本和貴, 櫻井一貴, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 横山寿行, 藤原亨, 藤原実名美, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　43rd　2021
Follicular lymphoma with drug-induced ulcerative colitis after bendamustine and obinutuzumab

猪倉恭子, 福原規子, 橋本和貴, 櫻井一貴, 道又大吾, 古川瑛次郎, 小野寺晃一, 市川聡, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Eight cases of allogeneic hematopoietic stem cell transplantation for follicular lymphoma

市川聡, 齋藤慧, 齋藤慧, 阿部未玲, 阿部未玲, 福原規子, 渡邊正太郎, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 大西康, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
The impact of HLA-DRB1 matching status on outcomes of UCBT: A single-institute retrospective study

小野寺晃一, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Four cases of carcinoma that primarily presented with cytopenia due to bone marrow dissemination

市川聡, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 福原規子, 大西康, 横山寿行, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Outcome of allogeneic stem cell transplantation in adult patients with EBV-positive T/NK LPDs

大西康, 小野寺晃一, 櫻井一貴, 橋本和貴, 道又大吾, 古川瑛次郎, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Four cases with discordant development of follicular and classic Hodgkin lymphoma

阿部未玲, 阿部未玲, 福原規子, 市川聡, 櫻井一貴, 橋本和貴, 道又大吾, 古川瑛次郎, 渡邊正太郎, 猪倉恭子, 小野寺晃一, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Sustained remission of atypical CML in accelerated phase after development of severe acute GVHD

櫻井一貴, 横山寿行, 橋本和貴, 猪倉恭子, 市川聡, 福原規子, 小野寺晃一, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
KIR-ligand mismatch effect on GVHD and NK-cell gene expression after cord blood transplantation

横山寿行, 渡邊正太郎, 橋本和貴, 櫻井一貴, 道又大吾, 古川瑛次郎, 猪倉恭子, 小野寺晃一, 市川聡, 齋藤慧, 八田俊介, 勝岡優奈, 和泉透, 鎌田真弓, 遠宮靖雄, 原崎頼子, 佐々木治, 福原規子, 大西康, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
FOG1-dependent transcriptional network involves glucose metabolic regulation of erythroid cells

藤原亨, 藤原亨, 鈴木千恵, 鈴木千恵, 小野浩弥, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Elucidation of the role of FAM210B in mitochondrial metabolism in erythroblasts

鈴木千恵, 鈴木千恵, 藤原亨, 藤原亨, 島弘季, 小野浩弥, 齋藤慧, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 五十嵐和彦, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
Significance of elevated serum vitamin B12 levels in myeloid malignancies

亀岡淳一, 沖津庸子, 小林匡洋, 野村順, 阿部正理, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 藤原実名美, 高橋伸一郎, 張替秀郎

日本血液学会学術集会抄録(Web)　83rd　2021
同種造血幹細胞移植後の菌血症に対しバック法で採取した顆粒球輸血を行った2症例

横山寿行, 諸田直哉, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 大西康, 島貫美和子, 関修, 成田香魚子, 藤原実名美, 張替秀郎, 張替秀郎

日本輸血細胞治療学会誌　67　(6)　2021

ISSN： 1881-3011
【免疫・炎症疾患のすべて】免疫・炎症疾患における検査/一般検査末梢血液検査

藤原亨, 張替秀郎

日本医師会雑誌　149　(特別2)　S84-S85　2020/10
Publisher: (公社)日本医師会
ISSN： 0021-4493
【貧血最新の薬物治療戦略と実践ポイント】要点整理!貧血の病態・検査の勘所貧血の分類・成因と留意すべき患者背景(解説/特集)

張替秀郎, 大学院医学系研究科血液免疫病学

薬局 (0044-0035)71巻10号 Page3076-3079(2020.09)　71　(10)　3076-3079　2020/09
TGF-βとluspatercept(解説)

藤原亨, 張替秀郎

がん分子標的治療 (1347-6955)　18　(1)　94-98　2020/08
貧血をめぐる最近の話題

張替秀郎

血液事業　43　(1)　75-76　2020/05
Publisher: 日本血液事業学会
ISSN： 0917-7833
今日の治療指針2020年度版—私はこうして治療している；10.赤芽球癆

張替秀郎

医学書院　(676)　675　2020/01
高校保健ニュース月経のある女性に多い鉄欠乏性貧血・思春期の鉄欠乏性貧血

張替秀郎

心と体保健総合大百科〈中・高校編〉 2020/4/30 （株）少年写真新聞社 ISBN978-4-87981-700-6　89-90　2020
HLA-DR Expression in Acute Myeloid Leukemia has an Impact upon the Outcome of Allogenic Stem Cell Transplantation

李尹河, 田中悠也, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　42nd　2020
Impact of peripheral blood absolute monocyte counts on the outcomes of cord blood transplantation

小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　42nd　2020
節外性NK/T細胞リンパ腫の同種移植後早期再発に対して短期L-asparaginase投与が著効した1例

市川聡, 福原規子, 齋藤慧, 横山寿行, 田中悠也, 李尹河, 小野寺晃一, 大西康, 一迫玲, 張替秀郎

臨床血液　61　(4)　2020

ISSN： 0485-1439
ABCB7異常に伴う鉄芽球性貧血モデルの樹立

藤原亨, 藤原亨, 大地哲朗, 鈴木千恵, 小野浩弥, 齋藤慧, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
X連鎖性鉄芽球性貧血へのフェロトーシスの関与

小野浩弥, 藤原亨, 藤原亨, 齋藤慧, 鈴木千恵, 鈴木千恵, 高橋昇之, 高橋昇之, 燕艶, 佐野沙矢香, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
完全分子学的寛解期におけるPh陽性ALLに対するフルダラビンを用いた前処置による同種移植の成績

大西康, 小野寺晃一, 橋本和貴, 櫻井一貴, 古川瑛次郎, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
抗PD-1抗体療法後早期に生じたγδTリンパ球のクローン性増殖

小野浩弥, 大西康, 渡邊正太郎, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 藤原亨, 藤原亨, 横山寿行, 鈴木千恵, 渡辺裕文, 及川麻理子, 山崎有人, 張替秀郎, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
宮城県におけるびまん性大細胞型B細胞リンパ腫を合併した濾胞性リンパ腫の予後

渡邊正太郎, 福原規子, 横山寿行, 小野寺晃一, 市川聡, 大西康, 勝岡優奈, 八田俊介, 齋藤慧, 佐々木治, 原崎頼子, 鎌田真弓, 遠宮靖雄, 一迫玲, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
同種臍帯血移植におけるサイトメガロウイルス再活性化の影響

横山寿行, 田中悠也, 李尹河, 齋藤慧, 小野寺晃一, 市川聡, 渡邉真威, 八田俊介, 勝岡優奈, 福原規子, 大西康, 目黒邦昭, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
びまん性大細胞型B細胞リンパ腫に対する市販後チサゲンレクルユーセルの単施設後方視的検討

齋藤慧, 市川聡, 小野寺晃一, 福原規子, 大西康, 横山寿行, 藤原実名美, 佐合健, 田地規朗, 大橋圭一, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
ATGを前処置に用いたHLA半合致移植後に中枢神経系移植後リンパ増殖性疾患を合併した2例

古川瑛次郎, 大西康, 中嶌真治, 小野寺晃一, 橋本和貴, 櫻井一貴, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
無顆粒球症を呈した成熟γδT細胞白血病の一例

市川聡, 齋藤慧, 福原規子, 横山寿行, 田中悠也, 李尹河, 小野寺晃一, 大西康, 藤原亨, 藤島史喜, 一迫玲, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
深部静脈血栓症を契機に診断されたフィラデルフィア染色体陽性急性白血病の3例

橋本和貴, 大西康, 小野寺晃一, 古川瑛次郎, 櫻井一貴, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

日本血液学会学術集会抄録(Web)　82nd　2020
Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis

Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii, Yuko Shirota, Hideo Harigae, Hiroshi Fujii

ARTHRITIS & RHEUMATOLOGY　71　2019/10

ISSN： 2326-5191

eISSN： 2326-5205
ゲノムDNAを用いたHRM解析によるSF3B1遺伝子変異スクリーニング

鈴木千恵, 藤原亨, 平泉敦子, 藤巻慎一, 張替秀郎

臨床病理　67　(補冊)　192-192　2019/10
Publisher: 日本臨床検査医学会
ISSN： 0047-1860
造血幹細胞移植に伴う赤血球生着マーカーとしてのsTfR測定の有用性

佐々木克幸, 藤原亨, 佐々木麻美, 藤巻慎一, 張替秀郎

臨床病理　67　(補冊)　295-295　2019/10
Publisher: 日本臨床検査医学会
ISSN： 0047-1860
【骨髄異形成症候群(MDS)】MDSの病態・病因鉄芽球性貧血

藤原亨, 張替秀郎

日本臨床　77　(9)　1444-1449　2019/09
Publisher: (株)日本臨床社
ISSN： 0047-1852
先天性鉄芽球性貧血の原因遺伝子に関する疫学調査

藤原亨, 張替秀郎

日本染色体遺伝子検査学会雑誌　37　(2)　49-49　2019/09
Publisher: 日本染色体遺伝子検査学会
ISSN： 1884-3026
鉄過剰症の原因遺伝子と一般疾患との関連

藤原亨, 張替秀郎

血液内科　79　(2)　234-239　2019/08
Publisher: (有)科学評論社
ISSN： 2185-582X
貧血をめぐる最近の話題

張替秀郎

血液事業　42　(2)　377-377　2019/08
Publisher: 日本血液事業学会
ISSN： 0917-7833
D血液系-11 遺伝性鉄芽球性貧血[指定難病286]

張替秀郎

日本医師会雑誌第１４８巻特別号（１）指定難病ペディア2019　191-192　2019/06/15
Daratumumab併用療法後にCD38陰性化した再発難治性多発性骨髄腫の1症例

大久保礼由, 菅原新吾, 鈴木千恵, 佐々木麻美, 平泉敦子, 藤巻慎一, 齋藤慧, 市川聡, 張替秀郎, 賀来満夫

日本検査血液学会雑誌　20　(学術集会)　S213-S213　2019/06
Publisher: (一社)日本検査血液学会
ISSN： 1347-2836
末梢血幹細胞採取バック中にHematogonesの混入が考えられた症例

関修, 成田香魚子, 菅原新吾, 新妻秀剛, 藤原実名美, 張替秀郎

日本検査血液学会雑誌　20　(学術集会)　S191-S191　2019/06
Publisher: (一社)日本検査血液学会
ISSN： 1347-2836
microBCR-ABL1を認めた慢性骨髄性白血病の1例

鈴木千恵, 菅原新吾, 佐藤亜耶, 安久美子, 平泉敦子, 藤巻慎一, 賀来満夫, 市川聡, 藤原亨, 張替秀郎

日本検査血液学会雑誌　20　(学術集会)　S214-S214　2019/06
Publisher: (一社)日本検査血液学会
ISSN： 1347-2836
【指定難病ペディア2019】個別の指定難病血液系遺伝性鉄芽球性貧血[指定難病286]

張替秀郎

日本医師会雑誌　148　(特別1)　S191-S192　2019/06
Publisher: (公社)日本医師会
ISSN： 0021-4493
前医で急性リンパ性白血病とされたがびまん性大細胞型B細胞リンパ腫の診断に至った1例

石塚静江, 菅原新吾, 大久保礼由, 安久美子, 藤巻慎一, 大西康, 藤原亨, 張替秀郎

宮城県臨床検査技師会誌　9　(1)　49-49　2019/06
Publisher: (一社)宮城県臨床検査技師会
ISSN： 2186-6899
非典型的転座を呈した慢性骨髄性白血病の1例

菊地桂, 佐々木麻美, 鈴木千恵, 安久美子, 藤巻慎一, 大西康, 藤原亨, 張替秀郎

宮城県臨床検査技師会誌　9　(1)　50-50　2019/06
Publisher: (一社)宮城県臨床検査技師会
ISSN： 2186-6899
Ⅶ サイトカイン療法１．エリスロポエチン

張替秀郎

日本輸血・細胞治療学会認定医制度指定カリキュラム（改訂第４版） 2019/5/15　228-231　2019/05/15
免疫抑制療法中に濾胞性リンパ腫と古典的ホジキンリンパ腫を合併した2例

渡邊正太郎, 福原規子, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 市川聡, 大西康, 中村直哉, 一迫玲, 張替秀郎

日本リンパ網内系学会会誌　59　134-134　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248
クローン病に合併したびまん性大細胞型B細胞リンパ腫再発に対して臍帯血移植を施行した一例

古川瑛次郎, 福原規子, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 大西康, 張替秀郎

日本リンパ網内系学会会誌　59　147-147　2019/05
Publisher: (一社)日本リンパ網内系学会
ISSN： 1342-9248
エリスロポエチン産生制御と赤血球造血

張替秀郎

日本透析医学会雑誌　52　(Suppl.1)　293-293　2019/05
Publisher: (一社)日本透析医学会
ISSN： 1340-3451

eISSN： 1883-082X
本態性血小板血症における出血傾向の機序と抗凝固療法の実際について血小板数の著増に伴うvon Willebrand因子の低下が原因。細胞減少療法を先行して行う

下田和哉, 張替秀郎

日本医事新報　(4959)　50-50　2019/05
Publisher: (株)日本医事新報社
ISSN： 0385-9215
【一般臨床医のための貧血診療これだけ】貧血の基本、病歴、身体所見、検査貧血とは何か、貧血が起こるメカニズムは

齋藤慧, 張替秀郎

診断と治療　107　(5)　523-528　2019/05
Publisher: (株)診断と治療社
ISSN： 0370-999X
アルブミン製剤使用量削減に伴う臨床的アウトカムへの影響

関修, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 秋山正年, 藤原実名美, 張替秀郎

日本輸血細胞治療学会誌　65　(2)　437-437　2019/04
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011
貧血を合併した陸上競技者への鉄剤注射の問題点と指針の意義は? 安易な注射による鉄過剰症の危険性が認識された

張替秀郎, 高橋直人

日本医事新報　(4956)　48-48　2019/04
Publisher: (株)日本医事新報社
ISSN： 0385-9215
血管炎(大型血管炎)-3 生物学的製剤を使用した大型血管炎患者の検討

白井剛志, 武藤智之, 藤田洋子, 藤井博司, 石井智徳, 平林泰彦, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　63回　452-452　2019/03
Publisher: (一社)日本リウマチ学会
リウマチ性疾患の合併症-1 膠原病関連肺動脈性肺高血圧症における各種自己抗体別にみた長期予後の違いについての検討

城田祐子, 白井剛志, 藤井博司, 小寺隆雄, 亀岡淳一, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　63回　465-465　2019/03
Publisher: (一社)日本リウマチ学会
ベーチェット病血管ベーチェット病の臨床的特徴と治療内容の検討

佐藤紘子, 星陽介, 町山智章, 鴨川由起子, 藤田洋子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　63回　561-561　2019/03
Publisher: (一社)日本リウマチ学会
免疫不全に合併したNTM症 MonoMAC症候群

福原規子, 藤原亨, 張替秀郎

結核　94　(3)　168-168　2019/03
Publisher: (一社)日本結核・非結核性抗酸菌症学会
ISSN： 0022-9776

eISSN： 1884-2410
免疫不全に合併したNTM症 MonoMAC症候群

福原規子, 藤原亨, 張替秀郎

結核　94　(3)　168-168　2019/03
Publisher: (一社)日本結核病学会
ISSN： 0022-9776
輸血依存の再生不良性貧血に対してeltrombopagが奏効しferritin値の改善とともに血球回復が得られた1例

田中悠也, 李尹河, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

臨床血液　60　(11)　2019

ISSN： 0485-1439
家族支援が奏効した血液腫瘍患者の2例

長谷川涼子, 今野朱美, 大西康, 福原規子, 福土審, 張替秀郎

心身医学　59　(1)　79-79　2019/01
Publisher: (一社)日本心身医学会
ISSN： 0385-0307
臨床検査技師を目指す学生の再生医療や細胞プロセッシングセンターに対する意識調査結果

伊藤貴子, 伊藤貴子, 沖田ひとみ, 吉田まなみ, 丹羽俊文, 張替秀郎, 後藤昌史, 下川宏明

日本再生医療学会総会(Web)　18th　ROMBUNNO.P‐01‐120 (WEB ONLY)　2019
宮城県合同輸血療法委員会について

清水貴人, 佐々木大, 長谷部洋, 藤原実名美, 今野朱美, 成田香魚子, 伊藤俊広, 高橋太郎, 遠藤一弥, 浅野陽子, 佐々木治, 佐藤美佳, 高橋伸一郎, 中川國利, 張替秀郎

日本輸血細胞治療学会誌　64　(6)　790-791　2018/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011
宮城県における学会認定・臨床輸血看護師育成の取り組み

清水貴人, 今野朱美, 島貫美和子, 藤原実名美, 佐藤美佳, 長田裕美, 佐々木治, 奥山亜希子, 及川伸治, 中川國利, 張替秀郎

日本輸血細胞治療学会誌　64　(6)　805-806　2018/12
Publisher: (一社)日本輸血・細胞治療学会
ISSN： 1881-3011
5-アミノレブリン酸を用いた多発性骨髄腫微小残存病変の光線力学診断

藤原亨, 張替秀郎

臨床病理　66　(補冊)　171-171　2018/10
Publisher: 日本臨床検査医学会
ISSN： 0047-1860
造血幹細胞移植に伴う造血回復と鉄代謝関連マーカーの動態解析

佐々木克幸, 藤原亨, 佐々木麻美, 藤巻慎一, 賀来満夫, 張替秀郎

臨床病理　66　(補冊)　244-244　2018/10
Publisher: 日本臨床検査医学会
ISSN： 0047-1860
Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis

Tomoyuki Muto, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　70　2018/09

ISSN： 2326-5191

eISSN： 2326-5205
膠原病の難治性病変全身性強皮症に伴う難治性皮膚潰瘍に対する新規治療法の開発低出力体外衝撃波療法を使っての臨床試験を題材に

石井智徳, 齋藤真一郎, 藤井博司, 張替秀郎, 下川宏明

臨床リウマチ　30　(3)　231-240　2018/09
Publisher: (一社)日本臨床リウマチ学会
ISSN： 0914-8760
CD56陽性皮膚T細胞リンパ腫6例の後方視的解析(A clinicopathological analysis of CD56-positive cutaneous T cell lymphoma)

大地哲朗, 福原規子, 佐野沙矢香, 那須健太郎, 小林匡洋, 市川聡, 沖津庸子, 大西康, 藤原実名美, 藤村卓, 一迫玲, 張替秀郎

臨床血液　59　(9)　1549-1549　2018/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
不明熱の精査で骨髄検査を契機に診断に至った血管内大細胞型B細胞リンパ腫の2症例

石塚静江, 菅原新吾, 安久美子, 平泉敦子, 藤巻慎一, 賀来満夫, 市川聡, 張替秀郎

宮城県臨床検査技師会誌　8　(1)　20-20　2018/08
Publisher: (一社)宮城県臨床検査技師会
ISSN： 2186-6899
short tandem repeat(STR)-PCR法を用いた造血幹細胞移植後のキメリズム解析の評価

関修, 成田香魚子, 大西康, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

日本検査血液学会雑誌　19　(学術集会)　S163-S163　2018/06
Publisher: (一社)日本検査血液学会
ISSN： 1347-2836
「指定難病最前線」“遺伝性鉄芽球性貧血”

藤原亨, 張替秀郎

月刊「新薬と臨牀」　67　153-158　2018
臨床研究推進センター再生医療ユニットの再生・細胞医療シーズの活性化に向けた細胞提供の取り組み

伊藤貴子, 伊藤貴子, 沖田ひとみ, 吉田まなみ, 新妻邦泰, 若尾昌平, 出澤真理, 冨永悌二, 張替秀郎, 後藤昌史, 下川宏明

日本再生医療学会総会(Web)　17th　ROMBUNNO.P‐01‐120 (WEB ONLY)　2018
Clinical Sequencing of 347 Children with Acquired and Inherited Bone Marrow Failure Syndromes

Hideki Muramatsu, Yusuke Okuno, Kenichi Yoshida, Yuichi Shiraishi, Sayoko Doisaki, Atsushi Narita, Hirotoshi Sakaguchi, Nozomu Kawashima, Xinan Wang, Yinyan Xu, Kenichi Chiba, Hiroko Tanaka, Asahito Hama, Masashi Sanada, Yoshiyuki Takahashi, Hitoshi Kanno, Hiroki Yamaguchi, Shouichi Ohga, Atsushi Manabe, Hideo Harigae, Shinji Kunishima, Eiichi Ishii, Masao Kobayashi, Kenichi Koike, Kenichiro Watanabe, Etsuro Ito, Minoru Takata, Miharu Yabe, Seishi Ogawa, Satoru Miyano, Seiji Kojima

BLOOD　130　2017/12

ISSN： 0006-4971

eISSN： 1528-0020
移植後リンパ増殖性疾患の再発に対して大量化学療法、自家末梢血幹細胞移植を施行し完全寛解を達成した1例

櫻井一貴, 福原規子, 市川聡, 氷室真仁, 沖津庸子, 渡邊正太郎, 大地哲朗, 那須健太郎, 八田俊介, 小林匡洋, 大西康, 張替秀郎

臨床血液　58　(12)　2473-2473　2017/12
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
胸水中に大型異型細胞を認めたIgD型多発性骨髄腫の一症例

金沢聖美, 賀来満夫, 張替秀郎, 菅原新吾, 大久保礼由, 岩木由紀, 佐藤亜耶, 藤巻慎一

日臨技北日本支部医学検査学会抄録集　6回　105-105　2017/10
Publisher: 日臨技北日本支部医学検査学会
Non-Randomized Controlled Trial to Evaluate the Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis

Tomonori Ishii, Yasushi Kawaguchi, Osamu Ishikawa, Naruhiko Takasaawa, Takao Kodera, Hidekata Yasuoka, Yuichi Takahashi, Osamu Takai, Izaya Nakaya, Hiroshi Fujii, Yukiko Kamogawa, Yuko Shirota, Tsuyoshi Shirai, Yoko Fujita, Shinichiro Saito, Hiroaki Shimokawa, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　69　2017/10

ISSN： 2326-5191

eISSN： 2326-5205
Molecular Mechanism for the Therapeutic Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers of Systemic Sclerosis

Yukiko Kamogawa, Hiroshi Fujii, Tsuyoshi Shirai, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　69　2017/10

ISSN： 2326-5191

eISSN： 2326-5205
Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries Peer-reviewed

Tsuyoshi Shirai, Hiroshi Fujii, Yoko Fujita, Yuko Shirota, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　69　2017/10

ISSN： 2326-5191

eISSN： 2326-5205
先天性および後天性造血不全375例に対するクリニカルシーケンス(Clinical sequencing of 375 patients with inherited and acquired bone marrow failure syndromes)

Muramatsu Hideki, Okuno Yusuke, Yoshida Kenichi, Shiraishi Yuichi, Narita Atsushi, Sakaguchi Hirotoshi, Kawashima Nozomu, Xu Yinyan, Chiba Kenichi, Tanaka Hiroko, Hama Asahito, Sanada Masashi, Takahashi Yoshiyuki, Kanno Hitoshi, Yamaguchi Hiroki, Ohga Shouichi, Manabe Atsushi, Harigae Hideo, Kunishima Shinji, Ishii Eiichi, Kobayashi Masao, Koike Kenichi, Watanabe Kenichiro, Ito Etsuro, Takata Minoru, Yabe Miharu, Miyano Satoru, Ogawa Seishi, Kojima Seiji

臨床血液　58　(9)　1519-1519　2017/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
後天性慢性赤芽球癆の長期予後を明らかにするための多施設共同前向き観察研究(PRCA2016)中間報告

廣川誠, 藤島直仁, 澤田賢一, 張替秀郎, 松田晃, 小松則夫, 通山薫, 米村雄士, 中尾眞二, 齋藤明子, 松村到, 荒井俊也, 黒川峰夫

臨床血液　58　(9)　1567-1567　2017/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
GENERATION OF INDUCED PLURIPOTENT STEM CELL-DERIVED ERYTHROBLASTS FROM A PATIENT WITH X-LINKED SIDEROBLASTIC ANEMIA

Shunsuke Hatta, Tohru Fujiwara, Takako Yamamoto, Mayumi Kamata, Yoshiko Tamai, Yukio Nakamura, Shin Kawamata, Hideo Harigae

AMERICAN JOURNAL OF HEMATOLOGY　92　(8)　E326-E326　2017/08

ISSN： 0361-8609

eISSN： 1096-8652
ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA

K. Saito, T. Fujiwara, M. Morita, Y. Okitsu, N. Fukuhara, Y. Onishi, Y. Nakamura, R. Shimizu, H. Harigae

HAEMATOLOGICA　102　241-241　2017/06

ISSN： 0390-6078
EXPLORING THE MECHANISM OF FOG1-DEPENDENT TRANSCRIPTIONAL REGULATION IN ERYTHROID CELLS

T. Fujiwara, K. Sasaki, K. Saito, S. Hatta, S. Ichikawa, M. Kobayashi, Y. Okitsu, N. Fukuhara, Y. Onishi, H. Harigae

HAEMATOLOGICA　102　454-454　2017/06

ISSN： 0390-6078
造血器腫瘍患者の終末期に関連した意思決定に関する意識調査

李美玲, 今野朱美, 福原規子, 宮下光令, 張替秀郎

Palliative Care Research　12　(Suppl.)　S543-S543　2017/06
Publisher: (NPO)日本緩和医療学会
皮膚筋炎との鑑別を要したPrimary Cutanous Aggressive Epidermotropic CD8+T-cell lymphomaの1例

吉田紗彩, 照井仁, 山崎研志, 相場節也, 福原規子, 張替秀郎

日本皮膚科学会雑誌　127　(5)　1151-1151　2017/05
Publisher: (公社)日本皮膚科学会
ISSN： 0021-499X
脳病変を伴った皮膚原発CD8陽性劇症型表皮向性細胞障害性T細胞リンパ腫に対して臍帯血移植を施行した1例

市川聡, 福原規子, 八田俊介, 氷室真仁, 那須健太郎, 小野浩弥, 渡邉真威, 猪倉恭子, 小林匡洋, 大西康, 石澤賢一, 一迫玲, 張替秀郎

臨床血液　58　(4)　403-403　2017/04
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
製造作業時に着用するCPCガウンの使用検討

伊藤貴子, 沖田ひとみ, 吉田まなみ, 張替秀郎, 後藤昌史, 後藤昌史, 下川宏明, 下川宏明

再生医療　16　376　2017/02/01

ISSN： 1347-7919
多点微粒子測定による塵埃発生ワーストポイントにおける環境菌採取箇所の検討

沖田ひとみ, 伊藤貴子, 伊藤貴子, 吉田まなみ, 張替秀郎, 後藤昌史, 後藤昌史, 下川宏明, 下川宏明

再生医療　16　376　2017/02/01

ISSN： 1347-7919
「先天性骨髄不全症診療ガイドライン2017」；遺伝性鉄芽球性貧血（診断と治療社） Invited

藤原亨, 古山和道, 張替秀郎

25-32　2017
1336専門家による〜私の治療〜；鉄芽球性貧血（日本医事新報社） Invited

藤原亨, 張替秀郎

685-687　2017
Generation of Induced Pluripotent Stem Cell-Derived Erythroblasts from a Patient with X-Linked Sideroblastic Anemia

Shunsuke Hatta, Tohru Fujiwara, Takako Yamamoto, Mayumi Kamata, Yoshiko Tamai, Yukio Nakamura, Shin Kawamata, Hideo Harigae

BLOOD　128　(22)　2016/12

ISSN： 0006-4971

eISSN： 1528-0020
Transcription Factor Bach1 and Bach2 Operate Erythro-Myeloid Competitive Differentiation By Responding to Environmental Changes

Hiroki Kato, Ari Itoh-Nakadai, Mitsuyo Matsumoto, Risa Ebina-Shibuya, Yuki Sato, Masahiro Kobayashi, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Kazuhiko Igarashi

BLOOD　128　(22)　2016/12

ISSN： 0006-4971

eISSN： 1528-0020
当科で経験したEBV陽性びまん性大細胞型B細胞リンパ腫の2例

渡邉真威, 小林匡洋, 小野浩弥, 氷室真仁, 那須健太郎, 八田俊介, 市川聡, 福原規子, 大西康, 張替秀郎

臨床血液　57　(12)　2604-2604　2016/12
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
脳死肺移植後に発症した移植後リンパ増殖性疾患の1例

石際康平, 市川聡, 福原規子, 小野浩弥, 渡邉真威, 那須健太郎, 八田俊介, 大西康, 松田安史, 岡田克典, 張替秀郎

臨床血液　57　(12)　2604-2605　2016/12
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface Peer-reviewed

Tsuyoshi Shirai, Hiroshi Fujii, Tomoyuki Muto, Yuko Shirota, Yoko Fujita, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　68　2016/10

ISSN： 2326-5191

eISSN： 2326-5205
Bortezomib Treatment Induces Higher Mortality Rate in Lupus Model Mice with High Disease Activity

Hiroshi Fujii, Tomoko Ikeda, Masato Nose, Tomoyuki Muto, Kanae Akita, Yukiko Kamogawa, Tsuyoshi Shirai, Yuko Shirota, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　68　2016/10

ISSN： 2326-5191

eISSN： 2326-5205
Positron Emission Tomography Images with an Amyloid-Specific Tracer 11C-BF-227 in Systemic Amyloidosis Patients Peer-reviewed

Yuko Shirota, Katsutoshi Furukawa, Manabu Tashiro, Tsuyoshi Shirrai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　68　2016/10

ISSN： 2326-5191

eISSN： 2326-5205
B細胞性リンパ腫合併膜性腎症に対してリツキシマブを投与した1例

島田佐登志, 中道崇, 山田元, 鳴海かほり, 市川聡, 福原規子, 山本多恵, 宮崎真理子, 張替秀郎, 佐藤博, 伊藤貞嘉

日本腎臓学会誌　58　(6)　776-776　2016/08
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385
T-LBLに対する骨髄移植後に発症した大脳限局リンパ増殖性疾患(DLBCL)の一剖検例

小谷健太郎, 勝嶌浩紀, 村上圭吾, 大西康, 藤島史喜, 北本哲之, 張替秀郎, 笹野公伸, 一迫玲

日本病理学会会誌　105　(1)　583-583　2016/04
Publisher: (一社)日本病理学会
ISSN： 0300-9181
SLE・抗リン脂質抗体症候群 SLE臨床難治性全身性エリテマトーデスに対するボルテゾミブの有効性・安全性探索試験(第II相多施設共同プラセボ対照無作為化二重盲検並行群間比較試験)

石井智徳, 田中良哉, 川上純, 齋藤和義, 一瀬邦弘, 藤井博司, 城田祐子, 藤田洋子, 鴨川由起子, 秋田佳奈恵, 町山智章, 武藤智之, 張替秀郎

日本リウマチ学会総会・学術集会プログラム・抄録集　60回　417-417　2016/03
Publisher: (一社)日本リウマチ学会
細胞プロセッシングセンター活用に向けた東北大学再生医療ユニットの取り組み

沖田ひとみ, 伊藤貴子, 伊藤貴子, 吉田まなみ, 張替秀郎, 後藤昌史, 後藤昌史, 下川宏明, 下川宏明

再生医療　15　337　2016/02/01

ISSN： 1347-7919
再生・細胞医療シーズの活性化に向けた東北大学再生医療ユニットの取り組み

伊藤貴子, 伊藤貴子, 沖田ひとみ, 吉田まなみ, 新妻邦泰, 出澤真理, 冨永悌二, 張替秀郎, 後藤昌史, 後藤昌史, 下川宏明, 下川宏明

再生医療　15　310　2016/02/01

ISSN： 1347-7919
Philadelphia染色体陽性ALLに対する同種造血幹細胞移植36例の後方視的解析

小林匡洋, 大西康, 横山寿行, 佐々木治, 突田真紀子, 沖津庸子, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　38th　2016
The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival

Hiroto Ohguchi, Teru Hideshima, Manoj Bhasin, Gullu Gorgun, Loredana Santo, Michele Cea, Naoya Mimura, Rikio Suzuki, Yu-Tzu Tai, Ruben D. Carrasco, Noopur S. Raje, Paul G. Richardson, Hideo Harigae, Takaomi Sanda, Kenneth C. Anderson

BLOOD　126　(23)　2015/12

ISSN： 0006-4971

eISSN： 1528-0020
Impaired Lysophosphatidic Acid Receptor 3 Signaling in Mesenchymal Stromal Cells Promotes Multiple Myeloma Progression through Cellular Senescence and Transdifferentiation into Tumor-Associated Fibroblasts

Masahiko Kanehira, Tohru Fujiwara, Shinji Nakajima, Yoko Okitsu, Yasushi Ohnishi, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

BLOOD　126　(23)　2015/12

ISSN： 0006-4971

eISSN： 1528-0020
Carbonic Anhydrase IX Promotes the Tumorigenicity of Adult T-Cell Leukemia/Lymphoma-Derived Cells in NOG Mice

Kentaro Nasu, Kazunori Yamaguchi, Yuka Takanashi, Kazuo Sugamura, Hideo Harigae

BLOOD　126　(23)　2015/12

ISSN： 0006-4971

eISSN： 1528-0020
Transcription Factor Bach1 and Bach2 Control Common Myeloid Progenitor Cell Differentiation Under Infectious Stimuli

Hiroki Kato, Ari Itoh-Nakadai, Risa Ebina-Shibuya, Masahiro Kobayashi, Mitsuyo Matsumoto, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Kazuhiko Igarashi

BLOOD　126　(23)　2015/12

ISSN： 0006-4971

eISSN： 1528-0020
GATA-2 Regulates Dendritic Cell Differentiation

Koichi Onodera, Tohru Fujiwara, Yasushi Onishi, Ari Itoh-Nakadai, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

BLOOD　126　(23)　2015/12

ISSN： 0006-4971

eISSN： 1528-0020
赤血球造血細胞への影響 (機能性アミノ酸 5-アミノレブリン酸の科学と医学応用 : がんの診断・治療を中心に) -- (代謝影響とヘルス・メディカルケア)

藤原亨, 張替秀郎

現代化学 : 増刊　(45)　144-148　2015/10
Publisher: 東京化学同人
ISSN： 0910-4747
鉄芽球性貧血症の治療と予防 (機能性アミノ酸 5-アミノレブリン酸の科学と医学応用 : がんの診断・治療を中心に) -- (代謝影響とヘルス・メディカルケア)

藤原亨, 張替秀郎

現代化学 : 増刊　(45)　149-155　2015/10
Publisher: 東京化学同人
ISSN： 0910-4747
The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus

Tomonori Ishii, Yoshiya Tanaka, Atsushi Kawakami, Kazuyoshi Saito, Kunihiro Ichinose, Yuko Shirota, Hiroshi Fujii, Yoko Fujita, Yukiko Kamogawa, Tomoaki Machiyama, Kanae Akita, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　67　2015/10

ISSN： 2326-5191

eISSN： 2326-5205
骨髄間質細胞におけるリゾホスファチジン酸受容体シグナルは多発性骨髄腫の進展を制御する

兼平雅彦, 福原規子, 一迫玲, 張替秀郎

日本癌学会総会記事　74回　P-2264　2015/10
Publisher: 日本癌学会
ISSN： 0546-0476
高造腫瘍能ATL細胞における炭酸脱水酵素IX(CA9)発現亢進の意義

那須健太郎, 山口壹範, 玉井恵一, 井根省二, 佐々木治, 佐藤賢一, 田中伸幸, 張替秀郎, 菅村和夫

日本癌学会総会記事　74回　P-1082　2015/10
Publisher: 日本癌学会
ISSN： 0546-0476
THE SIGNALING BALANCE BETWEEN LYSOPHOSPHATIDIC ACID RECEPTOR 1 AND 3 IN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS DETERMINES PROGRESSION OF MULTIPLE MYELOMA

Masahiko Kanehira, Tohru Fujiwara, Shinji Nakajima, Yoko Okitsu, Yasushi Onishi, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

EXPERIMENTAL HEMATOLOGY　43　(9)　S71-S71　2015/09

ISSN： 0301-472X

eISSN： 1873-2399
腹診シミュレータを用いた漢方医学教育の試み

富樫尭史, 高山真, 沼田健裕, 池野由佳, 金子聡一郎, 神谷哲治, 齊藤奈津美, 菊地章子, 田中淳一, 松向寺孝臣, 黒田仁, 阿部倫明, 加賀谷豊, 石井正, 張替秀郎

医学教育　46　(Suppl.)　242-242　2015/07
Publisher: (一社)日本医学教育学会
ISSN： 0386-9644
HIGH-THROUGHPUT SIRNA SCREENING REVEALS GATA-2 UPSTREAM TRANSCRIPTIONAL MECHANISMS IN HEMATOPOIETIC CELLS

Y. Saito, T. Fujiwara, M. Kobayashi, M. Suzuki, Y. Okitsu, N. Fukuhara, Y. Onishi, K. Ishizawa, H. Harigae

HAEMATOLOGICA　100　123-123　2015/06

ISSN： 0390-6078
アカデミアにおける細胞プロセッシングセンター活用の新しいスタイルの模索

沖田ひとみ, 伊藤貴子, 吉田まなみ, 堺香名子, 横倉俊二, 高柳泰, 大家義則, 西田幸二, 中澤徹, 張替秀郎, 後藤昌史, 下川宏明

再生医療　14　350　2015/02/01

ISSN： 1347-7919
現代化学・増刊45「5-アミノレブリン酸の科学と医学応用」；赤血球造血細胞への影響（東京化学同人） Invited

藤原亨, 張替秀郎

144-148　2015
現代化学・増刊45「5-アミノレブリン酸の科学と医学応用」；鉄芽球性貧血症の治療と予防（東京化学同人） Invited

藤原亨, 張替秀郎

149-155　2015
Impact of TET2 Deficiency on Iron Metabolism in Eryhroblasts: A Potential Link to Ring Sideroblast Formation

Kyoko Inokura, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Kazuya Shimoda, Hideo Harigae

BLOOD　124　(21)　2014/12

ISSN： 0006-4971

eISSN： 1528-0020
Exploring the Potential Usefulness of 5-Aminolevulinic Acid for X-Linked Sideroblastic Anemia

Tohru Fujiwara, Ryoyu Niikuni, Koji Okamoto, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Yukio Nakamura, Tohru Tanaka, Hideo Harigae

BLOOD　124　(21)　2014/12

ISSN： 0006-4971

eISSN： 1528-0020
Cellular Labile Iron Activates NLRP3 Inflammasome

Kyohei Nakamura, Tohru Fujiwara, Tomonori Ishii, Hideo Harigae, Kouetsu Ogasawara

BLOOD　124　(21)　2014/12

ISSN： 0006-4971

eISSN： 1528-0020
Circulating CD19(+)CD38(+)CD43(+) B Cell Subset in SLE Patients Have More Cell Cycle Related Genes Than Healthy Controls

Hiroshi Fujii, Tomoaki Machiyama, Kanae Akita, Yukiko Kamogawa, Ryu Watanabe, Yoko Fujita, Yuko Shirota, Shinichiro Saito, Tomonori Ishii, Hideo Harigae

ARTHRITIS & RHEUMATOLOGY　66　S858-S858　2014/10

ISSN： 2326-5191

eISSN： 2326-5205
リゾホスファチジン酸シグナルを標的とした新たな多発性骨髄腫治療法開発の試み(A novel therapeutic approach of multiple myeloma targeting lysophosphatidic acid signaling in tumor and stroma)

兼平雅彦, 福原規子, 石澤賢一, 張替秀郎

日本癌学会総会記事　73回　P-2285　2014/09
Publisher: 日本癌学会
ISSN： 0546-0476
免疫不全NOGマウスにより分画された高造腫瘍性ATL細胞の性状解析(Characterization of highly tumorigenic ATL cells fractionated by using immunodeficiency NOG mice)

山口壹範, 那須健太郎, 玉井恵一, 佐藤賢一, 井根省二, 佐々木治, 張替秀郎, 田中伸幸, 菅村和夫

日本癌学会総会記事　73回　P-1005　2014/09
Publisher: 日本癌学会
ISSN： 0546-0476
FATE OF COLLAGEN DISEASE RELATED DIGITAL SKIN ULCERS TREATED ONLY UNDER CURRENTLY APPROVED THERAPIES: A CONTROL STUDY COMPARING WITH THE NEW SHOCKWAVE THERAPY TOWARD DIGITAL ULCERS OF SCLERODERMA

S. Saito, Y. Kamogawa, K. Nakamura, R. Watanabe, Y. Fujita, T. Shirai, Y. Shirota, H. Fuji, T. Ishii, K. Ito, H. Shimokawa, H. Takemori, T. Konta, A. Komatsuda, T. Izumiyama, Y. Hirabayashi, Y. Sato, Y. Urata, Y. Kawaguchi, H. Harigae

ANNALS OF THE RHEUMATIC DISEASES　73　568-569　2014/06

DOI： 10.1136/annrheumdis-2014-eular.3064 　

ISSN： 0003-4967

eISSN： 1468-2060
IDENTIFICATION OF ACQUIRED MUTATIONS BY WHOLE-GENOME SEQUENCING IN MONOMAC SYNDROME EVOLVING INTO MYELODYSPLASIA AND ACUTE LEUKEMIA

T. Fujiwara, N. Fukuhara, R. Funayama, N. Nariai, M. Kamata, T. Nagashima, K. Kojima, Y. Onishi, Y. Sasahara, K. Ishizawa, M. Nagasaki, K. Nakayama, H. Harigae

HAEMATOLOGICA　99　81-82　2014/06

ISSN： 0390-6078
骨髄生検でB-リンパ芽球性白血病/リンパ腫と濾胞性リンパ腫が同時に認められた一例

勝嶌浩紀, 大田泰徳, 沖津庸子, 福原規子, 張替秀郎, 笹野公伸, 一迫玲

日本病理学会会誌　103　(1)　371-371　2014/03
Publisher: (一社)日本病理学会
ISSN： 0300-9181
骨髄破壊的前治療後の臍帯血移植で,臍帯血が拒絶され正常自己造血が生着した症例の検討

藤原実名美, 横山寿行, 大西康, 張替秀郎, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　36th　2014
再発・難治・予後不良因子を有するDLBCLに対する大量化学療法併用自家末梢血幹細胞移植

亀岡吉弘, 高橋直人, 高橋直人, 赤木智昭, 赤木智昭, 奈良美保, 奈良美保, 井根省二, 井根省二, 加藤裕一, 加藤裕一, 横山寿行, 横山寿行, 野地秀義, 野地秀義, 村井一範, 村井一範, 石田陽治, 石田陽治, 張替秀郎, 張替秀郎, 澤田賢一, 澤田賢一

日本造血細胞移植学会総会プログラム・抄録集　36th　2014
プリンシプル血液疾患の臨床新戦略による貧血治療；鉄芽球性貧血（中山書店） Invited

藤原亨, 張替秀郎

237-239　2014
5q-症候群に対する少量レナリドミド療法開始後に合併する肺サルコイドーシスが改善した1例

加藤浩貴, 大西康, 大橋圭一, 近藤愛子, 長谷川慎, 勝岡優奈, 沖津庸子, 福原規子, 亀岡淳一, 石澤賢一, 張替秀郎, 玉田勉

臨床血液　54　(12)　2213-2213　2013/12
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
A Low-Molecular-Weight Compound K7174 Represses Hepcidin: Possible Therapeutic Strategy Against Anemia Of Chronic Disease

Tohru Fujiwara, Takashi Ikeda, Yuki Nagasaka, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Naohisa Tomosugi, Hideo Harigae

BLOOD　122　(21)　2013/11

ISSN： 0006-4971

eISSN： 1528-0020
A CLINICOPATHOLOGICAL ANALYSIS OF LYMPHOPROLIFERATIVE DISORDERS IN RHEUMATOID ARTHRITIS

Y. Kamogawa, N. Fukuhara, M. Suzuki, S. Nakajima, Y. Okitsu, Y. Katsuoka, Y. Onishi, T. Ishii, K. Ishizawa, H. Harigae

ANNALS OF ONCOLOGY　24　2013/11

DOI： 10.1093/annonc/mdt459.98 　

ISSN： 0923-7534

eISSN： 1569-8041
Exploring The Mechanisms To Reveal The Contribution Of LMO2 To The Transcriptional Regulation In Human Erythroblasts

Al Inoue, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

BLOOD　122　(21)　2013/11

ISSN： 0006-4971

eISSN： 1528-0020
Natural Killer Cell Death Mediated By NKG2D-Trogocytosis

Kyohei Nakamura, Masafumi Nakayama, Mitsuko Kawano, Tomonori Ishii, Hideo Harigae, Kouetsu Ogasawara

BLOOD　122　(21)　2013/11

ISSN： 0006-4971

eISSN： 1528-0020
Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics (vol 26, pg 22, 2013) Peer-reviewed

Katsuyoshi Takata, Yasuharu Sato, Naoya Nakamura, Mami Tokunaka, Yukari Miki, Yara Yukie Kikuti, Kazuhiko Igarashi, Etsuro Ito, Hideo Harigae, Seiichi Kato, Eiko Hayashi, Takashi Oka, Yoshinobu Hoshii, Akira Tari, Hiroyuki Okada, Lamia Abd Al-Kader, Yoshinobu Maeda, Mitsune Tanimoto, Tomohiro Kinoshita, Tadashi Yoshino

MODERN PATHOLOGY　26　(8)　1152-1152　2013/08

DOI： 10.1038/modpathol.2013.118 　

ISSN： 0893-3952
臍帯血移植後腎血栓性微小血管症による透析導入期に脳幹型PRESを合併した一例

中道崇, 宮崎真理子, 山田元, 柳澤紀子, 山本多恵, 佐藤博, 伊藤貞嘉, 大西康, 張替秀郎

日本腎臓学会誌　55　(6)　1048-1048　2013/08
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385
トシリズマブが奏功したキャッスルマン病関連尿細管間質性腎炎の一例

山田元, 中道崇, 宮崎真理子, 柳澤紀子, 山本多恵, 沖津庸子, 張替秀郎, 佐藤博, 伊藤貞嘉

日本腎臓学会誌　55　(6)　1071-1071　2013/08
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385
LONG-TERM ADMINISTRATION OF TOCILIZUMAB INCREASES THE STRUCTURAL REMISSION RATE YEAR BY YEAR AND CONTINUOUSLY INHIBITS RADIOGRAPHIC PROGRESSION: 3 YEAR RESULTS FROM MICHINOKU TOCILIZUMAB STUDY GROUP

R. Watanabe, H. Okuno, T. Ishii, H. Harigae, Y. Hirabayashi

ANNALS OF THE RHEUMATIC DISEASES　72　888-888　2013/06

ISSN： 0003-4967

eISSN： 1468-2060
9. 多剤併用療法に抵抗性のループス腎炎に免疫吸着法(Immunoadsorption Plasmapheresis)を施行した2例(一般演題,日本アフェレシス学会第23回東北アフェレーシス研究会抄録)

鈴木舞, 鴨川由起子, 中村恭平, 渡部龍, 白井剛志, 藤田洋子, 城田祐子, 藤井博司, 齋藤真一郎, 石井智徳, 張替秀郎

日本アフェレシス学会雑誌　32　(3)　241-241　2013
Publisher: 日本アフェレシス学会
ISSN： 1340-5888
Weber-Christian病として治療中にsubcutaneous panniculitis-like T cell lymphomaが出現した一例

勝嶌浩紀, 谷内真司, 藤井博司, 張替秀郎, 笹野公伸, 一迫玲

日本リンパ網内系学会会誌　53　150-150　2013
Idiopathic thrombocytopenic purpura in pregnancy

65　(6)　788-793　2012/12
Publisher: 科学評論社
ISSN： 2185-582X
ヒト赤芽球特異的5-アミノレブリン酸合成酵素遺伝子の新たな赤芽球特異的エンハンサーの同定

古山和道, 金子桐子, 藤原亨, 張替秀郎, 柴原茂樹

日本生化学会大会プログラム・講演要旨集　85回　3T12-08　2012/12
Publisher: (公社)日本生化学会
Regulation of Erythropoiesis by Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin A (DZNep)

Tohru Fujiwara, Haruka Saitoh, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae

BLOOD　120　(21)　2012/11

ISSN： 0006-4971
Multicenter Phase II Clinical Trial of Nilotinib for Patients with Imatinib-Resistant or Intolerant CML From the East Japan CML Study Group (EJCML) Trial: Evaluation of Molecular Responses by the BCR-ABL1 Mutational Status and Plasma Trough Concentration of Nilotinib Peer-reviewed

Naoto Takahashi, Masatomo Miura, Jun Kuroki, Kinuko Mitani, Atsushi Kitabayashi, Osamu Sasaki, Hideo Kimura, Kiyotoshi Imai, Norifumi Tsukamoto, Hideyoshi Noji, Takeshi Kondo, Akihisa Kuwayama, Mutsuhito Motegi, Yuichi Kato, Kaoru Takahashi, Masayuki Mita, Hajime Saito, Chikashi Yoshida, Yoshihiro Torimoto, Tomofumi Kimura, Yuji Wano, Jun Nomura, Satoshi Yamamoto, Ko Mayama, Riko Honma, Tomohiro Sugawara, Shinji Sato, Atsushi Shinagawa, Akihiko Chubachi, Hideo Harigae, Kenichi Sawada

BLOOD　120　(21)　2012/11

DOI： 10.1182/blood.V120.21.1360.1360 　

ISSN： 0006-4971
Elucidation of the Role of LMO2 (LIM-only protein 2) in Erythroid Cells

A. I. Inoue, Tohru Fujiwara, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

BLOOD　120　(21)　2012/11

ISSN： 0006-4971
A Novel Method for Quantitative and Functional Analysis of Autophagy Using Flow Cytometry in Activated Human Primary T Cells Peer-reviewed

Ryu Watanabe, Hiroshi Fujii, Yukiko Kamogawa, Kyohei Nakamura, Tsuyoshi Shirai, Yumi Tajima, Shinichiro Saito, Tomonori Ishii, Hideo Harigae

ARTHRITIS AND RHEUMATISM　64　(10)　S982-S983　2012/10

ISSN： 0004-3591
CLINICAL FEATURES AND IMMUNOLOGICAL ABNORMALITIES OF GATA2 DEFICIENCY IN JAPAN

K. Honma, K. Imai, C. Kamae, H. Ishida, Y. Ito, S. Kojima, T. Yokosuka, H. Kanegane, T. Morio, Y. Sasahara, T. Fujiwara, H. Harigae, Y. Hashii, O. Ohara, S. Nonoyama

JOURNAL OF CLINICAL IMMUNOLOGY　32　84-85　2012/09

ISSN： 0271-9142
若年成人における節外性NK/T細胞性リンパ腫の臨床病理学的解析 MIYAGI試験(A clinicopathological analysis of extranodal NK/T-cell lymphoma in younger adults: MIYAGI study)

Fukuhara Noriko, Ichikawa Satoshi, Suzuki Makiko, Nakajima Shinji, Okitsu Yoko, Katsuoka Yuna, Kohata Katsura, Fujiwara Tohru, Onishi Yasushi, Yamamoto Joji, Yokoyama Hisayuki, Fujiwara Minami, Meguro Kuniaki, Takahashi Taro, Ishikawa Izumi, Ishizawa Kenichi, Kameoka Junichi, Ichinohasama Ryo, Harigae Hideo

臨床血液　53　(9)　1163-1163　2012/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
エンテカビル投与により寛解に至ったB型肝炎ウィルス感染、慢性リンパ性白血病合併ネフローゼ症候群の一例

吉田舞, 中道崇, 大場郁子, 柳澤紀子, 宮崎真理子, 佐藤博, 伊藤貞嘉, 福原規子, 張替秀郎

日本腎臓学会誌　54　(6)　728-728　2012/08
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385

eISSN： 1884-0728
トシリズマブが寛解導入に有効であったAAアミロイドーシスによるネフローゼ症候群の一例

中道崇, 中山恵輔, 宮崎真理子, 佐藤博, 伊藤貞嘉, 福原規子, 石井智徳, 張替秀郎

日本腎臓学会誌　54　(6)　741-741　2012/08
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385
心タンポナーデで発症し,外科的切除と術後化学療法により長期生存中の心臓原発悪性リンパ腫の1例

後岡広太郎, 福本義弘, 杉村宏一郎, 佐藤公雄, 三浦裕, 青木竜男, 建部俊介, 山本沙織, 下川宏明, 熊谷紀一郎, 齋木佳克, 山本譲司, 福原規子, 石澤賢一, 張替秀郎

日本循環器学会東北地方会(Web)　154th　2012
先天代謝異常症候群（第二版）；鉄芽球性貧血（日本臨床社） Invited

藤原亨, 張替秀郎

212-214　2012
Decreased Expression of HOXB4 Gene in Aplastic Anemia; Regulatory Interaction with GATA-2

Tohru Fujiwara, Hisayuki Yokoyama, Yoko Okitsu, Mayumi Kamata, Shinichi Fujimaki, Takashi Moriguchi, Shinichiro Takahashi, Emery H. Bresnick, Hideo Harigae

BLOOD　118　(21)　1469-1470　2011/11

ISSN： 0006-4971
Exploring the Mechanism of ETO2-Dependent Transcriptional Regulation in Erythroid Cells Peer-reviewed

Alqadi Yarob Wael, Tohru Fujiwara, Yoko Okitsu, Yasushi Onishi, Kenichi Ishizawa, Hideo Harigae

BLOOD　118　(21)　578-579　2011/11

ISSN： 0006-4971
Retrospective Comparison of Recombinant Thrombomodulin and Conventional Drugs in a Treatment of DIC Caused by Acute Leukemia Peer-reviewed

Hisayuki Yokoyama, Toshihiro Itoh, Hideo Harigae

BLOOD　118　(21)　548-548　2011/11

ISSN： 0006-4971
Retroviral Vector System Identified FLRT2 As a Novel Cell Surface Autoantigen Against Anti-Endothelial Cell Antibodies in Systemic Lupus Erythematosus.

Tsuyoshi Shirai, Hiroshi Fujii, Masao Ono, Kyohei Nakamura, Ryu Watanabe, Yumi Sasaki, Naruhiko Takasawa, Tomonori Ishii, Hideo Harigae

ARTHRITIS AND RHEUMATISM　63　(10)　S560-S561　2011/10

ISSN： 0004-3591
赤芽球特異的5-アミノレブリン酸合成酵素のカルボキシル末端は内因性抑制ドメインとして機能する

Senkottuvelan Kadirvel, 古山和道, 金子桐子, 張替秀郎, 柴原茂樹

日本生化学会大会プログラム・講演要旨集　84回　2T10a-2　2011/09
Publisher: (公社)日本生化学会
Flu/CY/ATGの前処置にてATGを先行投与し同種骨髄移植を施行した再生不良性貧血の1例

大場理恵, 猪倉恭一, 勝岡優奈, 沖津庸子, 福原規子, 大口裕人, 木幡桂, 大西康, 山本譲司, 石澤賢一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　33rd　2011
フルダラビン+大量エンドキサン+TBI 4Gyを前処置に用いた臍帯血移植の検討

大西康, 大場理恵, 猪倉恭子, 勝岡優奈, 沖津庸子, 木幡桂, 福原規子, 大口裕人, 山本譲司, 石澤賢一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　33rd　2011
マントル細胞リンパ腫長期生存例の後方視的解析

福原規子, 原崎頼子, 井根省二, 遠宮靖雄, 奥田光崇, 三浦由希子, 大口裕人, 大西康, 木幡桂, 横山寿行, 石澤賢一, 亀岡淳一, 一迫玲, 佐々木治, 張替秀郎

日本臨床腫瘍学会学術集会プログラム・抄録集　9th　2011
血液疾患モデル（貧血など） Invited

藤原亨, 張替秀郎

マウス•ラット疾患モデル活用ハンドブック（羊土社）　334-342　2011
当科におけるChurg‐Strauss症候群12例の臨床病理学的検討

渡部龍, 白井剛志, 田島結実, 藤井博司, 高澤徳彦, 鈴木直輝, 竪山真規, 糸山泰人, 石井智徳, 張替秀郎

末梢神経　21　(2)　247-248　2010/12/01

ISSN： 0917-6772
Epidemiological and Genetic Analysis of Sideroblastic Anemia - Multi-center Study In Japan Peer-reviewed

Ohba Rie, Furuyama Kazumichi, Tsuchiya Shigeru, Manabe Atsushi, Ito Etsuro, Kojima Seiji, Ozawa Keiya, Harigae Hideo

BLOOD　116　(21)　1716-1717　2010/11/19

ISSN： 0006-4971
Blockade of T Cell Anergy by Tyrosine Kinase Inhibitor, Sorafenib May Induce Exacerbation of Gvhd In Allogeneic Hematopoietic Stem Cell Transplantation. Peer-reviewed

Hisayuki Yokoyama, Hideo Harigae, Richard Childs

BLOOD　116　(21)　624-624　2010/11

ISSN： 0006-4971
COMPARISON OF PHENOTYPES BETWEEN T(14;18)-POSITIVE AND -NEGATIVE FOLLICULAR LYMPHOMA

Yukiko Miura, Katsura Kohata, Joji Yamamoto, Kenichi Ishizawa, Ryo Ichihasama, Hideo Harigae

ANNALS OF ONCOLOGY　21　39-39　2010/11

ISSN： 0923-7534
腸症型T細胞リンパ腫 MIYAGI研究会による臨床病理学的解析(Enteropathy-associated T-cell lymphoma: a clinicopathoiogical analysis from MIYAGI study group)

Fukuhara Noriko, Kamata Mayumi, Yamamoto Joji, Yokoyama Hisayuki, Takahashi Taro, Ishikawa Izumi, Sugawara Tomohiro, Takagawa Masanori, Sasaki Osamu, Katsuoka Yuna, Miura Yukiko, Ohba Rie, Okitsu Yoko, Kohata Katsura, Ohguchi Hiroto, Onishi Yasushi, Ishizawa Kenichi, Kameoka Junichi, Ichinohasama Ryo, Harigae Hideo

臨床血液　51　(9)　983-983　2010/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
妊娠合併ITP症例の後方視的検討

沖津庸子, 亀岡淳一, 鎌田真弓, 小林匡洋, 大場理恵, 福原規子, 大口裕人, 木幡桂, 山本譲司, 横山寿行, 千坂泰, 石澤賢一, 鈴木宗三, 八重樫伸生, 張替秀郎

日本血栓止血学会誌　21　(2)　209-209　2010/04
Publisher: (一社)日本血栓止血学会
ISSN： 0915-7441

eISSN： 1880-8808
血管炎・APS 当科膠原病診療におけるPR3-ANCA陽性患者の検討 (日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集)

白井剛志, 渡部龍, 田島結実, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎

日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　54回・19回　544-544　2010/03
後天性第X因子低下症の一例

沖津庸子, 鈴木宗三, 鎌田真弓, 小林匡洋, 福原規子, 大口裕人, 木幡桂, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 張替秀郎

東北止血・血栓研究会会誌　XXIII　(1)　12-16　2010/03
Publisher: 東北止血・血栓研究会
ISSN： 0914-6598
Agranulocytosis caused by clopidogrel

ICHIKAWA Satoshi, OKITSU Yoko, YAMAMOTO Joji, YOKOYAMA Hisayuki, ISHIZAWA Kenichi, KAMEOKA Junichi, HARIGAE Hideo, TAKEDA Morihiko, ITO Kenta

Nihon Naika Gakkai Zasshi　99　(2)　337-339　2010/02/10
Publisher: The Japanese Society of Internal Medicine
ISSN： 0021-5384

eISSN： 1883-2083
再発・難治低悪性度リンパ腫に対する90Y-イブリツモマブ・チウキセタン療法の有効性・安全性の検討

鎌田真弓, 木村淳, 新津秀孝, 木村朋文, 小林匡洋, 沖津庸子, 福原規子, 大場理恵, 木幡桂, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 張替秀郎

日本臨床腫瘍学会学術集会プログラム・抄録集　8th　2010
当科における同種造血幹細胞移植の経験-20年間の歩み

山本譲司, 鎌田真弓, 渡辺龍, 小林匡洋, 市川聡, 中嶌真治, 鈴木真紀子, 井上あい, 三浦由希子, 沖津庸子, 木幡桂, 大場理恵, 福原規子, 大西康, 横山寿行, 山田実名美, 石澤賢一, 亀岡淳一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　32nd　2010
骨髄線維化と巨脾を伴う移行期CMLに非血縁者間骨髄移植を施行した一例

小林匡洋, 鈴木真紀子, 沖津庸子, 福原規子, 鎌田真弓, 大場理恵, 大口裕人, 木幡桂, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 張替秀郎

日本造血細胞移植学会総会プログラム・抄録集　32nd　2010
当科におけるChurg‐Strauss症候群12例の臨床病理学的検討

渡部龍, 白井剛志, 田島結実, 藤井博司, 高澤徳彦, 鈴木直輝, 竪山真規, 糸山泰人, 石井智徳, 張替秀郎

日本末梢神経学会学術集会プログラム・抄録　21st　48　2010
可溶性インターロイキン2受容体--sIL-2R (特集新しい臨床検査) -- (血液・膠原病)

山本譲司, 張替秀郎

診断と治療　97　(9)　1916-1923　2009/09
Publisher: 診断と治療社
ISSN： 0370-999X
ALAS2のExon 11に遺伝子変異(T1731C変異)を認めたピリドキシン反応性X-linked鉄芽球性貧血の1例

玉井佳子, 太田健, 間山恒, 山形和史, 張替秀郎, 古山和道, 対馬健一, 福田眞作, 高見秀樹

臨床血液　50　(9)　1241-1241　2009/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
Ph染色体異常を有するB細胞性白血病の病態解析

鈴木真紀子, 市川聡, 中嶌真治, 大口裕人, 沖津庸子, 木幡桂, 福原規子, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 関正則, 遠宮靖雄, 張替秀郎

臨床血液　50　(9)　890-890　2009/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
宮城県における悪性リンパ腫の臨床および病理学的特徴

三浦由希子, 鎌田真弓, 小林匡洋, 中嶌真治, 市川聡, 鈴木真紀子, 井上あい, 沖津庸子, 大口裕人, 福原規子, 木幡桂, 大西康, 山本譲司, 横山寿行, 石澤賢一, 亀岡淳一, 一迫玲, 張替秀郎

臨床血液　50　(9)　1026-1026　2009/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
FISH法によるIgH転座解析を用いた濾胞性リンパ腫骨髄浸潤の検出

木幡桂, 三浦由希子, 大口裕人, 沖津庸子, 福原規子, 大西康, 山本譲司, 石澤賢一, 亀岡淳一, 張替秀郎, 横山寿行, 一迫玲, 安久美子, 賀来満夫

臨床血液　50　(9)　1043-1043　2009/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
24-283 血液腫瘍患者への緩和医療を視野に入れた心理的介入(心理療法4,一般演題(ポスター発表),近未来医療を担う心身医学,第1回日本心身医学5学会合同集会)

長谷川涼子, 吉田和子, 山田実名美, 亀岡淳一, 張替秀郎, 金澤素, 福土審

心身医学　49　(6)　679-679　2009/06/01
Publisher: 日本心身医学会
DOI： 10.15064/jjpm.49.6_679_1 　

ISSN： 0385-0307
末梢血幹細胞移植後に生じたporoid hidradenomasの1例

島田遼子, 奥山隆平, 亀岡淳一, 張替秀郎, 相場節也

日本皮膚科学会雑誌　119　(4)　771-771　2009
Bortezomibが著効したIgM型多発性骨髄腫の1例

鎌田真弓, 山本譲司, 市川聡, 中嶌真治, 鈴木真紀子, 小林匡洋, 沖津庸子, 福原規子, 木幡桂, 大西康, 石澤賢一, 亀岡淳一, 一迫玲, 張替秀郎

臨床血液　50　(9)　1073-1073　2009
フルダラビン、メルファランを用いた造血器腫瘍に対する同種造血幹細胞移植当科における経験

山本譲司, 鎌田真弓, 渡辺龍, 小林匡洋, 市川聡, 中嶌真治, 鈴木真紀子, 井上あい, 三浦由希子, 沖津庸子, 木幡桂, 福原規子, 大西康, 山田実名美, 石澤賢一, 亀岡淳一, 張替秀郎

臨床血液　50　(9)　983-983　2009
Erythroid Differentiation and Heme Biosynthesis

HARIGAE H.

120　(2)　177-179　2008/12/25
Publisher: 東北医学会
ISSN： 0040-8700
副腎偶発腫瘍の鑑別診断副腎原発非ホジキンリンパ腫の診断

森本玲, 山田友里恵, 佐藤文俊, 工藤正孝, 村上治, 石澤賢一, 張替秀郎, 石岡千加史, 高橋昭喜, 石戸谷滋人, 荒井陽一, 一迫玲, 伊藤貞嘉

日本内分泌学会雑誌　84　(3)　895-895　2008/12
Publisher: (一社)日本内分泌学会
ISSN： 0029-0661
PU.1 Epigenetically Represses the Expression of Metallothionein-1 Gene in Leukemia Cells Peer-reviewed

Shinichiro Takahashi, Mami Okada, Akemi Imoto, Masako Nakahara, Toshio Okazaki, Hideo Harigae

BLOOD　112　(11)　434-434　2008/11

ISSN： 0006-4971
Bidirectional Control of Transcription Factor GATA2 and Cyclin/Cdks in Hematopoietic Cells

Naoko Minegishi, Hideo Harigae, Masayuki Yamamoto

BLOOD　112　(11)　495-495　2008/11

ISSN： 0006-4971
Human parvovirus B19 up-regulates function of dendritic cells in patients with rheumatoid arthritis Peer-reviewed

Reiko Takahashi, Takako Ito, Tomonori Ishii, Yumiko Oka, Keiko Ishii, Yasuhiko Munakata, Takeshi Sasaki, Yasuhiko Hirabayashi, Hideo Harigae

ARTHRITIS AND RHEUMATISM　58　(9)　S701-S702　2008/09

ISSN： 0004-3591
維持透析中に発症したAML-M0の二例

阿部正理, 猪股美津恵, 目黒邦明, 鈴木真紀子, 大西康, 山本譲司, 山田実名美, 亀岡淳一, 張替秀郎, 大口裕人

臨床血液　49　(9)　1061-1061　2008/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
再発・難治性多発性骨髄腫に対するBortezomib療法の後方視的検討

大口裕人, 井根省二, 阿部正理, 大西康, 石川泉, 木幡桂, 山本譲司, 山田実名美, 石澤賢一, 遠宮靖雄, 奥田光崇, 菅原知広, 亀岡淳一, 張替秀郎

臨床血液　49　(9)　1083-1083　2008/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
8.血漿交換療法と免疫抑制療法の併用が奏効した特発性血栓性血小板減少性紫斑病(TTP)の1例(一般演題,日本アフェレシス学会第19回東北アフェレーシス研究会抄録)

田島結実, 長澤将, 加藤量広, 石井智徳, 高橋令子, 高澤徳彦, 平林泰彦, 張替秀郎, 相澤裕, 相馬龍子, 村田弥栄子, 城田祐子, 佐藤壽伸

日本アフェレシス学会雑誌　27　(3)　246-247　2008
Publisher: 日本アフェレシス学会
ISSN： 1340-5888
再生不良性貧血に対する免疫抑制療法後のシクロスポリン依存性の検討

亀岡淳一, 高橋直人, 菅原知広, 目黒邦昭, 奥田光崇, 野地秀義, 七島勉, 加藤裕一, 田嶋克史, 赤木智昭, 村井一範, 石田陽治, 張替秀郎, 澤田賢一

臨床血液　49　(9)　866-866　2008
Analyses of heme-regulated genes during erythoid differentiation Peer-reviewed

Fujiwara Tohru, Okitsu Yoko, Ikura Tsuyoshi, Takahashi Shinichiro, Furuyama Kazumichi, Igarashi Kazuhiko, Yamamoto Masayuki, Sassa Shigeru, Harigae Hideo

BLOOD　110　(11)　782A　2007/11/16

ISSN： 0006-4971
GATA-2による間葉系幹細胞から脂肪細胞への分化制御 (臨床血液)

沖津庸子, 高橋伸一郎, 峯岸直子, 亀岡淳一, 山本雅之, 張替秀郎

臨床血液　48　(9)　934-934　2007/09
Erratum: Identification of human GATA-2 gene distal IS exon and its expression in hematopoietic stem cell fractions (Journal of Biochemistry (2000) 127, (105-112))

Xiaoqing Pan, Naoko Minegishi, Hideo Harigae, Hironori Yamagiwa, Masayoshi Minegishi, Yasuyuki Akine, Masayuki Yamamoto

Journal of Biochemistry　141　(5)　767　2007/05

DOI： 10.1093/jb/mvm078 　

ISSN： 0021-924X
造血器腫瘍における微小残存病変(MRD)測定法の標準化に向けての施設間比較

藤原亨, 山田実名美, 石川泉, 張替秀郎, 亀岡淳一, 宮村耕一

臨床血液　48　(9)　1159-1159　2007
Clinical and pathological diagnosis of transplantation associated microangiopathy of gut: Successful reduction of immunosuppressant which is opposite treatment of GVHD.

Koichi Miyamura, Minami Yamada, Tetsuya Nishida, Yasuo Tomiya, Hideo Harigae, Junichi Kameoka, Takeshi Sasaki, Masafumi Ito

BLOOD　108　(11)　842A-842A　2006/11

ISSN： 0006-4971
Phenotypic changes of hematopoietic stem cells and stromal cells by aberrant expression of GATA-2; Possible role for the development of aplastic anemia.

Yoko Okitsu, Hideo Harigae, Shinichiro Takahashi, Naoko Minegishi, Norio Suzuki, Junichi Kameoka, Masayuki Yamamoto, Takeshi Sasaki

BLOOD　108　(11)　378A-378A　2006/11

ISSN： 0006-4971
急性骨髄性白血病検体におけるFlt3とPU.1の発現は負の相関を示す

猪股美津恵, 張替秀郎, 亀岡淳一, 佐々木毅, 高橋伸一郎, 賀来満夫

臨床血液　47　(5)　414-414　2006
Increased expression of insulin-like growth factor I is associated with Ara-C resistance in leukemia.

S Abe, H Harigae, T Funato, J Kameoka, S Takahashi, M Kaku, T Sasaki

BLOOD　106　(11)　435A-435A　2005/11

ISSN： 0006-4971
Induction of adipocyte differentiation and reduction of hematopoesis-supporting activity of mouse stromal cells by suppression of transcription factor GATA-2.

Y Okitsu, H Harigae, M Seki, T Fujiwara, S Takahashi, H Yokoyama, J Kameoka, N Minegishi, T Sasaki

BLOOD　106　(11)　402A-403A　2005/11

ISSN： 0006-4971
Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias

S Takahashi, M Inomata, H Harigae, J Katneoka, M Kaku, T Sasaki

BLOOD　106　(11)　352A-352A　2005/11

ISSN： 0006-4971
Evaluation of a fully automated system (RAISUS) for rapid identification and antimicrobial susceptibility testing of staphylococci

K. Kanemitsu, H. Kunishima, M. Hatta, K. Inden, T. Saga, H. Ouchi, K. Ishizawa, H. Harigae, H. Takemura, M. Kaku

Journal of Clinical Microbiology　43　(11)　5808-5810　2005/11

DOI： 10.1128/JCM.43.11.5808-5810.2005 　

ISSN： 0095-1137
血しょうを用いたPCR法による敗血症の診断

木幡桂, 張替秀郎, 石井恵子, 木村裕一, 栗林英人, 川口正浩, 山本伸子, 国島広之, 金光敬二, 賀来満夫

感染症学雑誌　79　(9)　2005

ISSN： 0387-5911
感染症診断用DNAマイクロアレイによる菌血症原因菌の同定

石井恵子, 木幡桂, 張替秀郎, 木村裕一, 川口正浩, 山本伸子, 賀来満夫, 大川淳雄, 宮村耕一, 渡邉成美, 佐々木千晴

感染症学雑誌　79　(1)　80-80　2005
転写因子GATA-2の発現抑制による骨髄ストローマ細胞の脂肪分化と造血支持能の変化 (日本血液学会・日本臨床血液学会回総会プログラム・抄録集)

沖津庸子, 張替秀郎, 関正則, 高橋伸一郎, 亀岡淳一, 賀来満夫, 佐々木毅

日本血液学会・日本臨床血液学会回総会プログラム・抄録集　(67回47回)　749-749　2005
赤血球系白血病細胞株K562における転写因子GATA-2の赤血球特異的遺伝子発現誘導

横山寿行, 張替秀郎, 沖津庸子, 高橋伸一郎, 峯岸直子, 賀来満夫, 佐々木毅

日本血液学会・日本臨床血液学会回総会プログラム・抄録集　67回・47回　(67回47回)　942-942　2005
Publisher: 日本臨床血液学会
ヘムに制御される赤血球特異的遺伝子群の発現制御機構と新規Histone Acetyltransferaseの同定

藤原亨, 張替秀郎, 高橋伸一郎, 五十嵐和彦, 賀来満夫, 佐々木毅

日本血液学会・日本臨床血液学会回総会プログラム・抄録集　67回・47回　(67回47回)　796-796　2005
Publisher: 日本臨床血液学会
AML1Bの転写抑制能はFlt3-ITDにより阻害される

高橋伸一郎, 張替秀郎, 亀岡淳一, 佐々木毅, 賀来満夫

日本血液学会・日本臨床血液学会回総会プログラム・抄録集　(67回47回)　754-754　2005
血漿を用いたPCR法による敗血症の診断

木幡桂, 張替秀郎, 石井恵子, 木村裕一, 栗林英人, 川口正浩, 山本伸子, 國島広之, 金光敬二, 賀来満夫

感染症学雑誌　79　(9)　712-712　2005
転写抑制因子に対するFlt3変異の影響

高橋伸一郎, 張替秀郎, 佐々木毅, 賀来満夫

臨床化学　34　(Suppl.2)　143-143　2005
急性骨髄性白血病検体におけるFlt3とPU.1の発現は負の相関を示す

高橋伸一郎, 猪股美津恵, 張替秀郎, 佐々木毅, 賀来満夫

臨床化学　34　(Suppl.2)　141-141　2005
Identification of tenascin-C as a key molecule determining the stromal cell dependent erythropoiesis.

M Seki, J Kameoka, S Takahashi, H Harigae, T Sasaki, M Obinata

BLOOD　104　(11)　367A-367A　2004/11

ISSN： 0006-4971
Functional analysis of a cation transporter OCT6: A mediator of the cellular influx of adriamycin.

Y Okitsu, H Harigae, S Takahashi, S Abe, M Okabe, M Unno, T Abe, M Kaku, T Sasaki

BLOOD　104　(11)　177B-177B　2004/11

ISSN： 0006-4971
Decreased expression of stem cell-specific genes in aplastic anemia; possible regulation of HOXB4 gene by GATA-2.

H Yokoyama, H Harigae, S Takahashi, Y Okitsu, J Yamamoto, Y Tohmiya, M Fujiwara, K Ishizawa, J Kameoka, N Minegishi, M Kaku, T Sasaki

BLOOD　104　(11)　771A-772A　2004/11

ISSN： 0006-4971
Over-expression of Flt3 induces the expression of NFkB target genes, cIAP-1 and IL-6.

S Takahashi, H Harigae, M Inomata, KK Ishii, JD Licht, T Sasaki, M Kaku

BLOOD　104　(11)　565A-565A　2004/11

ISSN： 0006-4971
Identification of novel heme-regulated genes during erythroid differentiation

T Fujiwara, H Harigae, S Takahashi, K Furuyama, M Kaku, S Sassa, T Sasaki

BLOOD　104　(11)　440A-440A　2004/11

ISSN： 0006-4971
同種骨髄移植を施行した節外性NK細胞リンパ腫の1例

大口裕人, 亀岡淳一, 沖津庸子, 小林美津恵, 横山寿行, 遠宮靖雄, 山田実名美, 石澤賢一, 佐々木毅, 高橋伸一郎, 張替秀郎, 一迫玲

臨床血液　45　(9)　1073-1074　2004/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
急性白血病患者の微少残存病変マーカーとしてのスタニオカルシンmRNAの有用性の検討

遠宮靖雄, 小出芳夫, 張替秀郎, 亀岡淳一, 石澤賢一, 船渡忠男, 山田実名美, 賀来満夫, 佐々木毅

日本内科学会雑誌　93　(Suppl.)　141-141　2004
キメラ遺伝子検出のための簡易型cDNAマイクロアレイの開発

舩渡忠男, 鈴木佳子, 高橋伸一郎, 張替秀郎, 賀来満夫, 吉川陽子

日本検査血液学会雑誌　5　(学術集会)　S59-S59　2004
急性骨髄性白血病におけるFlt3変異とp21WAF1/CIP1高発現との関連の検討

高橋伸一郎, 張替秀郎, 舩渡忠男, 佐々木毅, 賀来満夫

臨床化学　33　(Suppl.3)　281-281　2004
再生不良性貧血における造血幹細胞特異的遺伝子の発現

張替秀郎, 藤巻慎一, 高橋伸一郎, 舩渡忠男, 佐々木毅, 賀来満夫

臨床化学　33　(Suppl.3)　154-154　2004
SLEにおけるグルココルチコイド受容体遺伝子の変異解析

舩渡忠男, 李栄茂, 藤原淳子, 宗像靖彦, 石井智徳, 菅原明, 張替秀郎, 賀来満夫, 国分正一, 佐々木毅

臨床化学　33　(Suppl.3)　110-110　2004
急性骨髄性白血病におけるFlt3過剰発現とNFκB経路活性化の関連の検討

高橋伸一郎, 張替秀郎, 石井恵子, 猪股美津恵, 舩渡忠男, 佐々木毅, 賀来満夫

臨床化学　33　(Suppl.3)　83-83　2004
マウスES細胞由来赤芽球を用いた赤血球特異的ヘム制御遺伝子の同定

藤原亨, 張替秀郎, 高橋伸一郎, 石澤賢一, 亀岡淳一, 賀来満夫, 佐々木毅

日本血液学会・日本臨床血液学会回総会プログラム・抄録集　(66回46回)　936-936　2004
再生不良性貧血CD34陽性細胞におけるHOXB4遺伝子発現の抑制

横山寿行, 張替秀郎, 石澤賢一, 亀岡淳一, 賀来満夫, 佐々木毅

日本血液学会・日本臨床血液学会回総会プログラム・抄録集　66回・46回　(66回46回)　808-808　2004
Publisher: 日本臨床血液学会
Flt3過剰発現によるNFκB標的遺伝子の発現誘導

高橋伸一郎, 張替秀郎, 石井恵子, 横山寿行, 藤原亨, 石澤賢一, 亀岡淳一, 佐々木毅, 賀来満夫

日本血液学会・日本臨床血液学会回総会プログラム・抄録集　66回・46回　(66回46回)　774-774　2004
Publisher: 日本臨床血液学会
Flt3の変異は転写抑制因子の機能を阻害する

高橋伸一郎, McconnellMelanie, 張替秀郎, 佐々木毅, 賀来満夫, MelnickAri, LichtJonathan

日本血液学会・日本臨床血液学会回総会プログラム・抄録集　(66回46回)　740-740　2004
Interferon-γ,TNF-αによる幹細胞特異的遺伝子の発現の変化

張替秀郎, 高橋伸一郎, 鈴木千恵, 三浦利彦, 賀来満夫, 横山寿行, 遠宮靖雄, 石澤賢一, 亀岡淳一, 佐々木毅

臨床血液　45　(9)　1074-1075　2004
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
Differential gene expression profiling between the wild type and ALAS2-null erythroblasts: Toward identification of heme-regulated genes.

T Fujiwara, H Harigae, S Takahashi, K Furuyama, M Kaku, S Sassa, T Sasaki

BLOOD　102　(11)　158A-158A　2003/11

ISSN： 0006-4971
特発性血小板減少性紫斑病及びその周辺疾患に対するHelicobacter pylori除菌療法

大口裕人, 亀岡淳一, 関根仁, 佐野望, 遠宮靖雄, 山田実名美, 張替秀郎, 石澤賢一, 宮村耕一, 佐々木毅

臨床血液　44　(8)　830-830　2003/08
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
骨髄非破壊的同種末梢血幹細胞移植(NST)を施行した慢性肉芽腫症(CGD)の一例

藤原亨, 山田実名美, 木村朋文, 遠宮靖雄, 亀岡淳一, 宮村耕一, 佐々木毅, 張替秀郎, 土屋滋

臨床血液　44　(7)　491-491　2003
骨髄非破壊的同種末梢血幹細胞移植(NST)を施行した慢性肉芽腫症(CGD)の1例

藤原亨, 山田実名美, 遠宮靖雄, 石澤賢一, 峯岸正好, 張替秀郎, 亀岡淳一, 宮村耕一, 土屋滋, 佐々木毅

臨床血液　44　(8)　746-746　2003
血液疾患における染色体解析単一施設からの報告

関修, 小原保彦, 情野千文, 藤巻慎一, 張替秀郎, 舩渡忠男, 賀来満夫

日本検査血液学会雑誌　4　(学術集会)　S81-S81　2003
フローサイトメトリーによるGATA転写因子の検出

張替秀郎, 三浦利彦, 賀来満夫, 横山寿行, 佐々木毅

臨床血液　44　(7)　493-493　2003
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
不応性貧血(MDS-RA)の骨髄赤芽球における多機能蛋白質YB-1の発現

横山寿行, 張替秀郎, 亀岡淳一, 宮村耕一, 石澤賢一, 賀来満夫, 佐々木毅

臨床血液　44　(8)　821-821　2003
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
フローサイトメトリー(FCM)による血液疾患におけるGATA転写因子の定量解析

張替秀郎, 三浦利彦, 横山寿行, 峯岸直子, 石澤賢一, 宮村耕一, 亀岡淳一, 佐々木毅, 賀来満夫

臨床血液　44　(8)　780-780　2003
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
FISH法を用いた悪性リンパ腫の骨髄浸潤の検出

石澤賢一, 張替秀郎, 小原保彦, 亀岡淳一, 宮村耕一, 一迫玲, 賀来満夫, 佐々木毅

臨床血液　44　(8)　717-717　2003
フローサイトメトリーによる血液疾患におけるGATA因子発現量の解析

三浦利彦, 張替秀郎, 関修, 藤巻慎一, 舩渡忠男, 賀来満夫

臨床病理　51　(補冊)　258-258　2003
FISH法を用いた悪性リンパ腫骨髄浸潤の特異的検出法の確立

張替秀郎, 小原保彦, 関修, 藤巻慎一, 舩渡忠男, 佐々木毅, 賀来満夫

臨床病理　51　(補冊)　255-255　2003
Aberrant iron accumulation and peroxidized status of erythroid-specific delta-aminolevulinate synthase (ALAS2)-deficient definitive erythroblasts.

H Harigae, O Nakajima, K Furuyama, H Yokoyama, K Ishizawa, K Miyamura, J Kameoka, T Sasaki, M Kaku, M Yamamoto, S Sassa

BLOOD　100　(11)　6A-6A　2002/11

ISSN： 0006-4971
The multifunctional gene YB-1 is a novel target of GATA factors in erythroid differentiation.

H Yokoyama, H Harigae, S Takahashi, K Miyamura, J Kameoka, K Ishizawa, M Yamada, K Furuyama, M Kaku, T Sasaki, S Takahashi, M Yamamoto

BLOOD　100　(11)　718A-718A　2002/11

ISSN： 0006-4971
R452C/H mutation of the erythroid-specific 5-aminolevulinate synthase in patients with X-linked sideroblastic anemia: Mutation does not affect enzymatic activity.

K Furuyama, H Harigae, T Heller, E Minder, BCJ Hamel, S Shibahara, S Sassa

BLOOD　100　(11)　658A-658A　2002/11

ISSN： 0006-4971
赤血球型アミノレブリン酸合成酵素欠損赤芽球における鉄代謝異常

張替秀郎, 中島修, 古山和道, 横山寿行, 佐々木毅, 山本雅之, 佐々茂

臨床血液　43　(8)　122-122　2002/08
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439

eISSN： 1882-0824
血漿FDPの検討

佐藤昭子, 遠藤洋子, 山中梨沙, 張替秀郎, 賀来満夫

医学検査　51　(4)　607-607　2002
補正FISH法とG分染法におけるPh染色体陽性率の比較

藤巻慎一, 小関信子, 石田聡美, 張替秀郎, 舩渡忠男, 賀来満夫

日本検査血液学会雑誌　3　(学術集会)　S69-S69　2002
異なるクローンを起源とする前骨髄球性白血病と多発性骨髄腫を併発した1症例

関修, 藤巻慎一, 舩渡忠男, 張替秀郎, 賀来満夫, 菅原知広

日本検査血液学会雑誌　3　(学術集会)　S59-S59　2002
芽球回収剤ブラストレトリバー(BLASTRETRIVER)による白血病芽球における遺伝子発現定量の検討

舩渡忠男, 久保田知恵, 小澤鹿子, 藤巻慎一, 張替秀郎, 賀来満夫

日本検査血液学会雑誌　3　(学術集会)　S70-S70　2002
赤血球を用いたフローサイトメトリー(FCM)による新たな酸化ストレス検出法

相澤敦子, 菅原亜紀子, 関修, 藤巻慎一, 張替秀郎, 賀来満夫

東北医学雑誌　114　(1)　107-107　2002
フローサイトメトリーによる細胞周期におけるGATA因子発現の解析

三浦利彦, 張替秀郎, 関修, 藤巻慎一, 賀来満夫

臨床病理　50　(補冊)　263-263　2002
Altered production of leptin in the bone marrow in patients with hematological diseases.

J Kameoka, LJ Hou, M Yamada, H Harigae, K Meguro, T Sasaki

BLOOD　98　(11)　144B-144B　2001/11

ISSN： 0006-4971
Quantitative analysis of MDR1 transcript for prediction of drug resistance in acute leukemia.

H Harigae, S Fujimaki, T Funato, K Meguro, K Miyamura, J Kameoka, O Sasaki, M Yamada, H Yokoyama, M Kaku, T Sasaki

BLOOD　98　(11)　178B-178B　2001/11

ISSN： 0006-4971
Structure of the human succinyl CoA synthetase beta A-subunit gene and increased gene expression during erythroid differentiation.

K Furuyama, H Harigae, S Sassa

BLOOD　98　(11)　10A-10A　2001/11

ISSN： 0006-4971
Enhanced expression of BCL2 mRNA in CD34 positive cells in severe aplastic anemia.

H Harigae, S Fujimaki, K Meguro, K Miyamura, J Kameoka, O Sasaki, M Yamada, H Yokoyama, T Sasaki, M Kaku

BLOOD　98　(11)　11B-11B　2001/11

ISSN： 0006-4971
新規因子Klp1の構造及び発現調節機構の解析

高橋伸一郎, 張替秀郎, 横山寿行, 石川泉, 佐々木治, 亀岡淳一, 宮村耕一, 目黒邦昭, 佐々木毅

International Journal of Hematology. Supplement　73　(Supplement 1)　2001

ISSN： 0917-1258
ヘム欠損成体型赤芽球の形質解析

張替秀郎, 中島修, 古山和道, 佐々木毅, 佐々茂, 山本雅之

International Journal of Hematology　73　(Suppl.1)　80-80　2001
さい帯血バンクへの支援システムの現状

菊地美和子, 舩渡忠男, 張替秀郎, 吉田克己, 賀来満夫

日本検査血液学会雑誌　2　(2)　149-149　2001
抗凝固剤の種類と検体採取から分析までの検体放置時間

藤巻慎一, 関修, 三浦利彦, 張替秀郎, 賀来満夫

Cytometry Research　11　(Suppl.)　36-36　2001
フローサイトメトリーによるGATA因子の検出

三浦利彦, 張替秀郎, 関修, 藤巻慎一, 賀来満夫

臨床病理　49　(補冊)　131-131　2001
特発性血小板減少性紫斑病における血小板特異抗原の発現強度について検討

関修, 佐藤昭子, 張替秀郎, 賀来満夫

臨床病理　49　(補冊)　119-119　2001
特発性血小板減少性紫斑病(ITP)における血小板特異的抗原の発現強度についての検討

関修, 張替秀郎, 賀来満夫, 目黒邦昭, 宮村耕一, 亀岡淳一, 佐々木治, 石川泉, 高橋伸一郎, 佐々木毅

東北医学雑誌　113　(1)　104-105　2001
重症急性膵炎患者の末梢血単球におけるHLA-DR発現

佐藤晃彦, 正宗淳, 木村憲治, 境吉孝, 山極哲也, 水溜浩弥, 三浦利彦, 張替秀郎, 賀来満夫, 下瀬川徹

日本消化器病学会雑誌　98　(臨増)　A606-A606　2001
Cloning of a coproporphyrinogen oxidase promoter regulatory element binding protein.

S Takahashi, K Furuyama, A Kobayashi, S Taketani, H Harigae, M Yamamoto, K Igarashi, H Yokoyama, Ishikawa, I, O Sasaki, J Kameoka, K Miyamura, K Meguro, N Hayashi, T Sasaki

BLOOD　96　(11)　285A-285A　2000/11

ISSN： 0006-4971
Differential role of the erythroid-specific delta-aminolevulinate synthase in primitive and definitive erythropoiesis.

H Harigae, O Nakajima, N Suwabe, K Furuyama, T Sasaki, M Kaku, M Yamamoto, S Sassa

BLOOD　96　(11)　228A-228A　2000/11

ISSN： 0006-4971
Identification of a novel repressor element in the 5'-UTR of human BSAP/Pax5.

M Rahman, Y Hirabayashi, M Watanabe, H Harigae, T Sasaki

BLOOD　96　(11)　135B-135B　2000/11

ISSN： 0006-4971
Late-onset recessive delta-aminolevulinate dehydratase (ALAD) deficiency porphyria provoked by myeloproliferative disorder: Clonal expansion of the mutant allele.

R Akagi, C Nishitani, H Harigae, Y Horie, L Garbaczewski, A Hassoun, R Mercelis, L Verstraeten, S Sassa

BLOOD　96　(11)　698A-698A　2000/11

ISSN： 0006-4971
Decreased expression of transcription factor GATA-2 in hematopoietic stem cells in patients with aplastic anemia.

S Fujimaki, H Harigae, T Sugawara, N Takasawa, T Sasaki, M Kaku

BLOOD　96　(11)　11B-11B　2000/11

ISSN： 0006-4971
Post-translational control of erythroid-specific ALA synthase: Domains involved in mitochondrial targeting, translocation and prevention from aggregation.

K Furuyama, H Harigae, S Sassa

BLOOD　96　(11)　4A-5A　2000/11

ISSN： 0006-4971
血液疾患におけるHbF比率測定の検討

柳川京子, 矢吹重光, 張替秀郎, 舩渡忠男, 賀来満夫

医学検査　49　(4)　550-550　2000
造血器腫瘍における多剤耐性遺伝子発現量の定量とその有用性

藤巻慎一, 藤原淳子, 菊地美和子, 三浦利彦, 舩渡忠男, 張替秀郎, 賀来満夫, 佐々木毅

臨床病理　48　(補冊)　254-254　2000
骨髄異形成症候群のCD34陽性細胞における転写因子GATA-2,AML1,SCLmRNAの発現

張替秀郎, 藤巻慎一, 舩渡忠男, 賀来満夫, 佐々木毅

臨床病理　48　(補冊)　281-281　2000
CD45を用いた3-Color法による血液細胞表面及び細胞質内抗原の同時検出

三浦利彦, 藤巻慎一, 菊地美和子, 舩渡忠男, 張替秀郎, 高澤徳彦, 佐々木毅, 賀来満夫

臨床病理　48　(補冊)　172-172　2000
Two novel mutations of the delta-aminolevulinate synthase-2 gene in inherited and non-inherited sideroblastic anemia.

H Harigae, K Furuyama, K Kudo, A Kimura, T Sasaki, M Kaku, N Hayashi, Y Yamamoto, S Sassa

BLOOD　94　(10)　191A-191A　1999/11

ISSN： 0006-4971
遺伝性鉄芽球性貧血の分子診断とモデルマウス

山本雅之, 中島修, 古山和道, 張替秀郎, 林典夫

臨床血液　40　(9)　851-851　1999/09
Publisher: (一社)日本血液学会-東京事務局
ISSN： 0485-1439
簡便な定量的PCRシステムによる白血病MRDの遺伝子診断

藤巻慎一, 舩渡忠男, 張替秀郎, 今泉益栄, 金子安比古, 佐々木毅

International Journal of Hematology　69　(Suppl.1)　67-67　1999/04
Publisher: (一社)日本血液学会
ISSN： 0925-5710
遺伝性鉄芽球性貧血における赤血球型δ-アミノレブリン酸合成酵素(ALAS-E)の新たな遺伝子変異の解析

張替秀郎, 古山和道, 木村昭郎, 山本雅之, 佐々木毅

International Journal of Hematology　69　(Suppl.1)　195-195　1999/04
Publisher: (一社)日本血液学会
ISSN： 0925-5710
赤血球型5-アミノレブリン酸合成酵素の遺伝子ターゲティング

中島修, 高橋智, 古山和道, 張替秀郎, 佐々茂, 山本雅之

International Journal of Hematology　69　(Suppl.1)　195-195　1999/04
Publisher: (一社)日本血液学会
ISSN： 0925-5710
細胞質内及び細胞表面抗原の同時3-Color解析により白血病細胞の帰属の同定が可能であった1例

三浦利彦, 小関信子, 舩渡忠男, 張替秀郎, 佐々木毅, 賀来満夫

臨床病理　47　(補冊)　311-311　1999
白血病微量残存病検出の新しいマーカーとしてのスタニオカルシン

遠宮靖雄, 藤巻慎一, 小出芳夫, 張替秀郎, 舩渡忠男, 賀来満夫, 佐々木毅

臨床病理　47　(補冊)　311-311　1999
血液疾患におけるHbF比率測定の有用性

張替秀郎, 舩渡忠男, 亀岡淳一, 目黒邦昭, 木村淳, 今泉益栄, 渡辺則道, 佐々木毅, 賀来満夫

臨床血液　40　(9)　885-885　1999
赤血球型5‐アミノレブリン酸合成酵素の遺伝子ターゲッティング

中島修, 高橋智, 古山和道, 張替秀郎, 佐々茂, 山本雅之

日本分子生物学会年会プログラム・講演要旨集　21st　610　1998/11
赤血球型δ-アミノレブリン酸合成酵素欠損ES細胞の分化

張替秀郎, 諏訪部徳芳, 山本雅之, 五十嵐和彦, 藤田博美, 佐々茂

日本分子生物学会年会プログラム・講演要旨集　19　826-826　1996/08/01
In vitro differentiation of ES cells lacking the erythroid-specific delta-aminolevulinate synthase gene.

H Harigae, M Yamamoto, H Fujita, P Weinstock, S Sassa

BLOOD　86　(10)　1972-1972　1995/11

ISSN： 0006-4971
ABUNDANT GLOBIN MESSENGER-RNA EXPRESSION BUT THE LACK OF HEMOGLOBIN-SYNTHESIS IN A PH(1) CHROMOSOME-POSITIVE HUMAN LEUKEMIA-CELL LINE, YN-1

T NAGAI, H HARIGAE, K FURUYAMA, H MUNAKATA, N HAYASHI, K ENDO, M YAMAMOTO, S SASSA

BLOOD　84　(10)　A22-A22　1994/11

ISSN： 0006-4971
マウス胸腺中のT細胞初期分化におけるGATA-3の発現

松崎有未, 張替秀郎, 山本雅之, 中内啓光

日本免疫学会総会・学術集会記録　23　347-347　1993/10
Publisher: (NPO)日本免疫学会
ISSN： 0919-1984

Show all ︎Show first 5

Books and Other Publications 3

血液細胞アトラス

通山, 薫, 張替, 秀郎

文光堂　2018/02

ISBN: 9784830614262
血液科研修ノート

自治医科大学学長, 永井良三, 総監修, 自治医科大学内科学講座血液学部門教授, 神田, 善伸, 責任編集, 他

診断と治療社　2016/05
分子細胞治療

張替秀郎

先端医学社　2009/02

Presentations 219

Blinatumomab for ALL relapse after allogeneic hematopoietic stem cell transplantation
Azacitidine and venetoclax for molecular relapse of acute myeloid leukemia after allogeneic HSCT
Retrospective comparison of CBT with RIC using FLU-BU-MEL and FLU-MEL-TBI: single institute analysis
Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara TrialClinically Relevant Abstract

Martin Dreyling, Michael Dickinson, Joaquin Martinez Lopez, Arne Kolstad, Jason P Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, Phoebe Joy Ho, Jose A. Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J M Ferreri, Takanori Teshima, Piers E.M, Patten, Joseph, P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardo, Pier Luigi Zinzani, Ram Malladi, Ines Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O'Donovan, Roberto Ramos, Aisha Masood, Catherine Thieblemon, Nathan H. Fowler, Stephen J. Schuster

64th ASH Annual Meeting and Exposition
4 Altered Transcription By GATA1 Impairs Autophagy and Prevents Ferroptosis in X-Linked Sideroblastic Anemia

Koya Ono, Tohru Fujiwara, Hiroki Shima, Hironari Nishizawa, Chie Suzuki, Noriyuki Takahashi, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

64th ASH Annual Meeting and Exposition
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells

Ken Yasaka, Tomohide Yamazaki, Hiroko Sato, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

ACR Convergence 2022,
Integration of erythroid differentiation and autophagy by iron-heme metabolism
Targeting anti-apoptotic molecules combined with CXCR4 expressing CAR T-cell overcomes relapsed ALL
Impact of FECH deficiency on ring sideroblast formation in erythroblasts
Ferritinophagy is impaired in X-linked sideroblastic anemia models during differentiation
Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in MDS
Late-onset X-linked sideroblastic anemia due to heterozygous ALAS2 mutation
Management of CRS resistant to both tocilizumab and steroid: a case of B-ALL treated with CAR-T
特発性血小板減少性紫斑病に対するeltrombopag投与中に慢性骨髄性白血病を発症した1例

諸田直哉, 福原規子, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

第８４回日本血液学会学術集会福岡
Two cases of de novo anaplastic multiple myeloma
Chemorefractoriness in MUM1-positive high-grade follicular lymphoma with histological transformation
第８４回日本血液学会学術集会 2022/10/14-16 福岡国際会議場
Inhibition of anti-apoptotic molecules combined with CXCR4 expressing CAR T-cells eradicates human ALL cells in vivo.
本邦における鉄代謝異常に伴う貧血に関する包括的疫学研究

藤原亨, 大根田絹子, 佐々木克幸, 青木裕一, 工藤久智, 勝岡史城, 熊田和貴, 萩島創一, 山本雅之, 張替秀郎

第46回日本鉄バイオサイエンス学会学術集会昭和大学上條記念館
骨髄癌腫症を呈した原発巣不明の神経内分泌腫瘍の一例

牧優治, 菅原新吾, 吉岡翔, 佐藤亜耶, 佐々木麻美, 安久美子, 藤巻慎一, 猪倉恭子, 藤原亨, 張替秀郎

第23回日本検査血液学会学術集会東京大学本郷キャンパス/ハイブリッド
DICの原因精査のため行われた骨髄検査を契機に診断された骨髄癌腫症の1症例

石塚静江, 菅原新吾, 鈴木千恵, 佐々木麻美, 大久保礼由, 吉岡翔, 藤巻慎一, 市川聡, 藤原亨, 張替秀郎

第23回日本検査血液学会学術集会東京大学本郷キャンパス/ハイブリッド
当院におけるBD FACSDuet自動サンプル調整システムを用いたフローサイトメトリー検査効率化への取組み

佐藤亜耶, 菅原新吾, 大久保礼由, 鈴木千恵, 石塚静江, 牧優治, 佐々木麻美, 藤巻慎一, 藤原亨, 張替秀郎

第23回日本検査血液学会学術集会東京大学本郷キャンパス/ハイブリッド
初発時に非ホジキンB細胞性リンパ腫を併発した慢性骨髄性白血病の一例

佐々木麻美, 鈴木千恵, 大久保礼由, 牧優治, 安久美子, 菅原新吾, 藤巻慎一, 福原規子, 藤原亨, 張替秀郎

第23回日本検査血液学会学術集会東京大学本郷キャンパス/ハイブリッド
Long-term survival after cord blood transplantation for AML complicated with disseminated fusariosis
同種造血幹細胞移植後に急性GVHDによる結膜病変を来した2症例

諸田直哉, 小野寺晃一, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第44日本造血・免疫細胞療法学会学術集会 WEB/パシフィコ横浜
当院におけるCML-BCに対する同種造血幹細胞移植成績

道又大吾, 大西康, 諸田直哉, 木葉大地, 田中悠也, 小野浩弥, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 横山寿行, 張替秀郎

第44日本造血・免疫細胞療法学会学術集会 WEB/パシフィコ横浜
芽球増加を伴う骨髄異形成症候群における同種移植前化学療法の意義：単施設の後方視的解析

田中悠也, 小野寺晃一, 木葉大地, 諸田直哉, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

第44日本造血・免疫細胞療法学会学術集会 WEB/パシフィコ横浜
臍帯血移植時のGVHD予防におけるロイコボリンレスキューが移植成績に与える影響

小野寺晃一, 木葉大地, 諸田直哉, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第44日本造血・免疫細胞療法学会学術集会 WEB/パシフィコ横浜
持続勃起を契機に診断に至った慢性骨髄性白血病の1例

市村裕菜, 小野寺晃一, 諸田直哉, 田中悠也, 道又大吾, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第225回日本内科学会東北地方会 WEB
巨細胞性動脈炎に対するトシリズマブ導入後にサルモネラ敗血症を来した１例

星陽介, 成田衛, 丹野唯人, 秋田佳奈恵, 佐藤紘子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

第31回日本リウマチ学会北海道・東北支部学術集会仙台国際センター/ハイブリッド
全身性エリテマトーデスに合併した後天性第Ⅺ因子欠乏症の帝王切開に際して血漿交換を施行した１例

丹野唯人, 石井智徳, 成田衛, 星陽介, 秋田佳奈恵, 町山智章, 佐藤紘子, 白井剛志, 藤井博司, 張替秀郎

第31回日本リウマチ学会北海道・東北支部学術集会仙台国際センター/ハイブリッド
エタネルセプト開始後に抗MD45抗体陽性皮膚筋炎を発症した関節リウマチの一例(若手リウマチ医奨励賞受賞者セッション)

岡崎創司, 白井剛志, 髙橋幹弘, 石井悠翔, 秋田佳奈恵, 藤井博司, 石井智徳, 張替秀郎

第31回日本リウマチ学会北海道・東北支部学術集会仙台国際センター/ハイブリッド
Rigidity of Cell Fate and Function Among Monocytes

Catherine Rhee,Elizabeth, W Scadden, Lai Ping Wong, Giulia Schiroli, Michael Mazzola, Phillip Chea, Hiroki Kato, Friedrich F Hoyer, Meeta Mistry, Bum-Kyu Lee, Jonghwan Kim, Matthias Nahrendorf, Michael K Mansour, David Sykes, Ruslan I Sadreyev, David T. Scadden

63nd ASH Annual Meeting and Exposition 2021/12/10-14（オンライン開催）
Inhibition of S-Adenosylmethionine Synthesis Promotes Erythropoiesis Via Epigenetic Modifications

Hiroki Kato, Nguyen Chi Long, Yusho Ishii, Mitsuyo Matsumoto, Catherine Rhee, Daisuke Saigusa, Ryo Funayama, Hiroaki Okae, Tohru Fujiwara, Akihiko Muto, Hideo Harigae, David T. Scadden, Kazuhiko Igarashi

63nd ASH Annual Meeting and Exposition （オンライン開催）
Identification of Patient-Specific Anti-Apoptotic Molecules As Therapeutic Targets in Poor Prognosis Acute Lymphoblastic Leukemia (ALL)

Ryo Nakagawa, Yoriko Saito, Shinsuke Takagi, Sadaaki Takata, Hanae Amitani, Mikiko Endo, Naoyuki Uchida, Yukihide Momozawa, Shuichi Taniguchi, Hideo Harigae, Fumihiko Ishikawa

63nd ASH Annual Meeting and Exposition （オンライン開催）
Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Catherine Thieblemont, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason P Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Pérez-Simón, Andy Chen, Loretta Nastoupil, Bastian Von Tresckow, Andres JM Ferreri, Takanori Teshima, Piers EM Patten, Joseph, P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, C Lobetti Bodoni, Aisha Masood, Stephen J. Schuster, Nathan H. Fowler, Martin H. Dreyling

63nd ASH Annual Meeting and Exposition （オンライン開催）
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, sWerner Rabitsch, Yok Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquin Martinez-Lopez, Antonia MS Mueller, Richard T. Maziarz, Joseph, P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Chris Del Corral, Giovanna Andreola, Aisha Masood, Stephen J Schuster, Ulrich Jaeger, Peter Borchmann, Jason R. Westin

63nd ASH Annual Meeting and Exposition 2021/12/10-14（オンライン開催）
予後不良 ALL における個別最適化医療を目指した antiapoptotic molecules の同定

中川諒, 齋藤頼子, 高木伸介, 高田定暁, 網谷花枝, 遠藤ミキ子, 内田直之, 桃沢幸秀, 谷口修一, 張替秀郎, 石川文彦

第80回日本癌学会学術総会 WEB/パシフィコ横浜
PAI-1 阻害薬 TM5614 とチロシンリン酸化酵素阻害薬の併用は慢性骨髄性白血病慢性期患者に深い分子学的寛解をもたらす

安藤潔, 高橋直人, 鬼塚真仁, 張替秀郎

第80回日本癌学会学術総会 WEB/パシフィコ横浜
Follicular lymphoma with drug-induced ulcerative colitis after bendamustine and obinutuzumab
Sustained remission of atypical CML in accelerated phase after development of severe acute GVHD
Monosomy 7 following eltrombopag treatment: A report of two cases
Four cases of carcinoma that primarily presented with cytopenia due to bone marrow dissemination
Clinical features and prognosis of adult early T-cell precursor acute lymphoblastic leukemia: THF-24
One third of the patients with acquired chronic PRCA show macrocytic anemia: data from PRCA2016
A phase 3 trial of bendamustine/rituximab for relapsed or refractory diffuse large b-cell lymphoma
Four cases with discordant development of follicular and classic Hodgkin lymphoma
Retrospective analysis of ICI therapy for relapsed or refractory classical Hodgkin's lymphoma: THF26
Elucidation of the role of FAM210B in mitochondrial metabolism in erythroblasts
Cellular models of X-linked sideroblastic anemia based on immortalized human erythroid progenitors
FOG1-dependent transcriptional network involves glucose metabolic regulation of erythroid cells
Hepatic niche leads to aggressive NK-cell leukemia proliferation
Long-term survival in patients with follicular lymphoma following Rituximab maintenance in THF-19
Eight cases of allogeneic hematopoietic stem cell transplantation for follicular lymphoma
Outcome of allogeneic stem cell transplantation in adult patients with EBV-positive T/NK LPDs
Significance of elevated serum vitamin B12 levels in myeloid malignancies
Iron, heme, and erythropoiesis
KIR-ligand mismatch effect on GVHD and NK-cell gene expression after cord blood transplantation
PAI-1 inhibitor TM5614 combined with TKI induced deep molecular response in patients with CML-CP
Clinicopathological features of B-cell lymphoma with three-way chromosomal translocation
Identification of anti-apoptotic molecules as therapeutic targets in diverse ALL subgroup
Methionine metabolism controls erythropoiesis by epigenetic regulation
The impact of HLA-DRB1 matching status on outcomes of UCBT: A single-institute retrospective study
（誌上発表）末梢血幹細胞採取における Hematopoietic Progenitor Cells（HPC）測定の有用性の検討

関修, 細川真梨, 石岡夏子, 成田香魚子, 菅原新吾, 藤原実名美, 張替秀郎

第22回日本検査血液学会学術集会 WEB/東海大学湘南キャンパス
(誌上発表) 妊婦検診を契機に発見された第 XI 因子欠乏症の一例

牧優冶, 菅原新吾, 石塚静江, 大久保礼由, 佐藤亜耶, 藤巻慎一, 藤原亨, 石井智徳, 市川聡, 張替秀郎

第22回日本検査血液学会学術集会 WEB/東海大学湘南キャンパス
破砕赤血球の形態学的判定におけるばらつきの原因にアプローチした判定基準の考案

菅原新吾, 千葉拓也, 大井惇矢, 小笠原脩, 菊地優子, 佐藤牧子, 鈴木千恵, 中村美雪, 藤巻慎一, 藤原亨, 張替秀郎

第22回日本検査血液学会学術集会 WEB/東海大学湘南キャンパス
テクニカルセミナー 1 TS1-1 「ミエロペルオキシダーゼ」

菅原新吾, 藤巻慎一, 藤原亨, 張替秀郎

第22回日本検査血液学会学術集会 WEB/東海大学湘南キャンパス
Transcriptional Regulation of Ferroptosis in X-Linked Sideroblastic Anemia Program: Oral and Poster Abstracts

Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Yan Yan, Sayaka Sano, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

62nd ASH Annual Meeting and Exposition （オンライン開催）
Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory

Nathan H Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason P Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José, Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, MB.BS. (Hon, D.Phil (Oxon, Jose Antonio, Pérez-Simón, Sarah J. Nagle, Loretta J. Nastoupil, Bastian von Tresckow, Andres JM Ferreri, Takanori Teshima, Piers Patten,Joseph, P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Lida Bubuteishvili Pacaud, Alessandra Forcina, Aiesha Zia, Stephen J. Schuster, Catherine Thieblemont

62nd ASH Annual Meeting and Exposition （オンライン開催)
大型血管炎におけるステロイド寛解維持量の検討

白井剛志, 佐藤紘子, 藤井博司, 石井智徳, 張替秀郎

第64回日本リウマチ学会総会・学術集会(WEB)
ループスモデルマウスに対するMat2a阻害効果の検討

石井悠翔, 五十嵐和彦, 藤井博司, 張替秀郎

第64回日本リウマチ学会総会・学術集会(WEB)
HRM解析によるSF3B1遺伝子変異スクリーニング法の確立

鈴木千恵, 藤原亨, 藤巻慎一, 張替秀郎

第27回日本遺伝子診療学会大会（WEB)
HRM解析によるSF3B1遺伝子変異スクリーニング法の確立

鈴木千恵, 藤原亨, 藤巻慎一, 張替秀郎

第27回日本遺伝子診療学会大会(WEB)　2020/08/07
肺炎を契機に発症した後天性第X因子欠乏症の一例. （口演）

藤原亨, 大久保礼由, 佐々木麻美, 鈴木千恵, 菅原新吾, 藤巻慎一, 市川聡, 張替秀郎

第21回日本検査血液学会学術集会(WEB)
Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defcts: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?

Tohru Fujiwara, Chie Suzuki, Tetsuro Ochi, Koya Ono, Kei Saito, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Yukio Nakamura, Hideo Harigae

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Proteomic Analysis of Mitochondrial Membrane Protein FAM210B in Erythroid Cells

Chie Suzuki, Tohru Fujiwara, Hiroki Shima, Koya Ono, Kei Saito, Noriko hi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Yukio Nakamura, Hideo Harigae

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants

Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Koichi, Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis

Tsuyoshi Shirai, Tomoyuki Muto, Yuko Shirota, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

2019 ACR/ARP Annual Meeting Georgia World Congress Center Atlanta,GA
Endothelial protein C receptor and scavenger receptor class B type 1 negatively regulate vascular inflammation and are major autoantigens in Takayasu arteritis

Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori lshii, Yuko Shirota, Hideo Harigae, Hirohi Fujii
シンポジウム2 “Ring sideroblast and iron metabolism”

Toru Fujiwara, Kei Saito, Hideo Harigae
Retrospective analysis of anthracycline-induced cardiotoxicity in a single center

Kei Saito, Eijiro Furukawa, Satoshi Ichikawa, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Koichiro Sugimura, Hideo Harigae
Outcome of first alloSCT in adult patients with Phnegative B-ALL

Yasushi Onishi, Koichi Onodera, Yuya Tanaka, Yoonha Lee, Kei Saito, Satoshi Ichikawa, Noriko Fukuhara, Toru Fujiwara, Minami Fujiwara, Hideo Harigae
Establishment of cellular model of X-linked sideroblastic anemia using homology-directed CRISPR/Cas9

Koya Ono, Noriyuki Takahashi, Toru Fujiwara, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hideo Harigae
Role of mitochondrial membrane protein FAM210B during erythroid differentiation

Chie Suzuki, Toru Fujiwara, Kei Saito, Hiroki Shima, Koya Ono, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Hideo Harigae

2019
Causes of eosinophilia in Tohoku University Hospital over the past eight years

Junichi Kameoka, Masahiro Kobayashi, Yuko Shirota, Shori Abe, Jun Nomura, Takao Kodera, Yumiko Oka, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Hiroshi Fujii, Tomonori Ishii, Shinichiro Takahashi, Hideo Harigae
Three cases of MTX-associated Hodgkin lymphoma treated with brentuximab vedotin-containing regimen

Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Tsuyoshi Shirai, Yasushi Onishi, Hiroshi Fujii, Ryo Ichinohasama, Hideo Harigae
Preemptive therapy for CMV reactivation after daratumumab in patients with RRMM

Ryo Nakagawa, Yasushi Onishi, Akihisa Kawajiri, Koichi Onodera, Eijiro Furukawa, Sayaka Sano, Kei Saito, Satoshi Ichikawa, Toru Fujiwara, Noriko Fukuhara, Hideo Harigae

2019
Two cases of acquired PRCA associated with malignant lymphomas

Shin Hasegawa, Jun Kimura, Hideo Harigae
X-linked sideroblastic anemia with ALAS2 p.R170H mutation refractory to vitamin B6

Keita Igarashi, Akira Takebayashi, Kotoe Iesato, Masaki Yamamoto, Tsukasa Hori, Toru Fujiwara, Hideo Harigae
教育講演「貧血をめぐる最近の話題」

張替秀郎

第43回日本血液事業学会総会
MelDex療法にて臓器障害が改善し安全に自家末梢血幹細胞移植を施行し得た全身性ALアミロイドーシスの1例

山口知暁, 小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第218回日本内科学会東北地方会　2019/09/28
CRISPR/Cas9を用いたALAS2ミスセンス変異導入によるX連鎖性鉄芽球性貧血のモデル細胞

小野浩弥, 高橋昇之, 藤原亨, 細川奈津子, 齋藤慧, 鈴木千恵, 小野寺晃一, 市川聡, 福原規子, 大西康, 張替秀郎

第43回日本鉄バイオサイエンス学会学術集会
HRM解析による簡易SF3B1遺伝子変異スクリーニング法の確立

鈴木千恵, 藤原亨, 平泉敦子, 藤巻慎一, 張替秀郎

第43回日本鉄バイオサイエンス学会学術集会
CER-T細胞療法実施に向け輸血部門が果たす役割−事前適格性確認の監査経験から−

阿部真知子, 岩木啓太, 伊藤貴子, 沖田ひとみ, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

第115回日本輸血・細胞治療学会東北支部例会　2019/08/31
宮城県内医療機関における新鮮凍結血漿使用量の推移

清水貴人, 藤原実名美, 鈴木さち子, 高橋知子, 安藤京子, 佐々木大, 峯岸正好, 張替秀郎

第115回日本輸血・細胞治療学会東北支部例会　2019/08/31
著明な倦怠感を認め、血小板低下を来した一例

佐藤紘子, 永井泰地, 武藤智之, 町山智章, 鴨川由起子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

第18回東北臨床免疫研究会　2019/08/24
末梢血幹細胞採取バック中にHematogonesの混入が考えられた症例

関修, 成田香魚子, 菅原新吾, 新妻秀剛, 藤原実名美, 張替秀郎

第20回日本検査血液学会学術集会　2019/07/06
Daratumumab併用療法後にCD38陰性化した再発難治性多発性骨髄腫の1症例

大久保礼由, 菅原新吾, 鈴木千恵, 佐々木麻美, 平泉敦子, 藤巻慎一, 齋藤慧, 市川聡, 張替秀郎, 賀来満夫

第20回日本検査血液学会学術集会　2019/07/06
microBCR-ABL1を認めた慢性骨髄性白血病の1例

鈴木千恵, 菅原新吾, 佐藤亜耶, 安久美子, 平泉敦子, 藤巻慎一, 賀来満夫, 市川聡, 藤原亨, 張替秀郎

第20回日本検査血液学会学術集会　2019/07/06
エリスロポエチン産生制御と赤血球造血

張替秀郎

第64回日本透析医学会学術集会・総会教育講演３　2019/06/28
免疫抑制療法中に濾胞性リンパ腫と古典的ホジキンリンパ腫を合併した2例

渡邊正太郎, 福原規子, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 市川聡, 大西康, 中村直哉, 一迫玲, 張替秀郎

第59回日本リンパ網内系学会総会　2019/06/28
クローン病に合併したびまん性大細胞型B細胞リンパ腫再発に対して臍帯血移植を施行した一例

古川瑛次郎, 福原規子, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 大西康, 張替秀郎

第59回日本リンパ網内系学会総会　2019/06/28
診断・治療に苦慮したメソトレキセート関連ホジキンリンパ腫の１例

岩渕蒼太, 市川聡, 齋藤慧, 小野寺晃一, 白井剛志, 福原規子, 大西康, 藤井博司, 張替秀郎

第217回日本内科学会東北地方会　2019/06/22
MonoMAC症候群

福原規子, 藤原亨, 張替秀郎

第94回日本結核病学会総会シンポジウム１（生涯教育セミナー）“免疫不全に合併したNTM症”S1-5　2019/06/07
鉄代謝と鉄関連貧血の病態

張替秀郎

第9回日本検査血液学会東北支部総会・学術集会特別講演　2019/06/01
診断に苦慮した縦隔原発大細胞型B細胞性リンパ腫の一例

佐々木麻美, 佐藤亜耶, 大久保礼由, 鈴木千恵, 菅原新吾, 平泉敦子, 藤巻慎一, 入江正寛, 藤原亨, 張替秀郎

第9回日本検査血液学会東北支部総会・学術集会　2019/06/01
アルブミン製剤使用量削減に伴う臨床的アウトカムへの影響

関修, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 秋山正年, 藤原実名美, 張替秀郎

第６７回日本輸血・細胞治療学会学術集会　2019/05/24
Epidemiology and molecular characterization of congenital sideroblastic anamia

Tohru Fujiwara, Kei Saito, Chie Suzuki, Koya Ono, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Hideo Harigae
生物学的製剤を使用した大型血管炎患者の検討

白井剛志, 武藤智之, 藤田洋子, 藤井博司, 石井智徳, 平林泰彦, 張替秀郎

第63回日本リウマチ学会総会・学術集会ワークショップ　2019/04/16
膠原病関連肺動脈性高血圧症における各種自己抗体別にみた長期予後の違いについての検討

城田祐子, 白井剛志, 藤井博司, 小寺隆雄, 亀岡淳一, 石井智徳, 張替秀郎

第63回日本リウマチ学会総会・学術集会ワークショップ　2019/04/16
血管ベーチェット病の臨床的特徴と治療内容の検討

佐藤紘子, 星陽介, 町山智章, 鴨川由起子, 藤田洋子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

第63回日本リウマチ学会総会・学術集会ワークショップ　2019/04/16
臍帯血移植前に肺真菌症に対する外科的切除が有効であった急性骨髄性白血病3例

中川諒, 大西康, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 川尻昭寿, 小野寺晃一, 市川聡, 福原規子, 張替秀郎

第41回日本造血細胞移植学会総会　2019/03/08
成人発症の慢性活動性EBV感染症に対する臍帯血移植の成績

大西康, 小野寺晃一, 中川諒, 佐野沙矢香, 川尻昭寿, 齋藤慧, 市川聡, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

第41回日本造血細胞移植学会総会　2019/03/08
再生不良性貧血に対する同種造血幹細胞移植後にドナー型二次性着不全からAMLへと進展した一例

小野寺晃一, 中川諒, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 川尻昭寿, 市川聡, 福原規子, 大西康, 張替秀郎

第41回日本造血細胞移植学会総会　2019/03/08
IgG型抗B抗体価4096倍のABO血液型不適合肝移植への検査支援体制

石岡夏子, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

第114回日本輸血・細胞治療学会東北支部例会　2019/03/02
ゲルカラム凝集法の血球分注位置の違いにより反応強度に差が生じたweakDの１例

岩木啓太, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

第114回日本輸血・細胞治療学会東北支部例会　2019/03/02
Daratumumab併用療法後にCD38陰性化を伴って病勢増悪を来した再発難治性多発性骨髄腫の一例

齋藤慧, 古川瑛次郎, 佐野沙矢香, 中川諒, 川尻昭寿, 小野寺晃一, 市川聡, 大西康, 福原規子, 張替秀郎

第127回日本血液学会東北地方会　2019/02/17
腕神経叢炎を呈した全身性エリテマトーデス(SLE)の1例

荒木武弥, 藤井博司, 三須建郎, 矢坂健, 鴨川由起子, 佐藤紘子, 藤田洋子, 白井剛志, 石井智徳, 張替秀郎

第216回日本内科学会東北地方会　2019/02/16
進行期胃癌の診断に先行して認められた骨髄癌腫症の1例

古川瑛次郎, 市川聡, 矢坂健, 星陽介, 齋藤慧, 白井剛志, 福原規子, 大西康, 大内康太, 張替秀郎

第216回日本内科学会東北地方会　2019/02/16
Overall Survival in Acquired Pure Red Cell Aplasia in Adults Following Immunosuppressive Therapy: Preliminary Results from the Nationwide Cohort Study (PRCA2016)Clinically Relevant Abstract

Naohito Fujishima, Makoto Hirokawa, Kenichi Sawada, Shinji Nakao, Yuji Yonemura, Akira Matsuda, Norio Komatsu, Hideo Harigae, Akiko Saito, Kaoru Tohyama, Itaru Matsumura, Mineo Kurokawa, Shunya Arai, Kinuko Mitani

60th ASH Annual Meeting & Exposition San Diego Convention Center,
Generation and Molecular Characterization of Human Ring Sideroblasts

Kei Saito, Tohru Fujiwara, Shunsuke Hatta, Chie Suzuki, Noriko Fukuhara, Yasushi Onishi, Yukio Nakamura, Hideo Harigae

60th ASH Annual Meeting & Exposition San Diego Convention Center,
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis

Tsuyoshi Shirai, Tomoyuki Muto, Yuko Shirota, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

2018 ACR/ARHP Annual Meeting、 Chicago,
Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis

Tomoyuki Muto, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

2018 ACR/ARHP Annual Meeting、 Chicago,
Optimized Protocol for Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis

Tomonori Ishii, Yasushi Kawaguchi, Osamu Ishikawa, Hiromitsu Takemori, Naruhiko Takasawa, Hitoshi Kobayashi, Yuichi Takahashi, Hidekata Yasuoka, Takao Kodera, Osamu Takai, Izaya Nakaya, Tomomasa Izumiyama, Hiroshi Fujii, Yukiko Kamogawa, Yuko Shirota, Tsuyoshi Shirai, Yoko Fujita, Shinichiro Saito, Hiroaki Shimokawa, Hideo Harigae

2018 ACR/ARHP Annual Meeting、 Chicago,
Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

Yuko Shirota, Tomonori Ishii, Tsuyoshi Shirai, Hiroshi Fujii, Hideo Harigae

2018 ACR/ARHP Annual Meeting、 Chicago,
成熟T細胞性リンパ腫に対する臍帯血移植：10例の報告

佐野沙矢香, 大西康, 古川瑛次郎, 中川諒, 齋藤慧, 川尻昭寿, 小野寺晃一, 市川聡, 福原規子, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
T-LGL白血病に対するシクロスポリンA治療：単施設の経験

大西康, 藤原実名美, 佐野沙矢香, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 藤原亨, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
ダラツムマブ投与中にサイトメガロウイルス抗原血症陽性化を示した多発性骨髄腫の2例

小林匡洋, 佐野沙矢香, 大地哲朗, 那須健太郎, 市川聡, 福原規子, 大西康, 亀岡淳一, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
びまん性大細胞型B細胞リンパ腫におけるsIL-2R値の層別化予後因子としての意義

市川聡, 福原規子, 小林匡洋, 沖津庸子, 大西康, 一迫玲, 石澤賢一, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
Scurfyマウスにおける全身性のNRF2活性化がもたらす炎症抑制作用の解析

鈴木琢磨, 村上昌平, 張替秀郎, 本橋ほづみ

第80回日本血液学会学術集会　2018/10/13
CD56陽性皮膚T細胞リンパ腫6例の後方視的解析

大地哲朗, 福原規子, 佐野沙矢香, 那須健太郎, 小林匡洋, 市川聡, 沖津庸子, 大西康, 藤原実名美, 藤村卓, 一迫玲, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
APTT単独延長疾患の原因の検討

亀岡淳一, 沖津庸子, 小林匡洋, 市川聡, 城田祐子, 岡友美子, 小寺隆雄, 高橋伸一郎, 張替秀郎

第80回日本血液学会学術集会　2018/10/13
後天性赤芽球癆における予後不良因子とPRCA2016前向きコホート研究第2回中間解析の報告

廣川誠, 澤田賢一, 藤島直仁, 寺村正尚, 別所正美, 檀和夫, 鶴見寿, 中尾眞二, 浦部晶夫, 藤澤信, 米村雄士, 河野文夫, 押味和夫, 杉本耕一, 松田晃, 唐沢正光, 新井文子, 小松則夫, 張替秀郎, 通山薫, 齋藤明子, 松村到, 小峰光博, 小澤敬也, 黒川峰夫, 荒井俊也, 三谷絹子

第80回日本血液学会学術集会　2018/10/13
骨髄異形成症候群から進展した急性骨髄性白血病に対する化学療法中に急性心膜炎を発症した1例

竹中健太, 市川聡, 小松弘香, 中村嘉詞, 櫻井一貴, 猪倉恭子, 福原規子, 横山寿行, 大西康, 張替秀郎

第229回日本内科学会東北地方会仙台
自家移植後早期に中枢神経再発をきたしたマントル細胞リンパ腫の1例

田島隆斗, 市川聡, 櫻井一貴, 小松弘香, 竹中健太, 中村嘉詞, 猪倉恭子, 福原規子, 横山寿行, 張替秀郎

第229回日本内科学会東北地方会仙台
骨髄異形成症候群に対する同種造血幹細胞移植後に発症したノカルジア症の一例

竹中健太, 市川聡, 横山寿行, 小松弘香, 鳴海善洋, 渡邊樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, 福原規子, 大西康, 張替秀郎

第１３５回日本血液学会東北地方会仙台/ハイブリッド
骨髄検体のMYD88 L265P変異陽性から診断し得た血管内大細胞型B細胞リンパ腫の1例

小松弘香, 市川聡, 竹中健太, 中村嘉詞, 櫻井一貴, 猪倉恭子, 大西康, 福原規子, 横山寿行, 張替秀郎

第228回日本内科学会東北地方会 2023/2/18（土）仙台/WEB
高感度デジタルPCR法を用いて中枢神経再発を診断し得たMYD88 L265P変異陽性B細胞性リンパ腫の一例

小松弘香, 小野寺晃一, 竹中健太, 橋本和貴, 内堀雄介, 市川聡, 大西康, 福原規子, 横山寿行, 張替秀郎

第134回日本血液学会東北地方会ホテルメトロポリタン山形 /ハイブリッド
著明な血小板減少を伴った血管免疫芽球性T細胞リンパ腫の一例

渡邉樹也, 市川聡, 鳴海善洋, 中村嘉詞, 櫻井一貴, 猪倉恭子, 小松弘香, 竹中健太, 橋本和貴, 内堀雄介, 小野寺晃一, 福原規子, 大西康, 横山寿行, 一迫玲, 張替秀郎

第１３４回日本血液学会東北地方会ホテルメトロポリタン山形 /ハイブリッド
難治性の出血性十二指腸潰瘍を合併した後天性血友病Aの１例

鳴海善洋, 市川聡, 渡邉樹也, 中村嘉詞, 櫻井一貴, 小野寺晃一, 大西康, 福原規子, 横山寿行, 張替秀郎

第２２７回日本内科学会東北地方会山形テルサ/ハイブリッド
腹膜リンパ腫症を呈したびまん性大細胞型B細胞性リンパ腫の１例

中村嘉詞, 市川聡, 齋藤慧, 福原規子, 小野寺晃一, 大西康, 横山寿行, 張替秀郎, 一迫玲

第２２７回日本内科学会東北地方会山形テルサ/ハイブリッド
レムデシビルによる薬剤性尿細管障害を発症したと考えられたCOVID-19の一症例

真山晃史, 金沢聖美, 勝見真琴, 阿部裕子, 藤巻慎一, 藤原亨, 張替秀郎

第54回日本臨床検査医学会東北支部総会・第33回日本臨床化学会東北支部総会東北大学星陵オーディトリアム
Droplet Digital PCRを用いたNPM1変異定量法の構築

鈴木千恵, 真山晃史, 佐々木麻美, 菅原新吾, 勝見真琴, 阿部裕子, 藤巻慎一, 藤原亨, 張替秀郎

第54回日本臨床検査医学会東北支部総会・第33回日本臨床化学会東北支部総会東北大学星陵オーディトリアム
TBA-FX8における反応波形異常検知検出ツールの開発

佐々木克幸, 後藤好恵, 武田卓也, 蔵野智昭, 上野岳, 阿部裕子, 藤巻慎一, 藤原亨, 張替秀郎

第54回日本臨床検査医学会東北支部総会・第33回日本臨床化学会東北支部総会東北大学星陵オーディトリアム
インターロイキン6の早期炎症マーカーとしての有効性の検討

西原ゆり, 佐々木克幸, 木原純子, 佐藤郁美, 羽島房子, 武田卓也, 阿部裕子, 藤巻慎一, 藤原亨, 張替秀郎

第54回日本臨床検査医学会東北支部総会・第33回日本臨床化学会東北支部総会東北大学星陵オーディトリアム
鉄芽球性貧血の病態解析

藤原亨, 張替秀郎

第54回日本臨床検査医学会東北支部総会・第33回日本臨床化学会東北支部総会東北大学星陵オーディトリアム
寛解導入療法時にメトホルミンによる高乳酸血症を来したPh陽性急性リンパ性白血病の1例

中村捷, 道又大吾, 木葉大地, 田中悠也, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第226回日本内科学会東北地方会仙台（WEB)
凝固因子インヒビターが疑われたビタミンK欠乏症の一例

牧優冶, 菅原新吾, 吉岡翔, 佐藤亜耶, 藤巻慎一, 藤原亨, 市川聡, 張替秀郎

第11回日本検査血液学会東北支部学術集会岩手医科大学創立60周年記念館
Peritoneal lymphomatosisによって腹部コンパートメント症候群をきたしたB細胞性リンパ腫の一例

田中悠也, 小野寺晃一, 木葉大地, 諸田直哉, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 一迫玲, 張替秀郎

第133回日本血液学会東北地方会仙台（WEB)
完全房室ブロックを契機に診断に至ったびまん性大細胞型B細胞リンパ腫心臓浸潤の1例

木葉大地, 市川聡, 道満剛之, 田中悠也, 猪倉恭子, 福原規子, 横山寿行, 鈴木秀明, 安田聡, 張替秀郎

第224回日本内科学会東北地方会 WEB　2021/09/18
MDS に併発した心ヘモクロマトーシスに対し、デスフェラール投与により治療継続中の 1 例ラール投与により治療継続中の 1 例

藤原実名美, 矢尾板信裕, 張替秀郎

第 119 回日本輸血・細胞治療学会東北支部例会 WEB　2021/09/11
同種造血幹細胞移植後の菌血症に対しバック法で採取した顆粒球輸血を行った 2 症例

横山寿行, 諸田直哉, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 大西康, 島貫美和子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

第 119 回日本輸血・細胞治療学会東北支部例会 WEB　2021/09/11
当科における臓器移植後リンパ増殖性疾患の経験（優秀演題口演）

渡邊正太郎, 福原規子, 櫻井一貴, 橋本和貴, 古川瑛次郎, 道又大吾, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

第61回日本リンパ網内系学会総会岡山（WEB) 2021/6/24-26
CTで結節を認めなかった片側性原発性アルドステロン症の1例

岡部大輝, 尾股慧, 手塚雄太, 小野美澄, 森本玲, 宮崎真理子, 張替秀郎, 佐藤文俊

第223回日本内科学会東北地方会 WEB
脳腫瘍放射線治療に伴う晩発性下垂体機能低下症の1例

三嶋怜奈, 手塚雄太, 尾股慧, 小野美澄, 森本玲, 金森政之, 宮崎真理子, 張替秀郎, 佐藤文俊

第223回日本内科学会東北地方会 WEB
治療選択に難渋したエポプロステノール投与中の肺動脈性肺高血圧症合併バセドウ病の1例

竹石潤平, 小野美澄, 手塚雄太, 尾股慧, 森本玲, 山本沙織, 谷淳一, 宮崎真理子, 張替秀郎, 佐藤文俊

第223回日本内科学会東北地方会 WEB
CD45かつCD30陽性のため悪性リンパ腫と鑑別を要した未分化神経内分泌腫瘍の1例

諸田直哉, 小野寺晃一, 齋藤良太, 道又大吾, 猪倉恭子, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第223回日本内科学会東北地方会（WEB)
インフルエンザワクチン接種後に血球貪食症候群を発症した1例

高橋幹弘, 岡崎創司, 秋田佳奈恵, 丹野唯人, 高橋美岐, 星陽介, 佐藤紘子, 白井剛志, 石井智徳, 藤井博司

第223回日本内科学会東北地方会 WEB
血球貪食症候群を伴い発症したTCR陰性末梢性T細胞リンパ腫、非特定型の一例

澤田拓実, 諸田直哉, 小野浩弥, 道又大吾, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第132回日本血液学会東北地方会福島（WEB)
CRAB症候にて発症した骨髄原発B細胞リンパ腫の一例

道満剛之, 市川聡, 猪倉恭子, 櫻井一貴, 木葉大地, 田中悠也, 福原規子, 横山寿行, 小野寺晃一, 大西康, 張替秀郎

第132回日本血液学会東北地方会福島（WEB)
BCR-ABL1陽性急性骨髄性白血病（AML with BCR-ABLの2例

櫻井一貴, 勝岡優奈, 横山寿行, 斎藤慧, 八田俊介, 猪倉恭子, 市川聡, 福原規子, 小野寺晃一, 大西康, 和泉透, 張替秀郎

第132回日本血液学会東北地方会福島（WEB)
2回目のSARS-CoV-2 mRNAワクチン接種後に溶血が進行した遺伝性球状赤血球症（HS）の一例

野村順, 関雅文, 阿部正理, 小林匡洋, 沖津庸子, 福原規子, 高橋伸一郎, 張替秀郎, 亀岡淳一

第132回日本血液学会東北地方会福島（WEB)
妊娠に関連し発症した抗ARS抗体陽性と抗MDA5抗体陽性皮膚筋炎の２例

秋山悠歩, 白井剛志, 佐藤紘子, 髙橋幹弘, 丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 秋田佳奈恵, 藤井博司, 石井智徳

第６５回日本リウマチ学会総会学術集会神戸（WEB)
再燃を繰り返した治療抵抗性好酸球性多発血管炎症肉芽腫症に対してシクロホスファミド、リツキシマブ、メポリズマブ併用療法が有効であった１例（ポスター）

武藤智之, 白井剛志, 永井泰地, 佐藤紘子, 藤井博司, 石井智徳, 張替秀郎

第６５回日本リウマチ学会総会学術集会神戸（WEB)
腹部大動脈周囲炎を合併した好酸球性多発血管炎症肉芽腫症の一例

秋田佳奈恵, 藤井博司, 丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 佐藤紘子, 白井剛志, 石井智徳, 張替秀郎

第６５回日本リウマチ学会総会学術集会神戸（WEB)
当科における関節リウマチに対するゴリムマブの長期継続率の検討（ポスター）

武藤智之, 永井泰地, 佐藤紘子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

第６５回日本リウマチ学会総会学術集会神戸（WEB)
当院の関節リウマチ患者におけるMTX関連リンパ増殖性疾患40例の診断契機に関する検討

高橋美岐, 丹野唯人, 岡崎創司, 町山智章, 星陽介, 秋田佳奈恵, 佐藤紘子, 白井剛志, 石井智徳, 藤井博司, 張替秀郎

第６５回日本リウマチ学会総会学術集会神戸（WEB)
シンポジウムベーチェット病における血管病変の特徴と再燃に関連する因子の検討

佐藤紘子, 丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 町山智章, 秋田佳奈恵, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

第６５回日本リウマチ学会総会学術集会神戸（WEB)
SARFによる高安動脈炎の新規自己抗原の同定とその病的意義について

藤井博司, 白井剛志, 武藤智之, 石井智徳, 張替秀郎

第６５回日本リウマチ学会総会学術集会神戸（WEB)
シンポジウム高安動脈炎における自己抗体の意義

石井智徳, 白井剛志, 武藤智之, 藤井博司, 張替秀郎

第６５回日本リウマチ学会総会学術集会神戸（WEB)
レテルモビル予防終了後の CMV 再活性化の検討 Cytomegalovirus reactivation after letermovir prophylaxis in allogeneic HSCT

古川瑛次郎, 大西康, 橋本和貴, 櫻井一貴, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 横山寿行, 藤原亨, 藤原実名美, 張替秀郎

第43 回日本造血細胞移植学会総会東京/オンライン
非血縁者間骨髄移植前に Mogamulizumab 単剤治療を行った化学療法抵抗性 ATLL の一例 A case of adult T-cell leukemia/lymphoma receiving mogamulizumab monotherapy preceding URBMT

久保龍大, 大西康, 橋本和貴, 櫻井一貴, 猪倉恭子, 古川瑛次郎, 小野寺晃一, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

第43 回日本造血細胞移植学会総会東京/オンライン
同種造血幹細胞移植後に神経リンパ腫症として再発した濾胞性リンパ腫の 2 例 Two cases of relapsed follicular lymphoma as presenting neurolymphomatosis after allogenic HSCT

阿部未玲, 福原規子, 櫻井一貴, 橋本和貴, 古川瑛次郎, 猪倉恭子, 小野寺晃一, 市川聡, 大西康, 横山寿行, 藤原実名美, 張替秀郎

第43 回日本造血細胞移植学会総会東京/オンライン
同種臍帯血移植において KIR リガンド不適合が GVHD 予防法の効果に与える影響 The impact of KIR-ligand mismatch on the efficacy of GVHD-prophylaxis in cord blood transplantation

横山寿行, 櫻井一貴, 橋本和貴, 古川瑛次郎, 齋藤慧, 八田俊介, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 勝岡優奈, 大西康, 和泉透, 張替秀郎

第43 回日本造血細胞移植学会総会東京/オンライン
移植後早期再発した急性巨核芽球性白血病に対して臍帯血移植を行い長期寛解を達成した一例

櫻井一貴, 市川聡, 齋藤慧, 猪倉恭子, 福原規子, 横山寿行, 小野寺晃一, 大西康, 藤原亨, 亀岡淳一, 張替秀郎

第131回日本血液学会東北地方会 WEB
再発難治性浸潤性胸腺腫に併発した赤芽球癆に対してシクロスポリンが著効した1例

橋本和貴, 市川聡, 古川瑛次郎, 猪倉恭子, 小野寺晃一, 福原規子, 大西康, 横山寿行, 高橋昌宏, 張替秀郎

第222回日本内科学会東北地方会 WEB
自己免疫性膵炎に対するステロイド維持療法中にIgG4関連下垂体炎を発症した1例

大黒顕佑, 尾股慧, 古田銀次, 金沙織, 白井剛志, 小野美澄, 森本玲, 張替秀郎, 宮崎真理子, 佐藤文俊

第222回日本内科学会東北地方会 WEB
SLESjogren症候群を伴う肺多発結節影を来した肺MALTlymphomaの一例

髙橋幹弘, 岡崎創司, 秋田佳奈恵, 石井悠翔, 丹野唯人, 高橋美岐, 星陽介, 白井剛志, 石井智徳, 藤井博司, 張替秀郎

第３０回日本リウマチ学会北海道東北支部学術集会(WEB)
トシリズマブ、サリルマブで加療を行ったTAFRO症候群の一例

丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 秋田佳奈恵, 町山智章, 佐藤紘子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

第３０回日本リウマチ学会北海道東北支部学術集会(WEB)
若手リウマチ医奨励賞受賞者セッションシクロホスファミドとアザチオプリンによる寛解維持が困難でインフリキシマブが有効であった再発性多発軟骨炎の一例

秋田佳奈恵, 白井剛志, 丹野唯人, 高橋美岐, 岡崎創司, 星陽介, 佐藤紘子, 藤井博司, 石井智徳, 張替秀郎

第３０回日本リウマチ学会北海道東北支部学術集会(WEB)
Transcriptional Regulation of Ferroptosis in X-Linked Sideroblastic Anemia

Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Yan Yan, Sayaka Sano, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae
Two cases of central nervous system PTLD after ATG-based haploidentical HCT

Eijiro Furukawa, Yasushi Onishi, Shinji Nakajima, Koichi Onodera, Kazuki Hashimot, Kazuki Sakurai, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae
Three cases of Philadelphia-positive acute leukemia presenting with deep venous thrombosis

Kazuki Hashimoto, Yasushi Onishi, Koichi Onodera, Eijiro Furukawa, Kazuki Sakurai, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae
Establishment of SF3B1 mutation screening based on high resolution melting analysis

Chie Suzuki, Tohru Fujiwara, Tetsuro Ochi, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Hideo Harigae
Switching from eltrombopag to romiplostim in patients with aplastic anemia: A report of three cases

Koichi Onodera, Kazuki Hashimoto, Kazuki Sakurai, Eijiro Furukawa, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Hideo Harigae
Outcomes of allo-HCT using fludarabine-based regimens for Ph+ALL in complete molecular remission

Yasushi Onishi, Koichi Onodera, Kazuki Hashimoto, Kazuki Sakurai, Eijiro Furukawa, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae
The impact of cytomegalovirus reactivation on outcomes in cord blood transplantation

Hisayuki Yokoyama, Yuya Tanaka, Yoonha Lee, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Mai Watanabe, Shunsuke Hatta, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kuniaki Meguro, Hideo Harigae
Clinical outcomes of commercial tisagenlecleucel for diffuse large B-cell lymphoma in our center

Kei Saito, Satoshi Ichikawa, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Minami Fujiwara, Ken Sagou, Noriaki Tachi, Keiichi Ohashi, Hideo Harigae
The prognosis of FL with a concurrent DLBCL in the population-based lymphoma registry in Miyagi

Shotaro Watanabe, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Satoshi Ichikawa, Yasushi Onishi, Yuna Katsuoka, Shunsuke Hatta, Kei Saito, Osamu Sasaki, Yoriko Harazaki, Mayumi Kamata, Yasuo Tomiya, Ryo Ichinohasama, Hideo Harigae
An autopsy case of γδ T cell clonal proliferation early after PD-1 blockade

Koya Ono, Yasushi Onishi, Shotaro Watanabe, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Chie Suzuki, Hirofumi Watanabe, Mariko Oikawa, Yuto Yamazaki, Hideo Harigae
Parameters for distinguishing polycythemia vera from secondary erythrocytosis

Junichi Kameoka, Masahiro Kobayashi, Shori Abe, Jun Nomura, Yoko Okitsu, Shinichiro Takahashi, Noriko Fukuhara, Yasushi Onishi, Hideo Harigae
HSPA9 mutations in a patient with syndromic sideroblastic anemia and various congenital anomalies

Atsuko Watanabe, Yuki Shimizu, Atsuhiko Ohta, Takashi Fukushima, Hayato Sakurai, Hideo Harigae, Tohru Fujiwara, Ryuhei Tanaka
Impact of ferroptosis in X-linked sideroblastic anemia

Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Yan Yan, Sayaka Sano, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae
Establishment of congenital sideroblastic anemia model dueto ABCB7 defect

Tohru Fujiwara, Tetsuro Ochi, Chie Suzuki, Koya Ono, Kei Saito, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae
Mature γδT-cell leukemia complicated with agranulocytosis

Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Yuya Tanaka, Yoonha Lee, Koichi Onodera, Yasushi Onishi, Tohru Fujiwara, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae
重症高血圧症、心不全に対し抗腫瘍療法開始前の支持療法が奏功した副腎皮質癌の1例

古田銀次, 大黒顕佑, 尾股慧, 小野美澄, 森本玲, 張替秀郎, 宮崎真理子, 佐藤文俊

第221回日本内科学会東北地方会
気道感染を契機に重篤な出血症状を伴って発症した後天性第X因子欠乏の1例

八木櫻子, 市川聡, 齋藤慧, 福原規子, 小野寺晃一, 大西康, 横山寿行, 藤原実名美, 張替秀郎

第221回日本内科学会東北地方会
腑帯血移植により持続的寛解を得られた治療抵抗性血管免疫芽球性T細胞リンパ腫の一例

本江史門, 市川聡, 福原規子, 齋藤慧, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

第130回日本血液学会東北地方会
Pathogenic potential of novel autoantibodies in Takayasu arteritis

Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii, Yuko Shirota, Hideo Harigae, Hiroshi Fujii

第64回日本リウマチ学会総会・学術集会(WEB)
Effects of IFN alpha-priming on B cell activation and actions of the FOXM1 inhibitor on activated B cells

Kanae Akita, Tsuyoshi Shirai, Tomonori Ishii, Hideo Harigae, Hiroshi Fujii

第64回日本リウマチ学会総会・学術集会(WEB)
SLEに合併したADAMTS13インヒビター陰性二次性血栓性血小板減少性紫斑病の一例SLEに合併したADAMTS13インヒビター陰性二次性血栓性血小板減少性紫斑病の一例

佐藤紘子, 永井泰地, 武藤智之, 町山智章, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

第64回日本リウマチ学会総会・学術集会(WEB)
多発血管炎性肉芽腫症における臓器別にみた治療反応性についての検討

城田祐子, 白井剛志, 藤井博司, 佐藤紘子, 町山智章, 堤智美, 武田朋樹, 岡友美子, 小寺隆雄, 桑田亮, 石井智徳, 張替秀郎, 亀岡淳一

第64回日本リウマチ学会総会・学術集会(WEB)
混合表現型急性白血病初発時に肺血栓塞栓症を合併した１症例. （口演）

大久保礼由, 菅原新吾, 鈴木千恵, 佐々木麻美, 石塚静江, 安久美子, 藤巻慎一, 大西康, 藤原亨, 張替秀郎

第21回日本検査血液学会学術集会(WEB)
破砕赤血球判定収束法ver.1の提案

菅原新吾, 鈴木千恵, 大久保礼由, 佐々木麻美, 石塚静江, 藤巻慎一, 藤原亨, 張替秀郎

第21回日本検査血液学会学術集会(WEB)
当院救急科における大量輸血プロトコル（MTP）策定にむけたO型RBC輸血症例の解析

成田香魚子, 関修, 伊藤智啓, 細川真梨, 郷野辰幸, 岩木啓太, 石岡夏子, 阿部真知子, 佐藤裕子, 藤原実名美, 張替秀郎

第68回日本輸血・細胞治療学会東北支部例会(開催中止・誌上発表のみ）
CAR-T導入に伴う細胞治療部門のQMS構築と管理運営

岩木啓太, 阿部真知子, 伊藤貴子, 沖田ひとみ, 島貫美和子, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 佐藤裕子, 関修, 成田香魚子, 藤原実名美, 張替秀郎

第68回日本輸血・細胞治療学会東北支部例会(開催中止・誌上発表のみ）
「JAHIS医療情報システムの患者安全ガイド(輸血編)Ver.2.0」を用いた輸血管理システム導入の取り組み

岩木啓太, 成田香魚子, 伊藤智啓, 細川真梨, 郷野辰幸, 石岡夏子, 阿部真知子, 佐藤裕子, 関修, 藤原実名美, 張替秀郎

第68回日本輸血・細胞治療学会東北支部例会(開催中止・誌上発表のみ）
CAR-T療法に用いる自己リンパ球アフェレーシス採取の実際

松浦健, 小笠原亮太, 佐々木俊一, 島貫美和子, 岩木啓太, 阿部真知子, 藤原実名美, 張替秀郎

第68回日本輸血・細胞治療学会東北支部例会(開催中止・誌上発表のみ）
SAA に対するuBMT 後に、肝多発腫瘤で発症しR-EPOCH 療法が有効であったPTLD の1 例

中川諒, 大西康, 小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 藤原亨, 福原規子, 横山寿行, 藤原実名美, 張替秀郎

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
直接作用型抗ウイルス薬治療後のHCV 再活性化を認めた急性骨髄性白血病に対する臍帯血移植の一例

田中悠也, 李尹河, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
Comparison of the outcomes between cord blood transplantation and BMT/PBSCT from young or elderly donors

Hisayuki Yokoyama, Yuya Tanaka, Yoonha Lee, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Mai Watanabe, Shunsuke Hatta, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kuniaki Meguro, Hideo Harigae

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
臍帯血移植後の末梢血単球絶対数が移植成績に及ぼす影響

小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
急性骨髄性白血病においてHLA-DR の発現が同種移植の予後に与える影響についての検討

李尹河, 田中悠也, 齋藤慧, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第42回日本造血細胞移植学会総会（開催中止・誌上発表）
節外性NK/T 細胞リンパ腫の同種移植後早期再発に対して短期L-asparaginase 投与が著効した一例

市川聡, 福原規子, 齋藤慧, 横山寿行, 田中悠也, 李尹河, 小野寺晃一, 大西康, 一迫玲, 張替秀郎

第129回日本血液学会東北地方会
ルキソリチニブ投与中に低悪性度B細胞性リンパ腫を発症した原発性骨髄線維症の1例

戒能明, 小野寺晃一, 田中悠也, 李尹河, 齋藤慧, 市川聡, 福原規子, 大西康, 横山寿行, 張替秀郎

第219回日本内科学会東北地方会
JAK２変異陽性の真性多血症にIgA血管炎を合併し、ネフローゼ症候群に至った１例

金銅妃奈子, 渡部龍, 岡崎創司, 栗山香里, 杉浦章, 工藤正孝, 五十嵐勇彦, 大地哲朗, 張替秀郎, 藤井博司

第219回日本内科学会東北地方会
不明熱精査中にリウマチ性多発筋痛症と鑑別を要した血管内リンパ腫の1例

成田衛, 渡部龍, 岡崎創司, 栗山香里, 那須健太郎, 張替秀郎, 藤井博司

第219回日本内科学会東北地方会
後部虚血性視神経症による急性視力障碍を来たした小型血管炎の1例

李邱平, 白井剛志, 永井泰地, 町山智章, 鴨川由起子, 佐藤紘子, 藤井博司, 石井智徳, 張替秀郎

第29回日本リウマチ学会北海道・東北支部学術集会　2019/11/02
重症な急速進行性間質性肺炎を合併した抗MDA5抗体陽性皮膚筋炎に対して多剤併用療法が奏効した一例

町山智章, 白井剛志, 藤田洋子, 鴨川由起子, 佐藤紘子, 藤井博司, 石井智徳, 張替秀郎

第29回日本リウマチ学会北海道・東北支部学術集会　2019/11/02

Show all Show first 5

Research Projects 28

転写因子GATA2によるT細胞エピゲノムメモリー制御機構の解明

張替秀郎, 加藤浩貴

Offer Organization: 日本学術振興会

System: 科学研究費助成事業挑戦的研究(萌芽)

Category: 挑戦的研究(萌芽)

Institution: 東北大学

2022/06/30 - 2024/03/31
特発性造血障害に関する調査研究

三谷絹子, 金倉譲, 山崎宏人, 石田文宏, 赤司浩一, 宮崎泰司, 高折晃史, 黒川峰夫, 鈴木隆浩, 神田善伸, 真部淳, 張替秀郎, 太田晶子, 東條有伸, 井上義一

Offer Organization: 厚生労働省

System: 厚生労働科学研究費補助金

Category: 難治性疾患政策研究事業

Institution: 獨協医科大学医学部

2020/04 - 2023/03
新型コロナウイルス（SARS-CoV-2）肺炎に対するPAI-1阻害薬TM5614のプラセボ対照二重盲検第II相医師主導治験

張替秀郎, 平井豊博, 浅野浩一郎, 宮崎泰成, 関雅文, 富井啓介, 高橋史朗, 内藤幸嗣, 宮田敏男, 杉浦久敏, 青柳哲史, 安藤潔

Offer Organization: 国立研究開発法人日本医療研究開発機構

System: 日本医療研究開発機構研究費

Category: 新興・再興感染症に対する革新的医薬品等開発推進研究事業

Institution: 東北大学病院他

2021/04 - 2022/03
高齢者急性骨髄性白血病の化学療法が可能な症例に対して若年成人標準化学療法の近似用量を用いる第II相臨床試験: JALSG-GML219試験

山内高弘, 宮崎泰司, 伊藤良和, 齋藤俊樹, 齋藤明子, 石山謙, 前田智也, 張替秀郎

Offer Organization: 国立研究開発法人日本医療研究開発機構

System: 日本医療研究開発機構研究費

Category: 革新的がん医療実用化研究事業

Institution: 福井大学ほか

2020/04 - 2022/03
Elucidation of epigenetic regulation of erythropoiesis and translation to therapeutic strategy

IGARASHI Kazuhiko

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Challenging Research (Pioneering)

Category: Challenging Research (Pioneering)

Institution: Tohoku University

2018/06/29 - 2021/03/31

More details Close

We aimed to understand the roles of MAT2, which synthesizes S-adenosylmethionine (SAM), in red blood cell (RBC) development including the effect of SAM in their epigenome. We found that the expression of MAT2A, the catalytic subunit of MAT2, is gradually decreased along RBD differentiation with concomitant decrease in SAM. The reduction of SAM led to global alterations in the epigenome of precursor cells (erythroid cells) including DNA methylation and histone methylation. As MAT2A expression is maintained by a feedback regulation involving SAM in other types of cells like Hela cells, our results suggest that erythroid cells lack the feedback regulation, enabling them to use the reduction of SAM as a signal to drive RBC differentiation.
Age-related alterations of hematopoietic stem and progenitor cells due to failure of Bach transcription factors

IGARASHI Kazuhiko

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (A)

Category: Grant-in-Aid for Scientific Research (A)

Institution: Tohoku University

2018/04/01 - 2021/03/31

More details Close

We aimed to understand the functions of BACH1 and BACH2 in the regulation of hematopoietic cell differentiation. By generating and analyzing mice lacking both of these genes, we found that these mice showed reduced differentiation of red blood cells and lymphoid cells, which were similar to alterations observed in myelodysplastic syndrome (MDS). By analyzing gene expression of the bone marrow cells of patients of MDS, we found that the expression of BACH2 was reduced along the progression of the disease, suggesting that a reduction in the function of BACH2 is involved in the disease progress including anemia and immunodeficiency. BACH1 and BACH2 were found to promote differentiation of erythroid cells and lymphoid cells by repressing the expression of genes important for the differentiation and/or function of myeloid cells.
新型コロナウイルス(SARS-CoV-2)肺炎患者に対するPAI-I阻害薬TM5614の有効性および安全性を検討する探索的第II相医師主尊治験

張替秀郎, 杉浦久敏, 青柳哲史, 宮田敏男, 平井豊博, 浅野浩一郎, 安藤潔, 宮崎泰成, 髙橋史朗, 内藤幸嗣, 段孝他

Offer Organization: 日本医療研究開発機構

System: 令和2年度新興・再興感染症に対する革新的医薬品等開発推進研究事業「新型コロナウイルス感染症(COVID-I 9)に対する治療薬開発」(2次公募）

Institution: 東北大学

2020/07 - 2021/03
先天性骨髄不全症の登録システムの構築と診断基準・重症度分類・診断ガイドラインの確立に関する研究

伊藤悦朗, 張替秀郎矢部普正, 真部淳, 高橋義行, 菅野仁, 高田穣, 大賀正一, 照井君典, 古山和道, 多賀崇, 小林正夫, 渡邉健一郎, 金兼弘和, 山口博樹

Offer Organization: 厚生労働省

System: 厚生労働科学研究費補助金

Category: 難治性疾患等政策研究事業

Institution: 弘前大学医学研究科特任教授伊藤悦朗

2019/04 - 2021/03
International collaborative effort to study of pathophysiology and development of novel therapy of congenital sideroblastic anemia

Harigae Hideo

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2017/04/01 - 2020/03/31

More details Close

As congenital sideroblastic anemia (CSA)is very rare, there is a need to collect the data of patients and clarify the molecular pathogenesis to develop a novel therapy by the international collaborative study. In this study, 17 cases of congenital sideroblastic anemia were found at Chinese Academy of Medical Sciences and Peking Union Medical College. In 7 out of 17cases, mutations of 5-aminolevulinate synthase (ALAS2) gene, which is the first enzyme of heme biosynthesis in erythroid cells were identified. In addition, mutations of SLC25A38 gene, which codes the mitochondrial glycine transporter were identified in 3 out of 17cases. Gene mutations of 22 congenital anemia cases at National Institute of Immunohaematology in India were analyzed; however, mutations responsible for CSA were not identified. In Japan, a novel mutation of HSPA9 gene and SLC5A6 gene was found. The significance of mutations are being confirmed by in vitro differentiation system established in this study.
Development of a new strategy for tumor immunity activation

IGARASHI Kazuhiko

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research

Category: Grant-in-Aid for Challenging Exploratory Research

Institution: Tohoku University

2016/04/01 - 2018/03/31

More details Close

Cytotoxic T cells play critical roles in eliminating tumor cells with tumor-specific antigens. Although this tumor surveillance is effective during initial phases of tumorgenesis, it eventually fail to restrict tumor progression due to exhaustion of cytotoxic T cells. In addition, regulatory T cells and suppressor myeloid cells also inhibit the cytotoxic T cell activities. Based on our previous findings that the transcription factor Bach2 is essential for the differentiation of regulatory T cells, restricting cytotoxic T cell differentiation, this study was carried out to understand potential roles of Bach2 in the process of the T cell exhaustion and to develop a new strategy to activate tumor immunity. We found that Bach2-deficient T cells showed enhanced cytotoxic T cell differentiation and activity in vitro. Furthermore, many of the genes involved in T cell activation and cytotoxic activity were more highly expressed in Bach2-deficient T cells than in wild-type cells.
The photodynamic detection of MRD of multiple myeloma by flowcytometory

HARIGAE HIDEO

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research

Category: Grant-in-Aid for Challenging Exploratory Research

Institution: Tohoku University

2016/04/01 - 2018/03/31

More details Close

Heme is generated in mitochondria by insertion of iron to protoporphyrin IX (PPIX). As the activity of mitochondria is decreased in cancer cells, PPIX is accumulated by the administration of ALA. The aim of this study is to establish the novel method to detect minimal residual disease (MRD) of multiple myeloma by applying this characteristic of cancer cell biology to flowcytometory. First, the condition to detect the fluorescence of PPIX was established in KMS18 cell, a myeloma cell line. It was confirmed that the established condition can effectively differentiates KMS18 cells from normal blood cells. Next, transporters which incorporate ALA into cells, were identified by the competition assay. Then the movement of ALA after incorporated into cells was clarified using Caco cells. As a result, a part of ALA was used for the generation of PPIX, and unused ALA was exported from cells. These findings ｍay contribute to the development of a novel detection system of MRD.
Regulation of erythropoiesis and macrophages by the heme signal

IGARASHI Kazuhiko, MATSUI Miki, SAIGUSA Daisuke

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (A)

Category: Grant-in-Aid for Scientific Research (A)

Institution: Tohoku University

2015/04/01 - 2018/03/31

More details Close

We reported previously that heme binds to the transcription factors Bach1 and Bach2 to regulate gene expression. In this study, we have successfully established the regulatory roles and biological significances of the heme-mediated regulation of these transcription factors. We found that, unlike known heme-binding proteins, the heme-binding region of Bach2 is structurally disordered, and that this region remained disordered even in the presence of heme. Nonetheless, heme induced an interaction of Bach2 and protein kinase, which then phosphorylated Bach2. We also found that Bach1 was critical for adaptation of erythroid cells to iron deficiency. Bach1 kept expression of key erythroid transcription factor genes under such conditions. In stem and progenitor cells, Bach2 and Bach1 were found to promote lymphoid cell differentiation by restricting the expression of myeloid transcription factors as well as their target genes important for myeloid cell differentiation.
Generation and analysis of in vitro, in vivo model of sideroblastic anemia

Harigae Hideo, KAWAMATA Shin, FUJIWARA Tohru

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2014/04/01 - 2017/03/31

More details Close

Sideroblastic anemia is characterized by anemia with ring sideroblasts in the bone marrow. In order to develop a novel therapy for sideroblastic anemia, iPS cells were established from a patient of X-linked sideroblastic anemia (XLSA), which is caused by mutations of 5-aminolevulinate synthase (ALAS2) gene. The expression profiling of erythroblasts derived from XLSA iPS cells showed that the expression levels of globins and erythroid-specific transcription factors were decreased compared to those derived from control iPS cells. When XLSA derived iPS cells were co-cultured with stromal cells; aberrant mitochondrial iron deposition was detected by prussian blue staining and electron microscope analysis. In addition, XLSA model mouse has been generated by introducing mutations to the enhancer lesion of ALAS2 gene by CRISPR/CAS9 system. Mutant mice were anemic, and the expression level of ALAS2 of bone marrow was decreased. Iron metabolism and erythropoiesis are under investigation.
Identification and functional analysis of erythroid-specific genes regulated by heme

HARIGAE Hideo

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2006 - 2007

More details Close

Erythroid cells synthesize and accumulate an enormous amount of hemoglobin in the late stage of their differentiation. It is possible that, in addition to hemoglobin synthesis, heme may also play another important role in the erythroid cell differentiation program. To identify erythroid- specific heme-regulated genes, we performed differential expression analysis between wild-type and heme-deficient erythroblasts, which had been prepared from wild-type and δ-aminolevulinate synthase (ALAS2)-null mouse ES cells, respectively. As a result, the final 4 were considered as the newly identified erythroid-specific heme-regulated genes. These 4 genes were uncoupling protein 2 (UCP2), nucleolar spindle-associated protein (NuSAP), cellular nucleic acid binding protein (CNBP), and a novel acetyltransferase-like protein. Among them, the function of Nusap was further analyzed. NuSAP mRNA was remarkably more abundant in the subset corresponding to immature erythroblasts (TER119^+CD71^<high>) than mature erythroblasts (TER119^+CD7^<low>), and it was significantly increased in TER119^+ cells from in vivo phlebotomized mice. These results suggested that NuSAP gene might contribute to the expansion of immature erythroblast pool. These findings thus suggest that heme may regulate a wide variety of genes in erythroid cell differentiation.
Multiple mechanisms for the regulation of heme biosynthesis and catabolism.

FURUYAMA Kazumichi, SHIBAHARA Shigeki, HARIGAE Hideo

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2005 - 2006

More details Close

Heme is a prosthetic group of several enzymes, and essential for aerobic organisms. Since excess amount of heme in the cells increases reactive oxygen species, cellular heme level is strictly regulated under the balance of its biosynthesis and catabolism. To know how heme biosynthesis and catabolism is regulated by the mechanisms through protein-protein interaction, we have performed following experiments 1. To know what kind of proteins are involved in the regulation of heme biosynthesis and catabolism, we have screened human cDNA libraries using non-specific aminolevulinate synthase, erythroid-specific aminolevulinate synthase (ALAS2), heme oxygenase 1 or heme oxygenase 2 (HO-2) as a bait protein. As a result, we have found that one of the components of 20S proteasome could associate with HO-2 protein. Since over-expression of this protein reduced HO-2 protein expression level, this protein should be involved in the regulation of protein degradation of HO-2. 2. Using RNA interference (RNAi) technology, we have tried to establish the model cells for sideroblastic anemia. First, we have prepared effective small interfering RNA (siRNA) for suppression of ALAS2 expression, then, prepared expression vector, which express effective short-hairpin RNA (shRNA). This vector has been introduced into YN-1 cells, which is able to produce hemoglobin in the cells after the stimulation by transforming growth factor beta 1, and these cells were incubated with G418 to select the cells which constitutively express shRNA against ALAS2. YN-1 cells that express ALAS2 at low level were selected, and named as YN1-ALAS21ow cells. However, ringed sideroblast, which is the hallmark of the sideroblastic anemia, was not observed even after the erythroid differentiation by TGF-betal. We have confirmed that YN1-ALAS21ow cells expressed lower level of ALAS2 mRNA than control cells, YN1-ALAS21ow cells might expressed enough level of ALAS2 for protecting the cells from iron accumulation in mitochondria.
Analysis of new biomarker for evaluation of SLE activity with autoantibody penetration to cells

ISHII Tomonori, HARIGAE Hideo

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2005 - 2006

More details Close

Systemic lupus erythematosus (SLE) involves a variety of autoantibodies which may be responsible for the tissue injury. Immunoglobulin G (IgG), especially anti-DNA IgG from active SLE had an ability to penetrate into peripheral blood mononuclear cells in vitro. The target cells for the penetration are CD8 (+) T cells, B cells, NK cells, monocytes, dendritic cells (DC) in circulation. Anti-Fc antibodies failed to cause the inhibition of anti-DNA IgG penetration into cells, but the coexistence of methyl beta cyclodextrin, raft/caveolae inhibitor, or DNA antigen blocked the internalization. Immunofluorescence studies revealed that anti-DNA IgG used raft/caveolae for their entry into the cells, and were distributed in lysosome, but not detected in the nuclei. The penetration caused to alter the biological function of the immunocytes. Namely, purified anti-DNA IgG induced the maturation and activation of human monocyte-derived dendritic cell as observed by CD83 up-regulation, IL12 secretion and an enhanced stimulation of allogenic or autologus T cells to DC at mixed lymphocyte reaction. Our results provide a new sight for the role of anti-DNA autoantibodies at cell function such as maturation and production of several proteins like cytokines, and may explain a novel mechanism where peripheral tolerance is broken in SLE patients.
Mechanism for human parvovirus B19-induced rheumatoid arthjritis

SASAKI Takeshi, HARIGAE Hideo, ISHII Tomonori, ISHII Keiko

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

Institution: TOHOKU UNIVERSITY

2004 - 2006

More details Close

1.Clinical study: We compared clinical features of patients with rheumatoid arthritis(RA) who had or had not the evidences of human parvovirus B19 (B19) infection at the onset of RA. The result revealed no differences between the clinical profile of patients with B19 and that without B19. 2.Mechanism for the B19 infection to the targeted cells. B19 bound to Ku80 and P antigen as the cellular receptor on on the surface of targeted cells. The entry of B19 into cells occurred using claslin. It has been suggested that there may be an unknown factor that is responsible for the intracellular transportation of B19 to nucleus. 3.Neutralizing antibody activity to B19 in rheumatoid arthritis. Neutralizing antibodies has an important role on the host defence at B19 infection. We studied neutralizing antibody activity against B19 in patients with B19 infection and rheumatoid arthritis. The neutralizing activity was ddetermined through the ability of serum antibody to inhibit B19 infection in erythroid cell line KU812Ep6 using quantitative PCR assay. The levels of neutralizing ability elevated at symptomatic resolution in most cases with acute B19 infection. Despite the elevation of IgG anti-B19 antibodies, the neutralizing ability remained markedly low in patients with prolonged B19 infection in 41 of 62 patients with rheumatoid arthritis. 4.Inhibition of B19 proliferation by siRNA against B19. SiRNA to B19 NS1 inhibited B19 proliferation in B19-infected erythroid cell lines. The addition of NS1 siRNA to primary culture system using RA synovial cells in vitro caused marked inhibition of TNF α proliferation, indicating a possible application of NS1 siRNA to the therapy for RA.
Regulation of erythropoiesis mediated by heme

HARIGAE Hideo

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: TOHOKU UNIVERSITY

2004 - 2005

More details Close

To clarify the regulatory mechanism for erythropoiesis by heme, we performed differential expression analysis between wild-type and heme-deficient erythroblasts, which had been prepared from wild-type and δ-aminolevulinate synthase (ALAS2)-null mouse ES cells, respectively. From 8737 clones on cDNA array, clones which were highly expressed in wild-type erythroblasts were selected first and their expression was evaluated further for the erythroid-lineage specificity, heme-dependent expression, and expression in hematopoietic tissues in vivo. The final 4 genes were considered as the newly identified erythroid-specific heme-regulated genes. These 4 genes were uncoupling protein 2 (UCP2), nucleolar spindle-associated protein (NuSAP), cellular nucleic acid binding protein (CNBP), and a novel acetyltransferase-like protein. These findings suggest that heme may regulate a wide variety of hitherto unrecognized genes, and further analysis of these genes may clarify their role in erythroid cell differentiation.
The disruption of protein-protein interaction in mitochondria results in sideroblastic anemia.

FURUYAMA Kazumichi, HARIGAE Hideo

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2003 - 2004

More details Close

We have identified that beta-subunit of ATP specific succinyl CoA synthase (SCS-betaA) associate with the erythroid specific 5-aminolevulinate synthase (ALAS-E), which is the rate limiting enzyme of heme biosynthetic pathway in erythroid cells. This protein interaction occurred in mitochondria should be important for effective heme production, because succinyl CoA is one of the substrates of ALAS-E for producing aminolevulinic acid. In fact, we have identified that the mutation of the ALAS-E gene, which was identified in the pedigree of pyridoxine refractory X-linked sideroblastic anemia, disrupt this interaction with SCS-betaA, resulting sideroblastic anemia. Since the reduced enzymatic activity of ALAS-E in erythroblast results in X-linked sideroblastic anemia, we have speculated that the disruption of the interaction between ALAS-E and SCS-bataA cause sideroblastic anemia. Thus, we have tried to reduce the expression of SCS-betaA using siRNA technique in erythroid cells. As a result, we found that reduced level of mRNA of SCS-betaA in erythroid cells interfere the erythroid differentiation, which was judged by hemoglobin staining. Our results indicate that the disruption of the association between ALAS-E and SCS-betaA affect the effective heme production in erythroid cells, and it may cause sideroblastic anemia.
Pathogenic role of virus gene that was detected in patients with rheumatoid arthritis

MUNAKATA Yasuhiko, KAMEOKA Junichi, HARIGAE Hideo

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: TOHOKU UNIVERSITY

2003 - 2004

More details Close

Human parvovirus B19 (B19) often causes acute polyarthritis in adults. We analyzed nucleotide sequences of the B19 genome of patients with rheumatoid arthritis (RA), and then introduced the nonstructural protein 1 (NS1) gene of B19 into C57BL/6 mice that had a genetic origin not susceptible to arthritis. The transgenic mice developed no lesions spontaneously, but were susceptible to type II collagen (C II )-induced arthritis. B19 NS1 was expressed in synovial cells on the articular lesions that were histologically characten NS1 transgenic mice to the same levels as those of DBA/1 mice, which werendicating that a nonpermissive H-2b haplotype in the wild type of C57BL/6 can be made susceptible to polyarthritis through the expression of NS1. This study is the first to show that a viral agent from the joints in humans can cause C II-induced arthritis resembling RA. B19 protein, DNA and RNA were detectable repeatedly at different times in macrophages, T and B cells in the rheumatoid synovium, indicating persistent activation of B19 in the RA synovium. We also showed that transduction of the macrophage cell line, U937 with NS-1 gene-activated transcription factors, AP-1 and AP-2, resulted in the up-regulation of TNF-α gene expression and secretion of TNF-α from host cells. This indicated the persistent activation of B19 may constantly up-regulate the TNF-α gene in infected cells. NS1 transgenic model leads us to hypothesize that persistently activated B19 may induce an increased immune response, such as activating and proliferating synoviocytes by an autocrine and paracrine pathway in the joints, resulting in an inflammatory process resembling RA.
関節リウマチ発症におけるヒトパルボウイルスB19に関する研究

佐々木毅, 宗像靖彦, 張替秀郎, 八重樫伸生

Offer Organization: 日本学術振興会

System: 科学研究費助成事業特定領域研究

Category: 特定領域研究

Institution: 東北大学

2003 - 2003

More details Close

1.B19のレセプターはP抗原とされる。しかし、臨床知見から未知のB19レセプターの存在が推定されていた。我々はRA例の病変部滑膜の免疫系細胞ではP抗原が乏しいにも拘わらずB19DNA/RNA,B19蛋白VP-1存在を認めた。B19はT細胞株、マクロファージ系株に強い結合性を示した。一方、P抗原陽性であるHeLa細胞や、腎、膀胱由来細胞ではB19結合、増殖いずれもが陰性であった。そこでリコンビナントB19粒子をアビジン化しT細胞表面でB19が結合する因子を追求し、該当する蛋白としてp80を見出した。 2.P80はKu80であることが判明したが、Ku80はB19が結合性を示す各種細胞株の表面に存在し、また、ヒト骨髄の赤芽球、T細胞、B細胞、マクロファージ系細胞表面にも、更には活性化T細胞表面にも発現していた。一方、P抗原が証明されてもB19が結合しない各種細胞株ではKu80が陰性であった。 3.P抗原陽性だが、Ku80陰性でB19感染が成立しないHeLa細胞にKu80遺伝子を導入する(Heka・Ku)。この細胞ではB19の結合と細胞内へのB19 entryが誘導された。 4.赤芽球株Ku812 Ep6やヒト骨髄より得た細胞にB19を感染するとB19の著明な増殖を認める。このB19感染時に抗Ku80抗体、あるいはP抗原に対する抗体が併存するとB19の細胞の結合及びB19増殖が強く抑制された。 1-4はB19が未報告のレセプターp80を介して感染することを示す。p80単独ではb19増殖は認め難いことからp80はp抗原と共同し(coreceptorとして)B19感染において必須の役割を担うものと考えられる。また、B19が免疫系細胞に持続感染してRA病態を発現するというこれまでの成績を裏付けるものである。
新規酸化ストレス測定系の確立と臨床応用

賀来満夫, 張替秀郎

Offer Organization: 日本学術振興会

System: 科学研究費助成事業萌芽研究

Category: 萌芽研究

Institution: 東北大学

2002 - 2003

More details Close

現在、酸化ストレスが多くの疾患に関与していることが明らかとなっているが、その簡便な評価法は確立されていない。本研究は、酸化物質のより蛍光物質へと変換され、蛍光を生じる化学物質である2,7-dichlorofluorescin diacetate(DCFH-DA)を用いたフローサイトメトリーによる新規酸化ストレス検出法の確立をその目的としている。本年度は昨年度確立したこのフローサイトメトリーによる新規酸化ストレス検出法の有用性を確認した。赤血球型δ-アミノレブリン酸合成酵素(ALAS-E)は赤血球におけるヘム合成の初発酵素であり、この遺伝子の変異は遺伝性のX染色体連鎖性鉄芽球性貧血の原因と考えられている。我々はこのALAS-E欠損ES細胞を樹立し、さらにin vitroにて成体型赤芽球へと分化誘導した。その形質を詳細に解析した結果、このALAS-E欠損赤芽球内には鉄の蓄積が見られることが明らかとなった。そこで、このin vivoで得られたALAS-E欠損赤芽球の酸化ストレス状態を、新規に確立したフローサイトメトリーによる酸化ストレス検出法を用いて評価したところ、野生型赤芽球と比べ過剰な酸化ストレス状態にあることが明らかとなった。またこれらin vitroで得られた赤芽球はin vivoの赤芽球と比べ、酸化ストレスレベルが格段に高いことも明らかとなった。これらの結果から本研究で確立した新規酸化ストレス検出法は、実際に細胞レベルでの酸化ストレス状態が解析可能な系であることが確認できた。
Etiological agents responsible for systemic lupus erythrmatosus

SASAKI Takeshi, MUNAKATA Yasuhiko, HARIGAE Hideo, KAMEOKO Jynichi

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2001 - 2002

More details Close

1. First, we confirmed that human monoclonal anti-DNA antibody O-81 would be nephritogenic antibodies responsible for tissue injury in systemic lupus erythematosus(SLE). We established SLE model in SCID mice, where active SLE lymphocytes were injected. The coexistence of anti-81 ribozyme prevented the formation of immune deposits and elevation of anti-DNA activity in vivo. 2. O-81 scFV was obtained by using E coil-Pin Point TM system for the expression of protein from O-81 VH gene. O-81 scFV bound to DNA and anti-idiotypic antibodies to O-81. We also obtained cDNA library originated from SLE lymphocytes. The peptides expressing on the clones derived from SLE cDNA library, were examined for the binding ability to O-8 l scFV. As a result, 16 clones were obtained and the recombinant protein was obtained from some clones. 3. The recombinant protein reacted with O-81 indicating. This indicates that the determined protein may be specific to SLE.
Development of genetic diagmosis for drug resistance in cancer

FUNATO Tadao, KAMEOKA Jun

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2000 - 2002

More details Close

Drug resistance is acquired in the anticamcer drug in leukemia, and it is an important problem to become treatment resistance. Because of that, an anticancer drugresistant acquired is made clear, and the same has the gene which relates to the resistance, and it is necessary to decide early diagnosis. The various quantities to measure it in a small quantity were developed in the leukemia. First, the important factor involved in the acute leukemia cleared that it was deoxycytidine kinase (dCK) involved in a MDR1 gene to be involved in the multidrug resistance and a MRP1 gene, araCresistant. It was confirmed, and cut off value in the clinical inspection with patients, was established the quantitative way of detecting these amounts of genetic expression to establish realtime quantity to be excellent in the sensitivity and the peculiarity in the fundamental examination which it tried. The detection sensitivity of this way was high in comparison with usual multipledrug resistance, and it was shown by that result that it was useful for the diagnosis of anticancer resistant in the clinical target. Specially, relevance with the first treatment resistance and the amount of MDR1 expression with the acute leukemia and the recurrence was suggested, and it was shown that it was useful for the prediction of the treatment resistance in the MDR1 genetic. But, it isn't clear from the examination record until now, and it must pile up an examination more as for the relation between the amount of exprission and the treatment resistance between MRP1 and dCK. Therefore, it was proved that was the clinical way of introducing this way as an early diagnosis of anticancer resistant and of examining it, and clinical target meaning was explained. Furthermore, if it has the gene related to the resistance of every anticancer drug, it can be applied to the genetic quantity by this way, and it is suggested that it is useful for the comparison with the recent DNA array analysis
Antinucleic aid antibody gene therapy for rheumatoid Arthritis and adult T cell Leukemia

SASAKI Takeshi, KAMEOKA Junichi, HARIGAE Hideo, KITAGAWA Yoshichika, MUNAKATA Yasuhiko

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2000 - 2001

More details Close

1.Expression of antibody against DNARNA hybrid in the cells. We first obtained hybridoma producing monoclonal anti-DMA RNA hybrid antibody and prepared the fragments of VH and VL gene encoding the antibody. Both fragments were bound for the expression of ScFv antibodies and introduced into vectors for the expression in the cells. 2. Efficacy of gene therapy using anti-ScFv expression system for prevention of tabacco mosaic virus (TMV) infection. Tabacco which was introduced with anti-DNARNA hybrid ScFv genes, expressed ScFv mRNA and showed marked resistance to TMV infection. 3. Blocking experiment of human adult T cell leukemia virus (HTLV-1) infection by gene therapy using anti-ScFv expression system. We are establishing for evaluation of efficacy of ScFv strategy in order to block HTLV-1 infection in T cells.
Research for the relationship of hereditary sideroblastic anemia with enzyme complex formation in mitochondria

FURUYAMA Kazumichi, HARIGAE Hideo

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2000 - 2001

More details Close

1. To examine whether Erythroid specific 5-aminolevulinate synthase (ALAS-E) and ATP-specific succinyl CoA synthethase (A-SCS) form functional enzyme complex in vitro, we have expressed recombinant proteins of components of each enzyme (ALAS-E, SCS-α, SCS-βA and SCS-βG) using Baclo-virus based expression system. In this experiment, we have successfully purified enzymatically active ALAS-E recombinant protein, however, enzymatic activity of SCS could not be detected in any combination of purified component (SCS-α and SCS-βA = A-SCS, or SCS-α and SCS-βG = G-SCS). These results suggest that phosphorilation or glycosilation SCS might be needed for enzymatically active SCS, which specifically occur in only mammalian cells. Alternatively, mammalian SCS may request specific co-factor(s) for its catalytic activity. If such co-factor(s) exist, decrease amount of the co-factor may cause sideroblastic anemia. 2. To determine the specific region for interaction of ALAS-E and SCS-βA, several deletion mutants of ALAS-E protein were made. Then, the interaction of such mutant ALAS-E proteins and SCS-βA protein were determined using yeast two hybrid system. As a results, 147 amino acid deletion of N-terminal or 50 amino acid deletion of C-terminal of ALAS-E disrupt the interaction of ALAS-E and SCS-βA protein. Since these deletion mutant of ALAS-E results the disruption of homo-dimer formation of ALAS-E, homodimer formation of ALAS-E might be important for enzyme complex formation of ALAS-E and A-SCS in mitochondria.
Identification of the causative gene for inherited sideroblastic anemia and analysis of sideroblastis induced in vitro

HARIGAE Hideo, FURUYAMA Kazumichi

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

1999 - 2001

More details Close

alas2 encodes the erythroid specific 8-aniinoleyuIinate synthase (ALAS2), the first enzyme in heme biosynthesis in erythroid cells. In vivo in mice, alas2-null primitive erythroblasts showed a maturation arrest as well as massive cytoplasmic iron accumulation. However, the effect of ALAS2 deficiency, on definitive erythropoiesis still remains unclear, because alas2-null mice died in utero by embryonic day 11.5 before definitive erythropoiesis developed. To clarity the effect of heme deficiency on differentiation of definitive erythroid cells, ES cells lacking the alas2 gene were induced to differentiate specifically into erythroid lineage in vitro, and phenotypes of definitive erythroblasts were examined. In comparison to red cell pellets of Wild-type erythroblasts, alas2-null definitive erythroblasts were totally white due to a marked deficiency of heme, although the morphology was similar to wild-type erythroblasts. Consistent with their similar morphology, levels of erythroid-specific gene expression such as GATA-1, NF-E2 andTER119 in alas2-null definitive erythroblasts were also similar to those of wild-type cells, indicating that both alas2-null and wild-type erythroblasts developed to the stage of mature definitive erythroblasts. In contrast to their similar morphology, however, iron content in alas2-null definitive erythroblasts was twice more than that of wild-type, cells. Consistent with the aberrant increase in iron content, alas2-null definitive erythroblasts were more oxidized compared with wild-type erythroblasts as judged by increased formation of peroxidized metabolites. These findings suggest that alas2 deficiency does not influence erythroid differentiation per se, but induces aberrant iron accumulation and oxidized condition in definitive erythroblasts.
腫瘍マーカーとしてのカルシウム調節ホルモン・スタニオカルシン

佐々木毅, 舩渡忠男, 張替秀郎

Offer Organization: 日本学術振興会

System: 科学研究費助成事業萌芽的研究

Category: 萌芽的研究

Institution: 東北大学

1999 - 2000

More details Close

1.血中スタニオカルシン(STC)測定系の開発 (i)リコンビナントヒトSTC及びそのペプタイドをキャリア蛋白KLHと結合して免疫し、IgG型モノクロナル抗ヒトSTC抗体(STCmAb)産生ハイブリドーマを得た。 (ii)STCmAbは蛍光抗体法及びSDS PAGE後のイムノブロット法によりヒト腎尿細管細胞成分と反応することを確認した。 (iii)2種類のSTCmAb及びポリクロナル抗体を用いてサンドイッチ法によりSTC測定のためのELISA法を確立した。 (iv)リコンビナントヒトSTCをスタンダード抗原として(iii)の系で測定し、標準曲線を作成したところ5-10ng/ml以上のSTCが測定可能とされた。これに基づき、各種疾患、正常人血中でのSTCを測定した。しかし検出は難しく、より高感度の測定系の開発が必要とされた。 2.STCmRNA定量の臨床的意義の追求 (1)STCmRNAの定性的測定系をnested reverse transcription-polymerase chain reaction(nested RT-PCR)法として、定量的測定系はリアルタイムRT-PCR法として確立し、STCmRNA測定による白血病の診断、とくにminimal residual disease(MRD)マーカーとしての意義に関して追求した。 (2)白血病症例の骨髄血では、種々のタイプの白血病症例で高率にSTCmRNAを検出したが、健常人の骨髄血でも検出された。一方末梢血に関しては、白血病症例13例12例でSTCmRNAの発現を認めたが、健常人では28例全例でSTCmRNAの発現が認められなかった。 (3)白血病症例の末梢血におけるSTCmRNAを定量したところ、急性期AML20例中6例、T-ALL4例中3例、Adulr T cell leukemia(ATL)2例中2例がSTCmRNA値の高値を示した。STCmRNA値が高値であった例はいずれも寛解期に低値になった一方寛解期の多くはカットオフ値以内を示した。以上よりSTCmRNAの定量は白血病の診断、予後の推定に有用と考えられる。

Show all Show first 5

Social Activities 182

[日本国内]第76回日本血液学会学術集会

2014/10/31 - 2014/11/02

More details Close

座長として参加
[日本国内] 血液学教育プログラム

2011/11/16 - 2011/11/17

More details Close

講師として造血器腫瘍学とAPLA,MDSについて講義をした
[日本国内] 第１７回血液科学セミナー

2011/11/05 - 2011/11/06

More details Close

座長として
[日本国内] 日本検査血液学会学術総会

2010/07/24 - 2010/07/25

More details Close

一般演題において座長を務めた。
[日本国内] JSH International Symopsium 2010 in Akita

2010/07/16 - 2010/07/17

More details Close

セッション５「Heme and Iron」において座長を務める。
[日本国内] 骨髄移植推進財団移植調整医師

2008/04/01 - 2010/03/31

More details Close

非血縁者間骨髄移植実施のため、骨髄提供者への医学的な対応
[日本国内] 骨髄移植推進財団移植調整医師

2000/10 - 2008/03/31

More details Close

非血縁者間骨髄移植実施のため、骨髄提供者への医学的な対応
大崎市学校保健会講演会講師

2015/11/26 -

More details Close

小・中・高の養護教諭、保健主事、保健教育担当者並びに保護者を対象に「貧血について」講演をする。大崎市学校保健会の目的である「学校保健衛生の改善振興、特に児童生徒並びに学校職員の健康保持増進を図る」ため、本会の事業計画を実行し、もって会員自らの資質向上と学校教育発展の一助とする。
難病医療相談会仙台市宮城野区保健福祉センター

2015/11/21 -

More details Close

特発性血小板減少性紫斑病の患者・家族を対象に治療と日常生活の留意点を講話する。
第9回女性医師支援セミナー

2015/09/12 -

More details Close

東北大学病院における女性医師支援についての講演、シンポジスト
献血者に感謝する集い

2015/01/27 -

More details Close

医療に不可欠な血液製剤は、県民の献血により賄われており、献血に積極的に協力されている団体・個人に対し、感謝の意を表して「献血に感謝する集い」の場で、知事褒状の贈呈を行う
柴田郡医師会学術講演会

2014/12/15 -

More details Close

柴田郡医師会学術講演会における演者を務める。講演タイトル「貧血の診断と治療」
[日本国内]第12回JSLH沖縄支部学術集会における教育講演Ⅱ

2014/12/06 -

More details Close

講演会講師
[日本国内]第14回東北がん分子標的治療研究会

2014/11/28 -

More details Close

特別講演座長
リンパ腫医療in宮城

2014/11/24 -

More details Close

リンパ腫の患者様やご家族、その他関心のある皆様を対象とするセミナー
[日本国内]第24回日本リウマチ学会北海道・東北支部学術集会

2014/11/22 -

More details Close

演者として参加
[日本国内]第3回血液感染症フォーラム

2014/11/20 -

More details Close

座長として参加
[日本国内]平成26年度赤十字血液シンポジウム東北

2014/11/15 -

More details Close

座長として参加
[日本国内]宮城県医師会医師研修講習会(仙塩地区)

2014/11/10 -

More details Close

講演講師
[日本国内]最適な鉄過剰マネジメントに向けて

2014/11/01 -

More details Close

講演会座長
[日本国内]骨粗鬆症Up to Date

2014/10/01 -

More details Close

座長として参加
[日本国内]第26回東北リウマチ診療研究会

2014/09/27 -

More details Close

特別講演会の座長
[日本国内]東北トシリズマブ皮下注学術講演会

2014/09/20 -

More details Close

座長として参加
[日本国内]関節リウマチ治療セミナーin仙台

2014/09/11 -

More details Close

特別講演座長
[日本国内]第21回八幡平造血セミナー

2014/08/30 -

More details Close

座長
[日本国内]PsA Conference in Miyagi

2014/07/31 -

More details Close

座長として参加
[日本国内]第27回東北BMT研究会

2014/07/26 -

More details Close

座長として参加
[日本国内]Systemic Lupus Erythmatosus Seminar2014

2014/07/24 -

More details Close

特別講演における座長
[日本国内]第21回がんエピゲノム研究会

2014/07/17 -

More details Close

座長
[日本国内]第19回膠原病肺疾患研究会における特別講演

2014/07/12 -

More details Close

座長として参加
［日本国内］第7回研修医(初期・後期)のための血液学セミナー

2014/07/11 -

More details Close

講演会講師
[日本国内]第40回宮城臨床輸血研究会での特別講演

2014/07/05 -

More details Close

座長として参加
[日本国内]第3回血液Interactive Forum

2014/06/27 -

More details Close

座長として参加
[日本国内]第2回血液感染症フォーラム

2014/06/26 -

More details Close

座長
[日本国内]第6回信州血液疾患フォーラム

2014/06/21 -

More details Close

演者
［日本国内］第54回日本リンパ網内系学会

2014/06/20 -

More details Close

セミナー座長
［日本国内］多発性骨髄腫の治療戦略2014

2014/05/31 -

More details Close

座長として参加
［日本国内］日本輸血・細胞治療学会総会

2014/05/16 -

More details Close

セミナー講師
［日本国内］東北aHUS講演会

2014/04/26 -

More details Close

講演座長
［日本国内］ATL small meeting

2014/04/18 -

More details Close

講演座長
[日本国内] シーメンス東北ヘマトロジーセミナー

2012/04/21 -

More details Close

講師
[日本国内] 宮城Myeloma Seminar

2012/03/16 -

More details Close

講演会に座長として参加
[日本国内] Tohoku Leukemia Conference

2012/03/10 -

More details Close

座長として参加
[日本国内] TOHOKU HEMATOLOGY FORUM

2012/02/19 -

More details Close

座長として参加
[日本国内] 名古屋臨床血液フォーラム

2012/02/10 -

More details Close

特別講演演者
[日本国内] Professor Piet Van Riel Seminar

2012/02/07 -

More details Close

座長業務
[日本国内] 第３５回仙台BMT懇話会

2012/01/30 -

More details Close

司会、進行
[日本国内] 山形大学ー済生館血液Joint Meeting

2012/01/27 -

More details Close

特別講演演者
[日本国内] 八幡平造血セミナー宮城県実行委員会

2012/01/25 -

More details Close

世話人。セミナー開催に伴う具体的な内容の作成。
[日本国内] 福島血液学教育セミナー

2012/01/16 -

More details Close

特別講演の演者
[日本国内] 第７回つくば臨床血液学セミナー

2012/01/12 -

More details Close

特別講演会講師として講演をした
[日本国内] 第４回 Lymphoma Case Rounds

2012/01/06 -

More details Close

特別講演の座長
[日本国内] グラン発売２０周年記念・ロミプレート発売講演会

2011/12/03 -

More details Close

特別講演の座長として参加
[日本国内] 第９回 Ehime Hematology Forum

2011/12/02 -

More details Close

特別講演演者
[日本国内] 東北アカデミックフォーラムin仙台

2011/11/26 -

More details Close

講師として講演した
[日本国内] 新潟ＩＲＯＮセミナー

2011/11/25 -

More details Close

特別講演演者
[日本国内] 東北トシリズマブ学術講演会2011

2011/10/22 -

More details Close

閉会の辞を務めた
[日本国内] 末梢血幹細胞移植講演会

2011/10/21 -

More details Close

座長として参加
[日本国内] 末梢血幹細胞移植講演会‐非血縁者間PBSCTの開始にあたり‐

2011/10/21 -

More details Close

座長として参加
[日本国内] 第４回岩手血液疾患Up To Date

2011/10/19 -

More details Close

特別講演演者として参加
[日本国内] 第７３回日本血液学会

2011/10/16 -

More details Close

コーポレートセミナー座長として
[日本国内] オレンシア発売１周年記念講演会 in 仙台

2011/10/08 -

More details Close

座長として
[日本国内] がん医療と心のケア

2011/10/07 -

More details Close

座長として
[日本国内] 血液患者支援業務を考える会

2011/10/07 -

More details Close

座長として参加
[日本国内] コーディネーター会議・研修会

2011/10/01 -

More details Close

講師として
[日本国内] Iron Overload IN Sendai

2011/09/22 -

More details Close

特別講演の座長として
[日本国内] 第２２回寺子屋勉強会

2011/09/07 -

More details Close

特別講演の演者として
[日本国内] 第１８回八幡平造血セミナー

2011/09/03 -

More details Close

閉会の辞
[日本国内] 第３回 Miyagi Thronbomodulin Forum

2011/09/02 -

More details Close

特別講演の座長として
[日本国内] レブラミド発売一周年記念講演会

2011/08/27 -

More details Close

特別講演座長
[日本国内] RA Expert Meeting in SENDAI

2011/08/26 -

More details Close

特別講演の座長として
[日本国内] 第１０回東北臨床免疫研究会

2011/08/06 -

More details Close

世話人
[日本国内] 第１０回宮城さい帯血講演会

2011/07/30 -

More details Close

座長として
[日本国内] 東北医学会特別講演会

2011/07/27 -

More details Close

共催：セルジーン株式会社演者：Dr.Robert.P.Gale 座長として参加
[日本国内] 第１３回膠原病肺疾患研究会

2011/07/02 -

More details Close

特別講演の座長として参加
[日本国内] 仙台ＣＭＬ Seminar

2011/06/24 -

More details Close

特別講演の座長として
[日本国内] 第７回がん・エピゲノム研究会

2011/06/22 -

More details Close

座長として
[日本国内] Iron Overload Seminar

2011/03/05 -

More details Close

座長として
[日本国内] 南東北ＭＤＳ講演会

2011/03/04 -

More details Close

特別講演の座長として
[日本国内] 鉄過剰症座談会

2011/02/26 -

More details Close

座長・講師として
[日本国内] 地域医療連研修会

2011/02/24 -

More details Close

講師として
[日本国内] 第５回 TOHOKU HEMATOLOGY FORUM

2011/02/20 -

More details Close

座長として
[日本国内] 日本血液学会東北地方会

2011/02/20 -

More details Close

ランチョンセミナー座長として
[日本国内] レボレード発売記念講演会

2011/02/18 -

More details Close

座長として
[日本国内] リウマチ・膠原病セミナー

2011/02/10 -

More details Close

特別講演の座長として
[日本国内] 東北凝固線溶症例研究会

2011/02/05 -

More details Close

特別講演の座長として
[日本国内] 第３４回仙台ＢＭＴ懇話会

2011/01/31 -

More details Close

座長として
[日本国内] 第３４回自己血輸血研修会

2011/01/29 -

More details Close

特別講演の講師として
[日本国内] 多発性骨髄腫治療講演会

2011/01/28 -

More details Close

藤本製薬主催の同会に座長として出席
[日本国内] 1/7Lymphoma Case Rounds年首特別講演会

2011/01/07 -

More details Close

特別講演の司会として
[日本国内] オレンシア発売記念講演会in 仙台

2010/12/11 -

More details Close

座長として参加
[日本国内] 第一回関西血液疾患 Forum

2010/10/29 -

More details Close

特別講演の演者として参加
[日本国内] 多発性骨髄腫、最新の治療と検査

2010/10/23 -

More details Close

講師として参加
[日本国内] 関節リウマチ市民公開講座

2010/10/17 -

More details Close

総合司会として参加
[日本国内] 東北アクテムラ学術講演会2010

2010/10/16 -

More details Close

閉会の辞
[日本国内] ノバルティスファーマ主催学術講演会

2010/10/15 -

More details Close

座長として参加
[日本国内] ＣＭＬ Seminar In Sendai

2010/10/09 -

More details Close

特別講演の座長として参加
[日本国内] セルジーン主催の講演会

2010/10/02 -

More details Close

座長として参加
[日本国内] Multiple Myeloma Seminar In Sendai

2010/09/29 -

More details Close

座長として参加
[日本国内] 第72回日本血液学会学術集会コーポレートセミナー2-5

2010/09/25 -

More details Close

座長として参加
[日本国内] 第９回東北臨床免疫研究会

2010/08/07 -

More details Close

世話人として参加
[日本国内] 第９回宮城さい帯血講演会

2010/07/31 -

More details Close

座長として参加
[日本国内] 和歌山 Iron Over Load Forum

2010/07/09 -

More details Close

演者として「鉄過剰症の病態と治療の進歩」を発表。
[日本国内] 血液患者支援業務を考える会

2010/07/02 -

More details Close

特別講演での座長として参加
[日本国内] 日耳鼻宮城県地方部会

2010/06/23 -

More details Close

演者として「耳鼻咽喉科診療に関連する血液疾患について」を発表
[日本国内] がん・エピゲノム研究会

2010/06/23 -

More details Close

オープニングリマークスとして参加
[日本国内] 仙台医療センター講演会

2010/06/16 -

More details Close

講師として参加演題「血液疾患に遭遇したら」
[日本国内] Miyagi Thrombomodulin Forum

2010/06/11 -

More details Close

特別講演座長として参加
[日本国内] 関節リウマチ学術講演会 in SENDAI

2010/05/20 -

More details Close

opening remarksとして参加
[日本国内] 宮城ゼヴァリン講演会？臨床応用の実際？

2010/05/14 -

More details Close

座長として出席
[日本国内] ＰＮＨセミナー

2010/05/13 -

More details Close

講演の座長として出席
[日本国内] CML Expert Seminar in Sendai

2010/04/27 -

More details Close

特別講演の座長として参加
[日本国内] SPRYCEL発売一周年記念セミナー

2010/04/17 -

More details Close

座長として参加
[日本国内] 第２回三重鉄キレート療法学術講演

2010/04/16 -

More details Close

特別講演の演者として出席演題「鉄過剰症の病態と治療の進歩」
[日本国内] Nilotinib Japan Investigators Discussion Meeting

2010/04/10 -

More details Close

情報収集、意見交換
[日本国内] Iron Summit in NAGASAKI

2010/04/09 -

More details Close

特別講演の演者として出席演題「鉄過剰症の病態と治療の進歩」
[日本国内] 第１０回免疫病診療研究会

2010/04/03 -

More details Close

特別講演の座長として出席
[日本国内] 血液分子治療フォーラム

2010/04/02 -

More details Close

開会の挨拶、総合司会として出席
[日本国内] 第３回南部地区臨床診療勉強会

2010/03/18 -

More details Close

特別講演の演者として出席演題「日常診療の中でよくみられる血液疾患について」
[日本国内] Myeloma Workshop In Sendai

2010/03/16 -

More details Close

座長として出席
[日本国内] タシグナ発売１周年記念講演会

2010/03/12 -

More details Close

特別講演の座長として出席
[日本国内] 東北後天性血友病セミナー

2010/02/27 -

More details Close

セミナーオーガナイザーとして出席
[日本国内] 第１２回 TOCHIGI HEMATOLOGY SEMINAR

2010/02/25 -

More details Close

特別講演の演者として出席演題「赤血球におけるヘム合成・鉄代謝と鉄芽球性貧血」
[日本国内] 第４回 TOHOKU HEMATOLOGY FORUM

2010/02/21 -

More details Close

研究報告の座長として出席
[日本国内] 第13回東北リウマチ医の会第17回リウマチ診療研究会・仙台合同研究会

2010/02/14 -

More details Close

特別講演１の座長として出席
[日本国内] 関節リウマチフォーラム in Sendai 2009 -Infliximab Next Stage-

2009/11/28 -

More details Close

特別講演座長
[日本国内] 第９回東北がん分子標的治療研究会

2009/11/27 -

More details Close

一般演題座長
[日本国内] Ｄｒ．Martin J Bergman 仙台講演会

2009/11/25 -

More details Close

特別講演座長
[日本国内] 血液科学セミナー

2009/11/22 -

More details Close

座長
[日本国内] 献血者に感謝する集い（表彰式）

2009/11/18 -

More details Close

講演、医療現場での血液製剤の使用について
[日本国内] 血液疾患・真菌症フォーラム

2009/11/05 -

More details Close

司会
[日本国内] 岩手血液疾患セミナー

2009/11/04 -

More details Close

特別講演
[日本国内] 仙台ＣＭＬセミナー

2009/10/30 -

More details Close

座長
[日本国内] Hematology Symposium 2009 in Sendai

2009/10/10 -

More details Close

特別講演？座長
[日本国内] 第４回東京血液疾患フォーラム

2009/09/26 -

More details Close

特別講演「赤血球におけるヘム合成・鉄代謝の分子基盤と鉄芽球性貧血」演者
[日本国内] エクジェイド発売１周年記念講演会

2009/09/25 -

More details Close

司会
[日本国内] 第１６回リウマチ診療研究会・仙台

2009/09/19 -

More details Close

特別講演座長
[日本国内] 第３３回日本鉄バイオサイエンス学会学術集会シンポジウム

2009/09/12 -

More details Close

演者
[日本国内] 宮城造血幹細胞移植セミナー

2009/09/11 -

More details Close

座長
[日本国内] 宮城県医師会講演会

2009/09/10 -

More details Close

講演講師「貧血の診断と治療？産業医に必要な血液学の知識？」
[日本国内] 第１６回八幡平造血セミナー

2009/09/05 -

More details Close

特別講演座長
[日本国内] 第８回宮城さい帯血講演会

2009/08/01 -

More details Close

座長
[日本国内] 東北アクテムラ学術講演会 2009

2009/07/18 -

More details Close

閉会の辞
[日本国内] 第２２回東北ＢＭＴ研究会

2009/07/11 -

More details Close

特別講演・座長「造血幹細胞・白血病におけるポリコーム遺伝子の機能」
[日本国内] 血液リコモジュリンフォーラム

2009/07/08 -

More details Close

司会進行役
[日本国内] 第８回血液患者支援業務を考える会

2009/07/03 -

More details Close

特別講演での座長
[日本国内] ヒュミラ１周年記念講演会

2009/06/25 -

More details Close

特別演題の座長
[日本国内] 題５７回日本輸血・細胞治療学会総会ランチョンセミナー

2009/05/28 -

More details Close

演者
[日本国内] 県民のための医療公開講座

2009/05/23 -

More details Close

演者および患者、ドナーとのトークセッション
[日本国内] 宮城県多発性骨髄腫講演会

2009/05/09 -

More details Close

座長
[日本国内] 北関東スプリセル適正使用セミナー

2009/04/25 -

More details Close

特別講演演者
[日本国内] スプリセル錠発売記念講演会

2009/04/18 -

More details Close

座長
[日本国内] Haematology Seminar

2009/04/06 -

More details Close

特別講演座長
[日本国内] 宮城地区リウマチ教育研修会

2008/09/14 -

More details Close

世話人、座長
[日本国内] 第7回東北臨床免疫研究会

2008/08/09 -

More details Close

世話人
[日本国内] 日本におけるエタネルセプト前例調査に関する講演会

2008/07/30 -

More details Close

座長
[日本国内] 第6回宮城骨髄腫研究会

2008/07/26 -

More details Close

司会、座長
[日本国内] 宮城県県北血液・免疫セミナー

2008/07/18 -

More details Close

特別講演講師
[日本国内] 第21回東北BMT研究会

2008/07/12 -

More details Close

特別講演「転写因子GATA-2の造血における機能と役割」
[日本国内] STR(Southern TOHOKU Research)Medical Conference

2008/07/11 -

More details Close

総合南東北病院での特別講演「血液疾患の診断と治療」
[日本国内] 第55回福島血液研究会

2008/07/05 -

More details Close

特別講演「赤血球分化とヘム合成」
[日本国内] 特別講演第7回血液患者支援業務を考える会

2008/07/04 -

More details Close

座長
[日本国内] 東北アクテムラ学術講演会

2008/06/21 -

More details Close

討議への参加、閉会挨拶等
[日本国内] 血液免疫グループミーティングin石巻

2008/06/19 -

More details Close

講演「血液領域における最新の治療」
[日本国内] 仙台市内科医会学術部会

2008/06/06 -

More details Close

特別講演「造血器腫瘍の診断と治療の進歩」
[日本国内] 北海道血液腫瘍セミナー

2008/05/23 -

More details Close

講演「赤血球造血の制御因子とヘム合成」
[日本国内] 尚絅学院高等学校における講演会

2008/05/22 -

More details Close

臍帯血及び臍帯血バンクについて講演
[日本国内] Current and futur treatment strategies and New agents development for lymphoid malignancies in Europe

2008/04/27 -

More details Close

司会、座長
[日本国内] アドバイザリ・ボード・ミーティング（岩手）

2008/04/12 -

More details Close

コメンテーターとして参加
[日本国内] 第18回東北心臓疾患研究会

2008/04/04 -

More details Close

特別講演講師
[日本国内] CML講演会

2008/02/08 -

More details Close

座長
[日本国内] 第３１回仙台ＢＭＴ懇話会

2008/01/28 -

More details Close

特別講演および討議への参画
[日本国内] 第178回内科懇話会

2008/01/24 -

More details Close

血液疾患の治療の進歩
[日本国内] 一関医師会学術講演会

2008/01/18 -

More details Close

血液疾患の診断と治療
[日本国内] Dasatinib Advisory Board Meeting

2007/12/08 -

More details Close

アドバイザー
[日本国内] 仙南内科懇話会

2007/10/31 -

More details Close

血液疾患ー最新の治療
[日本国内] 宮城移植医療講演会

2007/09/20 -

More details Close

特別講演座長
[日本国内] 健康の医学教室（河北TBCカルチャーセンター）

2007/09/18 -

More details Close

「貧血と言われたら」
[日本国内] 東北キャンディ研究会

2007/09/15 -

More details Close

謝辞、開会の辞
[日本国内] 第１４回八幡平造血セミナー

2007/09/08 -

More details Close

実行委員会参加と特別講演の座長および討議への参加
[日本国内] 第６回秋田血液・腎・膠原病勉強会

2007/08/30 -

More details Close

特別講演「赤血球造血の制御因子と血液疾患」演者
[日本国内] 第1回TOHOKU HEMATOLOGY FORUM

2007/02/18 -

More details Close

討議への参加

Show all Show first 5

Media Coverage 4

[日本国内] つらい貧血、改善セラピー

2008/02/05

Type: Newspaper, magazine
[日本国内] なるほど健康雑学（白血病）

2007/11/05

Type: Newspaper, magazine
[日本国内] なるほど健康雑学（貧血）

2007/10/29

Type: Newspaper, magazine
[日本国内] なるほど健康雑学

2007/10/22

Type: Newspaper, magazine

Other 18

JSPS 学術動向

More details Close

JSPS 学術動向
遺伝性鉄芽球性貧血の診断分類と治療法の確立

More details Close

遺伝性鉄芽球性貧血の診断分類と治療法の確立
難治性疾患克服研究事業特発性造血障害に関する調査研究班（自治医科大学小澤敬也班）

More details Close

難治性疾患克服研究事業特発性造血障害に関する調査研究班（自治医科大学小澤敬也班）
Targeted absolute proteomicsに基づく薬剤感受性関連タンパク質ネットワークの解明IF（寺崎IF)

More details Close

Targeted absolute proteomicsに基づく薬剤感受性関連タンパク質ネットワークの解明IF（寺崎IF)
白血病や造血不全症などの難治血液疾患に対する新たな分子治療法の確立

More details Close

血液分子治療学寄付講座の設置
骨髄細胞の形態解析研究

More details Close

骨髄細胞の形態解析研究
ろ胞性リンパ腫におけるBACH２の発現に関する研究助成

More details Close

ろ胞性リンパ腫におけるBACH２の発現に関する研究助成
タンパク質ネットワークによる遺伝子情報制御と疾患発生機構の解明IF(五十嵐IF)

More details Close

タンパク質ネットワークによる遺伝子情報制御と疾患発生機構の解明IF(五十嵐IF)
Targeted absolute proteomicsに基づく薬剤感受性関連タンパク質ネットワークの解明IF

More details Close

Targeted absolute proteomicsに基づく薬剤感受性関連タンパク質ネットワークの解明IF
生体の恒常性を維持する幹細胞ネットワークIF

More details Close

生体の恒常性を維持する幹細胞ネットワークIF
濾胞性リンパ腫におけるBACH２の発現(血液学)

More details Close

濾胞性リンパ腫におけるBACH２の発現(血液学)
赤芽球におけるヘムを介した転写制御ネットワークの解明

More details Close

赤芽球におけるヘムを介した転写制御ネットワークの解明
超免疫不全NOGマウスを用いたがん幹細胞の増殖・維持機構の解明IF

More details Close

超免疫不全NOGマウスを用いたがん幹細胞の増殖・維持機構の解明IF
Tohoku Hematology Forum

More details Close

Tohoku Hematology Forum
臨床応用を目的とした臍帯血由来間葉系幹細胞の増幅

More details Close

臨床応用を目的とした臍帯血由来間葉系幹細胞の増幅
間葉系幹細胞の分化における転写因子の機能分析

More details Close

間葉系幹細胞の分化における転写因子の機能分析
骨髄不全症における制御性T細胞の臨床的意義

More details Close

骨髄不全症における制御性T細胞の臨床的意義
可溶性IL-2受容体レベルと自己免疫疾患の臨床的特異性との関連について

More details Close

可溶性IL-2受容体レベルと自己免疫疾患の臨床的特異性との関連について

Show all Show first 5